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Abstract 
The intestinal tract of humans and animals is colonized by trillions of microorganisms that 
constitute a community or ecosystem known as the gut microbiota. The gut microbiota 
undergoes remarkable alterations during early age, reaches a relative stable state in 
adulthood, and is driven by internal and external factors such as genotype of the host, diet 
and antibiotics. The objective of this research was to determine the effects of antibiotic 
treatment, microbial exposure and diet on the development of intestinal microbiota, 
focusing on the pig as an important production animal as well as a model for human. To 
achieve this objective, a series of intervention experiments were performed both in piglets 
and adult pigs.  
To determine the impact of antibiotic treatment on the development of intestinal microbiota 
of piglets, two experiments were performed. The first experiment aimed to determine the 
effect of perinatal maternal antibiotic treatment on the intestinal microbiota of piglets. In 
this experiment, the sows received amoxicillin orally around parturition, and their offspring 
was serially sacrificed up to 42 days of age for analysis of ileal and colonic microbiota. It 
was observed that amoxicillin treatment drastically impacted the sows’ faecal microbiota, 
and furthermore influenced specific microbial groups in the ileum and colon of the piglets 
before and after weaning. These findings indicated that maternal amoxicillin treatment may 
indirectly affect the gut microbiota of offspring through disturbing the maternal microbiota 
and the transfer of maternal microbiota to the offspring. In a second experiment, we 
determined the effect of early antibiotic treatment on intestinal microbial colonization and 
immune development of piglets. Additionally, the effect of stress factors associated with 
routine farm practice was investigated. Antibiotic treatment affected the composition and 
diversity of jejunal microbiota, and reduced the expression of a large number of genes 
involved in immune-related processes. The cumulative effect of management procedures on 
top of the use of an antibiotic was limited. This study reinforced the notion that the early 
phase of life is critical for intestinal immune development, also under regular production 
circumstances. 
Apart from antibiotic treatment, the effect of early microbial association on the 
development of intestinal microbiota and immune system of piglets was also studied in this 
thesis. One group of caesarean derived piglets was inoculated with a mixture of three 
microbial species (Lactobacillus amylovorus, Clostridium glycolicum, and Parabacteroides 
sp. ASF519) at day 1 and 2 after birth (the simple microbial association group), whereas a 
second group of piglets was inoculated with the above mixture at day 1 and 2 after birth as 
  
well as diluted adult sow faeces at day 3 and 4 after birth as the complex microbial 
association (CA) group. CA caused an increase of faecal microbial diversity and accelerated 
the faecal microbiota to develop into a stable and diverse microbiota. CA significantly 
affected luminal microbial composition and gene expression in jejunal and ileal mucosa, 
albeit in different ways. In the pig ileum, CA led to an increased relative abundance of 
microbial groups known to have beneficial effects, whereas it reduced the relative 
contribution of potential pathobionts. CA also induced the enrichment of immune-related 
gene sets in the ileal mucosa.  
Another research goal of this thesis was to determine the influence of diet on the microbiota 
in the large intestine of adult pigs. To this end, the effect of resistance starch (RS) was 
evaluated in two studies. In the first study, pigs were either assigned to an RS diet or a 
digestible starch (DS) diet for two weeks. Samples from along the intestine were collected 
for measuring luminal microbiota composition, short chain fatty acid (SCFA) 
concentrations and the expression of host genes involved in SCFA uptake, SCFA signalling, 
and satiety regulation in mucosal tissue. In both the caecum and colon, differences in 
microbiota composition and SCFA concentrations were observed between DS- and RS-fed 
pigs. Caecal tissue expression of genes encoding monocarboxylate transporter 1 and 
glucagon was induced by RS. Based on these results, an additional experiment was 
performed. In this study, ten pigs, fitted with a cannula in the proximal colon for repeated 
collection of tissue biopsies and luminal content, were fed a DS diet, or a diet high in RS 
(34%) for two consecutive periods of 14 days in a crossover design. RS increased the 
relative abundance of several butyrate-producing microbial groups and reduced that of 
potentially pathogenic members of the genus Leptospira and the phylum of Proteobacteria. 
Concentrations of acetate, propionate and butyrate in carotid plasma were significantly 
higher after RS consumption. Upon RS feeding, oxidative metabolic pathways, such as 
TCA cycle and beta-oxidation, were induced, whereas many immune response pathways, 
including adaptive and innate immune system, as well as cell division were suppressed. The 
nuclear receptor PPARG was identified as a potential key upstream regulator.  
In conclusion, this thesis provides direct evidence that maternal antibiotic treatment, early 
antibiotic admistration and microbial exposure affect the development of intestinal 
microbiota of the piglets. Moreover, both early antibiotic admistration and microbial 
exposure affected piglet mucosal tissue gene expression. These findings reinforce the 
notion that the early phase of life is critical for the development of intestinal microbiota and 
immune system. Furthermore, it is proposed that manipulation of the microbial association 
at early age may be a way of supporting functional gut development. In addition to the 
above discussed early life envents, a diet with RS can also affect the microbiota in the large 
intestine of adult pigs. This thesis provides an enhanced understanding of the interaction 
  
 
between diet, microbiota and host in a number of complementary pig models and revealed 
the impact of antibiotics in early life microbial colonization. The gained insight is expected 
to be instrumental in improving sustainable pig management. Moreover, it may also be 
useful in understanding similar processes in the human gut.
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General introduction and outline
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Development of intestinal microbiota  
The intestinal tract of humans and animals is colonized by trillions of microorganisms that 
constitute a community or ecosystem known as the gut microbiota. This complex gut 
microbiota develops after birth as newborns are considered to be virtually sterile. During 
and after birth, microorganisms originating from surrounding environments, including 
faecal material, rapidly colonize the gut of neonates and young animals [1-3]. However, 
recent studies reported the presence of microbes in the human intra-uterine environment, 
suggesting that some microbial colonization prior to the delivery can not be excluded [4-8]. 
Considerable knowledge has been assembled on the development of the intestinal 
microbiota in human. Generally, the first colonizers that dominate the human intestinal tract 
are facultative anaerobes including Escherichia coli and other Enterobacteriaceae, 
followed by anaerobic bacteria such as Bifidobacterium, Clostridium, Bacteroides, and 
Ruminococcus [9, 10]. The microbial succession during the first few weeks of life in the 
intestinal tract of chicken, pigs, and calves follows a similar pattern, and both coliforms and 
streptococci dominate the microbiota within a few days of birth. Obligate anaerobes appear 
some time later, even though neonatal animals are exposed to greater numbers of faecal and 
environmental bacteria than human neonates [11]. For infants it is known that after this 
initial colonization, the microbiota undergoes consecutive changes in composition and 
function until a relatively stable climax community is established at around 3 years after 
birth [12]. 
It is difficult to define a ‘normal’ intestinal microbiota for humans and animals at early age. 
The composition and temporal patterns of the microbial communities have been shown to 
vary widely from baby to baby [13], and furthermore the infant microbiome displays high 
interpersonal variability at an early age [14]. Nevertheless, some general trends can be 
inferred from previous studies. For example, Bifidobacterium, which decreases in 
abundance with age, has been generally reported as a predominant bacterial genus 
colonizing the early life infant gut [15-17]. The introduction of solid foods can significantly 
affect the gut microbiota, driving it into an adult type [13, 18]. In a single US baby follow 
up it was found that ingestion of table foods caused a sustained increase in the abundance 
of Bacteroidetes, elevated faecal short chain fatty acid (SCFA) levels, resulted in an 
enrichment of genes associated with carbohydrate utilization, vitamin biosynthesis, and 
xenobiotic degradation, and produced a more stable community composition, all of which 
are characteristic of the adult microbiome [19]. In this baby, the earliest microbiome was 
found to be enriched in genes facilitating lactose utilization, and functional genes involved 
in plant polysaccharide metabolism were present before the introduction of solid food, 
priming the infant gut for an adult diet [19]. Another study of Danish infants also showed 
that cessation of breastfeeding and introduction of a complementary feeding induce 
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replacement of a microbiota characterized by lactobacilli, bifidobacteria, and 
Enterobacteriaceae with a microbiota dominated by Clostridium spp. and Bacteroides spp. 
[2]. Currently, it is commonly believed that the key players of human intestinal microbiota 
development are assigned to five phyla, including Actinobacteria (with the genera 
Bifidobacterium and Colinsella), Bacteroidetes (genera Bacteroides and Prevotella), 
Firmicutes (including, but not restricted to the genera Lactobacillus, Clostridium, 
Eubacterium and Ruminococcus), Proteobacteria (e.g. Enterobacter), and Verrucomicrobia 
(consisting of one major species, the mucin-degrading Akkermansia muciniphila) [3].  
The microbiota plays a critical role in host immune system priming and gut maturation at 
early age, and can further influence the gut function through modifying gene expression of 
the host epithelium [20-23]. The host transcriptional pathways regulated in response to the 
colonizing microbiota involve nutrient uptake and metabolism, mucosal barrier function, 
xenobiotic metabolism, enteric nervous system and motility, hormonal and maturational 
responses, angiogenesis, cytoskeleton and extracellular matrix, signal transduction, and 
general cellular functions [24]. Interestingly, many host genes seem to be specifically 
altered in response to different members of the microbiota [25, 26]. Therefore, colonization 
of different microbes at early age may induce specific immune and metabolism system 
development, which consequently differentially influence the host intestinal and systemic 
health throughout life. 
Factors influencing the development of the intestinal microbiota 
There are many factors that influence the development of intestinal microbiota. Before 
delivery, a number of maternal and external factors during pregnancy are related to 
microbiota establishment in the gut, for instance, the mother’s body weight and microbiota, 
disturbance through stress, and administration of antibiotics and probiotics. During birth, 
the mode of delivery (vaginally or by caesarean section) is the main factor that affects the 
microbiota establishment in the gut. After delivery, additional factors can influence the 
process of gut microbiota development at early age, such as feeding (breast feeding vs. 
formula feeding), antibiotic treatment, probiotics, and microbial exposure. Although 
gestation time is also a factor that strongly influences establishment of the infant intestinal 
microbiota, here we focus on the development of intestinal microbiota in term offspring 
since this is encountered in the majority of animal deliveries.  
Prenatal and maternal factors  
Prenatal factors influencing the development of intestinal microbiota remain a largely 
unexplored area. Recent studies have suggested that the microbial contact of the offspring 
with their mothers may begin already prior to birth [5, 7, 27]. Therefore, maternal 
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influences on the fetal gut colonization should be considered as the first stage of intestinal 
microbiota development. Up to now, little is known about the maternal influences on fetal 
gut colonization. Studies so far have only shown that the maternal status during pregnancy 
is related to the intestinal microbiota development after birth. Mothers’ BMI, weight, and 
weight gain during pregnancy can influence the composition and development 
of infant gut microbiota after birth. Faecal Bacteroides and Staphylococcus concentrations 
were significantly higher in infants of overweight mothers during the first six months, 
whereas the abundance of bacteria related to Akkermansia muciniphila, Staphylococcus, 
and Clostridium difficile were lower in infants of normal-weight mothers and of mothers 
with normal weight gain during pregnancy [28]. Another study showed that overweight 
pregnant women had more Bacteroides and Staphylococcus than normal-weight pregnant 
women [29]. In addition, it was found that similarities between infant-mother microbiota 
increased with children's age [30]. These results suggest that the mothers’ microbiota is 
associated with the development of gut microbiota of offspring after birth.  
The mother’s faecal, vaginal and possibly breast microbiota probably represent the most 
influential inoculum source for the development of the offspring microbiota, due to intimate 
contacts during and after birth. During delivery, mothers’ vaginal bacteria, such as 
lactobacilli, can be transferred to their offspring [31]. Vaginally delivered infants acquired 
bacterial communities resembling their own mother’s vaginal microbiota, dominated by 
Lactobacillus, Prevotella, or Sneathia spp., whereas infants born by Caesarean section 
harboured bacterial communities similar to those found on the skin surface, dominated by 
Staphylococcus, Corynebacterium, and Propionibacterium spp. [32]. Moreover, vaginally 
delivered term infants generally have higher abundance of Bifidobacterium at early age 
compared with infants born by Caesarean section [33]. It was recently found that Caesarean 
section is associated with a lower total microbial diversity and delayed colonisation of the 
Bacteroidetes phylum in the infant gut [34]. 
For breastfed infants, the microbiota of breast milk could also be transferred from mothers 
to infants after birth. The diversity and function of microbiota in breast milk has been 
reviewed recently [35, 36]. Proposed theories for the microbiota composition of breast milk 
include retrograde flow from the infant's oral cavity, transfer of organisms from maternal 
skin, and movement of microbiota from the maternal enteric tract to the mammary gland. 
Breast-fed infants were found to have significantly higher counts of bifidobacteria, whereas 
formula-fed babies had significantly higher proportions of Bacteroides and clostridia [37, 
38]. Moreover, breast-fed infants were reported to be less colonized by Clostridium difficile 
and Escherichia coli than formula-fed infants [38].  
As described above, the mother’s microbiota plays an important role in the development of 
gut microbiota of offspring. Thus, factors that affect the maternal gut microbiota during 
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delivery and lactation should also be considered.  
Antibiotic treatment, as a common factor disturbing the gut microbiota, has been commonly 
used to control infections of pregnant women in hospitals and in pre- and post-partum 
animals on a farm. Antibiotic treatment of mothers can impact fetus development, and 
associates with low birth weight of neonates and high risk of diseases such as oral clefts at 
early age [39]. Recently, researchers also found that antibiotic use during pregnancy altered 
the commensal vaginal microbiota of women [40]. Intrapartum antibiotic treatment of 
mothers was found associated with a decreased transmission of vaginal Lactobacillus to the 
neonate during birth [41]. Moreover, newborns delivered by mothers treated 
with antibiotics perinatally had lower proportions of Bacteroides and members of the 
Atopobium cluster [37, 38]. Most antibiotics are either injected or administered orally, 
thereby circulating throughout the mother’s system and potentially affecting the entire 
mother’s microbiota [42]. Thus, more studies are needed to address the antibiotic effect on 
milk and skin microbiota during pregnancy and lactation, as well as its effect on the gut 
microbiota development in the offspring.   
Other external factors during pregnancy such as stress and probiotics can also impact the 
microbial composition in the gut of the offspring. In animal trials, prenatal stress reduced 
the overall numbers of bifidobacteria and lactobacilli in the gut of infant monkeys [43]. In 
other animal models, it was found that L. acidophilus and B. lactis administered as 
probiotics to mothers during late gestation were transferred to young animals born 
vaginally [44]. In addition, a human study showed that maternal consumption of L. 
rhamnosus strain GG affected transfer and establishment of faecal bifidobacteria in 
neonates [45].  
Microbial exposure at early age 
Apart from the mother’s microbiota, the early exposure to microbes in the surrounding 
environment of newborns could also be a strong influencing factor in the development of 
the intestinal microbiota. The infants can be subjected to different microbes in different 
indoor environments such as home, hospital, and daycare. Multiple studies have reported 
links between bacteria in the home and the microbial composition of the infant gut. 
Recently, a study based on high-throughput sequence analysis of bacterial 16S ribosomal 
RNA (rRNA) genes demonstrated an association between bacterial communities of house 
dust and the gut of infants at three months of age [46]. Fourteen bacterial OTUs 
co-occurred at a significantly higher frequency in matched dust and infant stool pairs than 
in random pairs, despite significant differences between the dust and infant faecal 
microbiota. These OTUs represented the classes Actinobacteria (genus Bifidobacterium), 
Bacilli (genera Planomicrobium, Streptococcus, and Lactococcus), Clostridia (genera 
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Veillonella and Faecalibacterium, and unknown bacteria clustering within families 
Lachnospiraceae and Peptostreptococcaceae) and Gammaproteobacteria (genus 
Escherichia). These bacteria probably originate from normal household activities such as 
diaper changing and possibly aerosolization of faecal bacteria [46], and some gut-borne 
lactic acid bacteria (especially members of the genus Lactococcus) proliferate naturally on 
some organic materials under suitable conditions (e.g., dairy products, sauerkraut, dough) 
and subsequently deposit and accumulate in house dust [46]. Interestingly, a study on 
pacifier cleaning showed that the salivary microbiota differed between children whose 
parents cleaned their pacifier by sucking it and children whose parents did not use this 
practice [47]. Taken all together, normal household items and activities, family members 
and pets may all serve as reservoirs for infant gut bacterial inoculation. Exposure to pets or 
siblings of infants has been suggested to afford protection against allergic disease. In order 
to determine the mechanism responsible for this effect, murine models have been used to 
examine the interaction between the gut microbiome and house dust microbiome in two 
homes, one with a dog and the other without pets as control [48]. This study revealed that 
exposure to dog-associated household dust results in a distinct caecal microbiome 
composition with a significant enrichment of, amongst others, Lactobacillus, and L. 
johnsonii (as represented by OTUs in the clade containing L. gasseri) was primarily 
responsible for the anti-inflammatory effect. With respect to human studies, healthy full 
term infants living with pets exhibited under-representation of bifidobacteria and 
over-representation of Peptostreptococcaceae, whereas infants with older siblings showed 
the opposite effect [49, 50].  
With respect to piglets, studies have shown that the surrounding environment during 
postnatal development can have long-term impact on gut community structure [51]. 
Different early-life environments were shown to be associated with major differences in 
mucosa-adherent microbial diversity in the ileum of adult pigs [52]. The raising 
environment attributes mostly to microbial association for piglets at early age. Pigs housed 
in a natural outdoor environment showed a dominance of Firmicutes, in particular 
Lactobacillus, whereas pigs housed in a hygienic indoor environment had reduced 
Lactobacillus and higher numbers of potentially pathogenic phylotypes [52]. Overall, 
environmentally-acquired bacteria influence the microbiota composition in the GI tract of 
piglets, as well as the microbiota of the adult pigs throughout life.  
Antibiotic treatment at early age 
As previously described, antibiotic treatment is a common disturbance that impacts the 
intestinal microbiota. Correspondingly, antibiotic administration at early age also influences 
the colonization process of microbiota in the gut of infants and young animals. A variety of 
studies have addressed the effects of antibiotics on the intestinal microbiota of infants and 
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piglets based on culture independent studies (summarized in Table 1). Generally, antibiotic 
treatment at early age has been shown to delay the colonization of bifidobacteria [10, 50, 
53-55]. However, some researchers reported that instead of a significant alteration of the 
abundance of bifidobacteria, antibiotic treatment decreased the diversity of Bifidobacterium 
species at early age [54, 56, 57]. Other publications have reported antibiotic effects on the 
composition of faecal microbiota, but only at genus level [56]. In a murine animal model, it 
was found that neonatal amoxicillin treatment significantly altered the levels of lactobacilli, 
and led to a significant impact on the diversity of the intestinal Lactobacillus community 
[58]. In newborn piglets, a single parenteral dose of long-lasting amoxicillin at the first day 
of life caused a significant decrease of faecal microbiota diversity for at least five weeks 
after administration [59]. Considering the various targets, doses, and durations of antibiotic 
treatment, it is not surprising that gut microbial communities respond to different antibiotics 
in different ways or even in opposite ways. For example, faecal Enterobacteriaceae of 
infants younger than 6-months were reported to be significantly reduced after a 5-day 
ceftriaxone treatment, whereas the relative abundance of Enterobacteriaceae was markedly 
higher in the faecal samples of 1-month old infants that were treated with cefalexin in the 
first four days of life [53, 60]. These results also indicated that, at early age, the microbiota 
present before the antibiotic treatment can also influence how microbial communities 
respond to the antibiotic treatment. Because the intestinal microbiota at early age is more 
dynamic and less resilient than that of adults [37, 61], common patterns of 
antibiotic-induced changes of intestinal microbiota may not be easily predicted at early age, 
and more studies should be directed at assessing the effect of different antibiotics over time 
during early age, and the impact of these effects later in life.  
Dietary components: Major regulators of the intestinal microbiota  
Since the first introduction of solid foods to infants at 4-6 months of age, and to piglets at 
weaning after 1-2 months, the diet becomes a major force that shapes the composition and 
activity of the gut microbiota [62-64]. This is evident from the fact that the introduction of 
solid foods drives the infant gut microbiome into an adult type as previous discussed [13, 
18], and that an alteration in gut microbiota has been shown after weaning or dietary 
changes [65-67]. The microbiota of healthy adult humans and other mammals is generally 
considered stable [68]. Especially elderly people have been shown to have a remarkably 
stable microbiota, although their core microbiota differs from that of younger people with 
greater proportion of Bacteroides spp. and distinct abundance patterns of Clostridium 
groups [69]. In addition, identical twin studies indicated that host genetic factors may be 
less important as extensive dissimilarity in gut bacterial communities was discovered [70]. 
Nevertheless, the faecal microbiota of monozygotic twins is more similar than that of 
unrelated subjects [71, 72]. Taken together, the diet may be the most important factor that 
impacts the intestinal microbiota in healthy humans and adult animals.  
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Table 1. Effects of antibiotic treatment on infant and piglet intestinal microbiota based on culture-independent 
studies. 
Antibiotic 
treatment 
Duration Age Sampling 
time 
Effect Reference 
Infant study 
Clavulanic acid & 
Amoxicillin, 
Trimethoprim & 
Sulfamethoxazol  
A mixture of 
clavulanic acid and 
amoxicillin for 13 
days, then a mixture 
of trimethoprim and 
sulfamethoxazol 
 Daily for the 
first 2 weeks, 
then once a 
week until at 
least 160 
days after 
birth 
A small stable community 
consisting 
of Ruminococcus species.  
No Bifidobacterium 
[10] 
Mainly amoxicillin During first 1 month 
of life 
 1 month  Numbers of bifidobacteria and B. 
fragilis-group species decreased 
[50] 
Cefalexin  In the first 4 days of 
life 
 Day 3 Bifidobacterium decreased 
Overgrowth of enterococci 
[53] 
 
Day 5 Overgrowth of enterococci 
1 month Enterobacteriaceae markedly 
higher 
Amoxicillin  7 days 18 month End of 
therapy 
No significant alteration of 
bifidobacteria concentration; 
Numbers of Bifidobacterium 
species per microbiota 
significantly decreased 
[56] 
 
Ampicillin & 
Gentamicin 
2-9 days  4 weeks, 8 
weeks 
Bifidobacteria detected not for 
all treated infants; 
Bifidobacterium spp. diversity 
decreased  
[57] 
Ceftriaxone 5 days  <6 months Last day of 
antibiotic 
therapy (d5) 
Significant reduction in total 
bacterial count, 
Enterobacteriaceae and 
enterococci;  
lactobacilli no longer detected 
[60] 
15 days after 
the end of 
antibiotic 
therapy 
Total bacterial count, 
Enterobacteriaceae, enterococci 
and lactobacilli significantly 
increased compared to d5, 
similar to the day before starting 
antibiotic therapy 
Ampicillin & 
Gentamicin 
Not described Treatment 
start within 
48 hours of 
birth 
4 weeks after 
the cessation 
of treatment 
Significantly higher 
Proteobacteria;  
Lower Actinobacteria (genus 
Bifidobacterium) and genus 
Lactobacillus 
[54] 
8 weeks after 
the cessation 
of treatment 
Significantly higher 
Proteobacteria; 
Number of different 
Bifidobacterium species reduced 
Not described During first 4 months  4 months Lower Bifidobacterium longum;  
Higher counts of Bacteroides 
fragilis group 
[55]  
 
Piglet study 
Amoxicillin 1 day after birth  39 days Lactobacillus amylovorus 
presented only in the control 
group; 
Roseburia faecalis-related 
population strongly reduced; 
Shigella spp., Escherichia coli, 
Salmonella enterica serovar 
Typhi enriched 
[59] 
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The digestion of food in the intestine is a complex process (see Figure 1 for an overview). 
The ingested food is first rendered more digestible by processing, chewing in the mouth, 
and wetting in the stomach; then, the food enters the small intestine where further 
enzymatic digestion occurs [73]. Unabsorbed food components enter the large intestine, 
which is the main site of microbial metabolism as it is colonized by the highest number of 
microorganisms [74, 75], and become available as substrates for bacterial fermentation and 
transformation. Dietary components that escape absorption in the upper gastrointestinal 
tract are comprised to a large proportion of nondigestible dietary carbohydrates. 
Approximately 40 g of dietary carbohydrates reaches the colon each day having escaped 
digestion by host enzymes; the main categories are resistant starches (RS), non-starch 
polysaccharides (NSP) and oligosaccharides, although some di- and mono-saccharides (e.g. 
sugar alcohols) may also reach the colon [76]. Nondigestible carbohydrates provide a major 
source of energy for bacteria in the large intestine, and influence microbial fermentation 
and composition of the microbiota both in short-term dietary interventions and in response 
to habitual long-term dietary intake [76, 77]. In the following this introduction will mainly 
focus on the impact of RS on microbiota in the large intestine.  
 
Figure 1. Fate of ingested dietary food components in the small and large intestine. 
RS have been extensively reviewed in general as well as from the standpoint of their 
function and impact on gut health [78-82], and are defined as a portion of starch that cannot 
be digested by amylases in the small intestine and pass to the colon where they are 
fermented by the microbiota [83, 84]. The main fermentation products of RS by gut 
bacteria include gases (methane, hydrogen, carbon dioxide) and SCFAs (acetate, propionate, 
butyrate, and valerate), while much lower amounts of other organic acids (lactate, succinate, 
and formate), branched SCFAs (isobutyrate and isovalerate), and alcohols (methanol and 
ethanol) are also produced [85]. Culture studies have shown that RS have a major effect on 
the microbial composition in the large intestine [86-90]. Currently, culture-independent 
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methods allow the detection of the effects of RS on the intestinal microbiota in vivo [91, 92]. 
It has been shown that phylotypes related to Ruminococcus bromii, which are abundant in 
the large intestinal of humans, increase in response to a diet high in RS [91]. Similarly, 
populations closely related to R. bromii and Eubacterium rectale were shown to be the key 
players in degradation of RS in a dynamic in vitro model of the proximal colon, the TIM-2 
model, using RNA stable isotope probing of models fed with 13C labeled RS [93]. 
Different forms of RS differ in their ability to modulate the intestinal microbiota [94]. 
There are five types of RS (see Table 2 for a summary). To date, studies have shown 
different effects of RSII, RSIII and RSIV on the human and animal intestinal microbiota. It 
is still unclear why different RS differ in changing the composition of the microbiota, and 
more studies should be conducted to identify the mechanisms by which specific bacterial 
taxa interact with the different forms of RS.  
Table 2. Effects of resistant starches (RS) on the intestinal microbiota of human and animals based on 
culture-independent studies (Adapted from Birt et at. [85]). 
Type of RS Description Example Effect Human or Animal 
study 
Reference 
RSI Physically 
inaccessible starch 
Coarsely ground or 
whole-kernel 
grains 
-1 - - 
RSII Granular starch with 
the B- or 
C-polymorph 
High-amylose 
maize starch, 
raw potato, raw 
banana starch 
Species level: 
Ruminococcus 
bromii, 
Eubacterium 
rectale increased 
Human [94] 
Bacteroidetes , 
Actinobacteria 
increased  
rats [95] 
RSIII Retrograded starch Cooked and cooled 
starchy foods 
Ruminococcus 
bromii , uncultured 
Oscillibacter,  
Eubacterium 
rectale increased 
Human [91], [96] 
RSIV Chemically 
modified starches 
Cross-linked starch 
and octenyl 
succinate starch 
Actinobacteria , 
Bacteroidetes 
increased 
Firmicutes 
decreased  
Bifidobacterium 
adolescentis, 
Parabacteroides 
distasonis increased 
Human [94] 
RSV Amylose-lipid 
complex 
Stearic 
acid-complexed 
high-amylose 
starch 
- - - 
1 “-” means that no related information has been found. 
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Molecular approaches for the study of the microbial communities 
residing in the mammalian gut 
The gut microbiota has been studied via cultivation-based techniques traditionally. 
However, these techniques are laborious and with limitations, for instance, they require 
selective media or anoxic conditions in most cases, and have difficulties with assessing 
complex microbial communities such as those found in the gut. To circumvent some of the 
limitations of cultivation-based techniques, researchers can use culture-independent 
methods, such as fingerprinting and sequencing techniques based on small subunit 
(16S/18S) rRNA and the encoding genes, according to their research aim. If the research 
goal is only to estimate the relative abundance of certain bacteria in a community, 
quantitative real time PCR (qPCR) is a better analysis method considering time and cost; 
while for monitoring variation of the microbiota of different samples, fingerprinting 
techniques such as denaturing gradient gel electrophoresis (DGGE) are the most rapid 
methods to show overall differences of the microbial profile. Comparing to fingerprinting 
techniques, phylogenetic microarrays are more powerful for gaining insights into the 
structure and population dynamics of a complex microbial ecosystem, as well as to provide 
a comprehensive overview of the microbial profile of the whole sampling set. However, 
due to the fact that microarrays are designed based on the publicly available sequence space, 
next-generation technology sequencing such as 454 pyrosequencing, and more recently also 
Illumina MiSeq and HiSeq sequencing, can provide novel insights on composition of gut 
microbial communities. In the present thesis, for pig intestinal microbiota analysis we 
mainly used phylogenetic microarrays targeting microorganisms reported to occur in the 
porcine gut, as well as a supplemental analysis with fingerprinting techniques.   
Fingerprinting techniques have been extensively used to monitoring community shifts 
among samples, e.g. in case of GI tract microbiota to assess the effect of dietary treatments, 
health state and age of a mammalian host. Fingerprinting techniques include DGGE, 
temperature gradient gel electrophoresis (TGGE), temporal temperature gradient gel 
electrophoresis (TTGE), single strand conformation polymorphism (SSCP) and 
terminal-restriction fragment length polymorphism (TRFLP) analyses. Although the 
principles and technical procedures vary, all these fingerprinting techniques are PCR-based 
and generate profiles representing the sequence diversity within the selected ecosystem. 
Among these fingerprinting techniques, DGGE has been most extensively used for human 
and animal GI tract microbiota analysis. One of the advantages of DGGE is that it enables 
rapid comparative analysis of microbial variation between samples, especially the microbial 
community response to treatment over time. In addition, the band intensities can be used as 
a semi quantitative measure for the relative abundance of a certain sequence in the 
community. Furthermore, DNA fragments can be cut from the gel and re-amplified for 
sequencing and thus identification of the corresponding microorganisms [97]. In general, 
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however, DGGE and other fingerprinting methods mentioned above, only allow to detect 
the most dominant bacteria that constitute at least 1% of the total bacterial community [98]. 
Therefore, these methods are now only being used for preliminary scanning of the gut 
microbiota in mammalian studies.   
More recently, phylogenetic microarrays constitute a high-throughput tool targeting in most 
cases the SSU rRNA gene, and are a superior alternative to the more traditional 
fingerprinting techniques to detect the variation of a microbial community at much 
improved spatio-temporal resolution. Phylogenetic microarrays are in most cases glass 
surfaces spotted with thousands of covalently linked DNA or RNA probes. These have 
been successfully applied in the diversity analysis of the microbiota in the mammalian gut, 
such as that from human [13, 99], mouse [100] as well as pig [97, 101, 102]. The Pig 
Intestinal Ttract Chip (PITChip) is the main method applied for microbiota analysis in this 
thesis. Currently, there are two versions of the PITChip. The PITChip version 1.0 is a 
phylogenetic microarray, with more than 2,980 oligonucleotides based on 16S rRNA gene 
sequences of 627 porcine intestinal microbial species-level phylotypes [97, 101]. The 
PITChip version 2.0 is an update of the previous version with more than 3200 
oligonucleotides targeting the 16S rRNA gene sequences of 781 porcine intestinal 
microbial phylotypes [102]. The PITChip as well as the corresponding Human Intestinal 
Tract Chip (HITChip) [103], provide a very deep and reproducible phylogenetic analysis 
that has been compared with deep pyrosequencing of 16S rRNA gene fragments [97, 104, 
105] and next generation parallel sequencing of intestinal metagenomes [106], indicating 
comparable resolution and a higher sensitivity of the chip based analysis at commonly used 
sequencing depth.  
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Thesis outline and aims 
The work presented in this thesis was embedded in two larger programs: 1) the EU-FP7 
funded project entitled “Interplay of microbiota and gut function in the developing pig – 
Innovative avenues towards sustainable animal production”, and 2) Wageningen University 
Strategic Research Agenda IP/OP funded program entitled “Satiety & Satisfaction”. The 
main objective of this thesis is to estimate the effects of antibiotic treatment, microbial 
exposure and diet on the development of intestinal microbiota, focusing on the pig as an 
important production animal as well as a model for humans.  
Chapter 1 gives an introduction of our current understanding of the development of 
intestinal microbiota early in life, including factors that potentially affect this development, 
such as perinatal and maternal factors, microbial exposure and antibiotic treatment at an 
early age after birth, as well as the influence of diet. Furthermore, an up to date account is 
given with respect to molecular approaches towards microbial community analysis, 
specifically focusing on the mammalian gut.  
Chapter 2 provides an overview of studying the mammalian intestinal microbiome using 
animal models. Animal models provide an alternative way to study the in vivo responses to 
beneficial, commensal and pathogenic microorganisms in the GI tract. The main animals 
used to study the mammalian gastrointestinal microbiota are rodents (mainly mice and rats) 
and pigs. Rodent and pig models, including gnotobiotic and humanized rodents and pigs 
and minipigs, have been extensively employed in gut microbiota studies, and especially the 
piglet has been suggested as an appropriate model for studying the human infant 
microbiota.  
The establishment and development of intestinal microbiota can be influenced by many 
external factors. Antibiotic treatment is one of those factors and a common disturbance of 
intestinal microbiota. This is also true for infants and young animals, with an additional 
factor that mothers can affect the intestinal microbiota of their offspring, and antibiotic 
treatment of mothers may indirectly affect the intestinal microbiota of their offspring. The 
influence of maternal amoxicillin treatment on microbiota development in piglets was 
estimated in Chapter 3. In this model, the sows received amoxicillin orally around 
parturition, and their offspring was serially sacrificed up to 42 days of age. Amoxicillin 
treatment drastically impacted the sows’ faecal microbiota, and furthermore influenced 
specific microbial groups in the ileum and colon of the piglets before and after weaning. 
Maternal amoxicillin treatment may indirectly affect the gut microbiota of offspring 
through disturbing the maternal microbiota and the transfer of maternal microbiota to 
offspring. 
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Direct administration of antibiotics at early age can also influence the intestinal microbiota, 
and furthermore immune competence development of infants and young animals. 
Experiments described in Chapter 4 evaluated the effect of early antibiotic treatment on 
the intestinal microbial colonization and immune development of piglets. Furthermore, the 
additional effect of stress factors associated with routine farm practice was investigated. 
This chapter provides direct evidence that different early-life conditions, specifically 
focusing on antibiotic treatment and exposure to stress, affect gut microbial colonization 
and intestinal immune development. This reinforces the notion that the early phase of life is 
critical for intestinal immune development, also under regular production circumstances. 
Apart from antibiotic disturbances, early microbial association with environmental 
microorganisms also plays an important role in the development of intestinal microbiota 
and host immune system. To study this effect, a model with caesarean derived piglets is 
applied in Chapter 5. In this model, one group of piglets was inoculated with a mixture of 
three microbial species (Lactobacillus amylovorus, Clostridium glycolicum, and 
Parabacteroides sp. ASF519) at day 1 and 2 after birth as the simple microbial association 
group, whereas the other group of piglets was inoculated with the above mixture at day 1 
and 2 after birth as well as a faecal inoculant of an adult sow at day 3 and 4 after birth as 
the complex microbial association group. The complex microbial association caused an 
increase of faecal microbial diversity and accelerated the faecal microbiota to develop into 
a stable and diverse microbiota. Complex microbial association significantly affected, 
althought in different ways, the microbial composition and host gene expression in the 
jejunum and ileum.  
After the first introduction of solid foods to infants and young animals, the diet becomes a 
major factor that shapes the composition and activity of the intestinal microbiota. Dietary 
components can have a large influence on microbiota especially in the large intestine, due 
to the fact that they escape absorption in the small intestine, entering the large intestine as 
substrates for microbial fermentation and transformation. Resistant starch is an example of 
such feed components that can be used by bacteria in the large intestine to produce mainly 
short chain fatty acids (SCFA). The effects of RS on intestinal microbiota of pigs are 
described in Chapter 6. Pigs were either assigned to an RS diet or a digestible starch (DS) 
diet for two weeks. Intestinal samples from along the intestine were collected for measuring 
luminal microbiota composition, luminal SCFA concentrations and the expression of host 
genes involved in SCFA uptake, SCFA signalling, and satiety regulation in mucosal tissue. 
In both the caecum and colon, differences in microbiota composition and SCFA 
concentrations were observed between DS- and RS-fed pigs. Caecal tissue expression of 
genes encoding monocarboxylate transporter 1 (SLC16A1) and glucagon (GCG) was 
induced by RS. Based on these results, an additional experiment was performed as 
described in Chapter 7 to identify genes the expression of which is affected by RS in the 
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proximal colon to infer which biological pathways were modulated. Ten pigs, fitted with a 
cannula in the proximal colon for repeated collection of tissue biopsies and luminal content, 
were fed a digestible starch (DS) diet, or a diet high in RS (34%) for two consecutive 
periods of 14 days in a crossover design. This study revealed that upon RS feeding, 
oxidative metabolic pathways, such as TCA cycle and beta-oxidation, were induced 
whereas many immune response pathways, including adaptive and innate immune system, 
as well as cell division were suppressed. The nuclear receptor PPARG was identified as a 
potential key upstream regulator.  
Finally, the general discussion (Chapter 8) summarizes and discusses the results of the 
work described in this thesis, relating them with the latest findings in the field, with 
emphasis on the different directions towards which the gut microbiota evolves under the 
effect of different external factors. Furthermore, this chapter provides an outlook and future 
perspectives with respect to the relevance and implementation of microbial function-related 
approaches, notably functional (meta) genomics, and their integration with host-derived 
data to arrive at innovative avenues towards description and prediction of development and 
functioning of the host microbe holo-organism using holistic systems biology approaches.
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Abstract 
The gastrointestinal (GI) tract of humans and animals is colonized by microorganisms 
immediately after birth. The composition of the GI tract microbiota undergoes remarkable 
alterations during early age, reaches a relative stable status in adulthood, and is driven by 
external factors such as habitual diet, location along the intestine, antibiotic therapy and 
maternal microbiota, and intrinsic factors such as host species and genotype. Whereas 
usually faecal samples are used for assessing the impact on the microbiota in human 
intervention studies, in vitro and animal models provide an easier way to collect many 
(invasive) samples, have multiple comparisons and regulating the genotype background. 
Animal models, and in particular mammalian models, provide an alternative way to study 
the in vivo responses to beneficial, commensal and pathogenic microorganisms in the GI 
tract, including studies that aim to see the impact of the host system as well. The main 
animals used to study the mammalian GI tract are rodents (mainly mice and rats) and pigs. 
Rodent and pig models, including gnotobiotic and humanized rodents and pigs and 
minipigs, have been extensively employed in gut microbiota studies, and especially the 
piglet model has been suggested as an appropriate model for human infant studies. With pig 
models, several intestinal sampling techniques can be applied in kinetic microbiota studies, 
including small intestinal segment perfusion and cannulation. In many cases, to test a 
certain treatment, a tiered approach consisting of complementary methods is employed, 
comprising in vitro, in vivo animal models, eventually leading towards human intervention 
studies. 
Key words: Microbiota, Pig, Mice, Rats, Gastrointestinal tract, Model  
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Introduction 
From birth onwards the gastrointestinal (GI) tract of humans and animals is colonized by 
microorganisms that constitute a community or ecosystem known as the microbiota. These 
microorganisms, predominantly from the bacterial kingdom, but also including archaea and 
eukaryotes such as fungi and protozoa, can reach a diversity of at least 160 species per 
individual, and over 1150 different species were detected in the human gut [99, 106, 107]. 
This complex ecosystem increases in numbers throughout the length of the GI tract, from 
10 to 1000 cells per ml in the stomach, reaching a density of 1011 cells per gram of 
intestinal content [108, 109] in the large intestine.  All three domains of life are present in 
the large intestine where the bacterial community is dominant as well as the most 
phylogenetically diverse. At least nine different bacterial phyla have been detected in the 
large intestine, among which the phyla Bacteroidetes and Firmicutes dominate [12, 99, 110]. 
So far, only a minority of the bacteria in the gut have been cultured. Nonetheless molecular 
techniques that have emerged over the last two decades provided the opportunity to 
understand this complex GI tract ecosystem much better [99, 105, 111, 112]. The microbial 
ecosystem differs in the anatomically distinct regions in the intestinal tract, which has been 
reviewed elsewhere [109].  
The composition of the intestinal microbiota is driven by external factors such as habitual 
diet, antibiotic therapy and maternal microbiota, and intrinsic factors such as host species 
and genotype [113-118]. Since the intestinal tract is the main point of contact of the host 
immune system and microorganisms, the role of microbiota in both local and systemic 
immune function plays an important role in immunity and health [119].  
Locations and their conditions along the GI tract 
pH, transit time and microbial density are just a few of the many factors that are changing 
along the GI-tract. These differences need to be considered during experiments. 
Oral cavity 
When food is chewed in the mouth, it will be broken into pieces, moisturized and mixed 
with digestive enzymes – amylases and lipases – from the salivary glands of the host [108]. 
The most common bacteria found in the mouth are species of the genera Gemella, 
Granalucatella, Streptococcus and Veillonella [108, 120]. Furthermore, additional niches 
exist in the oral cavity, such as supra- and subgingival plaque, which are densely populated 
by a large number of different microorganisms, the diversity of which can be similar to that 
of the intestinal tract [121, 122]. 
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Stomach 
The low pH of 1-2 in the stomach is too acidic for most microorganisms to survive. Until 
30 years ago, it was considered to be a barrier for microorganisms, especially pathogens, to 
enter the body and survive [123, 124]. However, in 1984, Barry Marshall and Robin Warren 
isolated a gastric bacterium, which was thought to be linked to gastritis. Later on this 
bacterium was named Helicobacter pylori and is now known to be present in 50% of 
human beings, whereas only a minority shows gastritis [24]. Besides the understanding of 
H. pylori’s survival and maintenance in the stomach, not much is known about other 
species that dwell in the stomach. Bik et al. [123] found 128 phylotypes from 8 bacterial 
phyla present in the stomach. This diversity was much higher than expected thus far. 
Moreover, 50% of the phylotypes were assigned to uncultivated bacteria, and of these 67% 
were described earlier as bacteria from the mouth. Nevertheless, it remains a question 
whether these bacteria dwell in the stomach and whether they have adapted to different 
environments – mouth and stomach. To collect gastric fluid or mucosal tissue, a nasogastric 
or orogastric catheter can be used, which enters via the nose or mouth, respectively, and 
passes the esophagus to enter the stomach. 
Small Intestine 
The small intestine is considered the first region of the gastrointestinal tract where food 
meets the microbiota. It can be subdivided into the duodenum, jejunum and ileum. This 
region of the GI tract is hard to access compared to the mouth and large intestine and 
therefore less well studied. The small intestine can be sampled (like the stomach) by using 
an intraluminal nasogastric or orogastric catheter,  that passes the stomach and part of the 
small intestine depending on the region where the sampling will occur by peristalsis [105, 
125, 126]. The location can be determined using short-interval fluoroscopic control and 
calculating the distance from the pylorus to the tip [112, 125]. This method provides an 
indication of in which region the catheter is situated. However, due to considerable 
differences in the length of the small intestine in different individuals, the precise location 
cannot be determined. As an alternative, ileostomy subjects provide easier access to small 
intestinal content, and recently allowed detailed insight into structure and function of small 
intestinal bacterial communities [105, 125, 127]. These individuals have their colon 
removed, and the end of the ileum is surgically attached to an abdominal stoma. Despite not 
having a colon, ileostomized individuals can have a healthy life, and it could be shown by 
above-mentioned studies that they provide a suitable in vivo model system that enables 
analysis of the proximal small intestinal microbiota, rather than the ileum.  
The microbial diversity in the small intestine is higher than in the stomach, but smaller than 
that found in the large intestine. The proximal small intestine is enriched with Clostridium 
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spp., Streptococcus spp. and Veillonella spp. [126]. In turn, the ileum shows a community 
dominated by Bacteroidetes and Clostridium cluster XIVa and is more similar to the 
ecosystem of the large intestine [105, 125, 127].  
In addition to the possibilities outlined above, autonomous, ingestible intestinal sampling 
devices are being developed (e.g. http://www.micropharma.net), which would allow direct 
and programmed sampling of luminal as well as mucosal samples from predefined 
locations along the entire GI tract. 
Large intestine 
The large intestine can be subdivided into subparts: cecum, proximal, transversal and distal 
colon [109]. This region is densely populated by microbiota, the number of which can 
exceed 1011 cells per gram content. The richness is large and reaches up to 160 bacterial 
species per individual [106], of which 90% belong to the Bacteroidetes and  the 
Firmicutes [128]. 
The transit time of the intestinal content through the large intestine is much longer than in 
the other regions of the intestinal tract. Here the more complex food ingredients remain at 
the end of the GI tract as the sole energy source for the microbiota. Undigested 
carbohydrates and some fraction of proteins are converted into a broad range of metabolites, 
of which short chain fatty acids (SCFA), including acetate, propionate and butyrate, are the 
most abundant. In turn, these metabolites are used by the host as an energy source. This 
area of the GI tract is almost entirely anaerobic, and many bacteria that inhabit this part of 
the intestine are (obligate) anaerobic bacteria. 
To study the large intestine, usually fresh faeces are collected and analysed. However, the 
microbial community of faeces is quite different from that residing in the proximal large 
intestine [129]. This part still contains a lot of substrate for microbial growth, 
concentrations of which decrease towards the distal colon. Additionally, the obligate 
anaerobic species are much less prevalent in faeces than in the proximal large intestine 
[129]. To obtain samples from the large intestine colonoscopy can be used. However, to 
actually enter with a colonscope into the colon, patients need to take sedatives and be sober 
in the last hours. More importantly, in case colonoscopy is performed with prior bowel 
cleansing, the obtained picture on the remaining microbiota will be affected, although it 
should be noted that it has recently been shown that colonoscopy doesn’t have a lasting 
effect on fecal microbiota composition [130]. Another option is to perform surgery on the 
patients in the large intestine; a more in depth review on sampling the large intestine is 
provided by Ouwehand & Vaughan [131]. Ingestible sampling devices such as those 
mentioned above might provide new possibilities also for undisturbed assessment of the 
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proximal colon. 
Models of the gut 
As described in the previous section, studying the different locations along the GI tract 
currently requires rather invasive sampling methods, however, invasive sampling from 
large numbers of healthy individuals is not feasible for practical and ethical reasons. In vitro 
and animal models provide an easier way to collect many (invasive) samples, have multiple 
comparisons and regulating the genotype background. 
In vitro models 
Solutions to the challenges explained above for in vivo studies can be the use of in vitro 
models, where a broad range of parameters can be measured during microbial fermentation. 
The in vitro models used to study the gut microbiota can be classified in batch fermentation 
models, continuous culture models and the TNO Intestinal Models (TIMs). The set-up and 
application of these different types of models has been extensively reviewed [132, 133]. In 
vitro models are usually inoculated with fecal samples. The fecal sample of an individual 
can be used in multiple comparisons at the same time, taking care that the different 
comparisons in the model are all originating from the same individual with the same 
genotype. By replicating particular conditions found in localized regions of the intestine, 
the gut microbiota in these models usually shifts to a microbial community more 
comparable to the corresponding intestinal region, validating to an extent the biological 
representativeness and value of the model. 
In vitro fermentation models are mainly used to study the adaptation of the microbiota and 
the degradation of food or food ingredients [93, 134]. In the continuous culture and TIM 
models, probiotics are also tested by researchers to study their effects on the community 
and the washout time for these bacteria [135, 136]. Moreover by using membranes and 
filters, metabolites that are usually taken up by the host can be monitored during the 
fermentation process. However, mucus associated bacteria will not be present in these 
models. For this reason the M-SHIME was developed, where mucin-covered microcosms 
are introduced in the original SHIME model [137]. Probiotics can now be better studied in 
the M-SHIME model with respect to their adhesion to the mucosal layer and their 
colonization.  
Animal models 
In general, in vitro models do not allow researchers to study interactions between the host 
and the microbiota. Animal models and in particular mammalian models provide an 
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alternative way to study the in vivo responses to beneficial, commensal and pathogenic 
microorganisms in the GI tract. The main animals used to study the mammalian GI tract are 
rodents and pigs. Below we will discuss how they are used. However, to translate the 
knowledge gained from animal studies to the human situation, differences in physiology 
(see Table 1 and Figure 1) and behavior between animals and humans concerning their GI 
tract need to be considered [109, 138, 139].  
Table 1. pH of the GI tract of humans, pigs and rodents [109, 138, 139]. 
pH Human Rat  Pig 
Stomach 
Small intestine 
Large intestine 
1.0-4.4 
5.5-7.5 
5.9-7.0 
3.3-5.1 
6.5-7.1 
6.6-7.4 
2.2-4.3 
6.0-7.5 
6.3-7.1 
Rodents 
Conventional microbiota rodents 
Rodents are often used to study the GI tract and relate this back to the human situation. 
These animals are relatively small, easy to keep and well known models to study drugs for 
humans. Like humans, the two main bacterial phyla of the rodent GI tract microbiota are 
the Bacteroidetes and the Firmicutes. Nevertheless, there are some differences in 
microbiota composition. For example, in mice bifidobacteria are present, but in lower 
abundance than in humans. Additionally, in mice, the phylum Fusobacteria is lacking, while 
presence of Deferribacteres and Gemmatimonadetes has been reported [117].  The mouse 
forestomach is colonized by a biofilm of Lactobacillus reuteri, and murine strains of this 
species are different from those found in humans that produce a vitamin B12 metabolosome 
[140]. Furthermore mice harbor segmented filamentous bacteria, related to clostridia, that 
have a profound effect on the maturation of the innate immune system but have been 
thought to be lacking in humans [141-143]. It should be noted that distinct populations of 
SFB have now also been shown in human infants during the first three years of life, even 
though no functional studies have yet been performed that would support a similar role in 
immune maturation as for their murine counterparts [144]. 
The microbiota composition in rodents is usually analyzed when diet-microbiota-host 
interactions are studied. To this end, rodents are usually on or shifted to a specific diet. 
After a certain time, animals are sacrificed in order to collect a range of different samples. 
For the purpose of microbiota analysis, in general two types of samples are collected from 
different locations along the GI tract, namely intestinal content as well as mucosal 
scrapings. The latter method allows recovery of the epithelial cell layer from the intestinal 
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tissue, and samples can be used to extract RNA for the analysis of host responses or to 
extract RNA or DNA to analyze the mucus associated microbiota. 
                                 
There are a large number of different strains of mice and rats available. For example, 
C57Bl/6 mice are generally used in studies related to diet-induced obesity, type 2 diabetes 
and atherosclerosis [100, 128]. Turnbaugh and co-authors [145], for example, showed that 
gut microbiota of obese mice have a more efficient fermentation then lean mice. This 
fermentation resulted in a higher energy yield for the obese mice then lean mice with the 
same food. Moreover the obese gut microbiota, with the corresponding phenotypes, could 
be transferred to germ-free mice.  
The choice of an animal model with a certain phenotype, is based on strains that have or are 
sensitive to this phenotype. For less obvious phenotypes, like response to a change of food 
ingredients, the choice is more likely to be made for practical reasons, including e.g. the 
Figure 1B. Gross anatomy of the 
rat GI tract.  
Figure 1C. Gross anatomy of the 
pig GI tract. 
Figure 1A. Gross anatomy of the 
human GI tract. 
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animals are already bred in the facility, they are commercially available, or there is in-house 
experience with a given strain. However, recent studies have shown that environment and 
genetic background of mice have a significant impact on the microbial composition [146], 
and this must be taken into account when experiments are designed that compare to or 
proceed from previous data.  
Next to these factors, behavioral aspects like eating patterns and coprophagy of rodents 
need to be considered when setting up experiments, as well as during the experiment itself. 
Rodents are usually eating around the clock, and have therefore always food in their system 
along the GI tract. Next to that they practise coprophagy – eating their own faeces, or that 
of their cage partners – which allows them to extract more nutrients from the food [147]. 
Also in terms of energy excretion coprophagy can have an impact, since the faeces that is 
eaten contains more water and nitrogen then normal faeces [148]. However, when studying 
the short-term effects of food intervention studies this can give a negative effect, unless at 
the start of intervention the faeces are removed.  
Germ-free animals 
Preferred animals for germ-free and gnotobiotic studies are mice. These animals are used 
for several purposes that include: to study the effect of colonization with one single 
bacterial species, a consortium of defined bacterial species or de novo colonization with a 
complex microbiota from animals with a specific genotypic and/or phenotypic background, 
or from other host species including humans. During conventionalization in mice it takes 
more than a week for the microbial community to stabilize, which needs to be taken into 
account in the experimental design [22]. Turnbaugh et al. [149] showed that transferring the 
microbiota of obese or lean mice into germ free mice resulted in a greater adiposity in those 
animals that received the faeces from obese mice. Another recent example of transferring a 
phenotype with its microbiota is the ability to transfer the production of testosterone from 
male mice to female mice. The female mice had higher testosterone levels when they 
received male microbiota via gavage [150]. 
Humanized rodents 
Rats and mice that are born germ-free can be colonized by a slurry of human faeces, often 
referred to as “humanization” [151]. Although the difference in physiology can have an 
effect on the colonization of the human microbiota, these humanized animals are valuable 
models to study the human microbiota, and can provide information on the interaction 
between food ingredients, the human microbiota and the host. The microbial shifts 
occurring in these models due to a certain treatment are likely to take place in humans as 
well [152]. For instance, the microbiota of human twins discordant for obesity was studied 
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in mice, where the impact of the microbiota was linked with the phenotype of the human 
donor [132]. They could furthermore show that specific dietary changes could affect the 
original phenotypes concomitant with alterations in composition and activity of the 
microbial community. 
Pigs 
Pig is an important livestock for human because of their meat production. Therefore, these 
animals are studied intensively by researchers with the objective of production optimization. 
In recent years, many studies have focused on the GI tract of pigs, because manipulation of 
the gut microbiota can be used as an alternative of feeding antibiotics to improve pig health 
and growth. Additionally, pigs are scientifically important as a result of their high 
similarities to human beings in physiology, anatomy and nutrition [153-155]. It makes these 
animals essential as models for human GI tract studies.  
Humanized pigs 
The model of human flora-associated piglets (HFAP) was established by Pang et al. [156] 
through orally inoculating a whole fecal suspension of a healthy 10-year-old boy to 
cesarean section derived piglets that were raised in specific-pathogen-free (SPF) conditions. 
Culture-independent analysis showed that transplantation of human gut microbiota 
produced a donor-like microbial community in piglet gut with minimal individual variation, 
and the succession with aging of piglets was similar to that observed in humans. As in 
humans, the introduction of solid food during weaning altered the gut microbial community, 
resulting in a decrease in bifidobacteria. This change suggested the HFAP may share 
similarities with human in the process of microbial colonization, and implied the HFAP 
could be an attractive model to explore the effect of dietary factors on human gut 
microbiota. Subsequently, the HFAP model was successfully employed in prebiotic study. 
In order to assess the effects of short-chain fructo-oligosaccharides (scFOS) on gut 
microbiota, Shen et al. [157] applied this model and confirmed the bifidogenic property of 
scFOS. They found that the genus Bifidobacterium was stimulated consistently except 
during weaning, however, the effect of scFOS on non-bifidobacterial species varied at 
different developmental stages of the animals.  
Gnotobiotic pigs 
Gnotobiotic pigs have been used to study various human GI tract pathogens, such as 
Helicobacter pylori [158]. Recently, gnotobiotic pigs have been used as an animal model to 
study the microbial colonization during early life. Laycock et al. [159] used the Altered 
Schaedler Flora (ASF), a murine intestinal microbiota and a new “Bristol” microbiota 
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containing Lactobacillus amylovorus DSM 16698T, Clostridium glycolicum and 
Parabacteroides sp (ASF519), to colonize caesarean-derived gnotobiotic pigs prior to their 
gut closure. The ASF inoculation resulted in unreliable colonization with most (but not all) 
strains of the ASF. In contrast, the Bristol microbiota reliably colonized the length of the 
intestinal tract of gnotobiotic piglets. This microbiota can be used to study the 
consequences of early microbial colonization on development of the intestinal mucosa and 
immune system, on later colonization by a complex microbiota, and on subsequent 
susceptibility to disease. 
Minipigs 
Minipigs are proposed to be good animal models for studying obesity [160-162]. Pedersen 
et al. [163] investigated the composition of gut microbiota in relation to diet, obesity and 
metabolic syndrome in two pig models, Göttingen and Ossabaw minipigs. They found that 
diet seems to be the defining factor that shapes the gut microbiota as observed by changes 
in different bacteria divisions between lean and obese minipigs. In the cecum, the lean 
Göttingen minipigs’ had significantly higher abundance of Firmicutes, Akkermansia, and 
Methanobrevibacter, while obese Göttingen had higher abundances of the phyla 
Spirochaetes, Tenericutes, Verrucomicrobia and the genus Bacteroides. With respect to the 
Ossabaw minipigs, the obese minipigs had a higher abundance of Firmicutes in terminal 
ileum and lower abundance of Bacteroidetes in colon compared with lean minipigs. Overall, 
the Göttingen and Ossabaw minipigs displayed different microbial communities in response 
to diet-induced obesity in the different sections of their intestine. This funding also 
reinforced the notion that the host genotype has to be taken into account when studying the 
links between microbiota, diet and phenotype.  
Piglet model for infant nutrition and development 
The piglet has been used extensively in infant nutrition researches. It has been suggested as 
an appropriate model for human infant because of similarities between piglet and infant in 
anatomy, physiology and gastrointestinal tract metabolism [153, 154, 164-167]. Moreover, 
piglet models have also been employed to evaluate the intestinal microbiota of neonates, 
and preterm and term infants. Development of the intestinal microbiota in neonates and 
infants is characterized by rapid and extensive changes in microbial abundance, diversity, 
and composition. These changes are influenced by medical, cultural, and environmental 
factors such as delivery mode, diet, familial environment, diseases, and therapies [9]. To 
study the effects of these factors, different piglet models have been developed. These piglet 
models allow us to generate more information of the dynamics of microbial colonization 
and its profound influence on intestinal and systemic health throughout life.    
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Piglet model for investigating effects of environmental microbial association on gut 
microbiota  
To study the effects of environmental association with microbiota on gut health and 
development in the postnatal period, a model of caesarean derived piglets was designed by 
Jansman et al. [168]. In this model, piglets were obtained by caesarean delivery and were 
equally divided over two treatment groups that were housed in SPF conditions. All piglets 
received orally the above-mentioned Bristol microbiota consisting of Lactobacillus 
amylovorus, Clostridium glycolicum, and Parabacteroides sp. ASF519 on days 1, 2, and 3 
after birth. On day 3 and 4 the piglets received either a complex microbiota by providing 
them with a fecal inoculant of an adult sow (complex association group) or a placebo 
inoculant (simple association group). By using 16S rRNA gene targeted microarray-based 
microbiota profiling method, they found fecal microbiota composition was less diverse in 
the simple association group than the complex association group. The differences of 
microbiota between treatments persisted for at least three weeks after birth. 
Furthermore, other studies revealed that the immediate environment during postnatal 
development has long-term impact on gut community structure in pigs [51]. To investigate 
the extent to which early-life environment impacts on microbial diversity of the adult gut, 
Mulder and colleagues established a model with genetically-related piglets, which were 
housed in either indoor or outdoor environments or in experimental isolators [52]. Analysis 
of over 3,000 16S rRNA sequences revealed major differences in mucosa-adherent 
microbial diversity in the ileum of adult pigs attributable to differences in early-life 
environment. Pigs housed in a natural outdoor environment showed a dominance of 
Firmicutes, in particular Lactobacillus, whereas pigs housed in a hygienic indoor 
environment had reduced Lactobacillus abundance and higher numbers of potentially 
pathogenic phylotypes. This result revealed a strong negative correlation between the 
abundance of Firmicutes and pathogenic bacterial populations in the gut, and the microbial 
composition differences were exaggerated in animals housed in experimental isolators. This 
study demonstrated strong influences of early-life environment on gut microbiota 
composition in adult pigs, leading to a follow-up study on the impact of limiting microbial 
exposure during early life on the development of the gut microbiota [169]. In the following 
study, the outdoor- and indoor-reared piglets, exposed to the microbiota in their natural 
rearing environment for the first two days of life, were transferred to an isolator facility; 
and the gut microbial diversity of adult pigs was analyzed by 16S rRNA gene sequencing. 
Although the initial maternal and environmental microbial inoculum of isolator-reared 
animals was identical to that of their naturally-reared littermates, the microbial succession 
and stabilization events reported previously in naturally-reared outdoor animals did not 
occur. In contrast, the gut microbiota of isolator-reared animals remained highly diverse 
containing a large number of distinct phylotypes. These results indicated that establishment 
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and maturation of the normal gut microbiota requires continuous microbial exposure during 
the early stages of life, and this process is compromised under conditions of excessive 
hygiene.  
Piglet model for studying gut microbiota in diseases  
For preterm neonates, one of the most serious diseases is the GI inflammatory disorder 
necrotizing enterocolitis (NEC). The development of this disease includes the interplay of 
nutritional, microbial and immunological determinants. For independent studies of each 
determinant under clinically relevant conditions, the preterm piglet has been utilized in 
virtue of its beneficial characteristics compared to other animal models [170]. With preterm 
piglets, Sangild et al. [171] found that NEC pigs showed bacterial overgrowth and a high 
mucosal density of C. perfringens in some but not all animals, however mucosal microbial 
diversity of healthy pigs remained low and independent of diet. This finding was further 
confirmed by Cilieborg et al. [172]; their study showed a different microbiota with high C. 
perfringens abundance in preterm pigs with NEC compared with healthy individuals. 
However, the C. perfringens inoculation failed to induce NEC. This indicated that C. 
perfringens is more abundant in pigs with NEC but rather as a consequence than a cause of 
disease. In addition to the above studies, Azcarate-Peril et al. [173] have used a unique 
preterm piglet model to characterize spontaneous differences in microbiome composition of 
NEC-predisposed regions of the gut. Their study provided strong support for ileal mucosa 
as a focus for investigation of specific dysbiosis associated with NEC and suggested a 
significant role for Clostridium spp., and members of the Actinobacteria and Cyanobacteria 
in the pathogenesis of NEC. 
The short bowel syndrome (SBS) piglet model is another application of the piglet model for 
studying gut microbiota in diseases. The development of a successful SBS model in 
neonatal piglets provides a possibility for characterizing the colonic microbiota following 
small bowel resection (SBR). By using 4-week old female piglets that received a 75% SBR, 
Lapthorne et al. [174] found a significant level of dysbiosis both two and six weeks 
post-SBR, particularly in the phylum Firmicutes, coupled with a decrease in overall 
bacterial diversity in the colon.  
Sampling techniques with pig models in kinetic microbiota studies 
Small intestinal segment perfusion technique with pig models  
The Small intestinal segment perfusion (SISP) technique was developed to study the effects 
of bacteria on net absorption of fluid and electrolytes, as a more comprehensive and ethical 
alternative to the ligated loop test in pig models [175]. Recently, this technique has been 
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widely applied to study enterotoxigenic Escherichia coli infection [176, 177], Salmonella 
typhimurium invasion [178, 179], and mannose-specific interaction of Lactobacillus 
plantarum with jejunal epithelium [180]. Furthermore, SISP can be applied in future 
research to investigate the functional physiological response of probiotics and the crosstalk 
between probiotics and the host [181]. In the SISP test, pigs are sedated with azaperone, 
induced with inhalation anaesthesia and maintained with sevoflurane and nitrous oxide. For 
pig small intestine, five pairs of segments are prepared and each segment is 20 cm long 
with inlet tubes at the cranial side and outlet tubes at the caudal side. The segments can be 
used to study up to 10 perfused ingredients within one pig. All 10 segments are perfused 
simultaneously either by an infusion system or manually with syringes attached to the 
cranial tubes for up to 10 hours. Effluent fluid during perfusion and mucosal scraping can 
be sampled for microbial analysis from each segment.  
Cannulation technique with pig models 
Cannulation is one of the most frequently applied methods for repeated sampling of digesta 
from pig gut. Different cannulation techniques, such as simple T-cannula, post-valvular 
T-cecum cannulation and steered ileocecal valve cannulation, can be employed based on the 
specific research purpose. Among these cannulation techniques, the simple T-cannula is 
widely used for evaluating the microbial composition and function in the ileum. A simple T- 
cannula is normally inserted 10 to 20 cm anterior to the ileo-cecal valve. It does not transect 
the small intestine wall, and can maintain a normal physiological state of the intestine [182]. 
Currently, surgical procedures for inserting a T-cannula and sampling methods have been 
established for young pigs [183, 184], growing pigs [185, 186] and pregnant sows [187].  
Conclusion 
Studying the human GI tract can be done with a wide range of methods and technical 
approaches. Even though each of the methods that we described here have advantages and 
disadvantages, usually human faeces are used for assessing the impact on the microbiota in 
intervention studies, whereas animal models are used for more detailed mechanistic studies, 
including those that aim to see the impact of the host system as well. Nowadays mainly 
rodents are used to study the human GI tract, while pigs show promising and maybe better 
comparison to the human GI tract. Since the optimal system is not yet established, generally 
to test a certain treatment a combination of methods is used, first in vitro, then in vivo in an 
animal model, ending up with a human intervention study. 
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Abstract 
Amoxicillin is a commonly used antibiotic to control infections of pregnant women in the 
hospital, and in reproduction and growing animals on a farm. However, it is unclear to what 
extent the maternal antibiotic treatment affects intestinal microbiota development and gut 
health in the offspring. Using a pig model, two groups of five sows each were defined as 
control and antibiotic group, respectively. In the antibiotic group, sows were given 
amoxicillin orally at a daily dosage of 40 mg/kg body weight during 10 days before and 21 
days after parturition. The sows’ offspring (piglets) were sacrificed at 14, 21, 28 (weaning) 
and 42 days after birth. The microbial composition of sows’ faeces and piglets’ ileal and 
colonic content was analyzed by using the Pig Intestinal Tract Chip (PITChip). The results 
indicated that amoxicillin treatment drastically impacted the sows’ faecal microbiota, and 
caused a decrease in relative abundance of bacteria related to the genera Lactobacillus, 
Staphylococcus and Streptococcus. Maternal amoxicillin treatment furthermore influenced 
the gut microbiota of the piglets. Especially in the ileum, maternal amoxicillin led to 
increased relative abundance of Proteobacteria during amoxicillin administration (at day 14 
and 21), mainly driven by a stimulation of Escherichia coli and Pseudomonas. Interestingly, 
most microbial groups that were affected in faeces of amoxicillin-treated sows showed an 
opposite trend in the ileal content of their offspring. Nevertheless, a significantly higher 
similarity of microbial composition was detected between the faeces of amoxicillin-treated 
sows and ileal content of their offspring compared with the control sows and piglets. Our 
findings indicate that maternal amoxicillin treatment indirectly affects the gut microbiota of 
offspring through disturbing the maternal microbiota and the transfer of maternal 
microbiota to offspring.  
Keywords: Maternal antibiotic treatment, Amoxicillin, Gut, Microbiota, Piglet, Sow, 
Offspring 
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Introduction  
Microbiota colonizing the intestinal tract around birth plays an important role in human and 
animal health. Establishment of microbiota at early age is instrumental in regulating and 
fine-tuning the immune system throughout life [20], and is also suspected to be associated 
with certain diseases such as obesity and inflammatory bowel disease later in life [3, 
188-190]. Establishment of gut microbiota of humans and animals can be influenced by a 
number of perinatal factors, including, most importantly, the maternal microbiota. 
Accumulating evidence suggests that the microbial contact of the offspring with their 
mothers may begin already prior to birth [5, 7, 27], and after birth, gut-associated bacteria 
can still be vertically transferred from mother to neonate via breastfeeding [191]. Thus, 
disturbances of maternal microbiota may influence the transfer of maternal microbiota from 
mother to her offspring, which may causally influence the gut microbiota development and 
the intestinal health of offspring throughout life.  
Antibiotics have been commonly used to control infections of pregnant women in hospitals 
and in reproduction and growing animals on farms. Antibiotic treatment of mothers can 
impact fetal development and associates with low birth weight of neonates and high risk of 
diseases such as allergy, metabolic syndrome, and obesity at early age [39, 192]. Recently, 
researchers also found that antibiotic use during pregnancy altered the commensal vaginal 
microbiota of women [40]. Intrapartum antibiotic treatment of mothers was found 
associated with a decreased transmission of vaginal Lactobacillus to the neonate during 
birth [41]. Together, these results indicate that maternal antibiotic treatment may influence 
the gut microbial colonization of offspring through changing maternal microbiota 
composition. In addition, it is well known that maternal antibiotic residues can be 
transferred from mothers to their offspring via breastfeeding [193]. However, it is still 
unknown to which extent the maternal antibiotic residues affect the gut microbiota 
establishment of infants and young animals, and hence, studies should be directed at 
assessing the effect of maternal antibiotic treatment on the gut microbiota development of 
humans and animals at early age.  
In the present study, we evaluated the effect of maternal amoxicillin treatment on sow’s 
faecal microbiota and on the ileal and colonic microbiota of their offspring up to 42 days 
after birth. Amoxicillin is a broad-spectrum antibiotic widely used during pregnancy in 
humans [194], and also the most used antibiotic for treating mastitis and urinary tract 
infections of sows during pregnancy as well as after farrowing in livestock. Currently, most 
studies have only focused on the effect of maternal amoxicillin usage on foetal 
development and risk of disease at early age [39, 195]. Therefore, we developed a pig 
model in which the mothers received amoxicillin orally around parturition, and piglets were 
serially sacrificed for assessing gut microbiota development. The pig is regarded as an 
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appropriate model due to its similarities to humans with respect to GI anatomy, physiology, 
metabolism and immunity [153-155, 196]. Especially, piglets have been extensively used in 
infant nutrition research [164, 166, 167]. Moreover, the pig is an important livestock animal, 
and therefore researchers have studied piglets intensively in order to enhance their 
robustness and pork production through regulating the gut microbiota of piglets at early age 
[168, 197]. All together, the outcome of this study will be beneficial for both human infant 
research and livestock production.  
Material and methods 
Animals, feeding and sample collection 
The animal experiment was conducted as described by Arnal et al [197]. Briefly, twenty 
four crossbred (Large White x Landrace) sows were used in two successive batches, taking 
into account parity and resistance of selected faecal bacteria (Escherichia coli, 
Campylobacter spp., and Enterococcus spp.) to amoxicillin. Sows with 
amoxicillin-sensitive bacteria were assigned to the antibiotic group in priority. The 
remaining sows were assigned to the control group. For the antibiotic group, sows were 
orally given the broad spectrum antibiotic amoxicillin (40 mg/kg body weight, Vetrimoxin 
PO containing 10% amoxicillin; CEVA Santé Animale, Loudéac, France) in their morning 
meal (2 kg/day) daily from 10 days before the estimated farrowing date till 21 days after 
farrowing. Sows and offspring were fed balanced diets formulated to meet nutritional 
requirements [197]: sows were fed the gestating diet (3.5 kg/day) or the lactating diet (ad 
libitum) in two meals, and offspring had ad libitum access to pre-starter diet from weaning 
at 28 days till day 42. Due to delays between conducting batch 1 and batch 2, only data 
from batch 1 was included in this manuscript. To this end, five sows and their offspring 
were randomly selected from both groups in the first batch of pigs for microbial analysis. 
Offspring were sacrificed at the age of 14, 21, 28 (age of weaning), and 42 days. Ileal and 
colonic content were collected from offspring for analyzing the microbial composition. 
Faecal samples were also collected from the sows at the start of the antibiotic treatment and 
21 days after farrowing (the end of antibiotic treatment) for assessing amoxicillin effects on 
sows’ microbiota. 
Microbiota analysis 
The microbial composition of intestinal content of piglets and faeces of sows was analyzed 
using the Pig Intestinal Tract Chip (PITChip) version 1.0. The PITChip is a phylogenetic 
microarray, with more than 2,980 oligonucleotides based on 16S rRNA gene sequences of 
627 porcine intestinal microbial species-level phylotypes [97, 101]. The PITChip as well as 
the corresponding Human Intestinal Tract Chip (HITChip) [103], provide a very deep and 
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reproducible phylogenetic analysis that has been compared with deep pyrosequencing of 
16S rRNA gene fragments [97, 104, 105] and next generation parallel sequencing of 
intestinal metagenomes [106], indicating comparable resolution and a higher sensitivity of 
the chip based analysis at commonly used sequencing depth. The protocol for hybridization 
and analysis of the generated data was performed essentially as described before for the 
HITChip [103]. Briefly, microbial DNA was extracted from 250 mg of intestinal content of 
piglets and faeces of sows using a faecal DNA extraction protocol adapted from Yu and 
Morrison [198] as described by Salonen et al. [199]. Bacterial 16S rRNA gene was 
amplified using the primers T7 prom-Bact-27-for and Uni-1492-rev. PCR products were in 
vitro transcribed into RNA and the purified resultant RNA was coupled with CyDye prior to 
fragmentation and hybridization to the array. Microarray images were processed using 
Agilent's Feature Extraction Software version 9.1 (http://www.agilent.com). Data was 
retrieved from the MySQL (version 5.1) database as describe by Rajilic-Stojanovic [200] 
and pre-processed using the R (Rx64 2.12.2) microbiome package 
(http://microbiome.github.com/), settings on default.  
Statistical methods 
Principal response curve (PRC) analysis was applied to detect the microbial variation 
between control and amoxicillin-treated sows over time. PRC is based on redundancy 
analysis (RDA) adjusted for overall changes in community response over time, as described 
by Van den Brink and Braak [201]. PRC focuses on the time-dependent treatment effects 
and allows these effects to be quantitatively interpreted at the species level. For PRC, the 
principal component is plotted against time, yielding a principal response curve of the 
community for each treatment. In the present study, treatment classes control and 
amoxicillin treatment were introduced as environmental explanatory variables. Sampling 
times (beginning and end of amoxicillin treatment) were introduced as co-variables. The 
responsive variables were the relative contribution of 143 level-2 (approximate genus-level, 
90% 16S ribosomal RNA similarity threshold) phylogenetic groups targeted by the PITChip 
1.0. Monte Carlo permutation tests were performed to evaluate statistical significance of the 
effect of amoxicillin on sow’s and piglets’ microbiota. These tests were also performed per 
sampling time, allowing to test the significance of the effect of the treatment for each 
sampling time. 
Univariate testing was performed to detect which microbial groups were affected by 
maternal amoxicillin treatment in the ileal and colonic content of piglets at each sampling 
time by using a Mann-Whitney U signed rank test. P-values were corrected for multiple 
testing using Benjamini–Hochberg’s approach [202]. 
Level-2 phylogenetic groups (143 microbial groups) of the PITChip 1.0 were used to 
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calculate Spearman’s correlation coefficient of microbiota between each sow and its 
offspring. Spearman’s correlation coefficients between treated sows and their offspring 
were compared with Spearman’s correlation coefficients between control sows and their 
offspring by a Student’s t-test.  
Results 
Amoxicillin affected sows’ microbiota 
The composition of the sows’ faecal microbiota was analyzed using the PITChip 
phylogenetic microarray, and was found to be significantly affected by the amoxicillin 
treatment as demonstrated by Principal Response Curve (PRC) analysis (Fig. 1). While no 
significant differences in microbiota composition were found between control and 
antibiotic treated sows at the start of antibiotic treatment (P=0.24), a significant difference 
was found when comparing microbiota of control and treated sows at the end of antibiotic 
treatment (P=0.01). Level-2 (approximate genus level, 90% sequence similarity threshold) 
groups with high positive weight were decreased in relative abundance in the faeces of 
Lactobacillus acidophilus, Lactobacillus delbrueckii, Lactobacillus gasseri, Lactobacillus 
plantarum, Staphylococcus aureus, Streptococcus bovis, Streptococcus intermedius, 
Streptococcus suis, Clostridium difficile, Clostridium perfringens, Pseudomonas and 
Staphylococcus aureus. In contrast, bacterial groups with low negative weight increased  
 
Figure 1. Principal response curves indicating the effects of amoxicillin on faecal microbiota of sows at the 
beginning (beginning) and the end (End) of amoxicillin treatment. 
Of all variance, 10.2% is attributed to sampling date and displayed on the horizontal axis, 26.5% is attributed to 
treatment, and 63.3% was attributed to differences between piglets. Of the variance explained by treatment, 75.9 % 
is displayed on the vertical axis. The lines represent the course of the treatment levels over time.  
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Table 1. Amoxicillin affected microbial groups in the faeces of sows. 
Class Group 
Species 
weight1  
Beginning ARC2 End ARC3 
Control Amoxicillin Control Amoxicillin 
Bacteroidetes Alistipes et rel. -2.56  0.28±0.29 0.38±0.25 0.16±0.17 1.10±0.98 
 
Bacteroides distasonis et rel. -1.04  0.35±0.24 0.36±0.12 0.15±0.05 0.43±0.20 
 
Porphyromonas asaccharolytica 
et rel. 
2.22  0.44±0.19 0.90±0.55 1.09±0.46 0.33±0.23 
 
Prevotella melaninogenica et rel. -1.13  0.18±0.07 0.21±0.08 0.12±0.04 0.43±0.19 
 
Uncultured Bacteroidetes -2.19  0.39±0.35 0.44±0.23 0.07±0.03 0.76±0.58 
 
Uncultured Prevotella -3.47  2.13±1.75 2.50±0.71 0.84±0.35 2.97±1.45 
Fibrobacteres Fibrobacter succinogenes et rel. 2.51  0.57±0.13 1.03±0.40 1.26±0.47 0.34±0.15 
Bacilli Bacillus et rel. 1.01  2.14±0.57 1.47±0.56 2.73±0.62 2.00±0.41 
 
Lactobacillus acidophilus et rel. 1.37  0.45±0.30 0.27±0.10 0.46±0.15 0.10±0.04 
 
Lactobacillus delbrueckii et rel. 2.51  0.37±0.18 0.75±0.35 0.77±0.53 0.02±0.01 
 
Lactobacillus gasseri et rel. 7.00  2.41±1.22 4.63±2.83 4.27±2.82 0.04±0.04 
 
Lactobacillus plantarum et rel. 2.78  2.76±1.53 2.36±0.92 2.79±2.27 0.91±0.24 
 
Staphylococcus aureus et rel. 0.80  1.27±0.29 0.91±0.38 1.58±0.31 1.18±0.26 
 
Streptococcus bovis et rel. 1.15  1.12±1.46 0.77±0.66 0.64±0.35 0.27±0.11 
 
Streptococcus intermedius et rel. 0.83  0.54±0.81 0.27±0.19 0.30±0.18 0.09±0.10 
 
Streptococcus suis et rel. 1.47  1.37±2.27 0.59±0.43 0.71±0.37 0.25±0.27 
Clostridium 
cluster I 
Clostridium perfringens et rel. 1.18  5.10±2.21 2.91±1.40 7.59±2.37 5.66±1.94 
Clostridium 
cluster IV 
Faecalibacterium et rel. -0.93  0.88±0.19 1.40±0.93 0.88±0.34 1.28±0.29 
 
Faecalibacterium prausnitzii et 
rel. 
-0.85  2.14±0.22 2.89±1.07 1.95±0.32 2.52±0.19 
 
Ruminococcus callidus et rel -0.93  3.83±0.86 2.67±0.95 3.13±0.62 3.91±0.47 
 
Sporobacter termitidis et rel. -1.28  8.84±1.67 10.46±1.77 8.06±1.94 10.64±1.14 
Clostridium 
cluster IX 
Megasphaera elsdenii et rel. 0.84  0.24±0.20 0.13±0.08 0.23±0.29 0.01±0.02 
Clostridium 
cluster XI 
Clostridium difficile et rel. 1.31  3.06±1.53 2.07±1.25 4.25±1.06 3.02±1.07 
Clostridium 
cluster XIVa 
Lachnospira pectinoschiza et rel. -0.84  2.42±0.47 2.23±0.37 2.19±0.24 2.78±0.15 
Mollicutes Mycoplasma 2.61  0.47±0.18 1.07±0.33 1.04±0.48 0.19±0.10 
 
Solobacterium moorei et rel. -1.00  0.98±0.55 0.80±0.22 0.72±0.37 1.07±0.12 
Planctomycetacia Uncultured planctomycetacia -1.40  0.03±0.02 0.05±0.05 0.02±0.01 0.39±0.28 
Gammaproteobac
teria 
Actinobacillus et rel. -0.95  0.44±0.16 0.45±0.08 0.42±0.09 0.74±0.28 
?  Pseudomonas et rel. 1.01  1.26±0.30 0.94±0.41 1.54±0.25 1.05±0.22 
1 Species weight: the affinity of the microbial groups with the Principal Response Curves (PRC). Microbial groups with a high 
negative weight are inferred to show the opposite pattern, whereas microbial groups with near zero weight either show no response 
or a response that is unrelated to the pattern shown by the PRC. The higher the weight, the more the actual response pattern of 
microbial groups is likely to follow the pattern in the PRC. Microbial groups with a species weight between -0.8 and -0.8 are not 
shown. 
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2 Beginning ARC: Average relative contribution [%] of a microbial group at the beginning of amoxicillin treatment. Values 
represent means ± SDs.  
3 End ARC: Average relative contribution [%] of a microbial group at the end of amoxicillin treatment. Values represent means ± 
SDs. 
their relative abundance in the faeces of treated sows after antibiotic treatment, including 
bacteria related to Bacteroidetes and Clostridium cluster IV (Table 1). Despite the change 
in relative abundance of specific microbial groups, the antibiotic treatment did not 
significantly alter the microbial diversity as indicated by Shannon indices (P>0.05) 
(Supplemental Fig. 1). 
Maternal amoxicillin treatment affected ileal microbiota of offspring 
To identify microbial groups affected by maternal amoxicillin treatment, we used univariate 
testing to assess phylogenetic groups at both phylum and genus-like (level-2) level at each 
sampling day. At phylum level, the relative abundance of Firmicutes tended to decrease in 
the ileum of treated piglets at day 14 after birth, whereas the relative abundance of 
Proteobacteria tended to increase (Table 2). This increase was driven by bacteria related to 
level-2 groups belonging to the uncultured Deltaproteobacteria, E. coli and Pseudomonas 
(Table 3). Despite a decreasing trend of Firmicutes at the phylum level, bacteria related to 
the level-2 groups Bacillus, Lactobacillus acidophilus, Staphylococcus aureus and 
Subdoligranulum increased their relative abundance in the piglets born to 
amoxicillin-treated sows at day 14 after birth (Table 3). At day 21 after birth, the increasing 
trend of Proteobacteria at phylum level was still detected for the maternal 
amoxicillin-treated piglets. As on day 14, bacteria related to the level-2 groups 
Lactobacillus acidophilus, E. coli, Pseudomonas and Leptospira increased for the maternal 
amoxicillin-treated piglets at day 21 (Table 3).  
Table 2. Phylum-level phylogenetic groups with different abundance in the ileum of control and maternal 
amoxicillin treated piglets. 
?  
P value Effect1  
ARC2 (%) 
?  Control Amoxicillin 
Day 14 
Firmicutes 0.095  - 69.876±2.328 66.667±2.527 
Proteobacteria 0.095  + 16.938±1.476 20.208±2.770 
Day 21 
Proteobacteria 0.095  + 18.930±2.575 22.099±3.082 
Day 28 
Fusobacteria 0.032  - 0.361±0.114 0.223±0.044 
Spirochaetes 0.056  - 1.439±0.270 1.088±0.271 
1 Effect: indicates whether the average relative contribution of a phylum was increased (+) or decreased (-) in the ileum of maternal 
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amoxicillin treated piglets in comparison with control piglets. 
2 ARC: Average relative contribution [%] of a phylum. Values represent means ± SDs. The phyla with a relative abundance lower 
than 0.1% in all treatments are not shown.  
Table 3. Genus-level phylogenetic groups with different abundance in the ileum of control and maternal amoxicillin treated 
piglets.  
?  ?  ?  ?  ?  ARC3 
Class Group p value C.p1 Effect2 Control Amoxicillin 
Day 14 
Bacteroidetes Alistipes et rel. 0.056  0.955  - 0.028±0.010 0.021±0.008 
Bacilli Bacillus et rel. 0.095  0.955  + 2.180±0.349 2.539±0.615 
Lactobacillus acidophilus et rel. 0.032  0.955  + 1.023±0.734 2.352±0.652 
Staphylococcus aureus et rel. 0.095  0.955  + 1.367±0.135 1.623±0.269 
Clostridium cluster IV Subdoligranulum et rel. 0.095  0.955  + 0.565±0.187 0.851±0.314 
Clostridium cluster IX Megasphaera elsdenii et rel. 0.016  0.955  - 0.026±0.024 0.006±0.001 
Deltaproteobacteria Uncultured deltaproteobacteria 0.095  0.955  + 0.413±0.117 0.524±0.134 
Epsilonproteobacteria Helicobacter 0.095  0.955  - 0.172±0.248 0.069±0.088 
Gammaproteobacteria Escherichia coli et rel. 0.056  0.955  + 1.595±0.534 2.634±0.719 
Pseudomonas et rel. 0.095  0.955  + 1.287±0.374 1.817±0.506 
Spirochaetes Leptospira 0.056  0.955  + 0.500±0.098 0.658±0.108 
Day 21 
Actinobacteria Aeriscardovia et rel. 0.008  0.567  - 0.284±0.133 0.105±0.034 
Bifidobacterium 0.008  0.567  - 1.435±0.615 0.641±0.192 
Olsenella et rel. 0.016  0.567  - 0.062±0.069 0.012±0.006 
Bacilli Lactobacillus acidophilus et rel. 0.095  0.676  + 0.937±0.596 2.485±1.206 
Tetragenococcus 0.016  0.567  - 0.121±0.080 0.049±0.010 
Clostridium cluster I Clostridium perfringens et rel. 0.056  0.676  + 3.272±0.581 4.405±0.890 
Clostridium cluster IV Uncultured Clostridia IV 0.032  0.676  + 0.764±0.111 1.001±0.109 
Clostridium cluster XIII Peptoniphilus indolicus et rel. 0.056  0.676  + 0.210±0.033 0.295±0.068 
Clostridium cluster XIVa Clostridium hylemonae et rel. 0.095  0.676  + 0.037±0.007 0.050±0.012 
Clostridium sphenoides et rel. 0.056  0.676  + 0.112±0.019 0.151±0.032 
Clostridium cluster XVII Catenibacterium 0.032  0.676  - 1.322±1.024 0.478±0.192 
Alphaproteobacteria Labrys methylaminiphilus et rel. 0.095  0.676  + 2.311±0.66 2.803±0.430 
Epsilonproteobacteria Candidatus helicobacter 0.095  0.676  - 0.230±0.125 0.117±0.071 
Gammaproteobacteria Acitenobacter et rel. 0.095  0.676  + 0.321±0.066 0.453±0.110 
Escherichia coli et rel. 0.095  0.676  + 2.072±0.910 2.988±0.702 
Pseudomonas et rel. 0.056  0.676  + 1.363±0.266 2.140±0.609 
Spirochaetes Leptospira 0.095  0.676  + 0.490±0.144 0.699±0.156 
Day 28 
Actinobacteria Tonsillophilus 0.095  0.681  - 0.401±0.209 0.222±0.079 
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Bacteroidetes Bacteroides distasonis et rel. 0.095  0.681  - 0.089±0.029 0.055±0.008 
Bacteroides fragilis et rel. 0.056  0.681  - 0.021±0.004 0.015±0.002 
Bacteroides pyogenes et rel. 0.032  0.681  - 0.019±0.005 0.012±0.002 
Bacteroides vulgatus et rel. 0.032  0.681  - 0.011±0.002 0.007±0.001 
Paludibacter propionicigenes et rel. 0.056  0.681  - 0.011±0.002 0.008±0.001 
Porphyromonas asaccharolytica et rel. 0.095  0.681  + 0.696±0.607 1.079±0.683 
Prevotella melaninogenica et rel. 0.095  0.681  - 0.087±0.027 0.054±0.008 
Prevotella ruminicola et rel. 0.095  0.681  - 0.022±0.007 0.014±0.002 
Uncultured Bacteroidetes 0.056  0.681  - 0.029±0.005 0.023±0.003 
Uncultured Prevotella 0.095  0.681  - 0.521±0.168 0.316±0.052 
Flavobacteria Myroides odoratus et rel. 0.095  0.681  - 0.021±0.007 0.013±0.002 
Deferribacteres Mucispirillum schaedleri et rel. 0.056  0.681  - 0.010±0.002 0.007±0.001 
Clostridium cluster XI Clostridium difficile et rel. 0.095  0.681  - 4.796±1.780 2.370±0.707 
Clostridium cluster XVII Catenibacterium 0.056  0.681  - 0.487±0.151 0.330±0.040 
Mollicutes Mycoplasma 0.095  0.681  + 0.598±0.494 0.989±0.600 
Fusobacteria Fusobacterium 0.032  0.681  - 0.361±0.114 0.223±0.044 
Alphaproteobacteria Sphingomonas et rel. 0.016  0.681  - 0.038±0.014 0.017±0.004 
Gammaproteobacteria Uncultured Gammaproteobacteria 0.056  0.681  + 1.784±0.205 2.182±0.324 
Spirochaetes Treponema et rel. 0.032  0.681  - 0.537±0.199 0.208±0.081 
Day 42 
Actinobacteria Eggerthella et rel. 0.056  0.835  - 0.595±0.107 0.463±0.079 
Bacteroidetes Bacteroides fragilis et rel. 0.056  0.835  + 0.017±0.006 0.023±0.004 
Bacteroides vulgatus et rel. 0.056  0.835  + 0.008±0.003 0.012±0.002 
Paludibacter propionicigenes et rel. 0.095  0.835  + 0.008±0.003 0.011±0.002 
Sphingobacteria Uncultured Sphingobacteria 0.056  0.835  + 0.009±0.001 0.013±0.004 
Deferribacteres Mucispirillum schaedleri et rel. 0.095  0.835  + 0.008±0.003 0.011±0.002 
Bacilli Tetragenococcus 0.056  0.835  + 0.057±0.004 0.066±0.007 
Mollicutes Mycoplasma 0.056  0.835  - 0.407±0.276 0.183±0.072 
1 C.p: P value corrected for multiple testing according to the procedure of Benjamini-Hochberg 
2Effect: indicates whether the average relative contribution of a microbial group was increased (+) or decreased (-) in the ileum of 
maternal amoxicillin treated piglets in comparison with control piglets. 
3 ARC: Average relative contribution [%] of a microbial group. Values represent means ± SDs. The microbial groups with a relative 
abundance lower than 0.01% in all treatments are not shown. 
On the contrary, maternal amoxicillin treatment caused a reduction in relative abundance of 
bacteria related to the level-2 group Bifidobacterium in piglets sacrificed at day 21 after 
birth. At day 28 after birth, we detected a significant decrease of Fusobacteria and a 
decreasing trend of Spirochaetes at the phylum level, and bacteria related to 10 level-2 
groups within the class of Bacteroidetes decreased their relative abundance in the ileum of 
maternal amoxicillin-treated piglets. Interestingly, bacteria related to the level-2 groups of 
Bacteroides fragilis, Bacteroides vulgatus and Paludibacter propionicigenes showed an 
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opposite trend at day 42 in comparison with day 28 as their relative abundance increased in 
the ileal content of treated piglets at day 42. Similar opposing trends at day 42 compared 
with day 28 were observed for bacteria related to level-2 groups Mucispirillum schaedleri 
and Mycoplasma. Strikingly, most microbial groups that were affected both in faeces of 
amoxicillin-treated sows and ileal content of their offspring showed an opposite direction of 
change (Supplemental Table 1). 
The similarity of the microbiota was calculated between the faecal sample of each sow and 
the ileal samples of its offspring by using Spearman’s correlation coefficients. The 
amoxicillin-treated sows and their offspring showed a significantly higher similarity of their 
microbiota compared with the control sows and their offspring at all sampling dates 
(P<0.01, Fig. 2).  
 
Figure 2. Box plots of total microbiota profile similarity between piglets’ ileal content and sows’ faeces at day 14 
(D14), 21(D21), 28(D28) and 42(D42) after birth. Spearman’s correlation coefficient was calculated for each sow 
and its offspring. The average microbiota similarity between amoxicillin treated sows and their offspring are 
significantly higher than between control sows and their offspring at all sampling time (P<0.01). Capital letters “C” 
and “T” represent the control piglets and maternal amoxicillin treated piglets, respectively.   
 
  
Chapter 3 
54 
Table 4. Phylum-level phylogenetic groups with different relative abundance in the colon of control and maternal 
amoxicillin treated piglets. 
?  P value Effect1 
ARC2 
Control Amoxicillin  
Day 14     
Bacteroidetes 0.095  - 3.665±2.237 2.559±2.711 
Day 21     
Fibrobacteres 0.095  - 0.865±0.211 0.535±0.279 
Day 42     
Fusobacteria 0.095  + 0.218±0.076 0.279±0.099 
1 Effect: indicates whether the average relative contribution of a phylum was increased (+) or decreased (-) in the colon of maternal 
amoxicillin treated piglets in comparison with control piglets. 
2 ARC: Average relative contribution [%] of a phylum. Values represent means ± SDs. Phyla with a relative abundance lower than 
0.1% in all treatments are not shown.  
Table 5. Genus-level phylogenetic groups with different abundance in the colon of control and maternal 
amoxicillin treated piglets at day 14 after birth. 
Class Group P value C.p1 Effect2 
ARC3 
Control Amoxicillin 
Bacteroidetes Bacteroides fragilis et rel. 0.056  0.799  - 0.123±0.108 0.046±0.062 
Sphingobacteria Sphingobacterium thalpophilum et rel. 0.032  0.799  - 0.118±0.062 0.034±0.021 
Bacilli Streptococcus thoraltensis et rel. 0.056  0.799  + 0.038±0.008 0.060±0.028 
Clostridium cluster IV Ruminococcus bromii et rel. 0.095  0.799  - 0.158±0.075 0.073±0.05 
Clostridium cluster IX Veilonella 0.095  0.799  + 0.073±0.009 0.103±0.038 
Clostridium cluster XIVa Clostridium nexile et rel. 0.056  0.799  + 0.089±0.048 0.300±0.203 
 Clostridium symbosium et rel. 0.056  0.799  + 0.171±0.029 0.220±0.048 
Deltaproteobacteria Desulfovibrio et rel. 0.008  0.378  - 1.615±0.271 1.009±0.236 
Epsilonproteobacteria Arcobacter 0.008  0.378  - 0.321±0.038 0.214±0.035 
Gammaproteobacteria Escherichia coli et rel. 0.008  0.378  + 1.265±0.235 2.176±0.478 
 Pseudomonas et rel. 0.095  0.799  + 1.051±0.278 1.437±0.280 
 Psychrobacter et rel. 0.056  0.799  + 0.462±0.062 0.572±0.124 
 Vibrio et rel. 0.095  0.799  + 0.111±0.029 0.211±0.091 
Spirochaetes Uncultured Spirochaetes 0.095  0.799  - 0.036±0.002 0.030±0.007 
1 C.p: P value corrected for multiple testing according to the procedure of Benjamini-Hochberg 
2Effect: indicates whether the average relative contribution of a microbial group was increased (+) or decreased (-) in the colon of 
maternal amoxicillin treated piglets in comparison with control piglets. 
3 ARC: Average relative contribution [%] of a microbial group. Values represent means ± SDs. The microbial group with a relative 
abundance lower than 0.01% in all treatments are not shown. 
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Maternal amoxicillin treatment affected colonic microbiota of offspring 
At the phylum level, we detected a decreasing trend of Bacteroidetes and Fibrobacteres in 
the colon of maternal amoxicillin-treated piglets respectively at day 14 and 21 after birth, 
whereas an increasing trend of Fusobacteria was detected at day 42 after birth (Table 4). As 
in the ileum, there was an increase in relative abundance of bacteria related to level-2 
groups E. coli and Pseudomonas of the maternal amoxicillin-treated piglets at day 14 
(Table 5). At day 21, 28 and 42, there was no obvious change of any microbial groups 
according to their corrected p value (> 0.978 in all cases, data not shown). 
Spearman’s correlation coefficients were calculated between the microbial profiles of the 
faecal sample of each sow and the colonic sample of its offspring. Similar to what was 
observed for ileal microbiota of the offspring, treated sows and their offspring showed a 
significantly higher microbiota similarity compared with control sows and their offspring at 
day 28 after birth (P<0.05, Fig. 3). Although the average Spearman’s correlation coefficient 
of the amoxicillin-treated sows and their offspring was higher than that of the control sows 
and their offspring at day 14, 21 and 42 after birth, the difference was not significant for 
these ages (P>0.05, Fig. 3). 
Figure 3. Box plots of total microbiota profile similarity between piglets’ colonic content and sows’ faeces at day 
14 (D14), 21(D21), 28(D28) and 42(D42) after birth. Spearman’s correlation coefficient was calculated for each 
sow and its offspring. Average microbiota similarity between amoxicillin treated sows and their offspring are 
significantly higher than between control sows and their offspring at day 28 (P<0.05). Capital letters “C” and “T” 
represent the control piglets and maternal amoxicillin treated piglets, respectively. 
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Discussion 
In this study, we evaluated the effects of maternal antibiotic treatment on the microbiota 
development of the offspring with a pig model reared in experimental farm conditions. In 
this model, the sows received amoxicillin orally around parturition, and their offspring was 
serially sacrificed up to 42 days of age. Amoxicillin treatment drastically impacted the sows’ 
faecal microbiota, and furthermore influenced specific microbial groups in the ileum and 
colon of the piglets. Overall, more microbial groups were affected by maternal amoxicillin 
treatment in the piglet ileum than in the colon.  
Effects of maternal amoxicillin treatment on the gut microbiota of their offpring  
Effect of maternal amoxicillin on ileal microbiota of offspring and its implications  
Maternal amoxicillin treatment stimulated Proteobacteria in the ileum of piglets during 
amoxicillin administration (at day 14 and 21), which was mainly driven by higher relative 
abundance of E. coli and Pseudomonas. Various strains of E.coli are considered to be 
pathobionts as they carry pathogenicity-islands and have been associated with diseases such 
as inflammatory bowel disease and colon cancer [203, 204]. Such pathobionts can cause 
disease when intestinal homeostasis is disrupted. Intestinal homeostasis can be affected by 
antibiotic treatment, which may consequently stimulate the pathobionts. A recent study has 
shown that multidrug-resistant E.coli can expand markedly in the microbiota of 
antibiotic-treated mice, and induce innate immune signalling and rapid sepsis-like death 
[205]. In line with this observation, studies on antibiotic effects suggested that a bloom in 
commensal E. coli populations in the pig gut could be a common response of disruption in 
the total intestinal bacterial community [59, 206]; E. coli may be capitalizing on a general 
disruption of the microbiota, temporarily expanding its niche in part due to its short 
doubling time [42]. 
Maternal amoxicillin treatment caused age-specific responses of microbial groups in the 
ileum of piglets. Except bacteria of level-2 groups belonging to Catenibacterium, E. coli, 
Lactobacillus acidophilus, and Leptospira, no microbial groups were continuously affected 
by the maternal amoxicillin treatment at two or more consecutive sampling times. 
Moreover, opposing trends at day 42 (i.e. two weeks after weaning) compared with day 28 
(day of weaning) were observed for some microbial groups, such as Bacteroides fragilis 
and Bacteroides vulgatus. It is not surprising to discover such age-specific effects of 
maternal amoxicillin treatment as specific temporal development patterns have been 
observed before. In general, the first colonizers in the human GI tract are facultative 
anaerobes including E. coli and other Enterobacteriaceae, followed by anaerobic bacteria 
such as Bifidobacterium, Clostridium, Bacteroides, and Ruminococcus [9]. Microbial 
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succession during the first few weeks of life in the intestinal tract of humans, chicken, pigs, 
and calves follows a similar pattern and both coliforms and streptococci dominate the 
microbiota within a few days of birth and obligate anaerobes appear some time later, even 
though neonatal animals are exposed to greater numbers of faecal and environmental 
bacteria than human neonates [11]. After this initial colonization, the microbiota undergoes 
consecutive changes in composition and function until a relatively stable climax community 
is established at around 3 years after birth [12]. On the other hand, marked changes in the 
gut microbiota do not only occur from birth to weaning, but also from weaning to 
adulthood [3]. The introduction of solid foods can significantly affect the gut microbiota 
and drive the microbiota into an adult-type profile [13, 18]. For instance, Bergström et al. 
reported that cessation of breastfeeding and introduction of a complementary feeding 
induced replacement of a microbiota characterized by Lactobacillus, Bifidobacterium spp. 
and Enterobacteriaceae with a microbiota dominated by Clostridium spp. and Bacteroides 
spp. in Danish infants [2]. Another study also showed ingestion of table foods caused a 
sustained increase in the abundance of Bacteroidetes [19]. Therefore, opposing trends for 
certain microbial groups, such as Bacteroides fragilis and Bacteroides vulgatus, may be 
attributed to the influence of weaning. 
Maternal amoxicillin differently affects offspring ileum and colon microbiota.  
Different microbial groups were affected by the maternal amoxicillin treatment in the ileum 
and colon of piglets in this study. Only bacteria related to genera Escherichia and 
Pseudomonas were affected by the maternal amoxicillin in both ileum and colon of piglets 
at the same age. In addition, more microbial groups were affected by the maternal 
amoxicillin treatment in the ileum than in the colon. These findings indicated a differential 
effect of maternal amoxicillin in the ileum and colon of their offspring. Due to differences 
in the architecture, physiological conditions and function of the gut along its length, 
bacterial diversity and composition also differs from the small intestine to the large 
intestine. Although recent studies in human adults showed that the ileum is colonized by 
relatives of Streptococcus and Veillonella spp. but also contains members of the 
Bacteroidetes and Clostridium cluster XIVa that are abundant members of large intestinal 
microbiota [105, 125, 127], little is known about the difference of microbiota in the ileum 
and colon at early age of humans. For piglets and other model animals, more detailed 
information is available due the possibility of taking samples from sacrificed animals [64]. 
In this study, we detected differences in the relative abundance of Bacteroidetes, Firmicutes, 
Planctomycetes and Proteobacteria in the colon compared with the ileum of the control 
piglets before weaning (Supplemental Table 2). Our study revealed that microbiota 
differed in the ileum and colon during microbial development at early age in piglets. Such 
differences could be one of the reasons why different microbial groups were affected by the 
maternal amoxicillin treatment in the ileum and colon. 
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Maternal antibiotic treatment influences the transfer of maternal microbiota to 
offspring 
The maternal amoxicillin treatment may influence the microbiota development of the 
offspring through two mechanisms. One possible way is that the amoxicillin residues in 
milk were transferred to offspring via breastfeeding, and directly affected certain members 
of the intestinal microbiota of the offspring [193]. On the other hand, maternal amoxicillin 
may indirectly affect microbiota of the offspring through modifying the mother’s 
microbiota of milk, skin, vagina, gut and faeces. Most antibiotics are either injected or 
administered orally, thereby circulating throughout the host system and potentially affecting 
the entire microbiota [42]. For instance, maternal antibiotic treatment during parturition can 
decrease transmission of vaginal Lactobacillus to the neonate during birth [41].  
In the present study, maternal amoxicillin treatment drastically impacted sows’ gut 
microbiota, and may consequently impact the transfer of maternal microbiota to offspring. 
Certain members of the maternal gut microbiota may reach breast milk via bacterial 
translocation and the bacterial entero-mammary pathway to subsequently colonize the gut 
of the breastfed neonate [191, 207]. Furthermore, the faecal-oral route of transmission is of 
specific importance especially for strict anaerobes. Therefore, alteration of maternal gut 
microbiota may result in changes of microbes colonizing in the gut of the offspring. We 
detected a higher similarity of microbial composition between the faeces of 
amoxicillin-treated sows and ileal content of their offspring compared with the control sows 
and their offspring. This finding seems to suggest that maternal antibiotic treatment affected 
gut microbiota of offspring through regulating the transfer of maternal gut microbiota to 
newborn piglets. Oral amoxicillin may also influence the entire sows’ microbiota, including 
milk and skin microbiota. Further studies are needed to confirm the maternal antibiotic 
effect on milk and skin microbiota, as well as its effect on the gut microbiota development 
of offspring.   
It is difficult to specify (or indicate) whether the maternal amoxicillin treatment affected the 
microbiota development of offspring in a direct or indirect fashion. However, some of our 
findings may indicate a weak direct amoxicillin effect on the microbiota of piglets. We 
found that amoxicillin showed an inhibition on bacteria related to genera L.acidophilus, L. 
delbrueckii, L. gasseri, L. plantarum, S. aureus, S. bovis, S. intermedius and S. suis in the 
faeces of sows. This result is in line with previous reports that amoxicillin commonly had 
an inhibiting effect on Lactobacillus, Streptococcus and Staphylococcus [59, 208-210]. 
However, we did not find such inhibiting effect in the ileum and colon of piglets. Moreover, 
most microbial groups that were affected both in faeces of amoxicillin-treated sows and 
ileal content of their offspring showed an opposite direction of change, such as bacteria 
related to Alistipes, Bacillus, Pseudomonas and S. aureus. These opposing findings suggest 
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breastfeeding transfer of amoxicillin may not be the main route of influencing the gut 
microbiota of piglets.  
Conclusion  
Maternal amoxicillin treatment affected the gut microbiota development of piglets. 
Especially in the ileum, maternal amoxicillin treatment led to a higher relative abundance 
of Proteobacteria during the administration, which was mainly driven by E.coli and 
Pseudomonas. However, most microbial groups that were affected both in faeces of 
amoxicillin-treated sows and ileal content of their offspring showed opposite direction of 
change, even though a significantly higher similarity of microbial profile was detected 
between the faeces of amoxicillin-treated sows and ileal content of their offspring 
compared with the control sows and their offspring. This finding indicates that, instead of a 
direct effect of amoxicillin transferred via breastfeeding, maternal amoxicillin treatment 
affected gut microbiota of the offspring through regulating the transfer of maternal 
microbiota to the offspring. Future studies are needed in order to assess the effects of 
antibiotic treatment on the mother’s entire microbiota such as milk and skin microbiota, as 
well as its consequent effect on the gut microbiota development of offspring.   
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Supplemental tables and figures 
 
Supplemental Figure 1. Microbial diversity of sows’ faeces over time. The Shannon index was calculated 
separately for both treatments at all sampling times. CB, control group at the start of amoxicillin treatment; CE, 
control group at the end of amoxcillin treatment; TB, amoxicillin treating group at the start of antibiotic treatment; 
TE, amoxicillin treating group at the end of amoxcillin treatment.  
Supplemental Table 1. Phylum-level phylogenetic groups with different relative abundance in the ileum and 
colon of control piglets at day 14 (D14), 21 (D21) and (D28) after birth. 
?  
D14 D21 D28 
Effect1 ARC Colon2 ARC ileum3 Effect ARC Colon ARC ileum Effect ARC Colon ARC ileum 
Actinobacteria  9.45±2.57 8.63±3.39  8.71±3.54 9.12±5.26 9.84±2.07 10.18±3.68 
Bacteroidetes 0.056+ 3.67±2.24 1.9±0.40  3.64±2.62 1.97±0.43 0.095+ 3.91±1.89 1.77±0.44 
Fibrobacteres  0.71±0.44 1.16±0.66  0.86±0.21 1.08±0.34 0.75±0.49 1.03±0.54 
Firmicutes 0.095- 66.04±3.57 69.88±2.33  69.01±4.03 67.1±4.60 67.22±2.64 66.14±4.12 
Planctomycetes 0.008+ 0.92±1.46 0.00±0.00 0.008+ 0.34±0.52 0.01±0.00 0.008+ 0.13±0.13 0.01±0.00 
Proteobacteria  17.58±1.29 16.94±1.48 0.016- 15.74±1.44 18.93±2.58 0.056- 16.16±1.18 19.07±2.30 
Spirochaetes ?  1.36±0.30 1.18±0.13 ?  1.44±0.36 1.43±0.21 1.67±0.31 1.44±0.27 
1Effect: indicates whether the average relative contribution of a phylum was increased (+) or decreased (-) in the colon in 
comparison with that in the ileum of control piglets. Numbers represent the p values. P values above 0.1 are not shown.  
2 ARC Colon: Average relative contribution [%] of a phylum in the colon. Values represent means ± SDs. The phyla with a relative 
abundance lower than 0.1% in all treatments are not shown. 
3 ARC Ileum: Average relative contribution [%] of a phylum in the ileum. Values represent means ± SDs. The phyla with a relative 
abundance lower than 0.1% in all treatments are not shown. 
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Supplemental Table 2. Phylum-level phylogenetic groups with different abundance in the ileum and colon of 
maternal amoxicillin treated piglets. 
 
D14 D21 D28 D42 
Effect1 ARC Colon2 ARC ileum3 Effect ARC Colon ARC ileum Effect ARC Colon ARC ileum Effect ARC Colon ARC ileum 
Actinobacteria  8.65±3.78 8.60±6.43 0.056+ 8.02±0.72 6.95±0.93 8.28±1.72 7.76±2.61 0.095+ 8.69±1.89 7.13±1.24 
Bacteroidetes  2.56±2.71 1.56±0.66  1.90±0.67 1.93±0.35 0.056+ 2.87±0.60 1.78±0.62 0.095+ 2.26±1.04 1.39±0.29 
Fibrobacteres 0.056- 0.50±0.23 1.10±0.58 0.056- 0.53±0.28 0.94±0.31 0.095- 0.96±0.49 1.38±0.41  0.60±0.56 0.98±0.41 
Firmicutes  67.96±1.79 66.67±2.53 0.095+ 69.76±1.14 66.11±2.67 68.95±3.26 68.9±3.14  69.16±1.40 65.33±4.05 
Planctomycetes 0.008+ 0.30±0.48 0.00±0.00 0.008+ 0.73±0.52 0.01±0.01 0.032+ 0.72±1.40 0.01±0.01  0.04±0.04 0.01±0.00 
Proteobacteria  18.34±1.72 20.21±2.77 0.032- 17.20±1.38 22.1±3.08 16.44±1.51 18.86±2.87 0.008- 17.29±0.59 23.18±3.83 
Spirochaetes ?  1.41±0.60 1.55±0.39 ?  1.57±0.04 1.62±0.35 0.056+ 1.54±0.35 1.09±0.27 ?  1.66±0.22 1.72±0.26 
1Effect: indicates whether the average relative contribution of a phylum was increased (+) or decreased (-) in the colon in 
comparison with that in the ileum of maternal amoxicillin treated piglets. Numbers represent the p values. P values above 0.1 are 
not shown.  
2 ARC Colon: Average relative contribution [%] of a phylum in the colon. Values represent means ± SDs. The phyla with a relative 
abundance lower than 0.1% in all treatments are not shown. 
3 ARC Ileum: Average relative contribution [%] of a phylum in the ileum. Values represent means ± SDs. The phyla with a relative 
abundance lower than 0.1% in all treatments are not shown.
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Abstract  
Background: Early-life environmental variation affects gut microbial colonization and 
immune competence development, however, the timing and additional specifics of these 
processes are unknown. The impact of early-life environmental variations, as experienced 
under real life circumstances, on gut microbial colonization and immune development, has 
not been studied extensively so far. We designed a study to investigate environmental 
variation, experienced early after birth, to gut microbial colonization and intestinal immune 
development.  
Methodology/Principal Findings: To investigate effects of early-life environmental changes, 
the piglets of 16 piglet litters were divided into 3 groups per litter and experimentally 
treated on day 4 after birth. During the course of the experiment, the piglets were kept with 
their mother sow. Group 1 was not treated, group 2 was treated with an antibiotic, and 
group 3 was treated with an antibiotic and simultaneously exposed to several routine, but 
stressful management procedures, including docking, clipping and weighing. Thereafter, 
treatment effects were measured at day 8 after birth in 16 piglets per treatment group by 
community-scale analysis of gut microbiota and genome-wide intestinal transcriptome 
profiling. We observed that the applied antibiotic treatment affected the composition and 
diversity of gut microbiota and reduced the expression of a large number of immune-related 
processes. The effect of management procedures on top of the use of an antibiotic was 
limited.  
Conclusions/Significance: We provide direct evidence that different early-life conditions, 
specifically focusing on antibiotic treatment and exposure to stress, affect gut microbial 
colonization and intestinal immune development. This reinforces the notion that the early 
phase of life is critical for intestinal immune development, also under regular production 
circumstances.  
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Introduction  
Maintenance of general health and prevention of infectious diseases are critically dependent 
on intestinal homeostasis and proper immune competence. In this regard, early colonization 
of the gut by microbiota as well as the concomitant development of the intestinal immune 
system has been proven to be important [143, 211, 212]. Immediately after birth, the 
intestine is colonized by bacteria derived from maternal and environmental sources [64, 
213]. During the early-life period, the composition and diversity of microbiota is unstable 
and highly influenced by environmental conditions, including the use of antibiotics, 
exposure to stress, and nutrition, as observed in several recent studies using a variety of 
experimental conditions and models [13, 132, 169, 214-218]. A significant difference in the 
diversity of microbiota has, for example, been identified between naturally-reared piglets 
and isolator-reared piglets that were separated from each other 24 hours after birth during 
which period natural colonization occurred [169]. The gut microbiota in the isolator-reared 
piglets remained very divers and contained a large number of phylotypes, whereas in the 
naturally-reared piglets the microbial diversity decreased as the piglets developed from 
neonate (day 5) to adult-like stage (day 56: near maturity) [52]. Naturally rearing is 
supposed to be superior over growing-up in isolators in terms of health with improved 
immune development and immune homeostasis [52].  
The structural and functional development of the mucosal immune system takes place 
concomitantly with the early-life microbial colonization of new-borns. There is now 
significant evidence that the process of immune maturation is influenced by the microbiota 
that colonize the gut at the early stages of life [119, 219-222]. A link has been discovered 
between the functionality of the host immune system and the early-life gut microbiota 
composition [21, 223, 224]. In addition, it has been observed that components of the 
early-life environment of piglets, most probably including the gut microbial diversity, affect 
the number of CD4+, CD4+CD25+ effector T-cells, and CD4+CD25+Foxp3+ regulatory 
T-cells, as well as the serum IgG antibody response [220]. Furthermore, it has been shown 
that host species specific microbiota is required for the development of the immune system 
[211] and that different epithelial cell lineages (e.g. paneth cells) are essential for 
colonization of commensal microbiota and homeostasis of the intestine [225]. Many of the 
studies that so far addressed the interaction between microbiota and the host immune 
system used (extreme) experimental conditions and do not account for the timing and 
specifics of events during early development encountered by the new born animals under 
normal production circumstances. 
To investigate the impact of early-life variations, as experienced under regular production 
circumstances, on gut microbial colonization and immune development, we used piglets 
and environmental conditions common in swine husbandry systems and with similarities to 
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environmental conditions experienced by young infants. In intensive swine husbandry 
systems, piglets are frequently exposed to antibiotics at young age, mainly to prevent 
outbreaks of respiratory and intestinal diseases; however, the impact on intestinal health has 
not yet been described on microbiota and/or gene expression level. On the other hand, new 
born piglets are also frequently exposed to a number of stressful handlings, including 
ear-tagging, tail docking, and nail clipping. These treatments are known to cause stress, 
which is in turn expected to have a negative influence on intestinal health of animals. As 
shown in rats, acute stress can lead to dysfunction of the intestinal barrier [226].  
The objective of this study was to investigate the effects of early-life exposure to antibiotics, 
and antibiotics in combination with stress at day 4 after birth on gut microbial colonization 
and immune development under regular production circumstances. The specific objective 
of this study was to identify and define changes in the composition and diversity of the 
microbiota in the gut and the concomitant immunological effects in intestinal tissue at day 8 
after birth. We studied the effect of an antibiotic exposure on the interaction between host 
immune development and microbiota, in the presence and absence of stressful management 
procedures, using community-scale analysis of gut microbiota and genome-wide 
transcriptome profiling of jejunum and ileum tissue. 
Material and methods 
Design 
The experiment was conducted with 16 sows (TOPIGS20, GY x NL) and their suckling 
piglets. The piglets of each sow were divided into 3 treatment groups (T1, T2, and T3) by 
colour-marks on their back, but stayed during the course of the experiment in the litter with 
their mother sow (Figure S1). Treatment group 1 (T1) piglets experienced no disturbance 
and were only handled at the time of drawing blood at day 8. Treatment group 2 (T2) 
piglets received an injection (subcutaneously in the neck) with 0,1 ml Tulathromycin 
(dosage was 2.5 mg/kg [1mL/40 kg] body weight) at day 4 after birth. Treatment group 3 
(T3) piglets received an identical injection with 0,1 ml Tulathromycin at day 4 after birth 
and at the same time the standard management procedures (i.e. docking, clipping and 
weighing) used at that particular farm (VIC Sterksel, The Netherlands). At day 8 after birth 
from each litter (n=16) and from each treatment group (n=3) 48 piglets were sacrificed by 
intravenous injection of 0,5-1 ml Euthasol (20% sodium pentobarbital; 200 mg/ml). 
Intestinal tissues (jejunum and ileum) were taken and immediately frozen in liquid nitrogen. 
From the same or adjacent locations luminal contents and mucosal scrapings were taken, 
rinsed (with PBS) and frozen in liquid nitrogen as well.  
We performed a power calculation (balanced one-way analysis of variance) in R (version 
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2.14.0), where the number of treatments was 3, number in each group was 4, significance 
level was 0.05, and power was 0.8. This resulted in an effect size of 1.07. This means that 
we can pick-up large effects in gene expression log2(Fold Change) ≥ 1.07 between 
treatments. For each treatment (T1, T2, and T3) the samples of 4 pools of 4 animals were 
analysed. This design reduces the effect of maternal genetics. The grouping of piglets in 
each pool were the same for microbiota, blood and tissue (scrapings) transcriptomic analyses, 
by pooling 4 animals (Supplementary Table A in File S1).  
Ethics statement 
This animal experiment was approved by the institutional animal experiment committee 
“Dier Experimenten Commissie (DEC) Lelystad” (2011077.b), in accordance with the 
Dutch regulations on animal experiments. 
Microbiota analysis  
Ileal content was not present in all piglets at day 8; therefore, only jejunal content was 
analysed. Jejunal contents were grouped into 4 pools as described in the ‘Design’ part. 
Microbial DNA was extracted from 250 mg of the mixture using a faecal DNA extraction 
protocol adapted from Yu and Morrison [198], as previously described by Salonen et al. 
[199]. After extraction of microbial DNA, the microbial composition was detected by the 
Pig Intestinal Tract Chip (PITChip) version 2.0. The PITChip is a phylogenetic microarray 
with 3,299 oligonucleotides based on 16S rRNA gene sequences of 781 porcine intestinal 
microbial phylotypes, it was designed according to the same principles previously described 
for the Human Intestinal Tract Chip (HITChip) [103] and the PITChip version 1.0 [97, 101, 
227]. The PITCip and the comparable tools targeting the human (HITChip) and mouse 
(MITChip) intestinal microbiota provide a highly reproducible profile of microbiota 
composition that has been compared with deep pyrosequencing of 16S rRNA gene 
fragments [97, 104, 105] and metagenome sequencing of intestinal microbiota [106], 
indicating comparable phylogenetic resolution and a higher sensitivity of the chip-based 
analysis. Furthermore, microarray-based analysis is not affected by differences in 
read-depth per sample as is frequently observed for next generation technology 
sequencing-based approaches. The protocol for hybridization and analysis of the generated 
data was performed essentially as described before for the HITChip [103]. Briefly, the 
bacterial 16S rRNA gene was amplified using the primers T7prom-Bact-27-for 
(5´-TGAATTGTAATACGACTCACTATAGGGGTTTGATCCTGGCTCAG-3´) and 
Uni-1492-rev (5´-CGGCTACCTTGTTACGAC-3´) [103, 200]. The PCR products were 
transcribed into RNA and the purified resultant RNA was coupled with CyDye prior to 
fragmentation and hybridization to the array. Microarray images were processed using 
Agilent's Feature Extraction Software version 9.5 (http://www.agilent.com). Data was 
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retrieved from the MySQL (version 5.1) database as describe by Rajilic-Stojanovic [103] 
and pre-processed using the R (Rx64 2.12.2) microbiome package 
(http://microbiome.github.com/), settings on default. Although this data is part of a larger 
dataset, we only provide the data related to day 8 in this study. Diversity of microbial 
profiles was assessed by calculating the Shannon index of diversity using normalized signal 
intensities of all probes on the array (http://microbiome.github.com/). Multivariate analysis 
was applied for PITChip data interpretation. In order to relate changes in total microbial 
composition to environmental variables, redundancy analysis (RDA) was used as 
implemented in the CANOCO 4.5 software package (Biometris, Wageningen, The 
Netherlands) [228]. Treatment classes were introduced as environmental (explanatory) 
variables. The signal intensities for 151 genus-level phylogenetic groups targeted by the 
PITChip were used as response variables. RDA was performed focusing on inter-sample 
correlation, and the Monte Carlo Permutation test was applied [229] to decide whether 
treatment had statistically significant influence on the microbial composition. The 
unrestricted permutation option (since the experiment had a randomized design) that yields 
completely random permutations was employed [230]. Treatment was considered to 
significantly affect microbial composition with p-values < 0.05. Triplot diagrams were 
generated using CanoDraw for Windows. To test the variation of an individual microbial 
group between treatments we performed a Mann-Whitney-Wilcoxon signed rank test in R 
(version 2.14.0) with multiple testing corrections (Benjamini Hochberg). 
Microarray analysis  
RNA extraction blood 
Blood was sampled using the PAXgene Blood RNA tube from PreAnalytiX (a Qiagen/BD 
company). Tubes were thawed for 2 hours at room temperature (RT). Subsequently tubes 
were centrifuged at 3,200x g for 10 minutes at RT and the supernatant was discarded. The 
pellet was suspended in RNase-free water and tubes were centrifuged as described above. 
The pellet was washed again with RNAse-free water by repeating the last two steps. After 
discarding the supernatant the pellet was dissolved in 1 ml TRIzol® reagent (Invitrogen). 
After 5 min at room temperature 0.2 ml of chloroform was added, the tubes were mixed 
vigorously for 15 seconds. After 2 min at RT, tubes were centrifuged for 15 min at 7,000x g. 
The watery phase containing the RNA was isolated and mixed with 0.5 ml of isopropanol. 
After centrifugation at 12,000x g for 10 minutes at RT, RNA pellets were washed with 75% 
(v/v) ethanol and dissolved in RNase-free water. Quality control was performed with the 
Bioanalyzer from Agilent. 
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RNA extraction tissue 
Total RNA was extracted from 50 to 100 mg tissue samples of jejunum and ileum. The 
jejunum and ileum samples were homogenized using the TisuPrep Homogenizer Omni TP 
TH220P) in TRizol reagent (Life Technologies) as recommended by the manufacturer with 
minor modifications. The homogenized tissue samples were dissolved in 5ml of TRizol 
reagent. After centrifugation the supernatant was transferred to a fresh tube. Subsequently a 
phase separation with chloroform was performed as described by the manufacturer. The 
RNA was precipitated and dissolved, and quantified by absorbance measurements at 260 
nm. 
RNA labelling, hybridization, scanning and feature extraction 
Labelling was done as recommended by Agilent Technologies using the One-Color 
Microarray-Based Gene Expression Analysis Low input Quick Amp Labeling. The input 
was 200 ng of total RNA and 600 ng of labelled cRNA was used on the 8 pack array. 
Hybridization was performed as described in the One-Color Microarray-Based Gene 
Expression Analysis Low input Quick Amp Labeling protocol from Agilent in the 
hybridization oven (G2545A hybridization Oven Agilent Technologies). The hybridization 
temperature was 65°C with rotation speed 10 rpm for 17 hours. After 17 hours the arrays 
were washed as described in the One-Color Microarray-Based Gene Expression Analysis 
Low input Quick Amp Labelling protocol from Agilent.  
The porcine Agilent microarray slides, G2519F Sus scrofa (035953; V2: 026440), 
harbouring 43,803 probes, were used and scanned using the DNA microarray scanner with 
Surescan high resolution Technology (Agilent Technologies). Agilent Scan Control with 
resolution of 5μ, 16 bits and PMT of 100%. Feature extraction was performed using 
protocol 10.7.3.1 (v10.7) for 1 colour gene expression. 
Data loading and statistical analysis 
The files generated by the feature extraction software were loaded in GeneSpring GX 12 
(also available in GEO, accession number; GSE53170, platform; GPL18045), in which a 
log2-transformation and quantile normalization were performed. After quantile 
normalization, quality control was performed and 2 samples were taken out, one sample of 
jejunum and one of ileum. The remaining 22 samples were analysed by principle 
component analysis, and a similar approach was followed for the 12 blood samples. 
Subsequently, the data was filtered based on the level of expression in which only the 
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(20-100)th percentile was included and control probes if present were removed, resulting in 
28,953 probes for the tissue samples, and 20,832 probes for the blood samples. Thereafter 
(multiple) probes were mapped to genes if possible, resulting in 21,660 probes/genes for 
tissue samples, and 15,296 probes for the blood samples. To calculate whether the 
difference between treatments was significant a 2-way ANOVA with multiple testing 
correction (Benjamini-Hochberg) was performed within GeneSpring, where we compared 
the following groups for blood, jejunum and ileum: T3 vs. T1, T2 vs. T1, and T3 vs. T2.  
Functional annotation clustering  
Functional annotation clustering analyses were performed with Database for Annotation, 
Visualization and Integrated Discovery (DAVID, version 6.7 [231, 232]). For each 
comparison, T3 vs. T1, T2 vs. T1, and T3 vs. T2, analyses were performed with lists of 
significantly up- and down-regulated genes (after filtering and mapping of probes). An 
overview of the number of up- and down-regulated genes is available in Supplementary 
Table B in File S1.  
Gene set enrichment analysis (GSEA)  
GSEA [233, 234] was performed separately for ileum and jejunum. The following settings 
were different from the default settings: permutations were performed on the gene set, chip 
platform was set to gene symbol. Six gene set databases (v3.0) were loaded for analysis, 
including the three Gene Ontology related gene sets biological processes, molecular 
function and cellular component, and three pathway related gene sets, BioCarta, Reactome 
and KEGG.  
InnateDB interactions 
Interactions were extracted from innateDB [235] and loaded into CytoScape (v2.8.1) [236, 
237]. To represent the cell location for all genes in the network, the Cerebral plugin was 
used [238]. 
Quantative RT-PCR  
For the quantification of expression levels based on array data, cDNA was made using 
random hexamer primers and reverse transcriptase, and qRT-PCR was performed targeting 
genes encoding IL-1βb [239], IL-6 [239], IL-8 [239] and TIMP1 [240] with on-line 
detection using Syber Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) 
in an ABI 7500 Real-Time PCR system (PE Applied Biosystems, Foster City, CA, USA). 
Quantitative results were determined and normalized with GAPDH gene expression 
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(Figure S2). For the quantification, a standard curve of a plasmid containing the cytokine 
gene of interest or GAPDH in pGEM-T easy (Promega Benelux b.v. Leiden, The 
Netherlands) was used.  
Results 
Microbiota analyses 
The PITChip was used to evaluate the impact of antibiotic treatment with or without 
routinely stressful management on jejunal microbiota. The most dominant phylum in all 
samples was the Firmicutes, followed by Proteobacteria, Bacteriodetes, Spirochaetes, and 
Actinobacteria (Supplementary Table C in File S1), whereas, the relative abundances of 
other phyla were not above 1%. Multivariate redundancy analysis of PITChip2 profiles at 
the approximate genus-level showed that samples of T3 separated from most samples of T1 
along the first canonical axis except for sample 12, and samples of T2 separated from those 
of T1 along the second canonical axis (Fig. 1). Both axes together explained 18.5 % of the 
variance in microbiota composition. Subsequently, univariate analysis was used to identify  
 
Figure 1. Triplot for RDA analysis of jejunal microbiota composition. Nominal environmental variables T1, T2 
and T3 are represented by red triangles (▲). Samples are grouped by treatment: T1 (red; ○), T2 (blue; □) and T3 
(green; ?), each symbol represents a pool of four pigs, and numbers represent pool identity number. Microbial 
groups contributing at least 60% to the explanatory axes are represented as vectors. Both axes together explain 
18.5% of the total variance in the dataset. 
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Table 1. Genus-level phylogenetic groups changed in T2 and/or T3. 
Microbial groups ?  
T2 vs. T1 T3 vs. T1 T3 vs. T2 ARC2 
P value C.P1 P value C.P P value C.P T1 T2 T3 
Actinobacteria          
 Actinobacteria          
  
Bifidobacterium et 
rel. 0.03↑
3 0.48 0.34 0.51 0.03↓ 0.1 0.27±0.08 0.48±0.08 0.34±0.04 
  Collinsella 0.49 0.71 0.11 0.51 0.03↓ 0.1 0.19±0.04 0.24±0.09 0.14±0.01 
  Olsenella et rel. 0.34 0.67 0.2 0.51 0.03↓ 0.1 0.18±0.04 0.24±0.09 0.14±0.02 
Bacteroidetes          
 Bacteroidetes          
  
Uncultured 
Prevotella 0.2 0.64 0.03↑ 0.33 0.89 0.96 0.20±0.03 0.29±0.08 0.32±0.05 
Fibrobacteres          
 Fibrobacteres          
  
Fibrobacter 
succinogenes et rel. 0.34 0.67 0.34 0.51 0.03↓ 0.1 0.58±0.23 0.70±0.11 0.43±0.02 
Firmicutes          
 Bacilli          
  Allofustis et rel. 0.49 0.71 0.34 0.51 0.03↑ 0.1 0.26±0.04 0.25±0.01 0.28±0 
  Bacillus et rel. 0.03↓ 0.48 0.06 0.51 0.34 0.52 0.39±0.01 0.34±0.02 0.36±0.02 
  
Carnobacterium et 
rel. 1 1 0.34 0.51 0.03↑ 0.1 0.64±0.16 0.57±0.06 0.68±0.06 
  
Staphylococcus 
aureus et rel. 0.03↓ 0.48 0.69 0.85 0.03↑ 0.1 0.22±0.03 0.19±0.01 0.22±0.01 
  
Streptococcus suis et 
rel. 0.06 0.54 0.89 1 0.03↓ 0.1 0.55±0.16 0.83±0.09 0.56±0.1 
 Clostridium cluster IV          
  Anaerotruncus et rel. 0.89 0.94 0.34 0.51 0.03↑ 0.1 1.27±0.35 1.16±0.14 1.44±0.07 
  
Faecalibacterium 
prausnitzii et rel. 0.03↑ 0.48 0.2 0.51 0.2 0.38 0.22±0.09 0.37±0.04 0.31±0.08 
  
Ruminococcus bromii 
et rel. 0.06 0.54 0.34 0.51 0.03↓ 0.1 0.27±0.06 0.41±0.06 0.31±0.02 
 Clostridium cluster XI          
  Anaerovorax et rel. 0.49 0.71 0.34 0.51 0.03↑ 0.1 3.35±0.59 3.07±0.18 3.57±0.09 
 Clostridium cluster XIII          
  Peptoniphilus et rel. 0.34 0.67 0.89 1 0.03↑ 0.1 1.02±0.19 0.9±0.09 1.1±0.08 
 Clostridium cluster XIVa          
  
Clostridium 
sphenoides et rel. 0.49 0.71 0.34 0.51 0.03↑ 0.1 0.69±0.15 0.62±0.07 0.8±0.04 
  
Ruminococcus obeum 
et rel. 0.69 0.82 0.2 0.51 0.03↑ 0.1 2.45±0.76 2.43±0.47 3.4±0.39 
 Clostridium cluster XV          
  Eubacterium et rel. 0.03↑ 0.48 0.89 1 0.03↓ 0.1 0.15±0.05 0.26±0.03 0.16±0.03 
 Clostridium cluster XVII          
  
Catenibacterium et 
rel. 0.11 0.54 0.49 0.7 0.03↓ 0.1 0.22±0.11 0.4±0.16 0.23±0.01 
 Erysipelotrichi          
  
Solobacterium 
moorei et rel. 0.03↑ 0.48 0.49 0.7 0.03↓ 0.1 0.11±0.05 0.22±0.04 0.14±0.02 
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Proteobacteria          
 Betaproteobacteria          
  Bordetella et rel. 0.11 0.54 0.89 1 0.03↓ 0.1 0.43±0.17 0.73±0.18 0.41±0.05 
  Oxalobacter et rel. 0.11 0.54 1 1 0.03↓ 0.1 0.12±0.04 0.21±0.07 0.11±0.01 
  
Sutterella wadsorthia 
et rel. 0.11 0.54 0.89 1 0.03↓ 0.1 0.12±0.06 0.24±0.09 0.11±0.01 
 Gammaproteobacteria          
  Psychrobacter et rel. 0.2 0.64 1 1 0.03↓ 0.1 0.31±0.08 0.41±0.07 0.33±0.01 
  
Ruminobacter 
amylophilus et rel. 0.11 0.54 1 1 0.03↓ 0.1 0.24±0.08 0.34±0.06 0.23±0.01 
Spirochaetes          
 Spirochaetes          
  Treponema et rel. 0.49 0.71 0.89 1 0.03↓ 0.1 1.31±0.32 1.46±0.13 1.19±0.09 
?  ?  Turneriella 0.2 0.64 1 1 0.03↓ 0.1 0.2±0.13 0.32±0.07 0.15±0.01 
1 C.P: P value corrected for multiple testing according to the procedure of Benjamini-Hochberg 
2 ARC: average relative contribution [%] of a microbial group. Values represent means ± SDs. The microbial groups with a relative 
abundance lower than 0.1% in all three treatments are not shown. 
3 “↑” or “↓” indicates whether the average relative contribution of the microbial group was increased or decreased. 
Figure 2. Diversity in microbiota in the three treatment groups. The Shannon index (y-axis) was calculated for all 
three treatments (T1, T2, and T3) (x-axis). 
microbial groups that significantly changed between treatments (Table 1). In the 
comparison of T2 versus T1, the relative contribution of Bifidobacterium-like, 
Erysipelotrichi-like, Eubacterium-like, Faecalibacterium prausnitzii-like, and 
Solobacterium moorei-like bacteria increased, whereas Bacillus-like and Staphylococcus 
aureus-like bacteria strongly decreased. In contrast, uncultured Prevotella group (i.e. a 
genus-level phylogenetic group comprising exclusively environmental sequences and no 
cultured representatives) increased in its relative abundance in T3 compared to T1 piglets. 
When comparing T3 versus T2, multiple microbial groups in different phyla were 
significantly different, including groups belonging to the Actinobacteria, Fibrobacteres, 
Firmicutes, Proteobacteria and Spirochaetes (see Table 1 for more detailed information). 
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Microbial diversity (Shannon index based on probe-level profiles) was significantly higher 
in T2 and T3 than in T1 (p<0.01); however, no significant difference was observed between 
T3 and T2. (p>0.05) (Fig. 2). 
Transcriptomic analysis 
To investigate the impact of the different treatments on the host, genome-wide gene 
expression was measured in intestinal tissue and blood samples. Initially, Principal 
Component Analysis (PCA) was performed to get more insight into the variability in blood 
and tissue transcriptome data and to get a visual inspection of the quality of the data. 
Representing transcriptome data by PCA showed clear aspects of quality control and outlier 
arrays and hybridization samples can be spotted and taken out based on their gene 
expression profile and hybridization pattern to ‘control’ probes. Because both intestinal 
tissues (jejunum, ileum) origin from the same ancestor cells, similar responses to the 
treatments were expected, and therefore jejunum and ileum data were analysed 
simultaneously (Fig. 3), whereas the data of blood samples were loaded separately (Fig. 4). 
For tissue-derived data, clustering occurred of similar treatments (red; T1, blue; T2, and 
green; T3) as well as similar tissues (squares; ileum, and triangles; jejunum). However 
treatment 3 samples were more dispersed compared to treatment 1 and 2, albeit grouping 
more closely with T1 samples (Fig. 3). Also, the different blood samples clustered, however, 
these clusters were dispersed when looking at principal component 1 (PC1; Fig. 4). This 
large variation within the treatment groups hinted that there were no significant differences 
in gene expression in blood cells between the treatments. 
To investigate the effect of the three treatments in jejunum, ileum, and blood, an ANOVA 
was performed. All probes/genes which were characterized by pcor < 0.05 and Fold Change > 
|1.5| in at least one of the six comparisons were taken for further functional and enrichment 
analysis (Table B in File S1). No differences were observed in blood, whereas in jejunum 
and ileum multiple probe signals (up to 80 genes) significantly differed between the 
treatment groups. In general more probe signals differed significantly in ileum compared to 
jejunum.  
The significantly up- and down-regulated genes were used as input for functional analysis. 
First, DAVID functional annotation clustering was performed resulting in multiple groups 
with a significant Enrichment Score (ES). The results are presented in Tables 2-4 (ES>1), 
where Table 2 shows the differences between T2 and T1, Table 3 between T3 and T1, and 
Table 4 between T3 and T2. In addition, Gene Set Enrichment Analysis (GSEA) was 
performed without pre-filtering of genes on e.g. p-value or fold change, so that all 
probes/genes were used as input. The GSEA analysis resulted in the identification of similar 
biological processes affected by the treatments as observed by the DAVID analysis (Suppl. 
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Table D and E in File S1). The main findings were that immune related processes 
appeared to be dominantly influenced by the treatments, for example cytokine/chemokine 
related processes differed between the treatments in both tissues. This was also verified for 
three genes (IL1B, IL6 and TIMP2) with qPCR, where we observed a trend between the 
qPCR and transcriptomics datasets (Figure S2).  
 
Figure 3. Principal Component Analysis on microarray data of intestinal tissue transcriptomes. A principal 
component analysis was performed on the 22 tissue transcriptome datasets which remained after quality control. 
All treatments (T1: red, T2:blue, and T3:green) are displayed for both jejunum (triangles) and ileum (squares). The 
x-axis depicts principal component 1 and the y-axis depicts principal component 2. Abbreviations: IL; Ileum, JEJ; 
Jejunum. 
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Figure 4. Principal component analysis of blood transcriptomes. A principal component analysis was performed 
on the 12 blood transcriptome data sets which remained after quality control. Treatment 1 (T1) is depicted in red, 
T2 in blue, and T3 in green. The x-axis depicts principal component 1, whereas the y-axis depicts principal 
component 2. 
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Table 2. Functional analysis of genes differentially expressed between treatment 2 versus 1. 
 DOWN 
JEJUNUM # Name 
 1 chemotaxis  
 2 cytokine activity 
 3 chemokine activity 
 4 regulation of secretion /immune effector process 
 5 cell migration/motion (leukocyte) 
ILEUM # Name 
 1 cytokine activity 
 2 chemotaxis  
 3 second-messenger-mediated signaling (cAMP) 
 4 chemokine activity 
 5 response to bacterium/regulation of systemic process 
Table 3. Functional analysis of genes differentially expressed between treatment 3 versus 1. 
 DOWN UP 
JEJUNUM # Name # Name 
1 chemotaxis  1 nucleotide binding 
2 cytokine activity 2 membrane fraction 
3 extracellular region 3 ATP binding 
4 chemokine activity 4 
5 second-messenger-mediated signaling (cAMP) 5 
ILEUM # Name # Name 
1 response to wounding/defense response 1 nucleotide binding 
2 cytokine activity 2 positive regulation of catalytic activity/signaling cascade 
3 chemotaxis  3 plasma membrane 
4 extracellular region 4 
5 chemokine activity 5 
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Table 4. Functional analysis of genes differentially expressed between treatment 3 versus 2. 
 DOWN  
JEJUNUM # Name 
 1 chemotaxis 
 2 nucleotide binding 
 3 
 4 
 5 
ILEUM # Name 
 1 Immunoglobulin 
 2 nucleotide binding 
 3 plasma membrane 
 4 nucleotide/ATP binding 
 5 positive regulation of catalytic activity/signaling cascade 
To visualize the differences in gene expression between the treatments, gene interactions 
networks associated with the dominant processes identified from the functional analysis by 
DAVID and GSEA were extracted from InnateDB, and the gene expression values were 
superimposed on these networks. Major differences were found in gene expression levels 
between the treatment groups for the chemokine signalling network (Fig. 5) and for the 
Toll-like Receptor (TLR) signalling network (Fig. 6). When focusing on the cellular 
location of the differentially expressed gene-encoded products of the cytokine and TLR 
networks, it is remarkable to see that especially the products situated extracellularly, on the 
cell surface, and the plasma membrane (Fig. 7 and 8), differed between the treatment 
groups. In T2 and T3 piglets lower expression was observed in these 2 networks compared 
to the untreated (T1) piglets. Further differentiation could be made between T2 and T3, 
where in T2 expression is lower compared to T3. In other words, expression of immune 
associated genes was high in T1, low in T2, and intermediate in T3. 
Discussion 
Effects of the different treatments on day 4 after birth were clearly visible at day 8 after 
birth, for both community-scale microbiota data and genome-wide transcriptomic data. The 
current study shows effects of early-life environmental variation on microbial colonization 
and immune development in the gut of piglets that were kept under regular-production 
circumstances. Here, we will focus specifically on comparison of T1 versus T2/T3 animals, 
for both microbiota and gene expression. 
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Figure 5. Snapshot of Toll-like receptor network. Interactions of genes involved in the Toll-like receptor (TLR) 
pathways were extracted from innateDB and visualized in CytoScape. Nodes (genes) are coloured by their 
expression, where blue is low expression and red is high expression (see legend on top). Abbreviations used: T1; 
Treatment 1,T2; Treatment 2, T3; Treatment 3. 
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Figure 6. Snapshot of chemokine network. Interactions of genes associated with chemokine pathways were 
extracted from innateDB visualized in CytoScape. Nodes (genes) are coloured by their expression, where blue is 
low expression and red is high expression (see legend on top). Abbreviations used: T1; Treatment 1,T2; Treatment 
2, T3; Treatment 3. 
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Figure 7. Toll-like receptor signalling pathway. Interactions of genes associated with Toll-like receptor pathways 
were extracted from innateDB [235] and visualized in CytoScape. Nodes (genes) are coloured by their expression, 
where blue is low expression and red is high expression. Furthermore, localization of gene products within the cell 
was predicted using Cerebral [238]. Abbreviations used: T1; Treatment 1,T2; Treatment 2, T3; Treatment 3. 
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Figure 8. Chemokine signalling network. Interactions of genes associated with chemokine pathways were 
extracted from innateDB [235] and visualized in CytoScape. Nodes (genes) are coloured by their expression, 
where blue is low expression and red is high expression. Furthermore, localization of gene products within the cell 
was predicted using Cerebral [238]. Abbreviations used: T1; Treatment 1,T2; Treatment 2, T3; Treatment 3. 
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Comparison of microbiota composition and diversity between treatment groups  
The diversity of microbiota as measured by the PITChip in jejunum digesta of T1 animals 
was significantly lower compared to that in the T2 and T3 animals. This study shows that a 
single antibiotic dose, administered at day 4 after birth, is able to modulate the microbial 
community for an extensive time. The antibiotic used in this study is regularly applied at 
pig farms with a one-time administration because of the long half-life (70h) of the product 
and elimination half-life was approximately 6-8 days (details on website European 
Medicines Agency). This is in line with previous observations, which showed that 
microbiota composition and diversity was affected for at least five weeks in new-born 
piglets after a single dose of parenteral amoxicillin treatment [59]. Different methodologies 
were used in our study as compared to Janczyk et al. to assess microbial diversity, i.e. 
microarray- and denaturing gradient gel electrophoresis (DGGE)-based profiling of 
PCR-amplified 16S rRNA gene fragments. Nevertheless, we observed that the trends in 
diversity are comparable, also with those obtained by next generation technology 
sequencing, albeit at different absolute values [97, 104-106]. Also the bacterial composition 
is not likely to return to its initial state, because the gastrointestinal tract undergoes a rapid 
dynamic development.  
In this experiment the antibiotic treatment (T2) caused a detectable change in relative 
abundance of most early gut colonizers. Among these colonizers, the abundance of all 
anaerobic bacteria including Bifidobacterium, Eubacterium, F. prausnitzii, and S. moorei 
increased, whereas facultative bacteria such as S. aureus decreased in quantitative terms. 
These results may contradict some previous reports, it has been reported that a range of 
different antibiotics (including Amoxicillin, Ciprofloxacin, Augmentin and Trimethoprim) 
can reduce Bifidobacterium in adult faecal microbiota [241, 242], however, a strong 
increase of Bifidobacterium relative abundance was observed in this study in response to 
the antibiotic tulathromycin. One possible reason could be that certain antibiotic resistant 
Bifidobacterium strains, such as B. longum and B. catenulatum [56], can survive under the 
tulathromycin antibiotic selection. Another explanation could be a difference in the activity 
of antibiotics in the intestinal lumen compared to the colon. Nevertheless, a higher 
microbial diversity in T2 detected in this study may indicate a relatively complex 
microbiota of T2 animals compared to T1 animals. In the complex gut microbial system, 
facultative bacteria, such as S. aureus can not withstand the competition and environmental 
changes brought by the anaerobes, as shown in young infants [190]. In addition, S. aureus 
colonization has been reported negatively correlated to certain antibiotic treatments at 6 
months of age in infants [243-245]. Thus, the reduction of S. aureus in T2 could be 
attributed to the acceleration of complex anaerobic microbiota establishment by the 
antibiotic and/or its sensibility to the antibiotic. On the contrary, we did not found a notable 
change of S. aureus between T3 and T1 animals. It appeared that the antibiotic effect was 
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counteracted by stress management, because the microbial groups observed in T2 animals 
were not observed in T3 animals. Interestingly, this was also observed for Bifidobacterium, 
Eubacterium, and S. moorei. 
In addition to the microbial groups discussed above, there are 20 microbial groups that only 
showed difference between T2 and T3 in this study. This result may be attributed to a yet 
unknown combined effect of antibiotic and management treatment (causing stress), which 
may involve complex host-microbial interactions in the gut. 
The results from these microbiota analyses show that microbial diversity and composition 
are affected by the different treatments. Earlier findings of Schmidt et al. also showed that 
continuous microbial exposure during early life stages is required for the development of a 
stable gut microbiota. However, it should be noted that, contrary to our study, Schmidt et al. 
measured the mucosa-adherent microbiota [169]. In the present study, piglets were housed 
under field conditions of commercial intensive farming systems that correspond to ‘natural’ 
and continuous exposure to microbial species. Compared to the control T1 group, the 
administration of tulathromycin caused a clear increase in microbial diversity, leading to a 
situation which is described by others as “more chaotic” [169]. The microbiota of ‘natural’ 
colonized piglets is characterized by a high abundance of lactobacilli and low abundance of 
microbial species related to pathogens. Such a ‘natural’ microbiota composition and 
diversity has been proposed to be important for immune homeostasis [52].  
At the phylum level similar relative abundance levels of microbial groups were observed 
between the different treatment groups (Supplementary Table C in File S1), which is in 
contrast to the observation of Mulder et al. (2009) where antibiotic treatment resulted in a 
severe reduction in abundance of Firmicutes and increase of Bacteriodetes and 
Proteobacteria compared to the outdoor situation [52]. However, in the study of Mulder a 
cocktail of antibiotics was administered daily from day 1 to 28 of age, as opposed to a 
single dose of one antibiotic at day 4 in this study. Furthermore the phylum level data in 
Mulder et al. represents an overall abundance of (mucosa-adherent) microbial groups in the 
whole experiment, thus including different time-points, which makes it more difficult to 
compare with our data. Despite of the differences in experimental setup, it is known that 
both mucosal and luminal microbiota are able to interact with the host [246], however, 
luminal microbiota might do this more indirectly. Both studies show that the microbial 
diversity is affected by the antibiotic treatment, and concomitantly gene expression data 
showed shifts in communicative/immune processes at day 5 and/or our day 8 data.  
Comparison of gene expression in host blood and intestinal tissues  
Simultaneous to the microbiota sampling, gene expression measurements were performed 
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of intestinal tissue (scrapings) at the same location (in case of jejunum). In addition, blood 
transcriptome analysis was performed in order to investigate whether cross-talk between 
host and microbiota during this neonatal period induced systemic changes. However, the 
lack of significant differences between the blood samples of the treatment groups suggests 
that affected immunological processes are still local 4 days after treatment. When 
comparing the two different tissues analysed here, more genes were differentially expressed, 
either up or down, in ileum in contrast to jejunum. The dominant processes that were 
affected by the treatments (T2 or T3) are mostly involved in immunological processes and 
the genes involved were down-regulated in comparison to T1 animals. In connection with 
this, we observed that most of the biological processes affected by the treatments (T2 or T3) 
are involved in various immune functions. The transcriptomic data suggest that the 
immunological development after birth can be influenced by external factors (e.g. 
antibiotics and/or stress), possibly by modulating the microbial colonization of the gut 
[247]. Surprisingly, the top 5 processes in the functional analyses were all of 
communicative nature for both jejunum and ileum, including “Chemotaxis” (cell or 
bacterial movement towards a chemical or protein); “chemokine activity”; and “cytokine 
activity”, the latter of which are associated with immune-modulating activities and involved 
in (intra)cellular communication. The term “cyclic adenosine monophosphate (cAMP) 
signaling” is also associated with cell communication (intracellular signal transduction, 
including suppression of regulatory T cells [248]), whereas “extracellular region” is 
associated with the space external to the outermost structure of a cell (e.g. plasma 
membrane). To investigate the above described immunological differences in more detail, a 
systems approach was applied, by extracting gene-gene interaction networks (InnateDB) for 
two immunological processes, namely chemokine and Toll-Like Receptor (TLR) signalling. 
These two networks were chosen because expression of many of the genes that were higher 
in T1 compared to T2 or T3 piglets belonged to these networks. Furthermore, chemokines 
play a major role into guiding the migration of cells, and TLRs play a key role in innate 
immunity and recognition of conserved microbial structures [249]. The data presented here 
suggests that in the intestine of T1 piglets more intensive immunological communication 
occurs compared to T2 and T3 piglets, which is reflected by high expression of chemokine 
and TLR receptors as well as their respective ligands. We hypothesize that the global 
down-regulation in the antibiotic treated animal (T2/T3) compared to the control (T1) 
piglets could be that due to the high diversity and more “chaotic” microbial population in 
the gut of piglets treated with the tulathromycin antibiotic. Similar observations (down 
regulation vs chaotic/high diversity) were observed by the Kelly group [52, 169, 216] .  
Interactions between host and microbiota  
The genes associated with the immunological processes that differ between the treatment 
groups are more strongly expressed in T1 animals compared to T2 and T3 animals, which 
Chapter 4 
86 
might be due to the observed lower diversity in microbiota and the abundance of specific 
(non-pathogenic) bacterial species (e.g. lactobacilli). We observed a trend towards higher 
abundance of lactobacilli in T1 piglets compared to the treatment groups (T1; 18%, T2; 
14%, and T3; 12%). A higher abundance of lactobacilli could lead to more cross-talk 
between these abundant microbiota and host (immune) cells, the more so because it has 
previously been shown that different lactobacilli strains can modulate the expression of 
immune pathways [250, 251]. It is known that communication between and within 
intestinal cells as well as between microbiota and intestinal cells is crucial to set up a proper 
development (shaping) and functioning of the immune system [20]. In case of early 
antibiotic treatment and a concomitant increase of microbial groups related to (intestinal) 
pathogens, it could be hypothesized that due to the antibiotic treatment (too much) 
immunological tolerance is build-up during early life stages against species related to 
pathogens, resulting in an inefficient immune response later in life upon pathogenic 
challenge. This hypothesis regarding the presumed interaction between microbiota and 
immune development is in line with previous conclusions [215, 217, 223, 224, 252]. We 
intend to study this specifically in a further project.  
General conclusion 
Different early-life exposure under real-life circumstances, no antibiotic treatment, 
antibiotic treatment, or antibiotic and stressful treatment, affect the microbial colonization 
and immune development of piglets. The results shown here suggest a different immune 
development due to the early life treatments in these piglets. The next step will be to 
investigate which effect the early-life environment variation has on the immune 
competence later in life. 
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Supplemental tables and figures 
 
Figure S1. Depicted is the experimental design, for each sow (n=16) piglets are divided over the three treatments 
(T1, T2, and T3). At the day of sampling 16 piglets, 1 of each sow are taken for analysis, for analysis, for each 
treatment. 
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Figure S2. In the x-axis the qPCR signal is depicted and in the y-axis the normalized expression value is depicted. 
Three genes are depicted IL1B (upper panel), IL6 (middle panel), and TIMP1 (lower panel).  
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Supplementary Table A in File S1. Pools for microbiota and transcriptomic analyses.  
T3* T2 T1 
Pool 1 Pool 5 Pool 9 
R2679 R2679 R2679 
R2705 R2705 R2705 
R2592 R2592 R2592 
R2704 R2704 R2704 
   
Pool 2 Pool 6 Pool 10 
R2687 R2687 R2687 
R2423 R2423 R2423 
R2369 R2369 R2369 
R2419 R2419 R2419 
   
Pool 3 Pool 7 Pool 11 
R2336 R2336 R2336 
R2504 R2504 R2504 
R2692 R2692 R2692 
R2514 R2514 R2514 
   
Pool 4 Pool 8 Pool 12 
R2591 R2591 R2591 
R2701 R2701 R2701 
R2596 R2596 R2596 
R2669 R2669 R2669 
* For each treatment 4 pools are created based on the same 4 piglets from 4 sows 
Supplementary Table B in File S1. Number of up- or down-regulated probes and genes at day 8 after birth when 
comparing the different treatments (T1, T2, and T3). Numbers of annotated genes are given in parentheses. 
Tissue T2 vs. T1 T3 vs. T1 T3 vs. T2 
 Down Up Down Up Down Up 
Jejunum 63 (27) 24 (5) 29 (15) 38 (16) 6 (0) 55 (23) 
Ileum 80 (34) 49 (16) 80 (24) 76 (29) 45 (6) 76 (32) 
Blood 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
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Supplementary Table C in File S1. Phylum level bacteria changed in T2 and T3.  
  T2 vs. T1 T3 vs. T1 T3 vs. T2 ARC1 
  p value p value p value T1 T2 T3 
Firmicutes 0.34 0.89 0.11 80.15±3.04 76.86±2.01 79.22±0.88 
Proteobacteria 0.34 1 0.11 11.40±2.28 13.45±1.41 12.13±0.52 
Bacteroidetes 0.49 0.69 0.69 2.55±0.40 2.74±0.60 2.74±0.23 
Spirochaetes 0.49 1 0.11 2.50±0.59 2.88±0.29 2.52±0.20 
Actinobacteria 0.34 0.89 0.2 2.29±0.48 2.72±0.32 2.42±0.10 
Fibrobacteres 0.34 0.34 0.03 0.58±0.23 0.70±0.11 0.43±0.02 
Deferribacteres 0.11 1 0.34 0.23±0.04 0.29±0.06 0.22±0.01 
Verrucomicrobia 0.11 1 0.11 0.19±0.03 0.25±0.05 0.18±0.01 
Fusobacteria 1 0.34 0.49 0.10±0.01 0.10±0.01 0.11±0.01 
Chlamydiae 0.49 0.03 0.03 <0.01 <0.01 <0.01 
Planctomycetes 0.49 0.03 0.03 <0.01 <0.01 <0.01 
1 ARC: average relative contribution [%] of a microbial group. Values represent means ± SDs. 
Abbreviations used: T1; Treatment 1,T2; Treatment 2, T3; Treatment 3. 
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Supplementary Table D in File S1. Summary of most prominent terms of GSEA analysis in jejunum. 
T3vsT1      T2vsT1 T3vsT2 
T3 T1 T2 T1 T3 T2 
DEGRADATION 
(VALINE, 
LEUCINE, 
ISOLEUCINE) 
Ribosome/translation x 
response 
immune/defense/wounding  x x 
 LOCOMOTORY_BEHAVIOR  LOCOMOTORY_BEHAVIOR   
 beta cell development  immune cell activation   
    Ribosome/translation   
   
cell cycle (arrest/apoptosis) 
 
  
Abbreviations used: T1; Treatment 1,T2; Treatment 2, T3; Treatment 3. 
Supplementary Table E in File S1. Summary of most prominent terms of GSEA analysis in jejunum. 
T3vsT1 T2vsT1 T3vsT2 
T3 T1 T2 T1 T3 T2 
membrane/ 
receptor 
Ribosome/ 
translation endosome/lysosome/membrane chemokine/cytokine x x 
metabole Immune/ chemokine metabole (lipids/insulin ) 
intestinal 
immunity/inflammation   
apoptosis behavior (locomotory) Biocarta_Integrin_Pathway behavior (locomotory)   
 
  golgi Wounding   
  cell junction Ribosome / translation   
Abbreviations used: T1; Treatment 1,T2; Treatment 2, T3; Treatment 3. 
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Abstract 
To evaluate the effects of early microbial association on microbial colonization of the 
gastro-intestinal (GI) tract and host gene expression in the intestinal mucosa, we established 
an animal model with caesarean derived piglets. All piglets received orally a mixture of 
three microbial species (Lactobacillus amylovorus, Clostridium glycolicum, and 
Parabacteroides sp. ASF519 on day 1, 2, and 3 after birth. Moreover, on day 3 and 4, the 
piglets received either a faecal inoculant of an adult sow as a complex microbial association, 
or a placebo inoculant as simple microbial association. Microbiota composition was 
analysed using the Pig Intestinal Tract Chip, a 16S ribosomal RNA targeted oligonucleotide 
microarray, showing that complex microbial association caused an increase of faecal 
microbial diversity over the whole experiment period and accelerated the faecal microbiota 
to develop into a stable and diverse microbiota. Complex microbial association 
significantly affected the microbial composition and gene expression in the jejunal and ileal 
mucosa, albeit differently in jejunum and ileum. In the ileum, complex microbial 
association led to increased relative abundance of microbial groups that are known to have 
beneficial effects such as bacteria related to the genus Lactobacillus and butyrate producing 
members of Clostridium clusters, whereas it reduced the relative contribution of potential 
pathobionts. Immune-related gene sets were enriched by the complex microbial association 
in the ileal mucosa, and immuneomodulatory genes were negatively correlated with the 
abundance of potential pathobionts in ileal digesta. In conclusion, complex microbial 
association at early age has drastic effects on the development of the intestinal microbiota 
and the immune system. Hence it is proposed that manipulation of the microbial association 
at early age may be a way of supporting functional gut development.  
Key words: piglets, microbiota, microbial association, transcriptome, gastrointestinal tract  
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Introduction 
The intestinal tract of humans and animals is colonized by trillions of microorganisms that 
constitute a community or ecosystem known as the gut microbiota. This complex gut 
microbiota develops after birth as newborns are considered to be virtually sterile. During 
and after birth, microorganisms originating from surrounding environments, including 
faecal samples, rapidly colonize the gut of neonates and young animals [1-3]. However, 
recent studies reported the presence of microbes in the human intra-uterine environment, 
suggesting that some microbial colonization prior to the delivery can not be excluded [4-8]. 
Considerable knowledge has been assembled on the development of the intestinal 
microbiota in human. Generally, the first colonizers that dominate the human intistinal tract 
are facultative anaerobes including Escherichia coli and other Enterobacteriaceae, 
followed by anaerobic bacteria such as Bifidobacterium, Clostridium, Bacteroides, and 
Ruminococcus [9, 10]. The microbial succession during the first few weeks of life in the 
intestinal tract of chicken, pigs, and calves follows a similar pattern. Both coliforms and 
streptococci dominate the microbiota within a few days of birth and obligate anaerobes 
appear some time later, even though neonatal animals are exposed to greater numbers of 
faecal and environmental bacteria than the human neonates [11]. For human infants, after 
this initial colonization, the microbiota undergoes consecutive changes in composition and 
function until a relatively stable climax community is established at around 3 years after 
birth [12]. 
Many factors influence the microbial colonization at early age, including delivery mode 
(vaginally or via caesarean section), feeding (breast feeding or formula feeding), probiotic 
and prebiotic treatment, administration of antibiotics and exposure to environmental 
microbial sources. Most of these factors have been widely studied and reported to have 
either positive or negative impacts on infant and neonate animal development [1, 9, 50, 
253]. However, the outcome of microbial association at early age cannot be easily predicted, 
due to the complexity and variability in especially environmental microbial exposure that 
newborns encounter. Infants may be subjected to different microbes in the hospital, at day 
care and in their home. Nevertheless, studies addressing these different sources of microbial 
exposure are still limited, especially those regarding exposure in hospital and day care . 
Regarding to the influence of the indoor house environment, studies have only shown that 
healthy full term infants living with pets exhibited under-representation of bifidobacteria 
and over-representation of Peptostreptococcaceae, whereas infants with older siblings 
exhibited under-representation of Peptostreptococcaceae and higher numbers of 
bifidobacteria [49, 50].  
With respect to animals, especially piglets, studies have shown that the surrounding 
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environment in the postnatal period can have long-term impact on gut community structure 
[51]. Early-life environment was shown to cause major differences in mucosa-adherent 
microbial diversity in the ileum of adult pigs [52]. The raising environment attributes 
mostly to microbial association of piglets at early age. Pigs housed in a natural outdoor 
environment showed a dominance of Firmicutes, in particular Lactobacillus, whereas pigs 
housed in a hygienic indoor environment had reduced Lactobacillus and higher numbers of 
potentially pathogenic phylotypes [52]. Overall, environmentally-acquired bacteria 
influence the microbiota composition in the gut of piglets, as well as the microbiota of the 
adult pigs throughout life.  
The microbiota plays a critical role in host immune system priming and gut maturation at 
early age, and can further influence the gut function through modifying gene expression of 
the host epithelium [20-23]. The host transcriptional pathways regulated in response to the 
colonizing microbiota involve nutrient uptake and metabolism, mucosal barrier function, 
xenobiotic metabolism, enteric nervous system and motility, hormonal and maturational 
responses, angiogenesis, cytoskeleton and extracellular matrix, signal transduction, and 
general cellular functions [24]. Interestingly, many host genes seem to be specifically 
altered in response to different members of the microbiota [25, 26]. Therefore, colonization 
of different microbes at early age may induce specific immune and metabolism system 
development, which consequently differentially influence the host intestinal and systemic 
health throughout life. 
The pig is an important production animal as well as an appropriate model for humans, 
because of its similarities to humans in terms of anatomy, physiology and GI tract 
metabolism [153, 154, 164-167]. Moreover, piglets have been extensively used as model 
for infant nutrition and for studies on GI tract microbiota thus providing valuable 
information to understand the dynamics of microbial colonization of the intestinal tract. 
Furthermore, what we provide here is also important for developing new strategies for 
improving animal development and performance in animal production. In the present study, 
we used a piglet model designed by Jansman et al. [168] to investigate the impact of 
postnatal association with a simple or a complex microbiota on microbiota development 
and gene expression of the intestinal mucosa at early age. This study includes two animal 
experiments. Firstly, we compared the faecal microbiota of piglets colonized with a simple 
microbial community to that of animals associated with a complex microbiota (i.e. faecal 
inoculum) over a time course of 28 days starting immediately after birth. Secondly, we 
compared the microbiota and host gene expression in the jejunal and ileal mucosa of piglets 
at age of 16 days using the same association model. The results of this study confimed that 
early microbial exposure can impact the gut microbiota and host gut gene expression. This 
study provides evidence for the interaction between environmental factor, microbiota and 
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host. The gained insight is expected to be instrumental in improving sustainable pig 
management, as well as to provide important insight for the study of human gut microbiota.  
Material and methods 
Animals, feeding and sample collection 
Experiment 1 was conducted as previously described by Jansman et al. [168]. Thirty piglets 
from two sows [(Great York×Pie) ×‘Dalland’ cross] were obtained by caesarean delivery 
(day 0). The piglets were divided over two treatment groups, housed in separate clean, 
non-sterile rooms, balanced for body weight and litter of origin. Each piglet received 30 ml 
of blood serum of an adult sow on day 0 and 20 ml on each of days 1, 2, and 3 and 5 mL of 
serum on day 4, as a source of immunoglobulins. All piglets received daily an oral 
inoculation of starter microbiota consisting of Lactobacillus amylovorus (3.6×107 cfu), 
Clostridium glycolicum (5.7×107 cfu) and Parabacteroides sp. ASF519 (4.8×107 cfu) from 
day 1 to 3 after birth. These three bacterial species have been reported to colonize 
throughout the length of the intestinal tract when administered to gnotobiotic piglets and 
induced a systemic increase in serum immunoglobulins. They were shown to be of value 
for highly controlled, reproducible experiments addressing the consequences of early 
microbial colonization [159]. On day 3 and 4, the piglets received either a complex 
microbiota by providing 2 mL of an inoculant consisting of 10% saline diluted faeces (DF) 
of an adult sow (complex association, CA), or a placebo (10% saline) inoculant (simple 
association, SA). Piglets were fed ad libitum a milk replacer diet during a period of 5 days 
(days 0-4) and a commercial moist diet during the remainder of the study as described 
previously [168]. Piglets were studied during a period of 28 days, and faeces of four 
representative piglets were repeatedly obtained for microbiota composition analysis on day 
3, 5, 7, 14 and 28. On day 28, faecal samples were only collected from three piglets due to a 
loss of one animal of the SA group on day 26.  
A second experiment was executed for a further evaluation of microbiota composition and 
mucosal gene expression in the jejunum and ileum using the same experimental model as 
used in experiment 1 [168]. Briefly, the piglets were assigned to one of the two treatments 
(SA or CA) taking into account litter origin, body weight and gender. Each piglet received a 
total of 50, 20, 20 and 20 ml of serum on day 0, 1, 2, and 3 after birth, respectively. For the 
first two days of the experiment, serum was used originating from experiment 1, whereas 
on day 3, serum was used originating from sows who delivered the piglets of the present 
experiment. As described before, all piglets received orally a mixture of Lactobacillus 
amylovorus, Clostridium glycolicum and Parabacteroides sp. ASF519 on day 1, 2 and 3 
after birth. On day 3 and 4 the piglets received either treatment SA or CA. Piglets were fed 
milk for SPF piglets (Sloten bv, Deventer Nederland), consisting of 35% skimmed milk 
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powder, 35% whey powder, 22% vegetable oil, 0.5% hydrolysed wheat protein, 3.3% wheat 
starch, 2.7% sugar and a premix containing 23% crude protein for the first 5 days. For the 
remaining period, a slurry diet for SPF piglets (Nutreco, Trouw Nutrition, Belgium) was fed 
to the piglets, which consisted of 33.1% whey powder, 20.2% maize,13.5% wheat, 9% 
coconut oil, 5% wheat gluten, 2.5% sugar, 5.1% soybean meal, 2.5% potato starch, 2.5% 
potato protein, 1.25% rice protein, 0.6% extruded wheat and a vitamin/mineral premix. At 
day 16, six piglets of each treatment were euthanized based on balance of litter, body 
weight and sex. Intestinal digesta and mucosal tissue samples were collected from the 
jejunum and ileum. Jejunal and ileal mucosal tissue were quickly rinsed in PBS and 
immediately frozen in liquid nitrogen and stored at -80°C for analysis of gene expression.  
Microbiota analysis 
Microbial DNA extraction 
Microbial DNA was extracted from 250 mg of DF, faeces and intestinal digesta of piglets 
using a faecal DNA extraction protocol adapted from Yu and Morrison [198], as described 
by Salonen et al.[199]. Briefly, cell lysis was achieved by bead beating in a Precellys®24 
(Bertin, Montigny-le-Bretonneux, FR) instrument, in the presence of 4% (w/v) sodium 
dodecyl sulphate (SDS), 500 mM NaCl, 50 mM Tris-HCL (pH 8), and 50 mM EDTA. 
Following bead beating, samples were incubated at 95? for 15 min, centrifuged and 
precipitated with 260 μL of 10 M ammonium acetate. Nucleic acids were subsequently 
recovered by precipitation with isopropanol. Nucleic acid pellets were washed with 70% 
ethanol, dried and re-suspended in 100 μl of TE buffer. Purification was attained by adding 
2 μl (10 mg/ml) RNase and incubating the samples for 15 min at 37°C. After incubation, 
15μl proteinase K and 200 μl Buffer AL was added, followed by the use of QIAamp 
columns to complete purification. 
Microbiota analysis 
The microbial composition of DF, faeces and intestinal digesta of piglets was analyzed by 
using the Pig Intestinal Tract Chip (PITChip), version 1.0 and 2.0, respectively, in 
experiment 1 and experiment 2. The PITChip is a phylogenetic microarray, with more than 
2,980 oligonucleotides based on 16S rRNA gene sequences of 627 porcine intestinal 
microbial species-level phylotypes for version 1.0, and with more than 3290 
oligonucleotides based on 16S rRNA gene sequences of 781 porcine intestinal microbial 
species-level phylotypes respectively for version 2.0 [97, 101]. Like its human microbiota 
counterpart, the Human Intestinal Tract Chip (HITChip) [103], it provides a very deep and 
reproducible phylogenetic analysis that has been compared with deep pyrosequencing of 
16S rRNA gene fragments [97, 104, 105] and next generation parallel sequencing of the 
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intestinal metagenome [106], indicating comparable resolution and a higher sensitivity of 
the chip based analysis. The protocol for hybridization and analysis of the generated data 
was performed essentially as described before for the HITChip [103]. The bacterial 16S 
rRNA gene pool was amplified using the primers T7 prom-Bact-27-for and Uni-1492-rev. 
The PCR products were in vitro transcribed into RNA that was subsequently purified and 
coupled with CyDye prior to fragmentation and hybridization to the array. Microarray 
images were processed using Agilent's Feature Extraction Software version 9.1 for 
experiment 1 and version 9.5 for experiment 2 (http://www.agilent.com). Data were 
retrieved from the MySQL (version 5.1) database as describe by Rajilic-Stojanovic [200] 
and pre-processed using the R (Rx64 2.12.2) microbiome package 
(http://microbiome.github.com/), using default settings.  
Denaturing Gradient Gel Electrophoresis (DGGE) analysis was applied to detect the faecal 
microbiota of the excluded piglets. See Supplemental methods for experimental details. 
Gene expression of intestinal tissue  
RNA extraction  
Total RNA was extracted from 50 to 100 mg jejunal and ileal mucosal tissue. The jejunum 
and ileum samples were homogenised using the TisuPrep (Homogenizer Omni TP TH220P) 
in TRizol reagent (Life Technologies) as recommended by the manufacturer with minor 
modifications. The homogenised tissue samples were dissolved in 5 ml of TRizol reagent. 
After centrifugation the supernatant was transferred to a fresh tube. Subsequently a phase 
separation with chloroform was performed as described by the manufacturer. The RNA was 
precipitated, dissolved and quantified by absorbance measurements at 260 nm. Furthermore 
quality control was performed with the BioAnalyzer 2100 (Agilent Technologies, Santa 
Clara, CA).  
Labelling, hybridization, scanning and feature extraction 
Labelling was done as recommended by Agilent Technologies using the One-Color 
Microarray-Based Gene Expression Analysis Low input Quick Amp Labelling. The input 
was 10 ng of total RNA and 600 ng of labelled cRNA was used on an 8-pack array, porcine 
Agilent microarray slides, G2519F Sus scrofa (035953; V2:026440).  
Hybridization was performed as described in the Agilent One-Color Microarray-Based 
Gene Expression Analysis Low input Quick Amp Labelling protocol in a dedicated 
hybridization oven (G2545A hybridization Oven Agilent Technologies). The hybridization 
temperature was 65°C with rotation speed 10 rpm for 17 hours. After 17 hours the arrays 
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were washed as described in the above-mentioned labelling protocol. 
The arrays were scanned using an Agilent Technologies DNA microarray scanner with 
Surescan high resolution Technology, using Agilent Scan Control with resolution of 5μ, 16 
bits and PMT of 100%. Feature extraction was performed using protocol 10.7.3.1 (v10.7) 
for 1 colour gene expression. 
Data loading and processing  
For each sample (n=24) a technical replicate was available, thus in total 48 samples were 
analyzed. The 48 files generated by the feature extraction software were loaded in 
GeneSpring GX 12, in which a log2-transformation and quantile normalization were 
performed. After quantile normalization, quality control was performed and data belonging 
to one ileal mucosa sample were removed. For each technical replicate pair the average was 
calculated and subsequently analysed by principle component analysis for each tissue 
separately.  
Statistical methods 
Microbiota analysis 
Multivariate analysis was applied for detecting the microbial variation between CA and SA 
piglets. Principal response curves (PRC) analysis was employed to detect the faecal 
microbial variation over time in experiment 1. As described by Van den Brink and Ter 
Braak [201], PRC is based on redundancy analysis (RDA) adjusted for overall changes in 
community response over time. PRC focuses on the time-dependent treatment effects and 
enables a quantitative interpretation of effects towards the microbial composition. For PRC, 
the principal component is plotted against time, yielding a principal response curve of the 
community for each treatment. For the present study, treatment classes (CA or SA) were 
introduced as environmental (explanatory) variables and five sampling times (day 3, 5, 7, 
14 and 28) were introduced as co-variables. The responsive variables were the relative 
contribution of 143 level 2 (approximate genus-level, 90% 16S ribosomal RNA similarity 
threshold) phylogenetic groups targeted by the PITChip (version 1.0). To evaluate the 
statistical significance of treatment effects on microbiota, Monte Carlo permutation tests 
were performed. These tests were also performed per sampling date, allowing the 
significance of the effect of a treatment regime to be tested for each sampling time. For day 
28, since only three faecal samples of SA piglets were collected, the geometric mean of the 
relative contribution of 143 approximate genus-level phylogenetic groups of the other 3 SA 
piglets was calculated and included in the dataset.  
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To relate the variation of microbiota in jejunal and ileal content to treatments in experiment 
2, RDA was used as implemented in the CANOCO 4.5 software package (Biometris, 
Wageningen, The Netherlands). RDA is the canonical form of principle component analysis 
and is a multivariate linear regression method where several response parameters are 
related to the same set of environmental variables of reduced rank [254]. The response 
variables in experiment 2 were the relative contribution of 150 approximate genus-level 
phylogenetic groups detected by the PITChip (version 2.0), and treatment classes (CA or 
SA) were introduced as environmental (explanatory) variables. RDA was performed 
focusing on inter-samples correlation, and the Monte Carlo Permutation test was applied to 
evaluate whether treatment class significantly contributed to the observed differences in 
microbial composition between CA and SA groups [228, 255]. Since the experiment had a 
randomized design, we used the unrestricted permutation option that yields completely 
random permutations. Treatment classes were considered to significantly affect microbial 
composition at P values < 0.05. Diagrams were plotted as biplots using CanoDraw 
(Biometris, Wageningen, The Netherlands).  
Univariate testing of differences for individual microbial groups in experiment 1 and 
experiment 2 was done using a Mann-Whitney U signed rank test. P-values were corrected 
for multiple testing using Benjamini–Hochberg’s approach [202]. 
Gene Set Enrichment Analysis (GSEA)  
GSEA [9,10] was performed separately for the ileal and jejunal mucosal tissue in 
experiment 2. The following settings were different from the default settings. Permutations 
were performed on the gene set, and chip platform was set to gene symbol. Six gene set 
databases (v3.0) were loaded for analysis, namely three Gene Ontology (GO) related gene 
sets, i.e. biological processes, molecular function and cellular component, and three 
pathway related gene sets, i.e. BioCarta, Reactome and KEGG. 
Correlation analysis  
Correlation analysis of microbiota (PITChip data) and gene expression (tissue) datasets was 
performed as previously described [256]. In brief, a correlation matrix between the PITChip 
data and intestinal tissue gene expression was computed using the 2log transformed 
expression values. To reduce the probability of type I errors (false positives) for multiple 
testing, the Benjamini–Yekutieli method [202] was employed and the data was corrected 
for multiple testing using an FDR method. FDR was set at < 0.05 % for expected 
proportion of false positive correlations in the multiple comparison testing. Detailed 
explanation of the methods used to perform correlation analysis can be obtained from the 
authors upon request. 
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Results 
Faecal microbial colonization 
In order to evaluate the effects of inoculation with diluted faeces (DF) on microbiota 
establishment over time, we calculated the similarity of microbiota between DF and faeces 
of CA piglets over time using Pearson’s correlation, taking the similarity between DF and 
SA piglets as a control (Fig. 1). The similarity was at the lowest value at day 3 for both SA 
(66.7±4.7%) and CA (63.7±4.3%) piglets. After inoculation with DF, the similarity between 
DF and CA piglets significantly increased at day 5 (P<0.05). It slightly dropped at day 7 
and then significantly increased at day 14 (P<0.05), reaching its highest value (86.6±4.1%) 
at day 28. As a control, the similarity between DF and SA piglets did not significantly 
change over time, although there was an increasing trend at day 5 and 28.  
 
Figure 1. Similarity of microbial profiles of sow faeces used for early microbial association and faeces of piglets 
in the SA and CA treatment over time in experiment 1. The microbiota similarity was calculated between DF and 
piglets at day 3 (D3), 5(D5), 7(D7), 14(D14) and 28(D28) using Pearson’s correlation. SA, simple association with 
a placebo inoculant; CA, complex association with inoculant consisting of diluted faeces of an adult sow. 
Microbial diversity of faecal samples as based on the Shannon index appeared to be higher 
for all piglets with increasing age, except at day 28 (Fig.2). When comparing the microbial 
diversity in CA-piglets to that of SA-piglets, we found that the CA piglets had a 
significantly lower diversity than SA piglets at day 3 (P<0.05). After DF inoculation, 
however, the diversity of CA piglets was higher than that of SA piglets, with significant 
differences observed for day 5 and 14 (P<0.05).  
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Figure 2. Microbial diversity of piglets’ faeces over time in experiment 1. The Shannon index was calculated 
separately for both treatments at all sampling times. SA, simple association with a placebo inoculant; CA, complex 
association with inoculant consisting of diluted faeces of an adult sow. Numbers following SA or CA indicate 
sampling time: day 3, 5, 7, 14 and 28.   
Principle Response Curves (PRC) analysis indicated that after DF inoculation, microbiota 
composition in CA piglets increasingly deviated from that of SA piglets especially after day 
5 (Fig. 3). Mont Carlo permutation testing confirmed that association with DF contributed 
significantly to the microbial differences between CA- and SA-piglets (P=0.045). The 
composition of microbiota of CA piglets tended to be different from that of SA piglets at 
day 7 (P=0.060) and day 28 (P=0.065), and the difference was significant at day 14 
(P=0.045). 
Univariate testing was applied to detect differences in microbial groups between CA and 
SA piglets at each sampling day. At day 3, we detected a different relative abundance of 
bacteria related to the genera Allofustis, Weissella, Sphingomonas and Leptospira (Table 1). 
After DF inoculation, there was an increase of six bacterial groups of Clostridium cluster 
XIVa and Treponema at approximate genus level at day 5 (Table 1). More bacterial groups 
varied between the SA and CA piglets at day 7. At phylum level, the relative abundance of 
Fibrobacteres decreased in CA-piglets in comparison with SA-piglets (Supplemental 
Table 1). At level 2 (90% 16S ribosomal RNA similarity threshold), there was a reduction 
in the relative abundance of bacteria related to Fibrobacter succinogenes, Gemella 
haemolysans, Lactobacillus gasseri, Turicibacter, uncultured Clostridium cluster IV, 
Clostridium sphenoides, Pseudomonas, and Brachyspira, whereas an increase was detected 
for the relative abundance of a number of anaerobic bacterial groups typically found in 
faeces, including fermenting microorganisms and populations especially within the 
Firmicutes known or predicted to be involved in production of short chain fatty acids, such  
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Table 1. Level 2 phylogenetic groups with different relative abundance in piglets faeces over time in experiment 
1.  
Class Group 
Effect1 
P value C.p2 
ARC3 
CA vs SA SA CA 
Day 3       
Bacilli Allofustis - 0.03  0.62  0.43±0.10 0.25±0.06 
 Weissella et rel. - 0.03  0.62  0.36±0.13 0.19±0.08 
Alphaproteobacteria Sphingomonas et rel. - 0.03  0.62  0.05±0.01 0.04±0.01 
Spirochaetes Leptospira + 0.03  0.62  0.52±0.08 0.65±0.03 
Day 5       
Clostridium cluster XIVa Clostridium lactifermentans et rel. + 0.03  0.48  0.11±0.05 0.27±0.12 
 Clostridium symbosium et rel. + 0.03  0.48  0.14±0.03 0.36±0.14 
 Coprococcus eutactus et rel. + 0.03  0.48  0.23±0.07 0.44±0.11 
 Eubacterium plexicaudatum et rel. + 0.03  0.48  0.03±0.00 0.06±0.04 
 Ruminococcus obeum et rel. + 0.03  0.48  0.87±0.20 3.13±2.07 
 Uncultured Clostridia XIVa + 0.03  0.48  1.04±0.30 2.38±0.51 
Spirochaetes Treponema et rel. + 0.03  0.48  0.15±0.04 0.32±0.10 
Day 7       
Actinobacteria Aeriscardovia et rel. + 0.03  0.20  0.12±0.04 0.26±0.11 
 Collinsella + 0.03  0.20  0.13±0.06 0.29±0.06 
 Olsenella et rel. + 0.03  0.20  0.01±0.00 0.04±0.01 
Sphingobacteria Sphingobacterium thalpophilum et rel. + 0.03  0.20  0.02±0.01 0.05±0.02 
Fibrobacteres Fibrobacter succinogenes et rel. - 0.03  0.20  1.39±0.75 0.20±0.08 
Bacilli Gemella haemolysans et rel. - 0.03  0.20  0.37±0.13 0.17±0.07 
 Lactobacillus gasseri et rel. - 0.03  0.20  6.18±4.82 0.04±0.05 
 Turicibacter et rel. - 0.03  0.20  1.46±0.96 0.12±0.04 
Clostridium cluster IV Clostridium leptum et rel. + 0.03  0.20  0.16±0.12 0.48±0.12 
 Faecalibacterium prausnitzii et rel. + 0.03  0.20  1.73±0.83 3.49±0.73 
 Ruminococcus bromii et rel. + 0.03  0.20  0.01±0.00 0.03±0.02 
 Sporobacter termitidis et rel. + 0.03  0.20  3.66±1.48 6.49±0.63 
 Subdoligranulum et rel. + 0.03  0.20  0.32±0.07 0.58±0.22 
 Uncultured Clostridia IV - 0.03  0.20  1.12±0.20 0.67±0.12 
Clostridium cluster IX Mitsuokella multiacida et rel. + 0.03  0.20  0.04±0.01 0.18±0.14 
Clostridium cluster XIVa Clostridium sphenoides et rel. - 0.03  0.20  0.25±0.05 0.12±0.04 
Clostridium cluster XIVb Uncultured Clostridia XIVb + 0.03  0.20  1.62±0.40 2.11±0.09 
Gammaproteobacteria Pseudomonas et rel. - 0.03  0.20  1.32±0.51 0.56±0.22 
 Psychrobacter et rel. + 0.03  0.20  0.27±0.09 0.46±0.08 
Spirochaetes Brachyspira - 0.03  0.20  0.03±0.02 0.01±0.00 
Day 14       
Bacteroidetes Alistipes et rel. + 0.03  0.19  0.05±0.03 2.21±1.28 
 Bacteroides pyogenes et rel. + 0.03  0.19  0.04±0.07 0.60±0.31 
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 Bacteroides vulgatus et rel. + 0.03  0.19  0.02±0.03 0.41±0.13 
 Prevotella melaninogenica et rel. + 0.03  0.19  0.07±0.07 1.68±0.36 
 Prevotella ruminicola et rel. + 0.03  0.19  0.03±0.04 0.20±0.12 
 Uncultured Bacteroidetes + 0.03  0.19  0.08±0.12 2.74±2.26 
 Uncultured Prevotella + 0.03  0.19  0.73±1.00 11.79±4.76 
Flavobacteria Flavobacterium cucumis et rel. + 0.03  0.19  0.01±0.00 0.06±0.04 
Sphingobacteria Uncultured Sphingobacteria + 0.03  0.19  0.02±0.02 0.17±0.06 
Bacilli Streptococcus intermedius et rel. + 0.03  0.19  0.34±0.25 1.33±0.45 
Clostridium cluster IV Clostridium cellulosi et rel. + 0.03  0.19  0.20±0.10 0.62±0.25 
Clostridium cluster IX Megasphaera elsdenii et rel. + 0.03  0.19  0.01±0.00 0.65±0.47 
 Mitsuokella multiacida et rel. + 0.03  0.19  0.06±0.04 0.65±0.26 
 Peptococcus niger et rel. + 0.03  0.19  0.00±0.00 0.02±0.01 
 Phascolarctobacterium faecium et rel. + 0.03  0.19  0.63±0.07 1.22±0.11 
Mollicutes Acholeplasma et rel. - 0.03  0.19  0.29±0.06 0.17±0.06 
Planctomycetacia Uncultured planctomycetacia + 0.03  0.19  0.01±0.00 0.09±0.06 
Gammaproteobacteria Avibacterium - 0.03  0.19  0.27±0.14 0.04±0.01 
 Bisgaard - 0.03  0.19  0.21±0.10 0.03±0.01 
 Escherichia coli et rel. - 0.03  0.19  1.93±0.39 1.13±0.33 
 Pasteurella - 0.03  0.19  0.43±0.18 0.10±0.04 
?  Ruminobacter et rel. - 0.03  0.19  0.26±0.12 0.04±0.02 
1 Effect: indicates whether the average relative contribution of a microbial group was increased (+) or decreased (-) in the CA 
group in comparison with the SA group. 
2 C.p: P value corrected for multiple testing according to the procedure of Benjamini-Hochberg 
3 ARC: Average relative contribution [%] of a microbial group. Values represented means ± SDs. 
as Clostridium leptum, Faecalibacterium prausnitzii, Sporobacter termitidis, Ruminococcus 
bromii and Mitsuokella multiacida (Table 1). The observed differences also reflected the 
significantly higher similarity between the faecal inoculum and CA piglet faecal microbiota 
profiles as described above. At day 14, we found an increase in Bacteroidetes and 
Planctomycetes, with a decrease in Proteobacteria at phylum level in CA-piglets 
(Supplemental Table 1). At approximate genus level, there was an increase of 16 bacterial 
groups belonging to the classes of Bacteroidetes, Flavobacteria, Sphingobacteria, Bacilli, 
Clostridium cluster IV, Clostridium cluster IX and Planctomycetacia in CA-piglets 
respectively, while a lower relative abundance was detected for Acholeplasma and bacterial 
groups belonging to Gammaproteobacteria, including Avibacterium, Bisgaard, Escherichia 
coli, Pasteurella and Ruminobacter (Table 1). At day 28, no significant differences in 
relative abundance of bacterial groups were detected between treatments, however, 
observed differences were similar to those found at day 7 (Supplemental Table 2).  
  
Chapter 5 
106 
 
Figure 3. Principal response curves indicating the faecal microbial variation over time of CA-and SA-piglets in 
experiment 1. Of all variance, 28.1% is attributed to sampling date and displayed on the horizontal axis, 21.5% is 
attributed to treatment, and 58.8% was attributed to differences between individual piglets. Of the variance 
explained by treatment, 51.6 % is displayed on the vertical axis. The SA treatment was set as the baseline 
throughout the experiment. Cdt, Cdt is calculated based on canonical coefficients in the output of CANOCO 
software according to formula: Cdt = Regression and canonical coefficient of environmental variable*total standard 
deviation/standad deviation of environmental variable. 
Microbial profile in jejunal and ileal digesta  
RDA showed that the complex microbial association significantly contributed to the 
observed difference of jejunal (P=0.002) and ileal (P=0.002) microbiota between CA and 
SA piglets in Experiment 2 (Fig. 4). Univariate analysis showed differences in microbial 
groups in digesta of the jejunum and ileum between treatments. In the jejunum, the relative 
abundance of the phyla Deferribacteres, Spirochaetes and Verrucomicrobia was 
significantly higher in the CA group, whereas the relative abundance of Bacteroidetes, 
Fibrobacteres and Fusobacteria was lower compared to the SA group (Supplemental Table 
3). At the genus level (i.e. 90% sequence similarity), CA resulted in a decrease of certain 
early gut colonizers, including Bifidobacterium and Faecalibacterium prausnitzii, as well 
as some opportunistic pathogens such as Streptococcus suis. A few presumed beneficial 
microbes such as Akkermansia muciniphila and Eubacterium rectale were increased; 
opportunistic pathogens such as Clostridium perfringens were increased in the CA piglets 
as well compared to SA piglets (Table 2).  
In ileal digesta, there was a significantly higher relative abundance of Firmicutes and 
Verrucomicrobia at phylum level in CA group, while a lower relative abundance was 
detected for Proteobacteria, Bacteroidetes, Fibrobacteres and Fusobacteria (Supplemental 
Table 3). At the approximate genus level, a stimulation of CA was found for some 
presumed beneficial microbes, including bacteria related to Akkermansia muciniphila, 
Lactobacillus plantarum, Lactobacillus salivarius and butyrate-producing Ruminococcus 
bromii and Eubacterium rectale, whereas opportunistic pathogens including Clostridium 
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leptum, Clostridium difficile, and members of the Gammaproteobacteria, e.g. Escherichia 
coli and Pseudomonas spp. were reduced in the CA group (Table 3).  
Despite the change in relative abundance of several microbial groups, CA did not 
significantly alter the microbial diversity in the jejunal and ileal digesta as indicated by 
Shannon indices (P>0.05) (data not shown). 
 
Figure 4. Biplots for RDA analysis of microbiota in jejunal (A) and ileal digesta (B) in experiment 2. Nominal 
environmental variables simple association (SA) and complex association (CA) are represented by triangles (▲). 
Samples are grouped by treatment: CA (■) and SA (●), each symbol represents a piglet. Both axes together explain 
72.7% of the total variance in the data for microbial composition in digesta obtained from the jejunum (A) and 
ileum (B).  
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Table 2. Level 2 phylogenetic groups with different relative abundance in the digesta of the jejunum of piglets at 
day 16 of age in experiment 2. 
Class Group 
Effect1 P 
value C.p
2 
ARC3 
CA vs 
SA CA SA 
Actinobacteria Bifidobacterium et rel. - <0.01 0.02  0.65±0.08 0.94±0.17 
Bacteroidetes Bacteroides distasonis et rel. - <0.01 0.02  0.25±0.13 0.71±0.18 
Prevotella melaninogenica et rel. - <0.01 0.02  0.12±0.05 0.27±0.06 
Uncultured Porphyromonadaceae - 0.03  0.07  0.40±0.04 0.46±0.06 
Uncultured Prevotella - <0.01 0.02  0.67±0.27 1.52±0.35 
Deferribacteres Mucispirillum schaedleri et rel. + 0.03  0.07  0.28±0.03 0.22±0.04 
Fibrobacteres Fibrobacter succinogenes et rel. - 0.01  0.03  0.23±0.14 0.61±0.23 
Bacilli Aerococcus urinaequi et rel. + <0.01 0.02  0.10±0.07 0.02±0.00 
Bacillus et rel. - <0.01 0.02  0.40±0.05 0.58±0.13 
Carnobacterium et rel. + <0.01 0.02  0.65±0.05 0.44±0.09 
Enterococcus et rel. + 0.01  0.03  4.42±0.51 3.35±0.58 
Lactobacillus salivarius et rel. + <0.01 0.02  3.41±0.47 1.56±0.27 
Lactococcus et rel. - <0.01 0.02  0.24±0.14 1.03±0.41 
Staphylococcus aureus et rel. + 0.02  0.05  0.18±0.02 0.14±0.03 
Streptococcus bovis et rel. - 0.03  0.07  2.25±1.30 4.35±1.19 
Streptococcus salivarius et rel. - <0.01 0.03  0.85±0.48 2.38±0.68 
Streptococcus suis et rel. - <0.01 0.02  1.04±0.58 2.60±0.68 
Uncultured Bacilli + 0.03  0.07  0.14±0.02 0.10±0.02 
Clostridium cluster I Clostridium perfringens et rel. + <0.01 0.03  0.74±0.06 0.52±0.18 
Clostridium cluster IV Anaerotruncus et rel. + 0.01  0.03  1.24±0.14 0.91±0.16 
Faecalibacterium et rel. - 0.01  0.03  0.51±0.05 0.62±0.08 
Faecalibacterium prausnitzii et rel. - 0.01  0.03  0.36±0.10 0.61±0.11 
Ruminococcus callidus et rel. + 0.02  0.05  2.90±0.30 2.22±0.43 
Uncultured Clostridia IV + 0.04  0.10  3.81±0.38 3.21±0.54 
Clostridium cluster IX Megasphaera elsdenii et rel. - <0.01 0.03  0.13±0.07 0.28±0.07 
Mitsuokella multacida et rel. - 0.01  0.03  1.02±0.61 2.39±0.56 
Peptococcus niger et rel. + 0.02  0.05  0.33±0.05 0.25±0.04 
Phascolarctobacterium faecium et rel. - 0.01  0.03  0.16±0.04 0.25±0.04 
Veillonella - 0.01  0.03  0.14±0.03 0.18±0.02 
Clostridium cluster XIVa Butyrivibrio crossotus et rel. - 0.04  0.10  1.16±0.06 1.24±0.05 
Coprococcus eutactus et rel. - <0.01 0.02  0.48±0.10 0.82±0.12 
Eubacterium hallii et rel. - 0.01  0.03  0.59±0.04 0.68±0.05 
Eubacterium rectale et rel. + 0.04  0.10  2.26±0.18 1.92±0.30 
Lachnobacillus bovis et rel. + 0.01  0.03  1.41±0.22 1.08±0.16 
Roseburia intestinalis et rel. - 0.01  0.03  1.08±0.10 1.35±0.17 
Ruminococcus obeum et rel. + 0.04  0.10  3.08±0.31 2.58±0.39 
Clostridium cluster XIVb Uncultured Clostridia XIVb - 0.03  0.07  1.39±0.16 1.53±0.08 
Mollicutes Uncultured Mollicutes + 0.01  0.03  0.68±0.07 0.49±0.11 
Fusobacteria Fusobacterium et rel. - 0.01  0.03  0.46±0.17 0.90±0.26 
Alphaproteobacteria Caulobacter et rel. + 0.01  0.03  1.04±0.11 0.80±0.17 
Labrys methylaminiphilus et rel. + <0.01 0.02  0.86±0.05 0.72±0.07 
Rhodobacter et rel. + 0.04  0.10  0.79±0.12 0.62±0.13 
Betaproteobacteria Neisseria et rel. - <0.01 0.03  0.30±0.05 0.44±0.08 
Sutterella wadsorthia et rel. - 0.04  0.10  0.37±0.08 0.49±0.05 
Deltaproteobacteria Desulfovibrio et rel. - 0.01  0.03  0.4±0.07 0.57±0.11 
Lawsonia intracellularis et rel. - <0.01 0.03  0.15±0.09 0.37±0.10 
Uncultured Deltaproteobacteria + 0.03  0.07  0.28±0.03 0.22±0.04 
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Gammaproteobacteria Aeromonas + 0.04  0.10  0.18±0.02 0.13±0.05 
Ignatzschineria et rel. + 0.01  0.03  0.44±0.05 0.30±0.06 
Psychrobacter et rel. - 0.03  0.07  0.42±0.04 0.51±0.07 
Vibrio et rel. + 0.04  0.10  0.18±0.02 0.13±0.05 
Spirochaetes Brachyspira - 0.04  0.10  0.20±0.06 0.25±0.05 
Treponema et rel. + <0.01 0.02  1.29±0.23 0.75±0.17 
Uncultured Spirochaetes + 0.02  0.05  0.51±0.06 0.37±0.09 
Verrucomicrobiae Akkermansia muciniphila et rel. + 0.04  0.10  0.25±0.03 0.20±0.04 
1 Effect: indicates whether the average relative contribution of a microbial group was increased (+) or decreased (-) in the CA 
group in comparison with the SA group. 
2 C.p: P value corrected for multiple testing according to the procedure of Benjamini-Hochberg 
3 ARC: Average relative contribution [%] of a microbial group. Groups with a relative abundance lower than 0.1% in all treatments 
are not shown. Values represent means ± SDs, n = 6 per treatment. 
Table 3. Approximate genus-level phylogenetic groups with different relative abundance in the ileum of piglets in 
experiment 2. 
? Class ? Group 
Effect1 
CA vs 
SA 
P 
value C.p
2 
ARC3 
CA SA 
Bacteroidetes Prevotella melaninogenica et rel. - <0.01 0.02  0.13±0.04 0.23±0.06 
 Uncultured Prevotella - <0.01 0.01  0.68±0.23 1.33±0.36 
Bacilli Aerococcus urinaequi et rel. + <0.01 0.01  0.14±0.05 0.02±0.01 
 Allofustis et rel. + 0.02  0.04  0.25±0.04 0.15±0.05 
 Carnobacterium et rel. + 0.01  0.02  0.66±0.12 0.33±0.15 
 Enterococcus et rel. + 0.02  0.04  4.92±1.02 3.18±0.82 
 Lactobacillus plantarum et rel. + 0.02  0.04  3.99±1.39 1.76±1.03 
 Lactobacillus salivarius et rel. + <0.01 0.01  3.68±0.74 1.49±0.38 
 Uncultured Bacilli + 0.02  0.04  0.13±0.04 0.08±0.03 
Clostridium cluster IV Anaerotruncus et rel. + <0.01 0.01  1.18±0.09 0.56±0.26 
 Clostridium cellulosi et rel. + <0.01 0.01  1.71±0.15 0.81±0.36 
 Eubacterium cellulosi et rel. + <0.01 0.02  0.40±0.07 0.16±0.09 
 Eubacterium siraeum et rel. + 0.02  0.04  0.59±0.09 0.43±0.12 
 Faecalibacterium et rel. + 0.02  0.04  0.52±0.11 0.40±0.06 
 Papillibacter cinnamivorans et rel. + <0.01 0.01  1.50±0.15 0.69±0.27 
 Ruminococcus bromii et rel. + <0.01 0.01  1.02±0.15 0.58±0.14 
 Ruminococcus callidus et rel. + <0.01 0.01  2.70±0.14 1.44±0.50 
 Sporobacter termitidis et rel. + <0.01 0.01  6.17±0.46 4.31±0.79 
Clostridium cluster IX Dialister et rel. + 0.02  0.04  0.73±0.18 0.48±0.19 
 Peptococcus niger et rel. + <0.01 0.02  0.28±0.04 0.10±0.08 
Clostridium cluster XI Anaerovorax et rel. - <0.01 0.01  1.08±0.67 3.67±1.06 
 Clostridium difficile et rel. - <0.01 0.01  1.75±1.78 9.65±2.81 
 Eubacterium pyruvativorans et rel. - <0.01 0.01  0.04±0.04 0.18±0.07 
Clostridium cluster XIII Peptoniphilus et rel. - 0.01  0.02  0.41±0.27 1.16±0.39 
Clostridium cluster XIVa Clostridium herbivorans et rel. + 0.01  0.02  0.68±0.10 0.42±0.13 
 Clostridium hylemonae et rel. - <0.01 0.01  0.03±0.02 0.10±0.03 
 Clostridium lactifermentans et rel. + 0.02  0.04  0.62±0.08 0.46±0.08 
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 Clostridium nexile et rel. + 0.01  0.02  0.17±0.02 0.10±0.03 
 Clostridium oroticum et rel. - <0.01 0.02  0.42±0.33 1.39±0.35 
 Clostridium sphenoides et rel. - <0.01 0.01  0.25±0.13 0.65±0.24 
 Clostridium symbiosum et rel. + 0.01  0.02  0.36±0.05 0.21±0.07 
 Dorea et rel. - 0.02  0.04  0.29±0.21 0.84±0.38 
 Eubacterium hallii et rel. + <0.01 0.01  0.57±0.05 0.37±0.08 
 Eubacterium plexicaudatum et rel. + 0.01  0.02  0.35±0.05 0.20±0.07 
 Eubacterium rectale et rel. + <0.01 0.01  2.24±0.13 1.18±0.40 
 Eubacterium ventriosum et rel. + <0.01 0.02  0.19±0.03 0.10±0.04 
 Lachnobacillus bovis et rel. + <0.01 0.01  1.40±0.13 0.50±0.26 
 Lachnospira pectinoschiza et rel. + <0.01 0.01  3.41±0.33 1.77±0.61 
 Roseburia intestinalis et rel. + <0.01 0.01  1.03±0.11 0.62±0.15 
 Ruminococcus obeum et rel. + <0.01 0.01  2.89±0.32 1.65±0.53 
 
Uncultured Clostridia  
close to Clostridium symbiosum et rel. - <0.01 0.02  0.40±0.20 0.87±0.16 
 Uncultured Clostridia XIVa + <0.01 0.01  2.25±0.19 1.28±0.35 
 
Uncultured Clostridia XIVa 
close to Anaerostipes caccae + 0.01  0.02  0.11±0.01 0.06±0.02 
Clostridium cluster XIVb Uncultured Clostridia XIVb - <0.01 0.01  1.26±0.22 2.21±0.40 
Mollicutes Uncultured Mollicutes + 0.01  0.02  0.60±0.06 0.43±0.13 
Alphaproteobacteria Caulobacter et rel. + <0.01 0.01  1.04±0.13 0.58±0.27 
 Rhizobium et rel. - <0.01 0.01  0.25±0.21 1.00±0.26 
Deltaproteobacteria Desulfovibrio et rel. - 0.01  0.02  0.34±0.06 0.47±0.05 
 Lawsonia intracellularis et rel. - <0.01 0.02  0.13±0.07 0.30±0.09 
Gammaproteobacteria Aeromonas - <0.01 0.01  0.13±0.04 0.30±0.09 
 Escherichia coli et rel. - 0.01  0.02  0.89±0.25 1.51±0.25 
 Halomonas et rel. - 0.01  0.02  0.18±0.05 0.28±0.04 
 Ignatzschineria et rel. + 0.01 0.02  0.37±0.05 0.25±0.07 
 Pseudomonas et rel. - <0.01 0.01  0.56±0.18 1.16±0.26 
 Psychrobacter et rel. - <0.01 0.01  0.40±0.04 0.56±0.05 
 Thiocapsa et rel. - <0.01 0.01  0.13±0.06 0.33±0.04 
 Vibrio et rel. - <0.01 0.01  0.13±0.04 0.29±0.09 
Spirochaetes Leptospira - <0.01 0.01  0.19±0.10 0.45±0.07 
 Turneriella + 0.01  0.02  0.78±0.12 0.40±0.25 
 Uncultured Spirochaetes + <0.01 0.02  0.53±0.10 0.25±0.13 
Verrucomicrobiae Akkermansia muciniphila et rel. + 0.04  0.08  0.21±0.02 0.16±0.06 
1 Effect: indicates whether the average relative contribution of a microbial group was increased (+) or decreased (-) in the CA 
group in comparison with the SA group. 
2 C.p: P value corrected for multiple testing according to the procedure of Benjamini-Hochberg 
3 ARC: Average relative contribution [%] of a microbial group. Groups with a relative abundance lower than 0.1% in all treatments 
are not shown. Values represent means ± SDs, n = 6 per treatment. 
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Gene expression in the ileal and jejunal mucosal tissue 
We performed gene set enrichment analysis (GSEA) to investigate whether gene sets were 
differently expressed in the jejunal and ileal mucosa between the different association 
treatments. GSEA showed fewer significantly different gene sets (FDR < 5%) in the 
jejunum compared to ileum (Table 4, 5). In the jejunum, there were no clear differences in 
mucosal gene expression between SA and CA piglets. In piglets of both SA and CA 
treatments, gene sets involved in (generic) metabolic processes were expressed (Table 4). 
In contrast, in the ileum clear differences between treatments were observed. Many gene 
sets were enriched in CA pigs, especially related to immune related processes. ‘T cell 
activation’, ‘cytokine activity’, and ‘regulation of lymphocyte activation’ were processes 
especially observed using the GO database, whereas ‘RIG I like receptor signalling 
pathway’ and ‘antigen processing and presentation’ were found to be stimulated using the 
KEGG database (Table 5). Compared to the ileum, fewer gene sets involved in immune 
related processes were observed to be expressed in the jejunal mucosa.  
Table 4. Significantly enriched gene sets in the jejunal mucosa on day 16 of piglets based on the KEGG and GO 
database.  
NAME SIZE NES1 NOM p-val FDR q-val2 
KEGG database 
CA 
Lysosome 61 2.775 <0.001 <0.001 
Vibrio cholerae infection 29 1.977 <0.001 0.019 
Aldosterone regulated sodium reabsorption 22 1.865 0.002 0.030 
Sphingolipid metabolism 16 1.879 0.005 0.033 
SA  
Ribosome 48 -2.098 <0.001 0.002 
Peroxisome 40 -1.953 0.001 0.005 
Metabolism of xenobiotics by cytochrome p450 16 -1.996 0.001 0.005 
Proteasome 23 -1.809 0.002 0.024 
GO database 
    
SA 
    
Structural constituent of ribosome 40 -2.177 <0.001 0.005 
1 NES: Normalized Enrichment Score 
2FDR < 5% 
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Table 5. Significantly enriched gene sets in ileal mucosa on day 16 of CA-piglets based on KEGG and GO 
database. 
NAME SIZE NES1 NOM p-val FDR q-val2 
KEGG database 
Proteasome 23 2.675 <0.001 <0.001 
RIG I like receptor signaling pathway 42 2.251 <0.001 <0.001 
Cytosolic dna sensing pathway 29 2.023 0.001 0.004 
Antigen processing and presentation 28 1.906 0.001 0.013 
Glycine serine and threonine metabolism 16 1.903 0.005 0.013 
Metabolism of xenobiotics by cytochrome p450 16 1.876 0.002 0.017 
Primary immunodeficiency 24 1.786 0.006 0.032 
Glycolysis gluconeogenesis 32 1.768 0.003 0.036 
GO database 
Alcohol metabolic process 39 2.255 <0.001 0.009 
T cell activation 29 1.961 0.001 0.035 
Gtpase activity 49 1.928 0.001 0.039 
Cytokine metabolic process 30 1.961 <0.001 0.039 
G protein signaling coupled to camp nucleotide second messenger 39 1.985 <0.001 0.040 
Cytokine activity 69 1.913 <0.001 0.042 
Lymphocyte activation 38 1.929 <0.001 0.043 
Cytokine biosynthetic process 30 1.962 0.001 0.044 
Regulation of lymphocyte activation 23 1.990 <0.001 0.045 
Guanyl nucleotide binding 26 1.894 0.003 0.047 
1 NES: Normalized Enrichment Score 
2FDR < 5% 
A criterion for selection of differentially expressed genes was introduced by setting a 
cut-off of fold change of expression (FC ≥2.0). This resulted in 338 differentially expressed 
genes in the jejunal mucosa and 412 genes in the ileal mucosa between association 
treatments. A total of 109 genes were found differentially expressed both in ileal and jejunal 
mucosa. Intriguingly, the majority of these identified genes displayed opposite direction of 
differential expression in the ileal versus the jejunal mucosa (Fig.5). In order to group the 
common annotated up- and down-regulated genes on shared biological function, or 
regulation, functional annotation clustering was performed at the online DAVID Database 
(version 6.7). In the ileal mucosa (and contrarily in the jejunum), CA treatment appeared to 
induce a set of genes involved in lipid, glutathione and amino acid metabolism, apoptosis, 
defence response and regulation of gastric motility (Fig. 5). However, genes known to be 
involved in inflammatory responses were repressed in the ileal mucosa of CA compared to 
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SA piglets (Fig. 5).  
 
Figure 5. Gene expression analysis in jejunal and ileal mucosa on day 16 in experiment 2. Venn diagram 
illustrating the numbers of genes the expression of which was differentially expressed comparing CA and SA 
treatments (FC≥2.0) in either jejunal or ileal mucosa, or in both compartments (Top). Heat-maps showing the GO 
of the genes observed both in jejunum and ileum in CA treated piglets (Bottom). 
In parallel, Ingenuity Pathway Analysis (IPA) showed GO annotation enrichment for genes 
that were differentially expressed in the jejunum and ileum in the CA piglets. The ileal 
mucosa comprised more modulated biological functions and signalling pathways compared 
to the jejunal mucosa. The majority of the modulated biological processes were involved in 
metabolism in the jejunal mucosa, whereas processes related to immune responses, cell 
trafficking and signalling were expressed at higher levels in the ileal mucosa (Figure 6). In 
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the ileum, the most significantly (P<0.05) altered signalling pathways were iNOS signalling, 
interferon signalling, and IL-12 signalling and production of macrophages (Figure 6). 
 
Figure 6. Biological functions and signaling pathways in the jenunal and ileal mucosa modulated in the CA 
treatment. Cellular functions and disease annotations calculated using Ingenuity Pathway Analysis (IPA) in (A) 
jejunum and (C) ileum. Signaling pathways significantly modulated in (B) jejunum and (D) ileum in CA treated 
piglets. Pathways were determined using IPA, and significance of differences in pathway modulation was 
calculated via a one-tailed Fischer’s Exact test in IPA and represented as –log (P-value); -log values exceeding 
1.30 were significant (P<0.05). 
Correlation between the host transcriptome and microbiota composition 
To further investigate the relationship between gene expression in the intestinal mucosa and 
composition of microbiota in digesta in the corresponding intestinal sections, correlation 
analyses were performed for each intestinal segment. A false discovery rate (FDR) method 
was employed to explore possible association of the small intestinal microbiota with gene 
expression patterns of CA-piglets. Genes which were differentially expressed in response to 
the CA treatment in jejunal and ileal mucosa were correlated to the microbial groups that 
varied between CA and SA piglet as identified by PITChip analysis (Supplemental figure 
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1 and 2). Significant correlations (FDR<0.01; Benjamini-Yekutieli correction) between the 
microbiota and specific mucosal gene expression changes were only detected in the ileum 
for several microbial groups previously identified as pathobionts such as C. difficile, C. 
hylemonae, C. oroticum, E. coli, Pseudomonas and Leptospira. The identified microbial 
groups, which decreased in abundance in the ileum of CA piglets, displayed a negative 
correlation to several genes involved in metabolism, immune modulation and SCFA 
(butyrate) transport. More specifically, negative correlations were found between the above 
mentioned microbial groups and acyl-CoA dehydrogenase family, member 10 (ACAD10), 
SMAD family member 1(BSP-1), fragments of the low-affinity receptor for IgE 
(FCER2/CD23), interleukin 12 receptor, beta 2 (IL12RB2), proopiomelanocortin (POMC), 
prostaglandin F receptor (PTGFR), solute carrier family 16, member 1 (monocarboxylic 
acid transporter 1, SLC16A1), member 7 (SLC16A7), transporter 1 (TAP1), and 
transmembrane protein 89 (TMEM89) (Fig. S2). 
Discussion 
In this study, caesarean derived piglets were associated with either a three component 
(“simple”) microbiota consisting of Lactobacillus amylovorus, Clostridium glycolicum and 
Parabacteroides sp. ASF519, or with both the simple microbiota and diluted faeces of an 
adult sow, as a complex microbial association model. The complex microbial association 
had a significant effect on microbiota establishment at early age. The complex microbial 
association caused an increase in faecal microbial diversity, and accelerated the faecal 
microbiota to develop into a stable composition. Meanwhile, the complex microbial 
association also had drastic effects on the microbiota in the jejunum and ileum, and gene 
expression in the ileal mucosa at early age.  
Diversified microbiota in the lower gut benefits the host at early age 
In experiment 1, a higher microbial diversity was detected in the faeces of CA piglets than 
in SA piglets after the inoculation with diluted faeces, and an increasing similarity of 
microbiota was discovered between CA piglets’ faeces and the faecal inoculant originating 
from an adult sow. The slightly lower similarity at day 7 may be caused by the change from 
the milk based diet towards the slurry diet with a different ingredient composition on day 5 
in combination with an increase in absolute feed intake in time after day 5. A drastic shift in 
diet composition as occurring at weaning of piglets, can result in changes of absorptive, 
secretory, and barrier properties of the piglet’s intestine, as well as in gut microbial 
composition [257, 258]. Consequently, many transient species may reduce and a subsequent 
complex microbial succession process may occur. In the present study, the effect of the diet 
change was more obvious in SA piglets compared to CA piglets. All SA piglets showed 
transient diarrhoea on day 7 and 8, whereas no piglets in the CA group showed diarrhoea 
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during the study (data not shown). Meanwhile, the microbial similarity of faeces of SA 
piglets and the faecal inoculant was temporally increased at day 5. This increase suggests a 
rapid microbial colonization in the SA piglet gut. The transient diarrhoea and gut dysbiosis 
of SA piglets may have resulted in the decrease of similarity between DF and SA at day 7. 
From day 12 onwards, all piglets in the SA group showed periods of diarrhoea. In total, 
nine piglets from the SA group were removed from the experiment due to severe health 
problems and poor physical conditions during the course of the study. Autopsy on these 
piglets revealed signs of an E. coli infection, which was confirmed by bacterial examination 
of the liver, pericard and abdominal fluid of several piglets, showing the presence of 
haemolytic E. coli in a number of cases. During infection, E. coli could become a dominant 
species in the intestinal tract and outcompete other species, as was confirmed by DGGE 
analysis of the faecal microbiota composition of piglets that were euthanized because of 
poor health status or died before day 28. On the DGGE gel, we found less than three bands 
for each of these piglets at the age of 7 and 14, and E.coli was the predominant band for all 
excluded piglets (data not shown). The above findings suggest that a higher intestinal 
microbial diversity and a more adult type of microbiota in the lower gut at early age may 
help the residing microbiota to resist external influences such as change in diet and 
outgrowth of pathobionts, such as E.coli. Furthermore, a low diversity of faecal microbiota 
at early age has been correlated with a higher predisposition for immune diseases in 
humans. It has been shown that a low microbiota diversity in early infancy preceded asthma 
at school age [259], and a more diversified microbiota early in life might prevent allergy 
development [260].  
Microbial colonization at early age differed along the GI tract 
Microbial groups that were found different between SA and CA differed along the GI tract. 
Distinct regions of the GI tract can represent unique habitats to which the resident 
microbiota are well adapted [108]. One of the reasons is that the function and architecture 
of the gut differs along its length. For instance, the first regions of the small intestine 
(duodenum and jejunum) are the primary site of contact between bacteria and the host, and 
this region makes bacteria face bile and pancreatic enzyme-mediated stress [74]. Moreover, 
several physiological conditions, such as pH, peristaltic movement of the tract, 
desquamation of epithelial cells and mucosal flow, also influence the microbiota 
distribution in the GI tract [261]. Consequently, bacterial diversity and composition differs 
from the small intestine to large intestine. For the human adult, the concentration of 
bacteria increases along the length of the gut, from 104 cells per g in the duodenum to 1012 
cells per g in the colon [74]. Studies on mucosal biopsies showed the bacterial diversity is 
lowest in the jejunum, and highest in the ascending colon while the diversity in the distal 
ileum, ascending colon and rectum is not significantly different from each other [262]. Up 
to now, most human neonate and infant studies are performed with faecal samples, while 
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studies with newborn animals seldomly compared the difference of microbiota between the 
jejunum and ileum. Studies of adult humans have shown that the proximal small intestine is 
enriched with Clostridium spp., Streptococcus spp. and Veillonella spp. [126], while the 
ileum shows a community dominated by Bacteroidetes and Clostridium cluster XIVa and is 
more similar to the ecosystem of the large intestine [105, 125, 127]. However, little is 
known about the difference of microbial colonization and composition in the jejunum and 
ileum at early age of humans and animals. Our study showed that the complex microbial 
association significantly increased Deferribacteres and Spirochaetes in the jejunum, while 
in the ileum, a significant increase of Firmicutes and a decrease of Proteobacteria was 
found. Correspondingly, we analysed the microbial composition of feacal samples on day 
14 and found that Bacteriodetes and Planctomycetes increased their relative abundance, 
whereas the relative abundance of Proteobacteria decreased. These results indicated that the 
complex microbial association promoted the development of the piglet ileal and faecal 
microbiota into a more adult type. Members of the Bacteroidetes are the principal degraders 
of complex plant polysaccharides in the adult GI tract, and a shift of a community 
dominated by Actinobacteria and Proteobacteria to one dominated by Firmicutes and 
Bacteroidetes suggests the establishment of an adult like microbiota characterized by a full 
suite of functions and greater stability [213]. The beneficial effect was more obvious when 
we evaluated the composition of genus-like level 2 microbial goups in the ileum. Most 
groups increased in piglets from the CA group were related to the class Bacilli, Clostridium 
cluster IV and Clostridium cluster XIVa, including presumed beneficial members of 
Lactobacillus and butyrate producing Ruminococcus, Eubacterium and Roseburia. On the 
contrary, potentially pathogenic Proteobacteria, such as E.coli and Pseudomonas were 
decreased in the CA piglets. With respect to the jejunum, the effect of complex microbial 
association on the microbial colonization was not as clear as in the ileum. We found a 
decrease of several butyrate producing Clostridia, bacteria related to genus Bifidobacterium 
spp., and potential pathogenic Strepocococcus. Taken together, the above findings indicate 
that complex microbial association may regionally benefit the gut microbiota, e.g. it may 
benefit the microbiota in the ileum while not affecting that in the jejunum. Reports have 
shown particular species that are beneficial to young age groups (e.g. Lactobacillus and 
Bifidobacterium) might actually be harmful if transplanted into elderly populations [213]. 
Accordingly, microbial groups that are beneficial in the ileum may not be of benefit in the 
jejunum. It should be noted, however, that we did not study the succession of 
mucosa-associated microbiota as was done previously by other studies [52, 169]. 
Early microbial association modified gut gene expression  
The gut microbiota has been proposed to have a crucial role in the establishment and 
maintenance of adaptive immunity and homeostasis [263]. In this study, complex microbial 
association lead to more immune signalling in the ileal mucosa. This result is consistent 
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with studies that have been performed with germfree and conventional mice. Gaboriau – 
Routhiau et al, with the main focus on the terminal ileum, have reported nearly 50% of the 
genes differentially expressed in the intestine of gnotobiotic mice regulated T-cell 
development in the response to colonizing gut microbiota [142]. More recently, studies of 
Larsson et al. and  El Aidy et al. confirmed “immune response” is the largest category of 
genes that is regulated in response to microbial colonization in the gut [21, 264]. However, 
unlike the ileum, fewer gene sets involved in immune related processes were observed in 
the jejunum, and hence, the effect of complex microbial association in the jejunum is 
difficult to predict in the present study. Moreover, the host gene expression pattern differed 
between the jejunal and ileal mucosa. The majority of the modulated biological processes 
were involved in metabolism in the jejunum, whereas in the ileal mucosa processes were 
more related to immune responses, cell trafficking and signalling such as iNOS signalling, 
interferon signalling, and IL-12 signalling and production of macrophages. These results 
can also be attributed to the differentiation of function and architecture of the GI tract. The 
main functions of duodenum and jejunum are related to the enzymatic degradation of 
dietary nutrients and constituents and subsequent absorption of nutrients, whereas the ileum 
is the predominant immune sampling site, because of a higher abundance of Peyer’s 
patches in the ileal mucosa. Therefore, the ileum is generally assumed to be an important 
site for interaction between the intestinal microbiota and the host’s immune system [74].  
Correlation of pathobionts and host transcriptome 
In the ileum, the decreased abundance of pathobionts in the CA group was associated with 
induction of immunmodulatory genes. Pathobionts are normally considered harmless 
symbionts that can become pathogenic under certain environmental conditions [204, 265]. 
The colonization of pathobionts in the gut may be a risk factor in IBD, colon cancer and 
perhaps for diseases outside of the intestinal compartment [204]. Hereby, identifying the 
molecular interactions between pathobionts and the mammalian immune system might be 
critical to understanding the etiology of certain diseases. Our study revealed a negative 
correlation between the relative abundance of a number of pathobionts and FCER2. FCER2 
plays a role in regulation of IgE synthesis when expressed on B cells, and has been reported 
to relate to asthma [266-269].  It encodes a low-affinity IgE receptor, CD23, and the 
activation of CD23 results in down regulation of IgE-mediated immune responses. IgE 
production is a hallmark of asthma and atopic disease. A high level of IgE can increase the 
risk of asthma. Therefore, complex microbial association at early age resulted in a decrease 
in pathobionts which may decrease the IgE level and reduce the risk of asthma. Besides 
FCER2, genes including BSP-1, IL12RB2 and TAP1 were also negatively correlated to 
most pathobionts. These genes have been reported to be involved in many immune 
response pathways. For instance, BSP-1 is involved in a range of biological activities 
including cell growth, apoptosis, morphogenesis, development and immune responses 
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[270-272].   
Conclusion  
Complex microbial association at early age accelerated faecal microbiota to develop into an 
adult type microbiota that may resist changes of GI tract conditions caused by diet and 
occurrence of pathogens. Complex microbial association significantly affected luminal 
microbiota development, and gene expression in the jejunal and ileal mucosa. Especially in 
the ileum, the complex microbial association influenced genes involved in immune 
pathways. Expression of immune modulatory genes was negatively correlated with the 
abundance of pathobionts in digesta. In conclusion, complex microbial association at early 
age has a drastic effect on the development of intestinal microbiota and the immune system. 
Manipulation of microbial association of the gut at early age may be a way to support the 
development of the immune system.   
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Supplemental methods 
Denaturing Gradient Gel Electrophoresis (DGGE) analysis 
PCR performed by using GoTaq® polymerase kit from Promega (Madison, WI, USA). 
Primers GC-968-f (5’-CGC CCG GGG CGC GCC CCG GGC GGG GCG GGG GCA 
CGG GGG GAA CGC GAA CCT TAC-3’) and 1401-r (5’- CGG TGT GTA CAA GAC 
CC-3’) were used to amplify the V6 to V8 regions of the bacterial 16S ribosomal RNA 
(rRNA) gene. Each PCR mixture (50 μl) contained 1.25 U of GoTaq® DNA polymerase, 
Green GoTaq® reaction buffer containing 1.5 mM MgCl2, 0.2 mM of each 
deoxynucleoside triphosphate, 0.2 μM of the primers, 1 μl of DNA solution (~1 ng/μl) and 
UV-sterilized water. A thermocycler T1 (Whatman Biometra, Gottingen, Germany) was 
used for amplification. The program was set as follow: pre-denaturation at 95°C for 2 min, 
35 cycles of denaturation at 95°C for 30 sec, annealing at 56°C for 40 sec, extension at 
72°C for 60 sec and final extension at 72°C for 5 min. The size of the PCR products was 
determined by electrophoresis on a 1 %(W/v) agarose gel containing ethidium bromide.  
The PCR amplicons were separated by denaturing gradient gel electrophoresis [273] with a 
Dcode TM system (Bio-Rad Laboratories, Hercules, CA, USA). Briefly, samples were 
loaded onto 8% polyacrylamide gels with a denaturant gradient of 30 - 60% (100% was 
defined as 40% formamide and 7 M urea), pre-run for 5 min at 200 V, and subsequently 
electrophoresed at 85 V for 16 h at 60 ?. Gels were developed by silver staining [274], and 
scanned at 400 d.p.i.. Further analysis was performed with BioNumerics 4.5 software 
(Applied Maths).  
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Supplemental tables and figures 
 
Supplemental Figure 1. Association of specific jejunal bacterial groups with differentially regulated genes in CA 
treatment. Correlation heat map shows the positive (red boxes) and negative (dark blue boxes) association between 
the approximate genus level of PITChip output and the genes that were differentially regulated in the CA 
treatment. 
 
Supplemental Figure 2. Association of specific ileal bacterial groups with differentially regulated genes in CA 
treatment. Correlation heat map showing the positive (red boxes) and negative (dark blue boxes) association 
between the approximate genus level of PITChip output and the genes that were differentially regulated in the CA 
treatment. Green-labeled text represents reduced abundance in case of the microbiota and repression in case of 
genes, red labeled text represents increased bacterial abundance or gene induction.  
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Supplemental Table 1. Phylum-level phylogenetic groups with different relative abundance in faeces between 
CA and SA piglets over time in experiment 1.  
?  ?  Effect1 ARC2 
?  P value CA vs SA CA SA 
Day 5    
Deferribacteres 0.06  - 0.02±0.01 0.05±0.02 
Firmicutes 0.06  + 64.13±6.08 52.81±4.34 
Day 7    
Fibrobacteres 0.03  - 0.20±0.08 1.39±0.75 
Planctomycetes 0.06  - 0.00±0.00 0.01±0.00 
Day 14     
Bacteroidetes 0.03  + 21.92±8.66 2.40±2.00 
Deferribacteres 0.06  + 0.03±0.01 0.01±0.01 
Planctomycetes 0.03  + 0.09±0.06 0.01±0.00 
Proteobacteria 0.03  - 12.52±1.95 19.05±2.85 
Day 28     
Bacteroidetes 0.06  + 5.41±2.96 1.64±0.17 
Deferribacteres 0.06  + 0.02±0.00 0.01±0.00 
Spirochaetes 0.06  + 1.69±0.32 1.19±0.09 
1 Effect: indicates whether the average relative contribution of a microbial group was increased (+) or decreased (-) in the CA 
group in comparison with the SA group 
2 ARC: Average relative contribution [%] of a microbial group. Values represent means ± SDs. 
Supplemental Table 2. Approximate genus-level phylogenetic groups tending to be different in faeces between 
CA and SA piglets over time in experiment 1.  
Class Group 
Effect2 
P value C.p1 
ARC3 
CA vs SA SA CA 
Day 5       
Bacteroidetes Paludibacter propionicigenes et rel. - 0.06  0.48  0.39±0.18 0.14±0.09 
 Prevotella melaninogenica et rel. - 0.06  0.48  0.28±0.11 0.13±0.06 
 Uncultured Porphyromonadaceae - 0.06  0.48  0.68±0.29 0.28±0.15 
Flavobacteria Myroides odoratus et rel. - 0.06  0.48  0.07±0.03 0.03±0.01 
Sphingobacteria Uncultured Sphingobacteria - 0.06  0.48  0.48±0.25 0.17±0.12 
Deferribacteres Mucispirillum schaedleri et rel. - 0.06  0.48  0.05±0.02 0.02±0.01 
Clostridium cluster XIVa Bryantella et rel. + 0.06  0.48  0.79±0.29 1.44±0.41 
 Eubacterium ventriosum et rel. + 0.06  0.48  0.02±0.00 0.03±0.00 
 Lachnospira pectinoschiza et rel. + 0.06  0.48  1.84±0.52 2.88±0.37 
 Roseburia intestinalis et rel. + 0.06  0.48  0.15±0.03 0.22±0.06 
Day 7       
Actinobacteria Actinomyces et rel. - 0.06  0.26  0.66±0.37 0.22±0.12 
 Bifidobacterium + 0.06  0.26  0.68±0.23 1.43±0.58 
 Microbacterium + 0.06  0.26  0.75±0.17 1.04±0.15 
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Bacilli Bacillus et rel. - 0.06  0.26  2.64±1.26 0.94±0.47 
 Weissella et rel. - 0.06  0.26  0.24±0.10 0.08±0.04 
Clostridium cluster IV Clostridium cellulosi et rel + 0.06  0.26  0.14±0.09 0.27±0.07 
Clostridium cluster XIVa Dorea et rel. - 0.06  0.26  0.51±0.11 0.26±0.10 
Planctomycetacia Uncultured planctomycetacia - 0.06  0.26  0.01±0.00 0.00±0.00 
Betaproteobacteria Uncultured betaproteobacteria + 0.06  0.26  0.02±0.01 0.07±0.03 
Gammaproteobacteria Vibrio et rel. - 0.06  0.26  0.25±0.11 0.09±0.08 
Spirochaetes Leptospira - 0.06  0.26  0.51±0.27 0.17±0.05 
Day 14       
Bacteroidetes Paludibacter propionicigenes et rel. + 0.06  0.26  0.02±0.04 0.08±0.03 
 Uncultured Porphyromonadaceae + 0.06  0.26  0.10±0.12 0.53±0.26 
Flavobacteria Chryseobacterium et rel. + 0.06  0.26  0.04±0.02 0.12±0.06 
Deferribacteres Mucispirillum schaedleri et rel. + 0.06  0.26  0.01±0.01 0.03±0.01 
Bacilli Gemella haemolysans et rel. - 0.06  0.26  0.30±0.05 0.19±0.05 
 Lactobacillus paracasei et rel. - 0.06  0.26  0.04±0.03 0.01±0.00 
 Streptococcus salivarius et rel. + 0.06  0.26  0.50±0.29 1.09±0.32 
 Streptococcus suis et rel. + 0.06  0.26  0.68±0.40 1.47±0.47 
Spirochaetes Treponema et rel. + 0.06  0.26  0.18±0.06 0.48±0.23 
Day 28       
Bacteroidetes Alistipes et rel. + 0.06  0.23  0.02±0.00 0.61±0.4 
 Bacteroides distasonis et rel. + 0.06  0.23  0.13±0.05 0.50±0.31 
 Bacteroides fragilis et rel. + 0.06  0.23  0.02±0.01 0.07±0.04 
 Bacteroides pyogenes et rel. + 0.06  0.23  0.02±0.00 0.10±0.06 
 Bacteroides vulgatus et rel. + 0.06  0.23  0.01±0.00 0.06±0.04 
 Paludibacter propionicigenes et rel. + 0.06  0.23  0.01±0.00 0.03±0.01 
 Prevotella melaninogenica et rel. + 0.06  0.23  0.08±0.02 0.27±0.07 
 Prevotella ruminicola et rel. + 0.06  0.23  0.02±0.01 0.05±0.01 
 Uncultured Bacteroidetes + 0.06  0.23  0.03±0.00 0.73±0.59 
 Uncultured Prevotella + 0.06  0.23  0.53±0.14 2.36±1.39 
Flavobacteria Chryseobacterium et rel. + 0.06  0.23  0.03±0.00 0.08±0.03 
 Flavobacterium cucumis et rel. + 0.06  0.23  0.01±0.00 0.02±0.01 
Deferribacteres Mucispirillum schaedleri et rel. + 0.06  0.23  0.01±0.00 0.02±0.00 
Bacilli Lactobacillus delbrueckii et rel. - 0.06  0.23  0.64±1.01 0.02±0.00 
 Lactobacillus gasseri et rel. - 0.06  0.23  1.85±2.89 0.02±0.01 
 Streptococcus intermedius et rel. + 0.06  0.23  0.16±0.14 0.87±0.30 
 Streptococcus suis et rel. + 0.06  0.23  0.27±0.13 0.81±0.29 
Clostridium cluster IV Clostridium cellulosi et rel + 0.06  0.23  0.31±0.04 0.64±0.17 
 Eubacterium cellulosi et rel + 0.06  0.23  0.06±0.01 0.11±0.03 
 Ruminococcus bromii et rel. + 0.06  0.23  0.03±0.01 0.23±0.21 
 Subdoligranulum et rel. - 0.06  0.23  1.02±0.11 0.48±0.10 
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Clostridium cluster IX Dialister et rel. + 0.06  0.23  0.01±0.00 0.01±0.00 
 Megasphaera elsdenii et rel. + 0.06  0.23  0.01±0.00 0.05±0.04 
 Mitsuokella multiacida et rel. + 0.06  0.23  0.03±0.00 0.21±0.15 
 Peptococcus niger et rel. + 0.06  0.23  0.00±0.00 0.03±0.01 
Clostridium cluster XI Clostridium difficile et rel. + 0.06  0.23  2.68±1.47 5.77±0.60 
Clostridium cluster XIVa Butyrivibrio crossotus et rel. + 0.06  0.23  0.31±0.04 0.48±0.10 
 Clostridium sphenoides et rel. - 0.06  0.23  0.37±0.21 0.18±0.06 
 Dorea et rel. - 0.06  0.23  0.36±0.02 0.30±0.04 
 Ruminococcus ganvus et rel. - 0.06  0.23  0.14±0.05 0.09±0.01 
Mollicutes Mycoplasma - 0.06  0.23  0.57±0.46 0.15±0.09 
Gammaproteobacteria Avibacterium - 0.06  0.23  0.08±0.02 0.04±0.01 
 Bisgaard - 0.06  0.23  0.08±0.02 0.04±0.01 
 Pasteurella - 0.06  0.23  0.19±0.03 0.13±0.04 
Spirochaetes Treponema et rel. + 0.06  0.23  0.30±0.09 0.82±0.16 
?  Turneriella - 0.06  0.23  0.47±0.06 0.27±0.02 
1 C.p: P value corrected for multiple testing according to the procedure of Benjamini-Hochberg 
2 Effect: indicates whether the average relative contribution of a microbial group was increased (+) or decreased (-) in the CA 
group in comparison with the SA group 
3 ARC: Average relative contribution [%] of a microbial group. Values represent means ± SDs. 
Supplemental Table 3. Phylum-level phylogenetic groups with different abundance in the jejunum and ileum 
between CA and SA piglets in experiment 2.   
Phylum 
CA vs SA Jejunum ARC1 Ileum ARC 
Jejunum ileum CA SA CA SA 
Bacteroidetes   -2 - 2.97±0.27 4.47±0.55 2.85±0.34 3.77±0.44 
Deferribacteres   + NSD3 0.28±0.03 0.22±0.04 0.23±0.03 0.19±0.06 
Fibrobacteres   - - 0.23±0.14 0.61±0.23 0.27±0.17 0.55±0.18 
Firmicutes   NSD + 76.94±1.12 76.31±1.50 78.38±0.82 74.31±1.72 
Fusobacteria   - - 0.46±0.17 0.90±0.26 0.46±0.12 0.72±0.16 
Proteobacteria  NSD - 13.37±0.88 12.22±1.69 11.99±1.19 15.30±1.43 
Spirochaetes   + NSD 2.88±0.35 2.27±0.25 2.81±0.40 2.39±0.60 
Verrucomicrobia  + + 0.25±0.03 0.20±0.04 0.21±0.02 0.16±0.06 
1 ARC: average relative contribution [%] of a phylum. Values represent means ± SDs. The microbial groups with a relative 
abundance lower than 0.1% in all treatments are not shown.   
2 ” +” or “-” indicates whether the average relative contribution of the microbial group was increased or decreased in the CA group 
in comparison with SA group. 
3 NSD: no significant difference of a of a phylum observed in the CA group in comparison with SA group 
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Abstract 
Resistant starch (RS) is highly fermentable by microbiota in the colon, resulting in the 
production of SCFAs. RS is thought to mediate a large proportion of its health benefits, 
including increased satiety, through the actions of SCFAs. The aim of this study was to 
investigate the effects of a diet high in RS on luminal microbiota composition, luminal 
SCFA concentrations and the expression of host genes involved in SCFA uptake, SCFA 
signalling and satiety regulation in mucosal tissue obtained from small intestine, caecum 
and colon. Twenty adult female pigs were either assigned to a digestible starch (DS) diet or 
a diet high in RS (34%) for a period of 2 wk. After the intervention, luminal content and 
mucosal scrapings were obtained for detailed molecular analysis. RS was completely 
degraded in caecum. In both the caecum and colon, differences in microbiota composition 
were observed between DS- and RS-fed pigs. In the colon these included the stimulation of 
the healthy gut-associated butyrate-producing Faecalibacterium prausnitzii, whereas 
potentially pathogenic members of the Gammaproteobacteria, including Escherichia coli 
and Pseudomonas spp., were reduced in relative abundance. Caecal and colonic SCFA 
concentrations were significantly greater in RS-fed pigs, and caecal gene expression of 
monocarboxylate transporter 1 (SLC16A1) and glucagon (GCG) was induced by RS. In 
conclusion, our data show that RS modulates microbiota composition, SCFA concentrations 
and host gene expression in pig intestine. Combined, our data provide an enhanced 
understanding of the interaction between diet, microbiota and host.  
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Introduction 
Obesity and related disorders, such as cardiovascular diseases and type 2 diabetes, have 
become major public health issues [275, 276]. Various lifestyle factors, of which diet is a 
major one, play an important role in the development of these disorders [277, 278]. A large 
amount of research has reported an inverse relationship between fibre consumption and the 
risk of obesity and diabetes [279]. Moreover, consumption of dietary fibre prevents the 
accumulation of fat mass [280, 281], increases insulin sensitivity [282, 283] and can 
enhance feelings of satiety [284]. 
Resistant starch (RS) is a type of dietary fibre that includes all starch and starch degradation 
products that are not absorbed in the small intestine of healthy humans [79]. It is known to 
be fermented to a large extent by microbiota in the colon, resulting in the production of 
SCFAs [73, 90]. These SCFAs can diffuse across the epithelial cell membrane, but SCFA 
absorption by the enterocytes is also mediated by the monocarboxylate transporter 1 
(SLC16A1, also known as MCT1) and sodium-coupled monocarboxylate transporter 1 
(SLC5A8 or SMCT1) [285]. 
Enhanced SCFA production provides an important link between dietary fibre consumption 
and health benefits. First, SCFAs lower the pH in the colon, which can prevent the 
overgrowth of pathogenic bacteria [286]. Acetate, propionate and butyrate are the major 
SCFAs produced in the colon, of which butyrate is thought to be most beneficial for health. 
Among the health benefits observed with butyrate are the prevention and inhibition of colon 
carcinogenesis, protection against mucosal oxidative stress, strengthening of the colonic 
defence barrier and butyrate also has anti-inflammatory properties [287]. Propionate has the 
potential to reduce cholesterol concentrations in blood [288]. 
In addition to these health benefits, SCFAs are thought to be involved in the increase in 
satiety observed with fibre consumption [289]. Studies in rodents have provided evidence 
that fermentation of RS is an important mechanism for increased endogenous secretion of 
the gut hormones glucagon-like peptide 1 (GLP-1) and peptide YY (PYY) [280, 290-292]. 
GLP-1 and PYY are satiety-stimulating hormones that are released in response to nutrient 
intake, mainly in the ileum and colon. SCFAs are agonists for free fatty acid receptor 2 and 
3 (FFAR2 and FFAR3 respectively), 2 G protein-coupled receptors present in the 
gastrointestinal tract. Both of these G protein-coupled receptors are expressed in 
enteroendocrine cells in the gut epithelium. It has been proposed that the activation of these 
receptors trigger the production and release of GLP-1 and PYY by enteroendocrine L-cells 
[293, 294]. 
In the experiments described in this chapter, we investigated the effects of a diet high in RS 
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on luminal microbiota composition, luminal SCFA concentrations and the expression of 
host genes involved in SCFA uptake, SCFA signalling and satiety regulation in mucosal 
tissue obtained from small intestine, caecum and colon. Adult pigs were used as a model for 
humans because the anatomy and physiology of the gastrointestinal tract of pigs and the pig 
genome are similar to those of humans [153, 154]. Because we recently reported that a diet 
high in RS decreases feeding motivation in pigs [295], special attention was given to 
selected genes involved in SCFA sensing and regulation of satiety.  
Materials and Methods 
Experimental design, pigs and housing 
Two independent studies were performed. First, a pilot experiment was carried out to 
ascertain whether the gene expression profile along the intestine of pigs is similar to the 
sites of expression in humans and rodents. Three multiparous female pigs with a mean (± 
SEM) body weight of 273 ± 1.15 kg were included is this study. 
The main study had a parallel design. Two groups of 10 female pigs (PIC Benelux B.V.), 
aged 22 mo, with an initial body weight of 268 ± 3.85 kg were assigned to 1 of 2 treatments. 
Treatments differed with regard to the type of starch in the diet: digestible starch (DS) or 
RS. Siblings were equally distributed between the 2 groups. Pigs were individually fed and 
housed in pairs that received the same diet. The area of each pen was 11 m2 and contained 2 
drinking nipples and 2 feeding troughs. Artificial lights were on from 06:30 h until 22:00 h 
and dimmed during the dark period. The animal protocol was approved by the Animal Care 
and Use Committee of Wageningen University. The same pigs were used previously for 
feeding motivation studies [295]. 
Diets and feeding 
The 2 experimental diets used in the main study were identical except for type of starch. 
The main source of starch in the DS diet was pregelatinized potato starch (Paselli WA4; 
AVEBE), which was replaced on a dry matter basis in the RS diet by retrograded tapioca 
starch (Actistar; Cargill). According to the supplier, this starch was ≥50% resistant to 
digestion in the small intestine. On the basis of physical and chemical characteristics, the 
RS used in this study can be classified as RS type 3 (RS3) [79]. Diets were isoenergetic on 
a gross energy basis. The detailed composition of the experimental diets is presented in 
Supplemental Table 1. Each diet was given to 10 pigs in pelleted form at 07:00 h and 
17:00 h for a period of 14 d. The daily feed allowance was 1.13 times the energy 
requirements for maintenance [net energy = 293 kJ/(kg0.75 ·  d)], and pigs were allowed 1 h 
to consume the meal. All pigs had free access to water throughout the entire day. 
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Blood collection 
Blood was collected 5 h postprandially on 2 separate days. Blood sampling was performed 
before the start of the treatment period when all pigs had consumed the DS diet for 2 d and 
at the end of the dietary intervention when pigs had been fed the DS or RS diet for 12 d. 
Blood was drawn from the jugular vein and collected in a BD Vacutainer EDTA tube with 
protease (Complete, EDTA-free; Roche) and dipeptidyl peptidase-4 (Millipore) inhibitors. 
Tubes were centrifuged for 10 min at 1300 g at 4°C immediately after blood collection. 
Plasma was separated into aliquots and stored at -80°C. 
Collection of digesta and tissue 
Digesta and tissue samples were collected 5 h after the morning meal. This time point was 
selected on the basis of a previous study in which an increase in SCFA concentration was 
observed 4-5 h after feeding [296]. Pigs were stunned and exsanguinated, after which the 
abdominal cavity was opened. The gastrointestinal tract from stomach to anus was removed 
from the cavity and the length of the small intestine and colon was determined. The small 
intestine was divided into 10 parts of equal length, the caecum was divided into 2 parts and 
the colon into 4 parts. The luminal content was collected from the 4 most distal parts of the 
small intestine (segment 7 to 10) and from all caecal and colonic parts. For subsequent 
analysis of SCFA concentrations, part of the content was collected in tubes with 1 mL of 
H3PO4, after which the samples were thoroughly mixed and stored at -20°C. Luminal 
content was also stored in empty tubes at -20°C to determine dry matter and degradation of 
RS. The remaining amount of digesta was collected in 1.5 mL Eppendorf tubes to 
determine microbiota composition. These tubes were immediately frozen in liquid nitrogen 
and stored at -80°C until further analyses. In addition, a small piece from the middle of 
each intestinal segment was excised and rinsed in PBS. Epithelial cells were collected from 
these tissues by scraping the mucosal lining with a glass slide. These samples were 
immediately snap-frozen in liquid nitrogen and then stored at -80°C for subsequent RNA 
isolation. 
Analysis of RS in luminal samples 
RS was analysed according to methods used by Goñi et al. [297], adapted for intestinal 
samples, including extra washing steps and the total volume set at 35-40 mL. Impurities 
were removed by deionization of the sample by using equal amounts of Q-sepharose and 
S-sepharose beads equilibrated with phosphate buffer, 20 mmol/L, pH 7. An aliquot (100 
μL) of the sample obtained in step 9 of the procedure was combined with an equal amount 
of the ion exchange mix and thoroughly mixed for 5 min at room temperature. For the 
glucose assay, 100 μL supernatant obtained after 5 min of centrifugation at 14,000 g was 
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used. Glucose was determined in the samples by using the Glucose Assay Kit from 
Sigma-Aldrich (product no. GAGO20). The amount of RS in the sample was calculated by 
using the method as described [297]. 
Microbiota analysis 
Microbial DNA was extracted from 250 mg of intestinal contents by using a faecal DNA 
extraction protocol [199]. Denaturing gradient gel electrophoresis (DGGE) analysis was 
performed for a preliminary scanning of the microbial profile. Briefly, universal primers 
S-D-Bact-0968-a-S-GC and S-D-Bact-1401-a-A-17 [298] were used to amplify the V6 to V8 
variable regions of the bacterial 16S rRNA gene. The V6-V8 PCR amplicons were separated 
by DGGE according to the specifications of Muyzer et al. [273] by using a DCode system 
(Bio-Rad Laboratories). Gel images were digitally normalized by comparison with an 
external standard pattern by using Bionumerics software package version 4.5 (Applied 
MathS). Observed bands were classified across all samples, and band class information, 
including relative band intensity, was used for multivariate analysis.  
After the preliminary scanning of microbiota composition by DGGE analysis, the luminal 
contents from the first part of caecum (from 9 DS-treated and 7 RS-treated pigs) and colon 
(from 7 DS-treated and 8 RS-treated pigs) were selected for further analysis by using the 
Pig Intestinal Tract Chip (PITChip). The PITChip is a phylogenetic microarray with >2900 
oligonucleotides based on 16S rRNA gene sequences of 627 porcine intestinal microbial 
species-level phylotypes [227]. The PITChip provides a very deep and reproducible 
phylogenetic analysis that has been compared with deep pyrosequencing of 16S rRNA gene 
fragments [104, 105, 227] and next-generation parallel sequencing of intestinal 
metagenomes [106], indicating comparable resolution and a higher sensitivity of the 
chip-based analysis. 
The protocol for hybridization and analysis of the generated data was performed essentially 
as previously described for the Human Intestinal Tract Chip [103]. The bacterial 16S rRNA 
gene was amplified by using the primers T7prom-Bact-27-for and Uni-1492-rev [103]. The 
PCR products were transcribed into RNA and the purified resultant RNA was coupled with 
CyDye (GE Healthcare Life Sciences) before fragmentation and hybridization to the array. 
Microarray images were processed using Agilent's Feature Extraction Software, version 9.1 
(Agilent Technologies). Data normalization and processing were performed as described 
[103, 227].  
Dry matter and SCFA measurement  
Dry matter was determined by drying the intestinal content to a constant weight at 103°C 
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(ISO standard 6496; International Organization for Standardization, 1999).  
The digesta samples collected in tubes with H3PO4 were thawed, mixed on a vortex and 
centrifuged at 20,000 g for 5 min. The supernatant was collected and diluted 1:1 with a 
solution containing isocaproic acid. SCFA concentrations were determined in the effluent by 
gas chromatography (Fisons HRGC Mega 2; CE Instruments) at 190°C by using a glass 
column fitted with Chromosorb 101 (Supelco). The carrier gas was N2 saturated with 
methanoic acid, and isocaproic acid was used as an internal standard. 
RNA isolation and quality control 
Total RNA was isolated from intestinal scrapings using TRIzol reagent (Life Technologies) 
according to the manufacturer’s instructions. Concentrations and purity of RNA samples 
were determined on a NanoDrop ND-1000 spectrophotometer (Isogen Life Science). RNA 
quality was verified with an Agilent 2100 Bioanalyzer (Agilent Technologies) by using 
6000 Nano Chips (Agilent Technologies) according to the manufacturer’s instructions.  
qRT-PCR 
Single-stranded cDNA was synthesized from 1 μg of total RNA by using the First Strand 
cDNA Synthesis Kit (Fermentas Life Sciences) according to the supplier’s protocol. 
qRT-PCR was performed on a CFX384 Real-Time PCR Detection System (Bio-Rad) by 
using SensiMix SYBR No-ROX (Bioline). Primers were designed in Beacon Designer 7.6 
by using sequences obtained from the ENSEMBL pig database. Specificity of the 
amplification was verified by melt curve analysis and evaluation of efficiency of PCR 
amplification. The primer sequences are listed in Supplemental Table 2. Samples were 
analysed in duplicate and mRNA expression of all genes reported was standardized to 
RPLP0 gene expression. 
Plasma measurements 
All plasma measurements were performed in duplicate. Glucose was measured by using an 
enzymatic glucose assay (Glucose PAP SL; Elitech Group). Triglyceride (TG) and 
cholesterol concentrations were determined by using the enzymatic methods (Triglycerides 
Liquicolor, Cholesterol Liquicolor; INstruchemie). Insulin and PYY concentrations were 
measured by EIA [insulin: (porcine/canine) EIA; ALPCO Diagnostics; peptide YY (3-36): 
(rat, mouse, porcine, canine) EIA kit; Phoenix Pharmaceuticals]. GLP-1 was analysed with 
ELISA [Glucagon-like Peptide-1 (active) ELISA Kit; Millipore]. 
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Statistical methods 
Results are expressed as means ± SEM. The significance of differences between the 2 
treatment groups of the variables determined at the end of the experimental period was 
evaluated by Student’s t test. ANOVA was used to test for differences in RS content in the 
small intestine, caecum and colon. Significance of differences of plasma variables, which 
were measured before and after the experimental period, was determined by linear 
mixed-model analysis treating pig as a random effect. Analyses were performed in 
GraphPad Prism, version 5.04, and IBM SPSS Statistics, version 19. Differences were 
considered significant if P <0.05. 
Multivariate analysis was applied for DGGE and PITChip data interpretation. To relate 
changes in total bacterial community composition to environmental variables, redundancy 
analysis (RDA) was used as implemented in the CANOCO 4.5 software package 
(Biometris). RDA is the canonic form of principle component analysis and is a multivariate 
linear regression method in which several response variables are related to the same set of 
environmental variables and in which the estimated matrix of regression coefficients is of 
reduced rank [299]. The relative abundance of bands on DGGE gels and signal intensities 
for 144 genus-level phylogenetic groups of PITChip were used as responsive variables. 
Treatment class (DS or RS), SCFA concentration and gene expression values of GCG and 
SLC16A1 were introduced as environmental (explanatory) variables. The latter were 
included because these variables were significantly different between the 2 treatment 
groups in the caecum and colon (see Results). RDA was performed by focusing on 
intersamples correlation, and the Monte Carlo permutation test was applied to evaluate 
whether treatment class, SCFA concentration and gene expression had significant influence 
on the microbial composition [228, 255]. Because the experiment had a randomized design, 
we used the unrestricted permutation option that yields completely random permutations. 
Treatment class or other environmental variables were considered to significantly affect 
microbial composition with P values <0.05. Diagrams were plotted as biplots for DGGE 
data and as triplots for PITChip data by using CanoDraw (Biometris).  
Univariate testing of differences for individual microbial groups was processed by using a 
Mann–Whitney U signed-rank test. P values were corrected for multiple testing by using 
Benjamini-Hochberg’s approach [300]. 
Results 
Longitudinal distribution of gene expression 
In the pilot experiment, the expression of several genes involved in luminal uptake and 
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sensing of nutrients and metabolites was measured in mucosal scrapings of 3 female pigs 
(Supplemental Fig. 1). As expected, the expression of apical sodium-dependent bile salt 
transporter (SLC10A2) was restricted to terminal ileum [301]. mRNA levels of fatty acid 
transport protein 4 (SLC27A4), liver-type fatty acid binding protein (FABP1) and 
intestine-type fatty acid binding protein (FABP2) were highest in the proximal jejunum and 
resembled the pattern observed in mice [302]. Furthermore, the gene expression pattern of 
glucagon (GCG; in the intestine the precursor for GLP-1 and GLP-2) and PYY (PYY) in the 
small intestine closely resembled the peptide concentrations found in pig intestine [303]. 
Taken together, these data show the validity of our gene expression measurements in the 
gastrointestinal tract of pigs. Moreover, we found that the distal part of the small intestine, 
the caecum, and the colon showed the highest expression of genes involved in SCFA uptake 
(SLC16A1, SLC5A8), SCFA sensing (FFAR2, FFAR3) and satiety (GCG, PYY). Therefore, 
these segments were sampled in the main experiment described in this chapter. 
Anthropometric variables 
Body weight and fat depth were measured in all pigs at the end of the experimental period. 
The lengths of the small intestine and colon were determined at section. No significant 
differences were found between the treatment groups with respect to body weight, fat depth, 
and the length of the small intestine and colon (Supplemental Table 3). 
Degradation of RS 
The amount of RS was measured in the intestinal content collected at section (5 h 
postprandially). In RS-fed pigs, 20-40 times more RS was found in the small intestine 
compared with that in DS-fed pigs (Fig. 1). Furthermore, in the caecum of RS-fed pigs, the 
concentration of RS was significantly lower compared with that in the small intestine, 
whereas in the colon, RS concentrations were significantly lower than in the caecum and 
were comparable to background concentrations, i.e., those measured in DS-fed pigs (Fig. 1). 
From these observations we conclude that RS was fully degraded in the caecum. 
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Figure 1. RS concentrations in luminal content of pigs fed the DS or RS diet for 2 wk. Values are means ± SEM, n 
= 1-4 pigs per treatment. Different letters indicate that segments differ significantly from each other, P <0.01 (a > 
b > c). From left to right, bars represent areas of the gastrointestinal tract from proximal to distal. The small 
intestine was divided into 10 equal parts; parts 7-10 refer to the 4 most distal segments of the small intestine, 
whereas the caecum and colon were divided into 2 respectively 4 segments of equal length. White horizontal bars 
indicate the intestinal parts that were combined for statistical analysis to determine differences between  anatomic 
locations. CA, caecum; CO, colon; DS, digestible starch; RS, resistant starch; SI, small intestine. 
Microbiota analysis 
Multivariate analysis of the DGGE data revealed a significant effect of RS treatment on the 
composition of the microbiota in the caecum (P = 0.016) and colon (P = 0.002), whereas no 
significant effect of treatment was found in the small intestine (P = 0.18) (Supplemental 
Fig. 2). 
Because treatment effects were observed in the caecum and colon, the luminal contents of 
the proximal part of caecum (P1 caecum) and colon (P1 colon) were selected for further 
analysis using the superior PITChip technique. RDA of the PITChip data showed a visual 
treatment effect on the microbiota in both caecum and colon. Caecal samples of RS-fed 
pigs were separated from those of DS-fed pigs except for pig 24 (Fig. 2A). The 
treatment-centered separation was more obvious for the colonic samples (Fig. 2B). 
Moreover, Monte Carlo Permutation testing showed that, of the environmental variables, 
only luminal propionate concentration significantly (P = 0.018) contributed to explaining 
the observed variation in microbiota composition in the colon.  
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Figure 2. Triplots of RDA results, representing the principal component analysis of the microbiota composition as 
measured by the mean hybridization signals for 144 genus-level phylogenetic groups in the luminal content of 
caecum (A) and colon (B) of pigs fed the DS or RS diet for 2 wk. Samples are grouped by treatment class. Each 
symbol represents 1 pig, and numbers represent pig identifiers. The average of the nominal environmental 
variables DS and RS are represented by triangles. GCG (expression), SLC16A1 (expression), acetate, propionate 
and butyrate concentrations are also included as environmental variables. For clarity, the microbial groups that 
contributed to the first 2 principal components used as explanatory axes were omitted in these triplots. Combined, 
both axes explain 30.9% of the total variance in the data set for (A) and 41.6% for (B). DS, digestible starch; RS, 
resistant starch. 
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To determine which microbial groups were changed by RS treatment, univariate analysis 
was employed (Tables 1 and 2). In the caecum, we found that microbial groups of 
Actinobacteria, Bacilli, Clostridium cluster IV and XIVa, Alphaproteobacteria, 
Betaproteobacteria and Spirochaetes changed in relative abundance, albeit at corrected P 
values of 0.81 (Table 1). More specifically, Streptococcus intermedius-like group, 
Streptococcus salivarius-like group, Streptococcus suis-like group and Neisseria-like group 
decreased by the RS treatment, whereas the uncultured Clostridia cluster IV and 
Rhodobacter-like microorganisms increased in relative abundance (Table 1).  
Table 1. Phylogenetic groups in the luminal content of the P1 caecum of pigs fed the DS or RS diet for 2 wk that 
were significantly affected by diet according to univariate analysis of PITChip data1. 
   ARC3  
Phylogenetic group Corr. P value2 P value DS RS Effect4 
Actinobacteria      
   Actinobacteria      
      Bifidobacterium 0.81 0.071 0.390 ± 0.037 0.355 ± 0.031 - 
      Olsenella et rel. 0.81 0.091 0.007 ± 0.002 0.010 ± 0.004 + 
Firmicutes      
   Bacilli      
      Streptococcus intermedius et rel. 0.81 0.042 0.399 ± 0.190 0.251 ± 0.077 - 
      Streptococcus salivarius et rel. 0.81 0.031 0.374 ± 0.178 0.244 ± 0.085 - 
      Streptococcus suis et rel. 0.81 0.016 0.353 ± 0.111 0.245 ± 0.047 - 
      Uncultured Bacilli 0.81 0.091 1.273 ± 0.056 1.331 ± 0.071 + 
   Clostridium cluster IV      
      Uncultured Clostridia IV 0.81 0.042 1.961 ± 0.358 2.218 ± 0.283 + 
   Clostridium cluster XIVa      
      Butyrivibrio crossotus et rel. 0.81 0.071 0.851 ± 0.108 0.763 ± 0.094 - 
      Clostridium sphenoides et rel. 0.81 0.091 0.820 ± 0.094 0.971 ± 0.095 + 
      Eubacterium rectale et rel. 0.81 0.091 0.746 ± 0.060 0.690 ± 0.060 - 
      Ruminococcus ganvus et rel. 0.81 0.055 0.854 ± 0.086 0.937 ± 0.080 + 
Proteobacteria      
   Alphaproteobacteria      
      Rhodobacter et rel. 0.81 0.042 1.263 ± 0.128 1.383 ± 0.118 + 
   Betaproteobacteria      
      Bordetella et rel. 0.81 0.091 1.052 ± 0.093 0.974 ± 0.095 - 
      Neisseria et rel. 0.81 0.042 0.904 ± 0.071 0.817 ± 0.081 - 
Spirochaetes      
   Spirochaetes      
      Brachyspira 0.81 0.091 0.009 ± 0.003 0.011 ± 0.003 + 
      Leptospira 0.81 0.071 0.642 ± 0.071 0.728 ± 0.082 + 
1 DS, digestible starch; P1, part 1; PITChip, Pig Intestinal Tract Chip; RS, resistant starch. 
2 Corr. P value indicates the P value corrected for multiple testing according to the procedure of Benjamini-Hochberg. 
3 ARC is the Average Relative Contribution of a microbial group. Values are means ± SDs, n = 9 for DS-fed pigs and n = 7 for 
RS-fed pigs. 
4 ”+” or “-” indicates whether the average relative contribution of the microbial group increased or decreased by the RS treatment. 
In the colon, 30 microbial groups were significantly changed by the RS treatment 
(corrected P value <0.05), whereas a trend toward significance was observed for 13 
additional microbial groups (corrected P value between 0.05 and 0.07) (Table 2). Members 
of the Actinobacteria, Weissella-like group, Clostridium cluster IV, IX, XV, XVI and XVII, 
Mollicutes, Fusobacteria and Betaproteobacteria increased in relative abundance in pigs 
fed the RS diet. In contrast, groups within the classes of Bacilli (e.g. Allofustis, 
Lactobacillus acidophilus-like group and Lactobacillus plantarum-like group), Clostridium 
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cluster XI and XIVa, Deltaproteobacteria and Gammaproteobacteria decreased upon RS 
consumption (Table 2). 
Despite the change in relative abundance of several microbial groups, treatment with RS for 
14 d did not significantly alter the microbial diversity in caecum and colon as indicated by 
Shannon’s and Simpson’s indices for diversity (data not shown). 
Table 2. Phylogenetic groups in the luminal content of the P1 colon of pigs fed the DS or RS diet for 2 wk that 
were significantly affected by diet according to univariate analysis of PITChip data1. 
   ARC3  
Phylogenetic group Corr. P value2 P value DS RS Effect4 
Actinobacteria      
   Actinobacteria       
      Eggerthella et rel. 0.045 0.009 0.731 ± 0.033 0.823 ± 0.081 + 
      Microbacterium 0.040 0.006 0.785 ± 0.057 0.911 ± 0.076 + 
      Micrococcus et rel. 0.045 0.009 0.806 ± 0.048 0.897 ± 0.069 + 
      Propionibacterium 0.069 0.021 1.258 ± 0.081 1.403 ± 0.093 + 
      Tonsillophilus 0.058 0.014 0.694 ± 0.035 0.791 ± 0.082 + 
Firmicutes      
   Bacilli      
      Allofustis 0.058 0.014 0.694 ± 0.043 0.622 ± 0.052 - 
      Lactobacillus acidophilus et rel. 0.069 0.021 0.956 ± 0.151 0.736 ± 0.173 - 
      Lactobacillus plantarum et rel. 0.040 0.006 2.083 ± 0.178 1.835 ± 0.124 - 
      Weissella et rel. 0.045 0.009 0.660 ± 0.032 0.735 ± 0.052 + 
   Clostridium cluster IV      
      Faecalibacterium et rel. 0.020 0.001 1.402 ± 0.188 1.748 ± 0.137 + 
      Faecalibacterium prausnitzii et rel. 0.020 0.001 1.648 ± 0.232 2.062 ± 0.134 + 
      Ruminococcus bromii et rel. 0.069 0.021 0.294 ± 0.049 0.367 ± 0.049 + 
      Sporobacter termitidis et rel. 0.015 0.001 3.300 ± 0.364 4.358 ± 0.283 + 
      Uncultured Clostridia IV 0.021 0.002 1.799 ± 0.107 2.232 ± 0.294 + 
   Clostridium cluster IX      
      Phascolarctobacterium faecium et 
rel. 0.015 <0.001 0.896 ± 0.098 1.134 ± 0.068 + 
      Veilonella 0.015 0.001 0.602 ± 0.088 0.793 ± 0.066 + 
   Clostridium cluster XI      
      Anaerovorax et rel. 0.045 0.009 1.078 ± 0.150 0.851 ± 0.111 - 
   Clostridium cluster XIVa      
      Bryantella et rel. 0.045 0.009 2.022 ± 0.110 1.810 ± 0.172 - 
      Dorea et rel. 0.069 0.021 0.913 ± 0.106 0.760 ± 0.105 - 
      Eubacterium plexicaudatum et rel. 0.045 0.009 0.371 ± 0.033 0.324 ± 0.024 - 
      Eubacterium ventriosum et rel. 0.058 0.014 0.363 ± 0.032 0.321 ± 0.022 - 
      Roseburia intestinalis et rel. 0.040 0.006 1.047 ± 0.112 0.898 ± 0.065 - 
      Ruminococcus ganvus et rel. 0.045 0.009 0.934 ± 0.110 0.769 ± 0.079 - 
      Uncultured Clostridia XIVa 0.040 0.006 2.002 ± 0.127 1.744 ± 0.141 - 
   Clostridium cluster XV      
      Eubacterium et rel. 0.015 0.001 0.604 ± 0.088 0.793 ± 0.066 + 
   Clostridium cluster XVI      
      Eubacterium biforme et rel. 0.021 0.002 0.732 ± 0.048 0.833 ± 0.053 + 
   Clostridium cluster XVII      
      Catenibacterium 0.021 0.002 0.274 ± 0.021 0.333 ± 0.024 + 
   Mollicutes      
      Acholeplasma et rel. 0.045 0.009 0.690 ± 0.039 0.778 ± 0.072 + 
      Bulleidia moorei et rel. 0.021 0.002 0.336 ± 0.035 0.407 ± 0.032 + 
      Erysipelothrix 0.015 0.001 0.715 ± 0.119 0.995 ± 0.081 + 
      Solobacterium moorei et rel. 0.040 0.006 0.525 ± 0.091 0.714 ± 0.149 + 
Fusobacteria      
   Fusobacteria      
      Fusobacterium 0.045 0.009 0.077 ± 0.003 0.090 ± 0.013 + 
Proteobacteria      
   Betaproteobacteria      
      Bordetella et rel. 0.069 0.021 0.932 ± 0.105 1.076 ± 0.081 + 
      Neisseria et rel. 0.069 0.021 0.795 ± 0.094 0.916 ± 0.083 + 
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      Oxalobacter et rel. 0.069 0.021 0.723 ± 0.091 0.832 ± 0.058 + 
      Sutterella wadsorthia et rel. 0.058 0.014 0.822 ± 0.098 0.943 ± 0.070 + 
   Deltaproteobacteria      
      Uncultured Deltaproteobacteria 0.021 0.002 0.094 ± 0.019 0.067 ± 0.009 - 
   Gammaproteobacteria      
      Escherichia coli et rel. 0.040 0.006 1.423 ± 0.108 1.161 ± 0.161 - 
      Pseudomonas et rel. 0.020 0.001 1.306 ± 0.154 0.975 ± 0.161 - 
      Psychrobacter et rel. 0.021 0.002 1.022 ± 0.062 0.870 ± 0.099 - 
      Uncultured Gammaproteobacteria 0.015 <0.001 1.314 ± 0.136 1.027 ± 0.134 - 
      Vibrio et rel. 0.058 0.014 0.673 ± 0.077 0.537 ± 0.098 - 
Spirochaetes      
   Spirochaetes      
      Uncultured Spirochaetes 0.069 0.021 0.518 ± 0.043 0.456 ± 0.048 - 
1 DS, digestible starch; P1, part 1; PITChip, Pig Intestinal Tract Chip; RS, resistant starch. 
2 Corr. P value indicates the P value corrected for multiple testing according to the procedure of  Benjamini-Hochberg. 
3 ARC is the Average Relative Contribution of a microbial group. Values are means ± SDs, n = 7 for DS-fed pigs and n = 8 for 
RS-fed pigs. 
4 ”+” or “-” indicates whether the average relative contribution of the microbial group increased or decreased by the RS treatment. 
SCFA concentrations  
SCFA concentrations were measured in the intestinal contents collected at section (5 h 
postprandially). Total SCFA concentration was highest in the caecum and gradually 
decreased along the colon (Fig. 3A). In the caecum and colon, SCFA concentrations were 
significantly higher in RS-fed pigs compared with DS-fed pigs (Fig. 3A). The most 
abundant SCFAs in the intestine were acetate, propionate and butyrate. The increase in total 
SCFA concentration on RS could mainly be attributed to higher concentrations of acetate 
and propionate (Fig. 3B, C). Butyrate concentration was significantly higher only in 
RS-treated pigs in the colon part 2 (P2 colon) (Fig. 3D). Although concentrations of 
valerate were low, the values for caecum and colon were significantly higher in RS-fed pigs 
(Fig. 3E). However, in the caecum we found significantly higher concentrations of 
isobutyrate and isovalerate in DS-fed pigs (Fig. 3F, G).  
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Figure 3. Total SCFAs (A), acetate (B), propionate (C), butyrate (D), valerate (E), isobutyrate (F) and isovalerate 
(G) concentrations in luminal contents of pigs fed the DS or RS diet for 2 wk. Values are means ± SEM, n = 6-10 
pigs per treatment. *, ** DS and RS differ within the intestinal segment, P <0.05 and P <0.01, respectively. # , ## 
DS and RS differ within the total caecum or colon, P <0.05 and P <0.01, respectively. From left to right, bars 
represent areas of the gastrointestinal tract from proximal to distal. The small intestine was divided into 10 equal 
parts; parts 7-10 refer to the 4 most distal segments of the small intestine, whereas the caecum and colon were 
divided into 2 respectively 4 segments of equal length. White horizontal bars indicate the intestinal parts that were 
combined for statistical analysis to determine differences between treatments. CA, caecum; CO, colon; DS, 
digestible starch; RS, resistant starch; SI, small intestine. 
Differential gene expression mucosal scrapings 
The expression of several genes was determined in the mucosal scrapings collected at 
section (5 h postprandially). We observed a significant increase in GCG gene expression in 
RS-fed pigs in the caecum (Fig. 4A), whereas PYY gene expression was not modulated (Fig. 
4B). In the most distal part of the small intestine, an increase in angiopoietin-like 4 
(ANGPTL4) expression was found with RS (Fig. 4C). In the caecum and P2 colon, 
expression of SLC16A1 was higher in RS-fed pigs compared with DS-fed pigs (Fig. 4G). 
However, the expression of the SCFA receptors FFAR2, FFAR3, G protein-coupled receptor 
119 (GPR119) and the SCFA transporter SLC5A8 was not different between the pigs fed RS 
or DS (Fig. 4D, E, F and H, respectively). 
 
Figure 4. Relative gene expression of GCG (A), PYY (B), ANGPTL4 (C), FFAR2 (D), FFAR3 (E), GPR119 (F), 
SLC16A1 (G) and SLC5A8 (H) in mucosal scrapings along the proximal-distal axis of the intestine of pigs fed the 
DS or RS diet for 2 wk, as determined by qRT-PCR. Messenger RNA levels were standardized to RPLP0. Values 
are presented as means ± SEM, n = 6-9 pigs per treatment. *, ** DS and RS differ within the intestinal segment, P 
<0.05 and P <0.01, respectively; ## DS and RS differ within the total caecum, P <0.01. From left to right, bars 
represent areas of the gastrointestinal tract from proximal to distal. The small intestine was divided into 10 equal 
parts; parts 7-10 refer to the 4 most distal segments of the small intestine, whereas the caecum and colon were 
divided into 2 respectively 4 segments of equal length. White horizontal bars indicate the intestinal parts that were 
combined for statistical analysis to determine differences between treatments. CA, caecum; CO, colon; DS, 
digestible starch; RS, resistant starch; SI, small intestine.  
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Plasma analyses 
Blood samples were taken from all pigs, both before and after the intervention. Glucose, 
insulin, cholesterol and GLP-1 concentrations were not affected by dietary treatment 
(Supplemental Fig. 3A, B, D and E, respectively). However, at the end of the intervention 
period, plasma TG concentrations were significantly higher in RS-fed pigs compared with 
pigs fed DS (Supplemental Fig. 3C). In addition, in DS-fed pigs, plasma PYY was 
significantly lower at the end of the experimental period than at the start (Supplemental 
Fig. 3F). 
Discussion 
In the set of experiments reported in this chapter we investigated the effects of a diet high in 
RS in pigs. We found that RS was completely degraded in caecum, changed caecal and 
colonic microbiota composition, increased caecal and colonic SCFA concentrations, and 
increased the expression of SLC16A1 and GCG in caecum. RS had no effect on plasma 
concentrations of GLP-1 and PYY measured 5 h postprandially. 
Our data on RS contents in intestinal segments show that RS was completely degraded in 
caecum, which is in line with observations on the degradation of inulin in the 
gastrointestinal tract of pigs [304]. As a result, the composition of the microbiota 
differentially changed in porcine caecum and colon, as also has been reported for inulin 
[305]. However, the RS-induced changes in the gut microbiota depend on the initial 
composition of an individual’s gut microbiota [96], which could explain why RS-fed pigs 
24 (caecum) and 1 (colon) were not clearly separated from the DS-fed pigs on the RDA 
triplots. Moreover, specific bacterial groups can be selectively affected by a certain type of 
RS [86, 94] and even by different crystalline polymorphism of the same type of RS [306] in 
different locations of the intestine. Young et al. [95] fed type 2 RS (RS2) to rats and found 
blooms of Bacteroidetes and Actinobacteria in colonic digesta. However, Martínez et al. 
[94] reported that type 4 RS but not RS2 significantly induced Bacteroidetes and 
Actinobacteria while decreasing Firmicutes at the phylum level. At the species level, type 4 
RS increased Bifidobacterium adolescentis and Parabacteroides distasonis, whereas RS2 
significantly raised the proportions of Ruminococcus bromii and Eubacterium rectale. In a 
study on RS3, the relatives of R. bromii (R-ruminococci) and E. rectale were found to be 
increased in the colon of most volunteers [96]. Moreover, when the effects of structural 
variation of RS3 on fermentability by human gut microbiota were studied, it was found that 
retrograded RS3 that formed a B-type pattern induced Bifidobacterium spp., whereas 
A-type pattern RS3 induced Atopobium spp. [306].  
In our study, the pigs were fed RS3, and we observed a clear change in caecal and colonic 
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microbiota composition compared with pigs fed DS. The relative abundance of R. bromii 
was increased in the colonic samples of RS-fed pigs, which is consistent with previous 
research [96]. However, E. rectale was not significantly changed in our study and its 
relative contribution in the RS group even decreased slightly. Interestingly, in addition to E. 
rectale, other bacterial groups that belong to Clostridium cluster XIVa showed either a 
significant decrease or a trend toward a decrease in RS-fed pigs, whereas bacterial groups 
belonging to Clostridium cluster IV , IX, XV, XVI and XVII increased in RS-fed pigs. This 
may be due to a low competitiveness of Clostridium cluster XIVa, because previous 
research indicated the Roseburia/E. rectale group was particularly dependent on residual 
dietary carbohydrate and pH to maintain its competitiveness in the colon [307]. It may also 
be related to the fact that we could not detect a significant effect of the RS diet on butyrate 
concentration in P1 colon, because several members of this group have been shown to 
produce butyrate [308]. In turn, we found increased relative abundance of populations 
related to the butyrate-producing Faecalibacterium prausnitzii, previously suggested as a 
health-promoting bacterium [309]. Furthermore, we found an increase in several 
propionate-producing microorganisms, including members of the genera Propionibacterium, 
Veilonella and Phascolarctobacterium. Propionate has previously been indicated as another 
health-promoting metabolite being produced in the large intestine [288]. In contrast, several 
groups of potentially pathogenic taxa within the Gammproteobacteria, including 
Escherichia coli and Pseudomonas spp., were found to be decreased in relative abundance 
in the colon. 
Currently, most studies focus on the colonic and faecal microbiota [94-96], whereas 
research on the effect of RS on caecal microbiota is limited. This study is the first to our 
knowledge to use comprehensive microarray-based profiling to detect the RS effect on 
caecal microbiota in an animal model. We observed major differences between caecum and 
colon with respect to microbial changes, possibly due to the change in the chemical 
structure of RS in colon compared with caecum, which determined the RS accessibility by 
groups of bacteria [94].  
We found that a diet high in RS increased SCFA concentrations in the luminal content 
compared with a DS diet, as was also observed previously in pigs [90]. However, 
because >95% of the SCFAs are rapidly absorbed from the colonic lumen and metabolized 
by the host, the total production of SCFAs is difficult to determine [310, 311]. Butyrate is 
almost entirely used by colonocytes as their preferred energy substrate, whereas acetate and 
propionate move to the liver via the portal vein. Propionate is metabolized by the liver and 
used for gluconeogenesis, whereas acetate is a substrate for cholesterol synthesis and 
lipogenesis. In addition, acetate is taken up by muscle and adipose tissue [310, 312]. It has 
been observed that RS especially results in an increased production of butyrate [73]. 
However, our experimental setup did not allow us to quantify total butyrate production, for 
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which preferably isotope dilution studies or direct measurements of arteriovenous 
differences in SCFA concentrations across the gut are required [310, 311]. Moreover, it has 
been suggested that butyrate is taken up by the colonocytes more rapidly than acetate and 
propionate [310]. This might explain why we did not observe a very profound increase in 
butyrate concentrations in pigs fed RS. 
We found that SLC16A1 was induced in pigs consuming the RS diet. This observation can 
be explained by the increased intestinal SCFA concentrations [313, 314]. Induction of 
SLC16A1 gene expression was also observed by Zhou et al [290], who measured gene 
expression in epithelial cells of the gastrointestinal tract from rats fed a DS or an RS diet for 
4 wk. They found that SLC16A1, PYY and GCG gene expression was induced in the 
caecum and colon. The fact that our study did not show an increase in GCG or PYY gene 
expression with RS consumption could be due to the different animal model used and the 
different duration of the dietary treatment. 
The presence of SCFA-activated FFA receptors in the intestinal mucosa could provide a 
link between intestinal SCFAs and appetite and energy homeostasis. FFAR2 
immunoreactivity was found to be almost completely colocalized with GLP-1 in terminal 
ileum, caecum and colon of rats [315]. Furthermore, it was shown in proximal colon that 
the densities of FFAR2-immunoreactive enteroendocrine cells and GLP-1-producing cells 
were increased >2-fold by fermentable fibre supplementation compared with control [315]. 
In addition, the activation of FFAR2 by SCFAs is suggested to facilitate or modify PYY 
secretion [316]. In this study, no significant differences in FFAR2 and FFAR3 gene 
expression were observed between the 2 diet groups. However, this observation does not 
exclude the possibility that the receptors were activated in RS-fed pigs, because gene 
expression levels do not necessarily reflect protein levels. Our experiment showed that 
GPR119, like GCG, is most abundantly expressed in the distal small intestine. GPR119 is 
expressed in intestinal endocrine L-cells and has been shown to stimulate the release of 
GLP-1 [317, 318]. However, in our study the expression of GPR119 and GCG was not 
modified upon RS feeding. 
TG concentrations in plasma were found to be higher in RS-fed pigs compared with control 
pigs. Two mechanisms might be responsible for this increase. At first, acetate resulting from 
fermentation of RS in the intestine is taken up by the liver, where it can serve as a substrate 
for TG synthesis [310]. A second explanation is that RS increases plasma ANGPTL4 
concentrations, because we observed increased ANGPTL4 gene expression in the distal part 
of the small intestine of RS-fed pigs. Because ANGPTL4 is an inhibitor of lipoprotein 
lipase, increased concentrations of ANGPTL4 result in increased plasma TG concentrations 
[319].  
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In conclusion, we showed that a diet high in RS modulates microbiota composition, SCFA 
concentrations and gene expression in pig intestine. These findings provide a detailed 
insight on the interaction between diet, microbiota, and host and may provide leads for 
designing functional food strategies that aim to reduce the risk of obesity and type 2 
diabetes in humans. However, additional investigation is required to further elucidate the 
underlying molecular mechanisms and the link to satiety.  
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Supplemental Figure 1. Relative gene expression of Apical sodium-dependent bile salt transporter, SLC10A2 (A), 
Fatty acid transport protein 4, SLC27A4 (B), Liver-type fatty acid binding protein, FABP1 (C), Intestine-type fatty 
acid binding protein, FABP2 (D), Villin 1, VIL1 (E), Intestinal alkaline phosphatase, ALPI (F), Chromagranin A, 
CHGA (G), Free fatty acid receptor 1, FFAR1 (H), G protein-coupled receptor 120, GPR120 (I), Glucagon, GCG 
(J), Peptide YY, PYY (K), Angiopoietin-like 4, ANGPTL4 (L), Free fatty acid receptor 2, FFAR2 (M), Free fatty 
acid receptor 3, FFAR3 (N), G protein-coupled receptor 119, GPR119 (O), Monocarboxylate transporter 1, 
SLC16A1 (P) and Sodium-coupled monocarboxylate transporter 1, SLC5A8 (Q) in mucosal scrapings along the 
proximal-distal axis of the intestine of adult female pigs, as determined by qRT-PCR. Messenger RNA levels were 
standardized to RPLP0. Values are presented as means ± SEM, n = 3 pigs. From left to right, bars represent areas 
of the gastrointestinal tract from proximal to distal. The small intestine was divided into 10 equal parts, whereas 
the caecum and colon were divided into 2 respectively 4 segments of equal length. CA, caecum; C, colon; SI, 
small intestine. 
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Supplemental Figure 2. RDA analysis of DGGE profiling data of samples from small intestine (A), caecum (B) 
and colon (C). Nominal environmental variables DS and RS are represented by triangles (▲). Samples are 
grouped by treatment: RS (■) and DS (●). Each symbol represents 1 pig. Combined both axes explain 22.2% of 
the total variance in the dataset for (A), 23.5% for (B) and 21.9% for (C). DS, digestible starch; RS, resistant 
starch. 
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Supplemental Figure 3. Glucose (A), insulin (B), TG (C), cholesterol (D), GLP-1 (E) and PYY (F) 
concentrations in plasma of pigs fed the DS or RS diet before the start of the treatment (T0) and on d12 of the 
treatment (T1). n = 10 pigs per treatment; *, ** DS and RS differ, P <0.05 and P <0.01, respectively. DS, digestible 
starch; RS, resistant starch. 
Supplemental Table 1. Composition of the DS and RS diet, expressed as g/kg diet1. 
Ingredient DS RS 
Native potato starch (Paselli WA4) 350.0 - 
Retrograded tapioca starch (Actistar, Cargill) - 338.8 
Wheat 249.0 249.0 
Barley 150.0 150.0 
Corn gluten meal 100.0 100.0 
Potato protein (Protastar) 50.0 50.0 
Soy bean oil 15.0 15.0 
Animal fat 15.0 15.0 
Vitamin mineral premix2 10.0 10.0 
CaCO3 17.0 17.0 
Monocalcium phosphate 11.0 11.0 
KCI 10.0 10.0 
NaHCO3 15.0 15.0 
NaCI 5.0 5.0 
L-lysine HCI 1.5 1.5 
Flavouring (Luctarom Advance Cherry Honey) 1.5 1.5 
Total 1000.0 988.8 
1 DS, digestible starch; RS, resistant starch. 
2 Provided the following per kg food (of the DS diet): retinol: 3.0 mg; cholecalciferol: 50 μg; α-tocopherol: 25 mg; menadione: 1.0 
mg; thiamine: 0.75 mg; riboflavin: 4.0 mg; niacin: 20 mg; pyridoxine: 1.0 mg; cyanocobalamin: 15μg; panthothenic acid: 13 mg; 
choline chloride: 300 mg; folic acid: 2.5 mg; biotin: 0.1 mg; Fe: 80 mg (FeSO4.H2O); Cu: 10 mg (CuSO4.5H2O); Mn: 30 mg 
(MnO); Zn: 60 mg (ZnSO4.H2O); Co: 0.20 mg (CoSO4.7H2O); I: 0.75 mg (KI); Se: 0.20 mg (Na2SeO3). 
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Supplemental Table 2. Primer sequences used for qRT-PCR. 
Gene symbol Primer sequence (Forward) Primer sequence (Reverse) 
ALPI CTACACATTGCGTGGAAG ATGGAGGTATATGGCTTGA 
ANGPTL4 AGATTCAGCAACTCTTCC AATTCTGGATTCTCAAGTG 
CHGA AAGAAACAGAGCAGTTATGA CCTCCTTCAACTCAGTCT 
FFAR1 CTTGTCCTCTGTCACCTG AGGGAGCTGGTAGTATTG 
FFAR2 CGTGTTCATCGTTCAGTA GAAGTTCTCATAGCAGGTA 
FFAR3 TGGAGACCTTACGTGTTG CGAGGATGAGAAGTAGTAGAT 
GCG (glucagon) CAAGAGGAACAAGAATAACAT AAGAACTTACATCACTGGTA 
GPR119 TATAGGCAGAAGGAGGTA AGAGAAGGAGGAGGAATG 
GPR120 TGGGATGTGTCGTTTGTT CCTTGATGCCTTGGTGAT 
FABP1(L-FABP)  TGAACTCAACGGTGACATA ATTCTCTTGCTGATTCTCTTG 
FABP2 (I-FABP)  AGATAGACCGCAATGAGA TCCTTCTTGTGTAATTATCAGT 
PYY AGATATGCTAATACACCGAT CCAAACCCTTCTCAGATG 
RPLP0 CTTTAGGCATCACCACTA TGTCTCCAGTCTTAATCAG 
SLC5A8 (SMCT1) CGCAGATTCCTACTAACC GATTGTCAGTTCCACCAT 
SLC10A2 (ASBT)  TGCCTCTTAATCTATACCA GGACACAGGAACAATAAG 
SLC16A1 (MCT1) CATCAACTACCGACTTCTG TACTGGTCTCCTCCTCTT 
SLC27A4 (FATP4) GGTTCTGGGATGATTGTG TGGTTGAGGAGGTATCTG 
VIL1 TATTATTGGTGTTCGTGCTA TCTGGAGGAATAGGATACTAA 
Supplemental Table 3. General characteristics of pigs fed the DS or RS diet for 2 wk. Values are presented as 
means ± SEM, n = 10 pigs per treatment1. 
 Diet  
Measurement DS RS P value 
Body weight (kg) 274 ± 6.3 271 ± 5.0 0.68 
Fat depth (mm) 29.0 ± 1.4 29.0 ± 1.1 0.98 
Length small intestine (m) 16.4 ± 1.6 16.9 ± 0.8 0.77 
Length colon (m) 5.8 ± 0.2 5.8 ± 0.2 1.00 
1 DS, digestible starch; RS, resistant starch 
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and cell division pathways and changes the microbiome in the 
proximal colon of male pigs  
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Abstract 
Consumption of resistant starch (RS) has been associated with various intestinal health 
benefits, but knowledge on its effects on global gene expression in colon is rather limited. 
The main objective of the current study was to identify genes affected by RS in the 
proximal colon to infer which biological pathways were modulated. Ten 17-wk-old male 
pigs, fitted with a cannula in the proximal colon for repeated collection of tissue biopsies 
and luminal content, were fed a digestible starch (DS) diet, or a diet high in RS (34%) for 
two consecutive periods of 14 days in a crossover design. Analysis of the colonic 
transcriptome profiles revealed that upon RS feeding oxidative metabolic pathways, such as 
TCA cycle and beta-oxidation, were induced whereas many immune response pathways, 
including adaptive and innate immune system, as well as cell division were suppressed. The 
nuclear receptor PPARG was identified as a potential key upstream regulator. RS 
significantly (P <0.05) increased the relative abundance of several butyrate-producing 
microbial groups, including the butyrate producers Faecalibacterium prausnitzii and 
Megasphaera elsdenii, and reduced the abundance of potentially pathogenic members of 
the genus Leptospira and the phylum of Proteobacteria. Concentrations in carotid plasma of 
the three main short-chain fatty acids acetate, propionate and butyrate were significantly 
higher with RS consumption compared to DS consumption. Overall, this study provides 
novel insights on effects of RS in proximal colon, and contributes to our understanding of a 
healthy diet.  
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Introduction 
Dietary resistant starch (RS) is a complex polysaccharide that resists digestion and 
absorption in the small intestine. Resistant starches occur for a variety of reasons including 
milling, thermal processing and chemical modifications such as cross bonding and 
acylation [320]. The effects and potential health benefits of RS have been extensively 
studied [73, 79, 81, 321]. Beneficial effects have been reported for large intestine, i.e. 
cecum and colon, where RS is highly fermentable by microbiota, resulting in among others 
the well-known formation of short-chain fatty acids (SCFAs), but also of a variety of 
phytochemical metabolites that have only be partially characterized [322]. Compared to 
other polysaccharides, RS preferentially favors the production of butyrate in humans [321, 
323, 324]. 
With regard to pigs, several studies showed that RS increases cecal, colonic and faecal 
concentrations of total SCFAs and the main individual SCFAs acetate, propionate and 
butyrate, concomitant with changes in microbiota composition [90, 101, 325-327]. 
Concentrations of SCFAs gradually decrease along the colon in pigs fed RS, with the 
lowest concentrations present in the distal part [101, 326], and these regional differences 
have been linked to the pathogenesis of colorectal cancer and inflammatory bowel disease 
[73, 321, 326]. Studies in rodents corroborated the findings that RS may play a role in the 
prevention of colorectal cancer [92, 328] and inflammatory bowel disease [329, 330].  
Genome-wide transcriptional profiling, or transcriptomics, is extensively used to study how 
cells respond to certain stimuli or to diagnose and predict clinical outcomes [331, 332]. 
Similarly, there is a major interest in characterizing the genes and networks that are 
regulated by food components, since this contributes to our understanding of a healthy diet 
[333, 334]. Remarkably, data on the genome-wide effects of RS in the intestinal tract is 
scarce. It has only been recently reported that differential gene expression due to 
consumption of type 2 RS for 4 weeks suggested improvement of structure and function of 
the GI tract in rats compared to a cornstarch diet with the same energy density [335]. In 
addition, the effect of colonic butyrate administration on gene expression profile in distal 
colonic mucosa has been investigated, showing that butyrate affects fatty acid metabolism, 
electron transport, oxidative stress and apoptosis pathways in healthy humans [336].  
We previously showed in pigs that 2-wk-consumption of a diet high in RS changed caecal 
and colonic microbiota composition, increased caecal and colonic SCFA concentrations and 
modified the mucosal gene expression of SLC16A1 (monocarboxylate transporter) and 
GCG (in intestine precursor for GLP-1 and -2) in caecum [101]. However, genome-wide 
transcriptional profiling was not performed in that study. Thus, extending these findings, 
the aim of the current study was to identify genes and corresponding biological pathways 
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that are modified by RS in the mucosa of the proximal colon (pCO), together with 
alterations in the luminal microbiome. To this end, a crossover study was performed in pigs 
that were fitted with a permanent cannula in the pCO for repeated collection of luminal 
content and tissue biopsies. The colonic gene expression profile and luminal microbiota 
composition were obtained by microarray techniques. Pigs were used as a model for 
humans, because the anatomy and physiology of the gastrointestinal tract of pigs and the 
pig genome bear a lot of similarities with those in humans [153, 154]. 
Materials and methods 
Experimental design, pigs and housing 
Ten male Landrace barrows (17 wk of age; initial body weight of 57.9 ±1.61 kg) from eight 
litters were fitted with cannulas and catheters and assigned to two dietary treatments in a 
crossover design. Each treatment lasted for 14d, and differed with regard to the type of 
starch in the diet: digestible starch (DS) or resistant starch (RS). Pigs were individually 
housed in metabolism pens of 2 m2, equipped with a feeder. Artificial lights were on from 
0500 until 1900 and dimmed during the dark period. All experimental protocols describing 
the management, surgical procedures, and animal care were reviewed and approved by the 
Animal Care and Use Committee of Wageningen University and Research Centre (Lelystad, 
the Netherlands). 
Diets and feeding 
The 2 experimental diets used were identical except for type of starch. The main source of 
starch in the DS diet was pregelatinized potato starch (Paselli WA4, AVEBE), which was 
replaced on dry matter basis in the RS diet by retrograded tapioca starch (Actistar, Cargill). 
According to the supplier, this starch was at least 50% resistant to digestion in the small 
intestine (Megazyme RS assay, certificate of analysis Actistar, Cargill). Based on physical 
and chemical characteristics the RS used in this study can be classified as RS type 3 [79]. 
Composition of the experimental diets is presented in Supplemental Table 1. Diets were fed 
twice a day at 0700 and 1600 as a mash, and mixed with water (ratio water:feed = 2.5:1) in 
the feeders immediately before feeding. The diets were isoenergetic on gross energy (GE) 
basis. The daily feed allowance was adjusted to 2.8 times the energy required for 
maintenance (MEm = 450 kJ/kg0.75 per day) and was based on metabolic body weight 
(kg0.75). Pigs were weighed every week to allow the adjustment of their feeding level in 
accordance to metabolic body weight. All pigs had free access to water throughout the study. 
During the 1-week adaptation period, before surgery, pigs were fed a 50:50 mix of the DS 
and RS diet, and adapted to the feeding pattern and individual housing.  
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Surgery 
In the second week after arrival, pigs underwent surgery for the placement of a cannula in 
the pCO and a catheter in the carotid artery. The pCO was chosen as site of investigation 
because of the greater fermentation and higher SCFA concentrations compared to more 
distal colonic regions [101, 326]. Pigs were surgically fitted with a simple T-cannula in the 
pCO 1.45 ±0.16 m distal from the ileocecal sphincter, as was confirmed at section. The 
cannula was inserted in the intestinal lumen, exteriorized through a hole, fastened to the 
exterior part and closed with a stopper [337]. In addition, pigs were fitted with a permanent 
blood vessel catheter (Tygon, Norton) as described previously [338]. The catheter for blood 
sampling was placed in the carotid artery, fixed firmly at the site of insertion, tunnelled 
subcutaneously to the back of the pig and exteriorized between the shoulder blades. See 
Supplemental methods for more details. 
Colon biopsies 
Biopsies from the intestinal wall were collected 300 min after the morning meal on d14 of 
each dietary treatment. See Supplemental methods for experimental details.  
Digesta collection  
Digesta were collected via the gut cannula on d14 of each dietary treatment, both 30 min 
before and 300 min after feeding. Samples were collected and stored for determination of 
microbiota composition, SCFA concentration, and dry matter content as described in the 
Supplemental methods. SCFA concentrations and dry matter content were determined in 
the luminal content as described before [101]. 
Blood collection 
Blood was drawn from the carotid artery on d14 of each dietary treatment, 300 min after 
feeding. Blood was collected in 6 mL Vacutainer EDTA tubes (Becton Dickinson) 
supplemented with protease (Complete, EDTA-free; Roche) and dipeptidyl peptidase-4 
(Millipore) inhibitors and then placed in ice water. Tubes were centrifuged for 10 min at 
1300 g at 4°C within 20 min after blood collection. Plasma was aliquoted and stored at 
-80°C. 
RNA isolation and quality control 
Total RNA was isolated from biopsies using TRIzol reagent (Life Technologies) according 
to the manufacturer’s instructions, followed by RNA Cleanup using the RNeasy Micro kit 
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(Qiagen). Concentrations, purity and quality of the RNA samples was determined as 
described in the Supplemental methods.  
Microarray hybridization and analysis 
The pCO biopsies of all 10 pigs, collected on d14 of both dietary treatments, were subjected 
to genome-wide expression profiling. To this end, total RNA (100 ng) was used for whole 
transcript cDNA synthesis using the Ambion WT expression kit (Life Technologies) and 
subsequently labeled using the Affymetrix GeneChip WT Terminal Labeling Kit 
(Affymetrix). Samples were hybridized on Porcine Gene 1.0 ST arrays (Affymetrix), 
washed, stained, and scanned on an Affymetrix GeneChip 3000 7G scanner. Detailed 
protocols for array handling can be found in the GeneChip WT Terminal Labeling and 
Hybridization User Manual (Affymetrix; P/N 702808, Rev. 4). Packages from the 
Bioconductor project [339], integrated in an online pipeline [340], were used to analyze the 
array data. Various advanced quality metrics, diagnostic plots, pseudoimages, and 
classification methods were used to determine the quality of the arrays prior statistical 
analysis [341]. Array data have been submitted to the Gene Expression Omnibus under 
accession number GSE45554. 
The approximately 600,000 probes on the Porcine Gene 1.0 ST array were redefined 
utilizing current genome information [342]. In this study probes were reorganized based on 
the gene definitions as available in the NCBI Sus scrofa Entrez Gene database, build 4.1 
(Sscrofa10.2 genome assembly) [343] as well as the gene predictions made by the 
AUGUSTUS software [344]. Since the annotation of the pig genome is still poor, the 
functional annotation was improved by mapping the AUGUSTUS gene predictions to the 
human RefSeq database [345]. Out of 17,118 pig gene predictions, 14,505 were found to 
have a human orthologous gene. Unless otherwise stated, the functional interpretation of 
the transcriptome data was performed using the human orthologs. 
Normalized gene expression estimates were obtained from the raw intensity values using 
the robust multiarray analysis (RMA) preprocessing algorithm available in the library 
‘AffyPLM’ using default settings [346]. Differentially expressed probe sets (genes) were 
identified using linear models, applying moderated t-statistics that implemented empirical 
Bayes regularization of standard errors (library ‘limma’) [347]. To adjust for both the 
degree of independence of variances relative to the degree of identity and the relationship 
between variance and signal intensity, the moderated t-statistic was extended by a Bayesian 
hierarchical model to define a intensity-based moderated T-statistic (IBMT) [348]. Probe 
sets that satisfied the criterion of P <0.01 were considered to be significantly regulated. 
Changes in gene expression were related to functional changes using gene set enrichment 
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analysis (GSEA) [234]. GSEA takes into account the broader context in which gene 
products function, namely in physically interacting networks, such as biochemical, 
metabolic, or signal transduction routes, and has the advantage that it is unbiased, because 
no gene selection step is used. The Enrichment Map plugin for Cytoscape was used for 
visualization and interpretation of the GSEA results [349]. See Supplemental methods for 
details. 
Upstream Regulator Analysis in IPA (Ingenuity Systems, Redwood City; content version 
14400082 released 1 Nov 2012) was used to identify the cascade of potential upstream 
transcriptional regulators that may explain the observed gene expression changes in the 
dataset, and whether they are likely activated or inhibited. 
Microbiota analysis 
Microbiota composition was determined in the luminal content collected from the pCO via 
the cannula 300 min after feeding on d14 of each dietary treatment, essentially as described 
before [101]. Due to technical issues, samples from only 9 of the 10 pigs could be analyzed. 
Samples were analyzed on the second generation Pig Intestinal Tract Chip (PITChip), an 
updated version of the original phylogenetic microarray [101, 227], which is comprised of 
more than 3,200 tiled oligonucleotides targeting the 16S rRNA gene sequences of 781 
porcine intestinal microbial phylotypes. PITChip images were processed using Agilent's 
Feature Extraction Software version 9.5 and further processed in R (library ‘microbiome’) 
[350]. 
To determine relative abundance of bacterial groups, the probe-level information was 
summarized based on non-negative matrix factorization, which removes cross-hybridization 
effects based on oligo-phylotype mappings. With the non-negative matrix factorization 
output, relative abundance of bacterial groups defined at approximate genus level (90% 16S 
ribosomal RNA similarity threshold) was calculated and used for further univariate testing. 
Univariate testing of differences for individual microbial groups was performed using the 
paired Mann–Whitney U signed rank test. P values were corrected for multiple testing using 
a false discovery rate (FDR) method [300]. Groups that satisfied the criterion of P <0.05 
were considered to be significantly affected. Multivariate analysis was applied for PITChip 
data interpretation as described in the Supplemental methods. 
SCFA determination by NMR spectroscopy 
SCFA concentrations were determined in plasma samples obtained from the carotid artery 
300 min after feeding on d14 of each dietary treatment as described in the Supplemental 
methods. 
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Standard statistical methods 
SCFA concentrations measured in digesta were analyzed using a mixed model in SAS 
(version 9.1; SAS Institute). For samples derived from the pCO cannula, time and 
individual pigs were included as repeated measurements. The model included period, diet, 
time, and interaction of diet and time as fixed effects, and pig as random effect. SCFA 
concentrations measured in plasma were analyzed using a paired samples t-test in IBM 
SPSS Statistics 19. Differences were considered significant if P <0.05. Results were 
expressed as means ± SEMs.  
Results 
Anthropometric variables 
All pigs remained healthy during the experiment and showed normal growth and appetite. 
Mean body weight at the start of the experiment was 57.9 ± 1.6 kg and increased with 21.8 
± 1.1 kg during the study period. No significant effect of treatment order was found with 
respect to body weight development (data not shown). The mean length of the small 
intestine and colon, determined at section, were similar for both treatment groups (16.1 ± 
0.62 m and 3.96 ± 0.18 m respectively). 
Differentially expressed genes in colon 
Microarray analysis was performed to identify genes that were differentially expressed in 
pCO by RS compared to DS. When remapping the probes to the Sscrofa 10.2 genome 
assembly, the expression of 748 genes was found to be significantly changed by RS (P 
<0.01). Of these genes, 459 were induced, whereas 289 genes were suppressed by RS 
(Supplemental Table 2). Among the changed genes were SLC16A1 and SLC5A8, both 
being involved in SCFA transport. RS treatment resulted in a 1.5-fold induction of 
SLC16A1 expression, as we observed before [101], whereas SLC5A8 expression was 
reduced by 1.4-fold. The most induced gene was Intestinal-type alkaline phosphatase-like 
(LOC100521756), showing a 2.9-fold increase with the RS treatment, whereas the most 
suppressed gene was Chitinase 3-like 1 (CHI3L1), with a 3.7-fold decrease (Supplemental 
Fig. 1). 
Functional implications of differential gene expression 
To gain better insight into the underlying biological phenomena affected by RS, pig genes 
were mapped to human orthologous and GSEA was performed. Results of GSEA were 
summarized in an enrichment map to enhance the functional interpretation of enriched gene 
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sets. Using conservative significance thresholds, an enrichment map was generated that 
consisted of 329 nodes (gene sets), of which 57 were positively and 272 were negatively 
enriched (Fig. 1). These numbers demonstrated that the majority of the tested gene sets was 
suppressed with RS feeding. To enhance the interpretation of the results, functionally 
related modified gene sets were then manually summarized in more general categories (Fig. 
1); a high resolution color map that includes names of all gene sets is available in 
Supplemental Fig. 2. Induced gene sets described clusters related to lipid and fatty acid 
metabolism, tricarboxylic acid (TCA) cycle, biological oxidation, olfactory system, and 
cell-cell contact. Moreover, sets containing target genes of the transcription factors 
peroxisome proliferator-activated receptor α (PPARA) and nuclear factor erythroid 
2-related factor 2 (NRF2) were enriched with RS feeding. The suppressed gene sets were 
similarly interpreted (Fig. 1 and Supplemental Fig. 2). The enrichment map revealed a 
very large cluster of 154 overlapping gene sets that contained descriptors of many, if not all, 
aspects of the immune response, including activation of innate and adaptive immune 
response and proliferation of immune cells. The second largest cluster described processes 
related to DNA replication, DNA assembly, histone acetylation, and mitosis. Other 
processes that were suppressed related to nuclear export of RNA, non-coding and 
messenger RNA processing, post-translational protein modification, and ER stress / 
unfolded protein response (UPR). 
Next, changes in the expression of genes that contributed to the enrichment of the 3 large 
clusters of processes, i.e. TCA cycle, lipid and fatty acid metabolism, and immune response 
were visualized (Supplemental Fig. 3). Most importantly, these results showed a modest 
yet consistent regulation of genes involved in the before-mentioned processes, supporting 
the robustness of the analysis. In addition, it revealed regulation of several key genes, 
including PDK1 and PDK4; both involved in controlling and connecting glucose and fatty 
acid metabolism and homeostasis, ANGPTL4; regulating plasma TG levels, as well as 
NFKB, TLR4, BCL6, ICOS and CR2 (that all play a role in controlling the adaptive and 
innate immune response). 
Upstream regulators 
The underlying mechanisms by which RS modulated gene expression changes are not well 
understood. We therefore aimed to identify potential upstream transcriptional regulators 
that could explain the observed shift in gene expression profile. Results of this analysis 
predicted the transcription factors peroxisome proliferator-activated receptor γ (PPARG) 
and v-ets avian erythroblastosis virus E26 oncogene homolog (ERG) to be significantly 
activated with RS treatment, whereas X-box binding protein 1 (XBP1) was predicted to be 
inhibited (Table 1). Because the highest Z-score (3.069) was found for PPARG, we had a 
closer look at the downstream PPARG target genes. Out of 21 PPARG-target genes affected 
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by RS, 15 genes had an expression change consistent with activation of PPARG (Table 2). 
Because TGFBR1 and CXCL14 are known to be down-regulated by PPARG and we indeed 
observed reduced expression of these target genes, this suggests that RS enhanced PPARG 
activation. The other 13 target genes were induced in our dataset, which corresponds with 
observations from literature suggesting PPARG activation. 
 
Figure 1. Enrichment map for effects of resistant starch on colonic gene expression. The map displays the 
enriched gene-sets in proximal colon after 2 wk consumption of the RS diet compared to 2 wk consumption of the 
DS diet. Nodes represent functional gene sets, and edges between nodes their similarity. Black indicates 
enrichment after RS consumption (i.e. induction after RS feeding), whereas white represents enrichment after DS 
consumption (i.e. reduction after RS feeding). Node size represents the gene set size, and edge thickness represents 
the degree of overlap between 2 connected gene sets. Clusters are manually grouped and labeled to highlight the 
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prevalent biological functions among related gene sets. See supplemental Fig. 2 for a high-resolution color version 
of the map that includes the names of the gene sets. 
Table 1. Upstream regulators.1 
Upstream  
Regulator 
Molecular Type 
Predicted  
activation state 
Activation  
Z-score2 
P value of overlap3 
PPARG Ligand-dependent nuclear receptor Activated 3.069 3.10?10-4 
ERG Transcription regulator Activated 2.828 1.33?10-2 
XBP1 Transcription regulator Inhibited -2.041 3.96?10-2 
1 Determined by Ingenuity Systems Pathway Analysis software. ERG, v-ets avian erythroblastosis virus E26 oncogene homolog; 
PPARG, peroxisome proliferator-activated receptor γ; XBP1, X-box binding protein 1. 
2 The activation Z-score predicts the activation state of the upstream regulator by using the gene expression pattern of its 
downstream genes in the data set and takes into account the consistency of target gene activation. Upstream regulators with 
Z-scores ≥ 2 were considered to be activated, if the Z-score was ≤ -2, the upstream regulator was considered to be inhibited. 
3 The overlap P value measures the significance of overlap between the data set genes and the genes reported to be regulated by the 
transcriptional activator. 
Table 2. PPARG target genes1. 
Name Gene Symbol 
Prediction of 
activation 
state2 
Observed 
mean log2 Literature 
Findings4 fold-change3 
Transforming growth factor, beta receptor 1 TGFBR1 Activated -0.25 Down 
Chemokine (C-X-C motif) ligand 14 CXCL14 Activated -0.26 Down 
Carbonic anhydrase II CA2 Activated 1.36 Up 
Angiopoietin-like 4 ANGPTL4 Activated 0.58 Up 
3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial) HMGCS2 Activated 0.49 Up 
Uncoupling protein 3 (mitochondrial, proton carrier) UCP3 Activated 0.39 Up 
Caveolin 1, caveolae protein, 22kDa CAV1 Activated 0.38 Up 
Vascular endothelial growth factor A VEGFA Activated 0.37 Up 
Peroxisome proliferator-activated receptor gamma PPARG Activated 0.33 Up 
Solute carrier family 25 (carnitine/acylcarnitine translocase), 
member 20 SLC25A20 Activated 0.32 Up 
3-hydroxybutyrate dehydrogenase, type 1 BDH1 Activated 0.31 Up 
Lipase, hormone-sensitive LIPE Activated 0.27 Up 
Diacylglycerol O-acyltransferase 1 DGAT1 Activated 0.25 Up 
Monoglyceride lipase MGLL Activated 0.23 Up 
Acyl-CoA dehydrogenase, C-4 to C-12 straight chain ACADM Activated 0.22 Up 
Phosphodiesterase 3B, cGMP-inhibited PDE3B Inhibited -0.45 Up 
Serpin peptidase inhibitor, clade A, member 1 SERPINA1 Inhibited -0.6 Up 
Angiotensinogen (serpin peptidase inhibitor, clade A, member 8) AGT - 0.87 Regulates 
Insulin-like growth factor 1 (somatomedin C) IGF1 - 0.62 Regulates 
Glutamic-pyruvate transaminase (alanine aminotransferase) GPT - 0.45 Regulates 
Protein tyrosine phosphatase, receptor type, F PTPRF - 0.27 Regulates 
1 Determined by Ingenuity Systems Pathway Analysis software. PPARG, peroxisome proliferator-activated receptor γ. 
2 Column indicates the predicted activation state of PPARG (either activated or inhibited) based on the direction of the gene 
expression change in the uploaded data set. 
3 Mean log2 fold-change of the signal intensity of resistant starch compared with digestible starch. 
4 Column indicates whether literature findings support the prediction. ‘‘Down’’ and ‘‘Up’’ indicate whether the literature suggests a 
down- or an upregulation of the target gene by PPARG, respectively. ‘‘Regulates’’ indicates that there is insufficient support from 
the literature that the target gene is either up- or downregulated by PPARG. 
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Microbiota analysis 
To take full advantage of this study, we also determined microbiota composition in the 
luminal content of the pCO using second generation PITChip. RS did not significantly 
change the microbial diversity as indicated by Shannon’s index for diversity (data not 
shown). Principal response curves analysis showed that diet (DS or RS) explained 15.7% of 
the total variation in microbiota, while period and the interaction of period and diet only 
explained 4.8% and 6.8% respectively (data not shown). This indicated that diet was the 
main factor driving the microbial variation. Partial RDA of the PITChip data confirmed that 
diet had a significant effect on microbial variation (P <0.05) (Fig. 2). 
At the phylum level, we observed a significant increase in the relative abundance of 
Bacteroidetes (P = 0.036) (Supplemental Fig. 4A). As a result, we found a significantly 
lower Firmicutes/Bacteroidetes ratio (P = 0.017) in RS-fed pigs (10.3 ± 2.0) compared to 
DS-fed pigs (20.1 ± 3.4) (Supplemental Fig. 4B). 
At the approximate genus level, the relative abundance of several groups that include 
known butyrate-producing bacteria, including those related to Faecalibacterium prausnitzii 
and Megasphaera elsdenii, was increased upon RS feeding compared to DS feeding (P 
<0.05) (Table 3). Other groups that increased in relative abundance comprised Prevotella 
melaninogenica-like, uncultured Prevotella, Enterococcus-like, Dialister-like, Mitsuokella 
multacida-like and Clostridium ramosum-like bacteria. On the other hand, Eggerthella-like, 
uncultured Bacteroidetes, Turicibacter-like, Clostridium perfringens-like, Anaerovorax-like, 
Peptoniphilus-like, uncultured Clostridia XIVa, uncultured Planctomycetacia, as well as a 
range of potentially pathogenic microbial groups, including Leptospira, and several 
facultative bacterial groups within the Proteobacteria, including Sphingomonas-like, 
uncultured Betaproteobacteria, Actinobacillus indolicus-like, Aeromonas, Alishewanel-like, 
Halomonas-like, Pasteurella-like, Pseudomonas-like, Psychrobacter-like, Ruminobacter 
amylophilus-like, Vibrio-like, and Xanthomonas-like, were found to be decreased on the RS 
diet (P <0.05) (Table 3). 
SCFA concentrations 
Total SCFA concentration in the luminal content of pCO, collected 30 min before and 300 
min after feeding, was not affected by dietary treatment (Supplemental Fig. 5A). However, 
the percentage of branched-chain fatty acids (BCFAs), i.e. isobutyrate and isovalerate, of 
total SCFAs was significantly lower in pigs fed RS (Supplemental Fig. 5B). Acetate, 
propionate, and butyrate concentrations determined in carotid plasma collected 300 min 
after feeding were significantly higher with RS consumption compared to DS consumption 
(Fig. 3). 
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Figure 2. Biplot of partial RDA results, representing the principal component analysis of the microbiota 
composition as measured by the mean hybridization signals for 151 genus-level phylogenetic groups in the 
luminal content of proximal colon of pigs fed the DS or RS diet for 2 wk. Samples are grouped by diet. Each 
symbol represents 1 pig, with numbers indicating pig identifiers. The mean of the nominal environmental variables 
DS and RS are represented by triangles. DS, digestible starch; RS, resistant starch. 
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Table 3. Phylogenetic groups in the luminal content of proximal colon of pigs fed DS or RS diet for 2 wk, which 
were significantly affected by diet according to univariate analysis of PITChip data. 
Phylogenetic group P value FDR ARC
2 Effect3 (RS-DS) DS RS 
Actinobacteria      
   Actinobacteria      
      Eggerthella et rel. 0.008  0.08  0.109 ± 0.050 0.033 ± 0.043 - 
      Microbacterium et rel. 0.055  0.22  0.586 ± 0.100 0.709 ± 0.193 + 
Bacteroidetes      
   Bacteroidetes      
      Parabacteroides distasonis et rel. 0.055 0.22  0.411 ± 0.278 0.622 ± 0.278 + 
      Prevotella melaninogenica et rel. 0.012  0.09  0.056 ± 0.055 3.079 ± 3.194 + 
      Uncultured Bacteroidetes 0.039  0.20  0.605 ± 0.934 0.080 ± 0.241 - 
      Uncultured Prevotella 0.008  0.08  0.836 ± 0.531 2.501 ± 1.679 + 
Firmicutes      
   Bacilli      
      Enterococcus et rel. 0.039  0.20  2.480 ± 0.576 3.025 ± 0.657 + 
      Lactobacillus amylovorus et rel. 0.055  0.22  1.094 ± 0.963 0.400 ± 0.458 - 
      Lactobacillus salivarius et rel. 0.055  0.22  0.926 ± 0.356 1.267 ± 0.426 + 
      Turicibacter et rel. 0.004  0.08  0.197 ± 0.069 0.062 ± 0.036 - 
   Clostridium cluster I      
      Clostridium perfringens et rel. 0.008 0.08 2.398 ± 1.763 0.403 ± 0.810 - 
   Clostridium cluster IV      
      Faecalibacterium prausnitzii et rel. 0.020  0.12  0.969 ± 0.398 1.925 ± 1.142 + 
      Uncultured Clostridia IV 0.055  0.22  2.404 ± 0.863 1.697 ± 1.005 - 
   Clostridium cluster IX      
      Dialister et rel. 0.004  0.08  0.453 ± 0.248 0.852 ± 0.328 + 
      Megasphaera elsdenii et rel. 0.008  0.08  0.850 ± 0.210 1.386 ± 0.600 + 
      Mitsuokella multacida et rel. 0.008  0.08  1.084 ± 0.301 1.776 ± 0.743 + 
   Clostridium cluster XI      
      Anaerovorax et rel. 0.004 0.08 1.811 ± 0.681 0.495 ± 0.973 - 
   Clostridium cluster XIII      
      Peptoniphilus et rel. 0.008 0.08 0.601 ± 0.350 0.176 ± 0.364 - 
   Clostridium cluster XIVa      
      Uncultured Clostridia XIVa 0.039 0.20 2.412 ± 0.828 1.657 ± 0.928 - 
   Clostridium cluster XVIII      
      Clostridium ramosum et rel. 0.008 0.08 0.213 ± 0.057 0.296 ± 0.101 + 
Planctomycetes      
   Planctomycetacia      
      Uncultured Planctomycetacia 0.012 0.09 0.159 ± 0.114 0.037 ± 0.048 - 
Proteobacteria      
   Alphaproteobacteria      
      Rhizobium et rel. 0.055 0.22  0.552 ± 0.085 0.382 ± 0.153 - 
      Sphingomonas et rel. 0.027  0.17  0.214 ± 0.203 0.059 ± 0.154 - 
   Betaproteobacteria      
      Uncultured Betaproteobacteria 0.012 0.09 0.329 ± 0.046 0.246 ± 0.066 - 
   Gammaproteobacteria      
      Actinobacillus indolicus et rel. 0.008  0.08  0.332 ± 0.058 0.227 ± 0.079 - 
      Aeromonas 0.020  0.12  0.671 ± 0.147 0.389 ± 0.268 - 
      Alishewanella et rel. 0.020  0.12  0.472 ± 0.093 0.255 ± 0.176 - 
      Escherichia coli et rel. 0.055  0.22  0.397 ± 0.190 0.166 ± 0.196 - 
      Halomonas et rel. 0.004  0.08  0.747 ± 0.204 0.448 ± 0.225 - 
      Pasteurella et rel. 0.012  0.09  0.145 ± 0.041 0.093 ± 0.037 - 
      Pseudomonas et rel. 0.008  0.08  0.697 ± 0.253 0.279 ± 0.340 - 
      Psychrobacter et rel. 0.008  0.08  0.629 ± 0.126 0.408 ± 0.173 - 
      Ruminobacter amylophilus et rel. 0.039  0.20  0.211 ± 0.022 0.153 ± 0.057 - 
      Thiocapsa et rel. 0.055  0.22  0.675 ± 0.163 0.450 ± 0.202 - 
      Vibrio et rel. 0.008  0.08  0.690 ± 0.149 0.438 ± 0.207 - 
      Xanthomonas et rel. 0.020  0.12  0.852 ± 0.063 0.682 ± 0.140 - 
Spirochaetes      
   Spirochaetes      
      Leptospira 0.012 0.09 0.717 ± 0.172 0.402 ± 0.208 - 
1 ARC, average relative contribution; DS, digestible starch; et rel., and related species; FDR, false-discovery rate; PITChip, Pig 
Intestinal Tract Chip; RS, resistant starch. 
2 ARC is the mean relative contribution (%) of a microbial group. Values are means±SDs, n = 9/treatment. 
3 ‘‘+’’ or ‘‘-’’ indicates whether the mean relative contribution of the microbial group increased or decreased with the RS treatment.
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Figure 3. Acetate, propionate, and butyrate concentrations in peripheral plasma of pigs fed the DS or the RS diet 
for 2 wk. Samples were collected 300 min after feeding. Values are means ± SEM, n = 10 for DS-fed pigs and n = 
9 for RS-fed pigs. ** indicates P <0.01. DS, digestible starch; RS, resistant starch.  
Discussion 
In the present study, we examined the effects of 2-wk-consumption of a diet high in RS on 
the mucosal transcriptome, and luminal microbiota composition and SCFA concentrations 
in proximal colon of pigs. Our results suggested that compared to a DS diet, the RS diet 
shifted colonic gene expression profile of the host from immune regulation and cell division 
towards oxidative metabolic pathways and reduced the abundance of several potentially 
pathogenic bacteria in the colonic lumen. In addition, plasma SCFA concentrations 
increased on the RS diet. The nuclear receptor PPARG was identified as a potential key 
upstream regulator. 
Functional implications in the colon 
Genome-wide expression profiling revealed that RS modified many biological pathways. 
Regarding the metabolic pathways, we observed increased expression in RS-fed pigs of 
genes involved in fatty acid beta-oxidation and TCA cycle, two catabolic pathways 
responsible for generating energy through the oxidization of acetyl-CoA. This is to be 
expected since SCFAs, and especially butyrate, are known to serve as energy source for 
colonocytes as precursor to the TCA cycle and electron transport chain [351, 352]. Since 
the generation of ATP from NADH and succinate results in the formation of reactive 
oxygen species [353], this may explain the ostensible activation of gene sets describing 
oxidative processes, including NRF2 antioxidant response pathways, that comprises 
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induction of HMOX, NQO1 and GST levels [354]. Interestingly, other parts of lipid 
metabolism, i.e. absorption and metabolism of triglycerides, were also induced with RS 
feeding. However, because these processes typically occur in small intestine, the functional 
implications for colon remain to be demonstrated. In contrast, the induction of genes 
involved in cell-cell contact may be related to the reported improved intestinal barrier 
function observed upon RS consumption in rodents [329, 355]. 
The array data also showed that RS suppressed genes involved in both the innate and the 
adaptive immune response. This implies that the colon of RS-fed pigs is less 
immuno-active, which we believe is partially due to reduced exposure to potential 
pathogens, as was substantiated by microbiota analysis of luminal content that showed that 
especially members of the Proteobacteria were reduced in relative abundance in the RS 
group. Alternatively, this suppression may be directly due to the increase in SCFA 
concentrations [356-358]. In any case, this observation is in line with previous studies on 
RS in relation to immune regulation, showing amelioration of inflammatory bowel disease 
upon RS feeding in rodents [330, 355] and reduction of colonic and systemic immune 
reactivity in pigs [359]. However, it should also be kept in mind that immune signaling may 
affect microbiota composition, as was shown by altered gut microbiota in mice lacking 
toll-like receptor 5, an essential protein for pathogen recognition and activation of innate 
immunity [360]. Other large clusters of gene sets suppressed by RS functionally represent 
processes related to DNA replication and assembly, histone modification, mitosis, RNA 
processing and post-translational protein modification, i.e. the full machinery of gene 
transcription and translation. Suppression of these gene sets are in line with observations in 
pigs that RS inhibits cell growth and proliferation of mucosal epithelium and intraepithelial 
immune cells [359]. 
Our analysis identified three potential upstream regulators that may mediate the effects of 
RS on gene expression. PPARG and ERG were predicted to be activated by RS, whereas 
XBP1 was predicted to be inhibited. PPARG is a member of the peroxisome 
proliferator-activated receptor (PPAR) subfamily of nuclear receptors, and is well expressed 
in colon [361]. PPARG has been implicated in the pathology of numerous diseases, 
including the inhibition of  inflammatory bowel disease in mice [362], pigs [363], and 
humans [364]. Moreover, PPARG activation suppresses the activity of NF-κB, thereby 
blocking pro-inflammatory gene transcription [365]. Since PPARG has recently been 
shown to be activated by SCFAs, especially butyrate [366], this provides strong evidence 
for a molecular mechanism by which RS may modulate colonic gene expression. ERG is a 
member of the erythroblast transformation-specific (ETS) family of transcriptions factors. 
All members of this family are key regulators of cell proliferation, differentiation, 
angiogenesis, inflammation, and apoptosis [367]. The physiological function of ERG is 
largely unknown, but it has been demonstrated to play a role in the specification of 
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lymphocytes to the T lineage [368]. Our data point to a role for ERG in the suppression of 
the T-cell mediated adaptive immune response by RS. XBP1 is a transcription factor known 
to regulate multiple processes. XBP1 is required for the transcription of class II major 
histocompatibility genes and the differentiation of immunoglobulin secreting plasma B 
cells [361]. More recently, XBP1 has been shown to have an important function in the 
unfolded protein response (UPR), a process that intersects with many different 
inflammatory and stress signaling pathways, including the NF-κB pathway [361, 369]. 
Importantly, the UPR is required for maintenance of normal epithelial function, and 
disturbances in the UPR have been linked to the etiology of IBD and other intestinal 
inflammatory disorders [370]. The results of our study hint to a reduced UPR with RS 
feeding, which may have important physiological and immunological implications. The 
exact way RS feeding realized this remains to be investigated. 
Microbiota composition 
Evidence suggesting that the gut microbiome is highly important in the regulation of energy 
homeostasis and fat storage is accumulating [343, 371]. Supporting this view, the 
Firmicutes/Bacteroidetes ratio has been linked to adiposity in humans, because obese 
individuals were found to have fewer Bacteroidetes compared to lean controls. In addition, 
the relative abundance of Bacteroidetes increased while the abundance of Firmicutes 
decreased with weight loss in obese participants [215]. Because we found a significantly 
lower Firmicutes/Bacteroidetes ratio in RS-fed pigs compared to DS-fed pigs, the microbial 
profile might have shifted towards a more healthy phenotype in RS-fed pigs. Although the 
relative abundance of Firmicutes slightly, albeit not significantly, decreased 
(Supplementary Fig. 2), we observed a significant increase in the relative abundance of 
several microbial groups previously shown to produce butyrate, including 
Faecalibacterium prausnitzii and Megasphaera elsdenii [308, 344, 345]. Other microbial 
populations stimulated by RS included fermenting microorganisms such as members of the 
Parabacteroides, Prevotella, Mitsuokella multacida, and lactic acid bacteria, that produce 
organic acids such as acetate, lactate, and succinate that are in turn used as main substrates 
for the production of propionate and butyrate [308]. Furthermore, the RS diet also led to the 
decrease in relative abundance of several potentially pathogenic microorganisms, including 
members of the genus Leptospira [350], as well as a range of facultative anaerobes within 
the phylum of Proteobacteria, including for example Escherichia coli, Pseudomonas spp., 
Actinobacillus spp. [372] and Pasteurella spp. [373]. Thus, despite major differences 
between our previous study and the current study regarding, among others, pigs’ sex (gilts 
vs. barrows) , age (22 vs. 5 mo) and body weight (270 vs. 60 kg), the microbial changes 
were very similar to what we observed before [101], demonstrating the consistent 
modulation of the microbiota by RS .  
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Fermentation products 
In contrast with our previous study in pigs consuming the same RS diet , in the current 
study no significant difference in SCFA concentration was observed in the pCO digesta 300 
min after feeding. However, the reduction in percentage of BCFAs in colonic digesta 
confirms the applied dietary contrast. These branched-chain products are formed by amino 
acid fermenting microbial species that metabolize undigested and endogenous proteins, 
peptides, and amino acids [374], particularly when carbohydrates as preferential energy 
source are absent. The lower percentage of BCFAs thus reflects the use of RS as energy 
source by microbiota whereas in the DS diet the microbiota used proteinaceous energy 
sources due to the digestion and fermentation of starch in the upper gastrointestinal tract 
and the cecum. Moreover, plasma SCFA concentrations are known to be a more reliable 
measure of colonic SCFA production [375]. As expected, we observed increased plasma 
SCFA concentrations upon RS feeding.  
Conclusion 
We demonstrated that compared with an iso-caloric DS diet, a diet high in RS provoked 
major changes in colonic gene expression, that represent induction of oxidative metabolic 
pathways, and suppression of immune response and cell division pathways. We also 
showed that RS favored the growth of microbial populations producing organic acids, and 
inhibited a range of potentially pathogenic microbial groups. Our results provide a 
comprehensive overview on effects of RS in colon, that emphasize the resilience of the 
colon and contributes to our understanding of a healthy diet. Because pigs are known to be 
a good model for humans, our study outcomes are highly relevant to human health. 
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Supplemental methods 
Surgery 
After an overnight fast, all pigs were sedated with intramuscular Ketamine 10 mg/kg 
(Ketamine; Alfasan) and Midazolam 0.75 mg/kg (Dormicum; Roche) and anesthesia was 
intravenously induced with the anodyne Sufentanil 1 μg/kg (Sufenta; Janssen-Cilag). Pigs 
were intubated and anaesthesia was maintained by inhalation of 2% Sevoflurane (Abbott) 
combined with 40% oxygen and nitrous oxide. A Sufentanil infusion was maintained at 1 
μg/(kg∙h). 
The first 3 d after surgery, pigs were fed a restricted amount of the 50:50 mix of the DS and 
RS diet, i.e. 25%, 50% and 75% of their daily feed allowance on d 1, 2 and 3 respectively, 
to allow a gradual recovery and to avoid problems with the gut cannula. Pigs were 
habituated to digesta collection from the cannula and blood sampling in the first week after 
surgery. After 4 to 6 d of postsurgical recovery, pigs were gradually switched to one of two 
dietary treatments (DS and RS). 
Colon biopsies 
Pigs were acutely sedated by i.v. injection with propofol (Alfasan). The stopper was 
unscrewed from the cannula and digesta was removed to expose the mucosal wall of the 
pCO. An endoscope (OES Colonofiberscope, Olympus CF type ITIOL/1, Olympus Optical 
Co; LTD) was inserted via the permanent cannula into the lumen of the pCO, the intestinal 
wall was illuminated (OES Halogen light source with flash, Model CLE-F10, Olympus 
Optical Co; LTD) and visualized on a monitor (Endovision 538; Karl Storz). Biopsies were 
taken by an endoscopic biopsy forceps (Olympus FB-28U-1, 2 mm, 225 cm, Olympus 
Optical Co; LTD) and collected in screw cap tubes, after which they were immediately 
frozen in liquid nitrogen and stored at -80°C until further analysis. 
Digesta collection 
To determine microbiota composition, digesta were collected in 1.5 mL Eppendorf tubes, 
after which the tubes were immediately frozen in liquid nitrogen and stored at -80°C until 
further analyses. In addition, digesta was collected in pre-weighed 2 mL Eppendorf tubes 
with 0.75 mL H3PO4 for determining SCFA concentrations. These tubes were weighed 
again, thoroughly mixed on a vortex and stored at -20°C until further analysis. For 
measuring dry matter content, digesta were collected in empty pre-weighed Eppendorf 
tubes and stored at -20°C until further analysis.  
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RNA quality control 
Concentrations and purity of colonic RNA samples were determined on a NanoDrop 
ND-1000 spectrophotometer (Isogen Life Science). RNA quality was verified on an Agilent 
2100 Bioanalyzer (Agilent Technologies) by using 6000 Nano Chips (Agilent Technologies) 
according to the manufacturer’s instructions. RNA was judged as suitable for array 
hybridization only if samples exhibited intact bands corresponding to the 18S and 28S 
ribosomal RNA subunits, and displayed no chromosomal peaks or RNA degradation 
products (RNA Integrity Number >8.0). 
GSEA analysis 
GSEA was used to find enriched gene sets in the induced or suppressed genes. Genes were 
ranked based on the paired IBMT-statistic and subsequently analyzed for over- or 
underrepresentation in predefined gene sets derived from Gene Ontology, KEGG, National 
Cancer Institute, PFAM, Biocarta, Reactome and WikiPathways pathway databases. Only 
gene sets consisting of more than 15 and fewer than 500 genes were taken into account. 
Statistical significance of GSEA results was determined using 1,000 permutations.  
Enrichment map 
Results from GSEA were displayed in an enrichment map. Only gene sets passing 
conservative significance thresholds (p-value <0.001, False Discovery Rate (FDR) <2%) 
were selected for visualization in the enrichment map, resulting in 329 total gene sets (out 
of 4,293) significantly enriched after RS feeding (57 induced and 272 suppressed gene sets, 
respectively). The cutoff for the overlap coefficient was set at 0.5 
Multivariate analysis microbiota 
To relate changes in total bacterial community composition to diet (DS or RS), period, and 
the interaction of period and diet, redundancy analysis (RDA) and Principal response 
curves were used as implemented in the CANOCO 5 software package (Biometris, 
Wageningen, the Netherlands). RDA is the canonical form of principle component analysis 
and is a multivariate linear regression method where several response parameters are 
related to the same set of environmental (explanatory) variables. The signal intensities for 
151 genus-level phylogenetic groups of PITChip were used as responsive variables. Partial 
RDA was employed to analyze the effect of diet on microbiota. RDA was performed by 
centering the species and samples, using freely exchangeable whole-plot permutations. 
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SCFA determination by NMR spectroscopy 
Plasma samples were diluted 1:1 in a 75 mM phosphate buffer (pH 7.4) and filtered using 
Nanosep centrifugal devices with Omega Membrane (Pall Corporation). The molecular 
weight cut-off of the filter was 10K. Subsequently, 200 μL of the eluate was transferred to a 
3 mm NMR tube (Bruker match system). Samples were stored at -20 ?C until analysis using 
NMR spectroscopy. Before NMR measurements, samples were slowly warmed up to room 
temperature and measured at 310 K (calibrated temperature) in an Avance III NMR 
spectrometer operated at 600.13 MHz. After transfer of each sample into the magnet, the 
sample was equilibrated at 310 K for 5 min. Subsequently automated locking, automated 
shimming and automated 90 degree pulse angle determination was performed. 1H NMR 
NOESY datasets were acquired for each sample. In addition, each dataset was 
automatically processed and aligned using the alanine signal (upfield resonance of the 
alanine doublet signal) at 1.49 ppm. From the aligned spectra, integrals for resonances of 
the metabolites of interest were selected and quantified. Concentrations of metabolites were 
calculated based on the number of hydrogens for each metabolite selected. 
 
  
Resistant starch, mucosal gene expression profile, and microbiota in the proximal colon 
175 
Supplemental tables and figures 
Top induced genes       Individual log
2 
FC 
Gene Description Gene symbol Entrez ID Mean log2 FC 1 2 3 4 5 6 7 8 9 10 
Intestinal-type alkaline phosphatase-like LOC100521756 100521756 1.55                     
Carbonic anhydrase II CA2 100154873 1.35 
Uncharacterized LOC100621113 LOC100621113 100621113 1.01 
Hydroxysteroid (17-beta) dehydrogenase 2 HSD17B2 100312973 1.00 
Transmembrane 4 L6 family member 20-like LOC100513630 100513630 0.96 
Uncharacterized protein C5orf4 homolog LOC100525263 100525263 0.95 
Solute carrier family 30, member 10 SLC30A10 100623097 0.92 
Angiotensinogen-like LOC100157073 100157073 0.86 
Carbonic anhydrase 12-like LOC100152749 100152749 0.83 
Carcinoembryonic antigen-related cell adhesion molecule 7-like LOC100524810 100524810 0.81 
ATP-binding cassette, sub-family A (ABC1), member 6 ABCA6 100520861 0.79 
Agmatinase, mitochondrial-like LOC100519548 100519548 0.74 
ADAM metallopeptidase domain 23 ADAM23 100518044 0.74 
Claudin 10 CLDN10 100153752 0.73 
Thiopurine S-methyltransferase TPMT 100157630 0.72 
Ubiquitin carboxyl-terminal hydrolase 2-like LOC100520041 100520041 0.72 
Transient receptor potential cation channel subfamily M member 
6-like LOC100157775 100157775 0.71           
Transmembrane protein 117 TMEM117 100524623 0.71 
Poly (ADP-ribose) polymerase family, member 15 PARP15 100520273 0.70 
Serine palmitoyltransferase, long chain base subunit 3 SPTLC3 100519280 0.68 
Collagen alpha-6(VI) chain-like LOC100516642 100516642 0.67 
Guanylate cyclase activator 2A (guanylin) GUCA2A 100301560 0.66 
EGF containing fibulin-like extracellular matrix protein 1 EFEMP1 100512046 0.66 
Pancreatic lipase-related protein 2 PNLIPRP2 100462755 0.66 
Olfactory receptor 9K2-like LOC100737562 100737562 0.66                     
Top suppressed genes Individual log2 FC 
Gene Description Gene Symbol Entrez ID Mean log2 FC 1 2 3 4 5 6 7 8 9 10 
Chitinase 3-like 1 (cartilage glycoprotein-39) CHI3L1 396865 -1.88 
C4b-binding protein alpha chain-like LOC100520761 100520761 -1.42 
Secretory leukocyte peptidase inhibitor SLPI 396886 -1.13 
C-type lectin domain family 7, member A CLEC7A 100038025 -0.94 
Immunoresponsive 1 homolog (mouse) IRG1 100524951 -0.93 
Chemokine (C-X-C motif) receptor 4 CXCR4 396659 -0.89 
P2Y purinoceptor 13-like LOC100524766 100524766 -0.86 
BPI fold containing family B, member 2 BPIFB2 100113424 -0.84 
Tryptophan hydroxylase 1 TPH1 100511002 -0.80 
Chromosome 1 open reading frame 162 ortholog C4H1orf162 100627962 -0.78 
SLAM family member 7-like LOC100154053 100154053 -0.78 
Placenta-specific gene 8 protein-like LOC100525175 100525175 -0.78 
Antileukoproteinase-like LOC100512873 100512873 -0.74 
Rho GTPase activating protein 15 ARHGAP15 100520808 -0.74 
Monocarboxylate transporter 7-like LOC100739042 100739042 -0.71 
Lymphoid enhancer-binding factor 1 LEF1 100170126 -0.70 
Transmembrane protein 156-like LOC100525349 100525349 -0.69 
Membrane-spanning 4-domains, subfamily A, member 1 MS4A1 100627952 -0.68 
SLAM family member 6 SLAMF6 100156912 -0.67 
Sorting nexin-10-like LOC100520876 100520876 -0.66 
Acyloxyacyl hydrolase (neutrophil) AOAH 100522290 -0.64 
Clusterin CLU 397025 -0.63 
CD1B antigen PCD1B 100038007 -0.62 
Interleukin 2 receptor, gamma IL2RG 397156 -0.60 
A-kinase anchor protein 5-like LOC100153460 100153460 -0.60                     
Supplemental Figure 1. Top 25 induced genes and bottom 25 suppressed genes observed in pigs after 2 wk 
consumption of the RS diet compared to 2 wk consumption of the DS diet, based on the gene definitions of the 
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NCBI Sus scrofa Entrez Gene database, build 4.1. Mean log2 fold changes of the signal intensity of RS compared 
with DS were determined from the individual response of the 10 pigs, which are expressed as a heatmap. The 
intensity of the red and green color indicates the degree of induction or suppression per pig, respectively. 
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Supplemental Figure 2. High resolution color enrichment map for effects of resistant starch on colonic gene 
expression. The map displays the enriched gene-sets in proximal colon after 2 wk consumption of the RS diet 
compared to 2 wk consumption of the DS diet. Nodes represent functional gene sets, and edges between nodes 
their similarity. Red node color indicates enrichment after RS consumption (i.e. induction after RS feeding), 
whereas blue represents enrichment after DS consumption (i.e. reduction after RS feeding). Node size represents 
the gene set size, and edge thickness represents the degree of overlap between 2 connected gene sets. Clusters are 
manually grouped and labeled to highlight the prevalent biological functions among related gene sets. The 
abbreviation before the name of the gene set indicates the database the gene set was derived from: no abbreviation: 
Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; BIOC: Biocarta; REACT: NCI: National 
Cancer Institute; Reactome, WiP: WikiPathways, PFAM: protein family.  
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COX10 0.23   MLXIPL 0.24   DDOST -0.16   
HMOX2 0.21   ABCD3 0.24   PIK3R2 -0.18   
OGDH 0.18   CYP17A1 0.23   P2RX7 -0.18   
UQCRC1 0.16   MGLL 0.23   PTPN12 -0.19   
UQCRH 0.15   HSD17B8 0.23   FYN -0.19   
PCK2 0.14     SLC35D1 0.23   ABI1 -0.21   
DLST 0.14   PPAP2B 0.23   NFATC2 -0.22   
ACO1 0.13   MBOAT1 0.22   PIK3CD -0.22   
SDHB 0.12   DEGS2 0.22   LYST -0.23   
PCK1 0.97     GPAT2 0.22   LAT -0.23   
PDK4 0.70     ACADM 0.22   SKAP1 -0.24   
SLC16A1 0.61     SLC25A1 0.21   ARHGDIB -0.24   
PC 0.31     ACOT7 0.20   TGFB1 -0.24   
LDHA -0.16     ACOX1 0.20   CD47 -0.25   
C5orf4 1.16   UGDH 0.19   MAP3K1 -0.26   
AGT 0.87   HNF4A 0.19   DEF6 -0.28   
SPTLC3 0.68   PLIN2 0.19   CD5 -0.28   
PNLIPRP2 0.67   SGPP2 0.19   TBX21 -0.29   
CYP27A1 0.63   ACBD4 0.18   CD40 -0.30   
IGF1 0.62   PCCB 0.18   CD83 -0.31   
NR1H4 0.59   KIF1B 0.17   FCRL3 -0.32   
ANGPTL4 0.58   CAB39 0.17   RASGRP2 -0.33   
HPGD 0.56   GPD2 0.16   INPP5D -0.33   
ACSF2 0.50   HADHA 0.15   SH2D3C -0.34   
HMGCS2 0.49   CRAT 0.15   LAT2 -0.34   
GPT 0.45   COL4A3BP 0.15   DOCK2 -0.34   
PLD1 0.42   SPTLC2 0.15   RHOH -0.35   
THRB 0.42   GOT2 0.14   LCK -0.36   
FABP1 0.41   ACADS 0.14   TXK -0.37   
PRDX6 0.41   ADIPOR1 -0.14   JAK3 -0.38   
ACADSB 0.41   MTHFS -0.16   CD3D -0.38   
ECHDC2 0.40   TNFRSF1A -0.17   FCER2 -0.39   
UCP3 0.39   LTA4H -0.19   IL21R -0.40   
PLCE1 0.38   DGKE -0.20   NFKB1 -0.40   
ADH7 0.37   GPX1 -0.24   MAP3K8 -0.40   
FAAH 0.37   LDLR -0.28   KLHL6 -0.42   
SRD5A1 0.37   DEGS1 -0.29   MNDA -0.42   
CYP26B1 0.37   BCAT1 -0.29   HSH2D -0.42   
CES1 0.36   SCPEP1 -0.29   RASGRP1 -0.42   
AGPAT2 0.36   FAR2 -0.29   LCP2 -0.42   
PNPLA2 0.35   FADS1 -0.30   CD2 -0.43   
FA2H 0.35   FADS2 -0.32   BCL6 -0.43   
DGAT2 0.35   DGKA -0.33   IL10 -0.45   
STX3 0.35   ABAT -0.38   PTPN22 -0.46   
ADH5 0.34   SMPDL3A -0.40   PRKCB -0.48   
GLYCTK 0.33   AKR1C1 -0.40   AICDA -0.49   
HMGCL 0.33   HAL -0.42   LCP1 -0.49   
GBA3 0.33   IRG1 -1.07   ITGA4 -0.49   
PPARG 0.33   CAV1 0.38     CD79A -0.52   
SLC25A20 0.32   CREBBP -0.14     PTPRC -0.53   
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KDSR 0.32   MUC1 0.37   CD274 -0.55   
GGT5 0.32   FZD5 0.32   CD19 -0.55   
BDH1 0.31   ERBB2 0.23   CD3G -0.57   
EPHX2 0.30   BAD 0.23   TLR4 -0.57   
RBP1 0.30   JUN 0.23   PRKCQ -0.60   
TXNIP 0.30   PTPRH 0.23   CXCR5 -0.68   
TNFRSF21 0.29   JMJD6 0.22   ICOS -0.70   
MGST2 0.29   HDAC5 0.22   LEF1 -0.76   
CERS6 0.29   BMP4 0.19   CLEC7A -0.77   
CYP2J2 0.29   NCK2 0.19   MASP2 -0.21     
CPT1A 0.28   MAPKAP1 0.17   SERPING1 -0.26     
ACAT1 0.28   PIK3R1 0.16   CD55 -0.26     
ACAA2 0.27   PAG1 0.15   C4BPB -0.39     
LIPE 0.27   KLF6 0.15   C2 -0.47     
SGMS2 0.27   STIM1 0.12   CFH -0.47     
AASDH 0.26   ELF1 -0.11   C4B -0.58     
ALDH6A1 0.26   TUBB -0.11   C4BPA -0.62     
PPM1L 0.26   KAT5 -0.13   CLU -0.63     
DGKG 0.26   PAK2 -0.13   CR2 -0.97     
DGAT1 0.25   FOXP1 -0.14   CFB -0.23   
CYP7B1 0.25   PPP3CA -0.14   F5 -0.38   
CIDEC 0.24   CD24 -0.16   PDK1 -0.23         
DECR1 0.24   PTPN6 -0.16   
Supplemental Figure 3. Heatmap of significantly regulated genes (P <0.05) present in the positively enriched 
gene sets describing TCA cycle or lipid metabolism, or present in the negatively enriched gene sets describing 
processes involved in adaptive or innate immune response. Mean and individual log2 fold changes are presented. 
The intensity of the red and green color indicates the degree of induction or suppression per pig, respectively, and 
ranged from -0.65 (green) to 0.65 (red). Pigs are ranked based on their identifier. The vertical color bars indicate 
gene set membership; dark blue: TCA cycle, light blue: lipid metabolism, olive green: adaptive immune response, 
tan: innate immune response. 
 
 
 
 
 
 
 
 
 
Supplemental Figure 4. The abundance of the phyla Bacteroidetes and Firmicutes (A) and the ratio 
Firmicutes/Bacteroidetes (B) in pigs fed DS or RS for 2 wk, as determined by PITChip. Data are presented as 
means ± SEM, n = 9 per treatment. * indicates P <0.05. DS, digestible starch; RS, resistant starch. 
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Supplemental Figure 5. Total SCFAs (A) and percentage of BCFAs from total SCFAs (B) measured in luminal 
content from proximal colon, collected 30 min before feeding (-30) and 300 min after feeding in pigs fed the DS 
and the RS diet. Data are presented as means ± SEM, n = 10 per treatment. ** indicates P <0.01. BCFAs, 
branched-chain fatty acids; DS, digestible starch; RS, resistant starch. 
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Supplemental Table 1. Ingredient and nutrient composition of the experimental diets. 
  DS RS 
Ingredient composition (g/kg)     
Pregelatinized purified potato starch1  350.0 0.0 
Retrograded tapioca starch2 0.0 342.6 
Soy oil 29.2 29.5 
Wheat 200.0 202.3 
Beet pulp (sugar<100 g/kg) 50.0 50.6 
Barley 150.0 151.7 
Wheat gluten meal 60.0 60.7 
Potato protein3 100.0 101.1 
Premix4 10.0 10.1 
CaCO3 13.5 13.7 
Ca(H2PO4)2  11.0 11.1 
NaCl 3.0 3.0 
L-lysine HCl 2.2 2.2 
L-tryptophan 0.2 0.2 
MgO (80%) 0.4 0.4 
NaHCO3 14.0 14.2 
KCl 3.0 3.0 
TiO2 2.0 2.0 
Flavor5 1.5 1.5 
Nutrient (g/kg dry matter)   
Dry matter (g/kg) 894.5 910.0 
Organic matter 941.4 941.9 
Crude protein (N x 6.25) 190.9 194.3 
Crude fat 16.1 28.6 
Starch 524.7 477.1 
Sugar 13.1 69.4 
TiO2 1.6 1.6 
Energy content (MJ/kg)   
GE 16.48 16.78 
DS, digestible starch diet; RS, resistant starch diet. 
1PaselliTM WA4, Avebe Food, Veendam, the Netherlands.  
2C*Actistar 11700, Cargill, Amsterdam, the Netherlands. 
3Protostar, Avebe Food, Veendam, the Netherlands. 
4Provided the following per kg of feed: vitamin A: 7500 IU; vitamin D3: 1500 IU; vitamin E: 60 mg; vitamin K3: 1.0 mg; vitamin 
B1: 1.0 mg; vitamin B2: 4.0 mg; vitamin B6: 1.0 mg; vitamin B12: 20 μg; niacin: 20 mg; calcium-D pantothenate: 10.5 mg; 
choline chloride: 100 mg; folic acid: 0.4 mg; Fe: 120 mg (FeSO4.H2O); Cu: 15 mg (CuSO4.5H2O); Mn: 60 mg (MnO); Zn: 75 mg 
(ZnSO4.H2O); I: 4.0 mg (KI); Se: 0.30 mg (Na2SeO3); anti-oxidant: 75 mg. 
5Luctarom Advance Cherry Honey, Lucta S.A., Barcelona, Spain. 
Supplemental Table 2. All significantly regulated genes (P <0.01) observed in pigs after 2 wk consumption of the 
RS diet compared to 2 wk consumption of the DS diet. See Appendices.
  
Chapter 8  
 
General discussion 
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Main findings of the research  
The central objective of this research was to determine the effects of antibiotic treatment, 
microbial exposure and diet on the development of intestinal microbiota, focusing on the 
pig as an important production animal as well as a model for humans. To achieve this 
objective, a series of experiments were performed both in piglets and adult pigs to 
determine the impact of maternal antibiotic treatment (Chapter 3), early antibiotic 
administration (Chapter 4), and early microbial exposure (Chapter 5) on piglets’ intestinal 
microbiota (Chapter 3, 4 and 5) and mucosal tissue gene expression (Chapter 4 and 5), as 
well as the effect of a diet high in resistant starch (RS) on microbiota, short-chain fatty acid 
(SCFA) concentration and host gene expression in the large intestine of adult pigs (Chapter 
6 and 7). The approaches taken included analysis of the microbiota in intestinal content and 
faeces by using a phylogenetic microarray specific for pigs, determination of the 
metabolites in samples taken at various locations in the gut, and in some cases global gene 
expression of the pig epithelial cells (Table 1, 2 and 3).  
Table 1. Overview of microbiota analysis in this thesis.  
Study Animals  Treatment Treatment duration    Sample Sampling time Method 
Chapter 3  
Sow  Amoxicillin 
10 days before the 
estimated farrowing date 
till 21 days after 
farrowing 
Faeces Start/End of treatment 
PITChip 
1.0 
Piglet(Offspring) - - Ileal/Colonic content 
14/21/28/42 day 
after birth 
Chapter 4 Piglet Tulathromycin At day 4 after birth Jejunal content 8 day after birth PITChip 2.0 
Chapter 5 Piglet Group 1: tri-partite microbiota1 
Day 1 to 4 after birth2 
Faeces  3/5/7/14/28 day after birth 
PITChip 
1.0 
?  ?  
Group 2: tri-partite 
microbiota & Diluted 
faeces of an adult sow  
Jejunal/ileal 
content 
16 day after 
birth 
PITChip 
2.0 
Chapter 6 Pig (4 month) RS 14 days Caecal/colonic content   
14 days after 
RS treatment 
PITChip 
1.0 
Chapter 7 Pig (22 month) Cross feeding of RS and DS  14 days each  
Content from 
proximal colon 
14 days after 
each treatment 
PITChip 
2.0 
1Tri-partite microbiota1, a mixture of Lactobacillus amylovorus, Clostridium glycolicum, and Parabacteroides sp. ASF519 
2 From day 1 to 3 after birth, all piglet received the tri-partite microbiota, at day 4 and 5, piglets of group 1 received a placebo 
inoculant, piglets of group 2 received  diluted faeces of an adult sow 
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Table 2. Main analysis in this thesis focusing on host gene expression. 
Study Sample Method 
Chapter 4 
Mucosal scrapings of jejunum 
Porcine Agilent microarray slides, G2519F Sus scrofa 
Mucosal scrapings of ileum 
Blood 
Chapter 5 
?  
Mucosal tissue of jejunum 
Porcine Agilent microarray slides, G2519F Sus scrofa 
Mucosal tissue of ileum 
Chapter 6 
Mucosal scraping of proximal colon 
qRT-PCR 
Mucosal scraping of Caecum 
Mucosal scraping of Colon 
Chapter 7 Biopsies in proximal colon Porcine Genen 1.0ST arrays (Affymetrix) 
Table 3. Main analysis focusing on SCFA concentration.  
Study Location Method 
Chapter 6 Distal small intestine 
Gas chromatography  Caecum 
?  Colon 
Chapter 7 
Distal small intestine 
Gas chromatography 
Caecum 
Proximal colon1 
Colon2 
Peripheral Plasma NMR spectroscopy 
1SCFAs measured in luminal content collected from the location of the cannula. 
2SCFAs measured in luminal content collected at section. 
There are three main findings that can be derived from the work described in this thesis 
(Fig.1). 
Firstly, administration of antibiotics to either sows or piglets impacted the intestinal 
microbiota of piglets at early age. In Chapter 3, antibiotic treatment of sows during the 
perinatal period drastically impacted the sows’ faecal microbiota, and caused a decrease in 
relative abundance of bacteria related to the genera Lactobacillus, Staphylococcus and 
Streptococcus. This maternal antibiotic treatment furthermore influenced the gut microbiota 
of the piglets, especially that present in the ileum, leading to increased relative abundance 
of Proteobacteria mainly driven by a stimulation of Escherichia coli and Pseudomonas 
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during administration (at day 14 and 21 of age). As described in Chapter 4, early antibiotic 
administration to piglets affected the composition and diversity of gut microbiota and 
reduced the mucosal tissue expression of host genes associated with a large number of 
immune-related processes.  
Secondly, exposure of newborn piglets to a complex microbiota at early age drastically 
affected the piglet’s intestinal microbiota and mucosal tissue gene expression, when 
compared to association with a simple tri-partite microbiota composed of Lactobacillus 
amylovorus, Clostridium glycolicum, and Parabacteroides sp. ASF519. Gene sets linked to 
immune system development were significantly enriched in the ileum of piglets exposed to 
complex microbiota (Chapter 5). The complex microbial association led to increased 
relative abundance of microbial groups that are known to have beneficial effects such as 
members of the genus Lactobacillus and butyrate producing members of Clostridium 
clusters, whereas it reduced the relative contribution of potential pathobionts, albeit 
differently in jejunum and ileum. The complex microbial association furthermore induced 
enrichment of immune related gene sets in the ileal mucosa, and immune modulatory genes 
were negatively correlated with the abundance of pathobionts in ileal digesta.  
Thirdly, a diet high in resistant starch (RS) modulated the microbiota composition, short 
chain fatty acid (SCFA) concentration and mucosal tissue gene expression in the large 
intestine of adult pigs. The RS diet induced the stimulation of health associated 
butyrate-producing bacteria, whereas potentially pathogenic members were reduced in 
relative abundance (Chapter 6 and 7). In Chapter 6, caecal and colonic SCFA 
concentrations were significantly higher in RS-fed pigs, and caecal expression of genes 
encoding for monocarboxylate transporter 1 (SLC16A1) and glucagon (GCG) was induced 
by RS. As reported in Chapter 7, concentrations in carotid plasma of acetate, propionate, 
and butyrate were significantly higher following RS consumption. RS induced oxidative 
metabolic pathways, whereas many immune response pathways and cell division were 
suppressed. 
Effect of antibiotics on the development of intestinal microbiota at early 
age 
Antibiotics are commonly used to control bacterial infection of humans and animals in 
hospitals and on farms. Administration of antibiotics can strongly affect the composition of 
the intestinal microbiota of both adult pigs (Chapter 3) and piglets (Chapter 4). In 
Chapter 3, when amoxicillin was administrated to the sows, it inhibited bacteria related to 
L.acidophilus, L. delbrueckii, L. gasseri, L. plantarum, S. aureus, S. bovis, S. intermedius 
and S.suis. This result is in line with previous reports showing that amoxicillin commonly 
had an inhibiting effect on Lactobacillus, Streptococcus and Staphylococcus [59, 208-210].  
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Figure 1. Overview of the main findings described in this thesis. This thesis determined the impact of maternal 
antibiotic treatment (Orange), early antibiotic administration (Red), and early microbial exposure to sows’ faeces 
(Purple) on piglets’ intestinal microbiota and mucosal tissue gene expression at early age, as well as resistant 
starch (RS, Green) on microbiota, short-chain fatty acid (SCFA) concentration and host gene expression in the 
large intestine of adult pigs. Antibiotic treatment of sows during the perinatal period (Orange pies) caused a 
decrease in relative abundance of bacteria related to Lactobacillus, Staphylococcus and Streptococcus of sows’ 
faeces, and led to increased relative abundance of Proteobacteria in piglets’ faeces, mainly driven by a stimulation 
of Escherichia coli and Pseudomonas during administration (Orange plate). Early antibiotic administration to 
piglets (Red pie) affected composition and diversity of gut microbiota and reduced the mucosal tissue expression 
of host genes associated with a large number of immune-related processes (Red plate). Exposure of caesarian 
derived newborn piglets to sows’ faeces (Purple pie) affected the piglet’s intestinal microbiota and enriched ileal 
mucosal gene sets linked to immune system development, whereas effects on jejunal microbiota and gene 
expression was less clear (Purple plate). RS (Green pie) modulated the microbiota composition, short chain fatty 
acid (SCFA) concentration and mucosal tissue gene expression in the large intestine of adult pigs (Green plate). 
The RS diet induced the stimulation of health associated butyrate-producing bacteria, whereas potentially 
pathogenic members were reduced in relative abundance. Caecal and colonic SCFA concentrations were 
significantly higher in RS-fed pigs, and caecal expression of genes encoding for monocarboxylate transporter 1 
(SLC16A1) and glucagon (GCG) was induced by RS. Concentrations in carotid plasma of acetate, propionate, and 
butyrate were significantly higher following RS consumption. RS induced oxidative metabolic pathways, whereas 
many immune response pathways and cell division were suppressed. 
However, in the study described here, such inhibiting effect was not observed in the 
intestinal microbiota of piglets. Moreover, microbial groups that were affected both in 
faeces of amoxicillin-treated sows and ileal content of their offspring, showed an opposite 
direction of change. For example, amoxicillin caused an increased relative abundance of 
bacteria related to Alistipes in treated sows’ faeces, whereas this population was decreased 
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in the ileal content of the offspring at the age of 14 days. These opposing findings may 
suggest that the maternal amoxicillin treatment may indirectly affect the gut microbiota of 
the offspring through disturbing the maternal microbiota. Since maternal microbiota can be 
transferred to the offspring (see Chapter 1), the impact will be manifested in the next 
generation. Another possible explanation is that amoxicillin-resistance genes or bacteria 
harbouring these have been selected and transferred from the mothers to their offspring. 
Therefore, these genes or bacteria that harbour them in the piglet gut showed increased 
relative abundance, whereas sensitive bacteria were reduced by the maternal amoxicillin. 
However, the present study is not conclusive on the main mechanism by which maternal 
amoxicillin affected the intestinal microbial of the offspring. Further analysis should be 
performed to characterize the milk microbiota as well as determine potential amoxicillin 
residues directly transferred from the mothers to their offspring.  
Chapter 4 describes that when the antibiotic was directly administered to the piglets at an 
early age, it caused an increase of the microbial diversity as well as the relative abundance 
of Bifidobacterium. This finding differs from the conclusion of most previous human infant 
studies summarized in Chapter 1. One possible reason could be that all the previous infant 
studies determined the effect of antibiotics in faecal samples, whereas in the current piglet 
study we analyzed the microbiota in jejunal content. Therefore, our piglet study can not 
directly be compared to the previous human infant studies. On the other hand, the used 
antibiotics also differ. In our present study, piglets received an injection (subcutaneously in 
the neck) with 0.1 ml tulathromycin at day 4 after birth. Tulathromycin is a triamilide 
macrolide antibiotic found to be safe and effective against respiratory bacterial pathogens in 
cattle and swine. However, the effect of tulathromycin on the gut microbiota has not been 
studied in detail up to now. This thesis is the first report that tulathromycin impacts the gut 
microbiota of piglets. As shown in Chapter 1, most of the human infant studies evaluate 
β-Lactam antibiotics such as amoxicillin, cefalexin and ampicillin. Considering the various 
targets, doses, and durations of antibiotic treatment, it is not surprising that gut microbial 
communities respond to different antibiotics in different ways or even in opposite ways. 
Microbial exposure at early age 
Microbial exposure at early age is probably the most complicated factor to determine when 
studying the development of intestinal microbiota. Just like the individual variation of each 
person’s or animal’s gut microbiota, the microbial exposure at early age for each individual 
can also strongly vary, due to the fact that microbial exposure of infants and young animals 
seems to happen everywhere. Starting from birth, the neonates are exposed to either their 
mothers’ vaginal and faecal bacteria or a more complex indoor microbial environment 
which includes their mothers’ skin microbiota, mostly depending on the mode of delivery 
[31-33]. Later on, the infants and young animals may continue to be exposed to their 
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mother’s milk, skin and faecal microbiota during daily contact [37, 38, 191, 207, 376]. At 
the same time, infants and young animals are exposed to a broad range of indoor and 
outdoor microbial environments, such as hospital and day care for infants and farms for 
animals [46, 48-50]. It seems that the microbial exposure at early age is to some extent 
accidental, and earliest colonization events are determined by opportunistic colonization by 
bacteria to which an infant or a piglet is exposed in its environment [13]. Such 
opportunistic colonization can be one of the reasons that explain the individual variation of 
the intestinal microbiota.  
Impact of external factors on the intestinal microbiota differs along the 
intestine 
The impact that external factors have on the development of intestinal microbiota at early 
age differs along the intestine. In the present reaserch, different microbial groups were 
affected by the maternal amoxicillin treatment in the ileum and colon of the newborn 
piglets (Chapter 3). Similarly, most microbial groups that were affected by the complex 
microbial association were different when comparing jejunal and ileal digesta (Chapter 5). 
Such site-specific microbiota responses to external factors were also found in the study of 
adult pigs. Most microbial groups that changed in their relative abundance in response to 
inclusion of RS in the caecum showed no significant change in the colon (Chapter 6). 
These findings may be a result of the interaction of external factors and internal gut 
physiological conditions. The function and architecture of the gut differs along its length 
[74]. Moreover, several physiological parameters, such as pH, peristaltic movement of the 
tract, desquamation of epithelial cells and mucosal flow, also influence the microbiota 
distribution in the gut [261]. Consequently, bacterial diversity and composition differs from 
the small intestine to large intestine (Chapter 2), which can explain the site-specific 
responses of microbial communities that were induced by the external factors in the studies 
described in this thesis. Therefore, future studies should consider these site-specific effects 
of external factors on the intestinal microbiota before drawing conclusions. To date, faecal 
sampling has been extensively used to characterize intestinal microbial communities of 
humans, especially in infant studies. However, this approach may lead to inaccurate 
assessments of the intestinal microbiota of newborns. A recent study of human neonates 
showed that site-specific microbial communities established in faecal and mucosal samples 
[377]. Interestingly, in contrast to adult studies, intestinal bacterial diversity was higher in 
mucosal tissue than in faecal samples. This finding questions the reliance on faecal 
microbiota as a proxy for the developing intestinal microbiota of human infants and animals, 
and also reinforces the need for a proper model for studying the infant intestinal microbiota. 
Pigs and mice are the most common models used for study the human microbiota (Chapter 
2). Recently, human gut microbiota has been successfully transplanted into germ-free 
piglets and mice, resulting in a human-like microbial community [156, 378]. Moreover, the 
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microbial shifts occurring in these models due to a certain treatment are likely to take place 
in humans as well [152]. For instance, the microbiota of two human twins discordant for 
obesity was studied in mice, where the impact of the microbiota was linked to the 
phenotype of the human donor [132]. Therefore, such “humanized” neonatal piglets or mice 
seem a promising model to be applied in studies addressing infant intestinal microbiota.  
Effect of RS on microbiota in the large intestine of adult pigs 
Many studies have been done to study the effects of RS on the intestinal microbiota. 
However, most of these studies either only focused on the numbers of certain bacteria of 
the intestinal microbiota using culture methods, or assessed the effect of RS on intestinal 
microbiota with in vitro models. Only few studies have addressed the impact of RS on the 
intestine in vivo with culture-independent methods as reviewed in Chapter 1. The present 
study provides a detailed analysis of the RS effects on the intestinal microbiota, SCFA 
concentration and host gene expression data in adult pigs by using microarrays (Chapter 6 
and 7). The 2-week feeding of RS was found to modulate the microbial composition in the 
large intestine. However, since no longitudinal sampling was performed, it was impossible 
to predict in which order colonic changes occurred. In addition, determining the main 
driving force of observed microbial changes, either RS itself or the SCFA produced by its 
microbial fermentation, is difficult based on current observations, and should be addressed 
in further studies that provide improved spatio-temporal resolution of measurements. 
Finally, it should be noted that research findings in pigs can be used to improve the welfare 
of restrictedly fed animals, such as adult pigs, which may suffer from hunger and related 
welfare problems [379], and for which acceleration of satiation through dietary means 
could provide innovative avenues towards alleviating such issues. 
The pig as a model 
In this thesis, the pig was selected as study model, because the pig is an important 
production animal as well as a model for humans. As pig is an important livestock for meat 
production, this animal is studied intensively with the object of optimizating production. In 
recent years, due to the ban on the application of in-feed antibiotics as growth promotors in 
many countries, more studies have focused on identifying alternatives to feeding antibiotics, 
including the inclusion of prebiotics and probiotics in the feed [380] to improve the pig 
health. As shown here, manipulation of microbial colonisation of the intestinal tract at early 
age is also an alternative. It can be a powerful tool to strengthen intestinal barrier function, 
robustness and immunological competence of young piglets, and furthermore contribute to 
improved pig health and thereby providing new avenues towards more sustainable animal 
production. The output of this thesis, development of microbiota at early life (Chapter 3, 4 
and 5) as well as the interaction between early microbial colonization and the development 
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of gut function (Chapter 5), provides basic knowledge and clues for manipulation of the 
gut microbiota. Such knowledge is useful for providing a sound basis for the design of 
innovative management strategies as alternatives to in-feed antibiotics, especially for 
low-input farming systems.  
In addition to its role as an important livestock, the pig is also regarded as a good model for 
human studies because of the high similarities to human beings in physiology, anatomy and 
nutrition (see Chapter 2) [153-155]. In human microbiota research, invasive sampling from 
the intestine of large numbers of healthy individuals is not feasible for both practical and 
ethical reasons. In contrast, the pig model can provide an easier way for collecting many 
(invasive) samples along relevant spatio-temporal gradients, and also allow multiple 
comparisons and regulating the genotype background. In addition, the pig model allows to 
study the interaction between the host and the microbiota, as well as provide an alternative 
way to study the in vivo responses to beneficial, commensal and pathogenic 
microorganisms in the intestinal tract. These advantages make the pig essential as model for 
human intestinal studies. However, the pig as a model for human studies has some 
limitations notably as there are differences in the intestinal tract, diet and behaviour 
(Chapter 2) between pigs and humans. These should be taken into account when 
translating the knowledge gained from pig studies to the human situation [109, 139]. On the 
other hand, the long history of pig breeding has improved pig meat production and growth 
rate [381]. The pig breeding may also impact the pig genetics and furthermore the 
interaction of the pig with its gut microbiota, for example, gaining more energy from 
microbial fermention in the large intestine to adapt a fast growth. To this end, it is 
interesting to note that marked differences were found in microbial composition and 
function when comparing lean and obese pig genotypes [382, 383]. In spite of the 
above-mentioned limitations, promising pig models such as gnotobiotic pigs and 
humanized pigs may be even more helpful for translating the output from the pig research 
to human studies. As introducted in Chapter 2, gnotobiotic pigs have been used to study 
various human intestinal pathogens and recently been successfully used as an animal model 
to study the microbial colonization. With respect to humanized pigs, transplantation of 
human gut microbiota produced a donor-like microbial community in the piglet gut, and the 
microbial succession with aging of such humanized piglets was similar to that observed in 
humans [156]. Taken all together, gnotobiotic and humanized pigs could be appropriate 
models for studying the human intestinal microbiota, especially human infant microbiota.  
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Outlook and future perspectives 
Antibiotic useage 
Since the first antibiotic, penicillin, became available, the antibiotic usage has always been 
a heavily debated issue. Although antibiotic usage improves our lives and that of farm 
animals by preventing and treating disease, its collateral effects on the mammalian gut 
microbiome should not be ignored [42]. The present research suggested a negative effect of 
the maternal amoxicillin treatment during pregnancy and lactation with an increase of 
E.coli in the offspring intestine (Chapter 3). However, the main mechanism, by which 
maternal amoxicillin affects the intestinal microbial of the offspring, is still not clear. The 
findings in Chapter 3 indicated that the maternal amoxicillin treatment may indirectly 
affect the gut microbiota of offspring through disturbing the maternal microbiota and the 
transfer of maternal microbiota to offspring. Most antibiotics are either injected or 
administered orally, thereby circulating throughout the mother’s system and potentially 
affecting the entire mother’s microbiota [42]. Therefore, antibiotic effects on maternal milk 
and skin microbiota should also be considered when determining the maternal antibiotic 
effects. Especially, more studies should be performed to determine the effects of antibiotic 
treatment on the microbiota of breast milk, since breast milk is the main food for 
breast-feeding neonate humans and animals. Currently, the analysis of microbiota in breast 
milk is quite limited, and no reports on the antibiotic effects on the breast milk microbiota 
are available. The knowledge of antibiotic effects on the breast milk microbiota will be 
important for both doctors and mothers taking decisions of choosing antibiotics during 
lactation. To this end, knowledge regarding antibiotic resistance genes and their distribution 
throughout the microbiome will also be important [384, 385]. 
Long-term effects of pre-and post-natal factors on the intestinal microbiota 
As introduced in Chapter 1, many factors are involved in the intestinal microbiota 
development, including both prenatal factors and postnatal factors. There is no doubt that 
the introduction of solid foods and weaning will significantly affect the gut microbiota and 
may drive the microbiota into an adult type [2, 13, 18, 19]. Considering the drastic effects 
caused by dietary factors later in life, it is possible that pre-and post-natal influences can be 
at least partially be overcome by later colonization events. For example, Matsumiya et al. 
investigated mother-to-newborn infant transmission of Lactobacillus species, and found 
that the acquired lactobacilli from mother do not last in the intestine of the infant long-term, 
but rather, are replaced by other populations derived from milk or unknown sources after 
birth [31]. Moreover, the RS studies described in this thesis have shown that already two 
weeks of RS treatment can modify the intestinal microbiota of adult pigs (Chapter 6 and 
7). This finding further questions how long the effects of pre-and post-natal factors can last. 
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The present research only provides evidences on the impact of early-life events on the 
intestinal microbiota of piglets either before weaning or at early post weaning. The 
knowledge of the long-term effects of these early-life events is lacking. Therefore, 
longitudinal studies are required for determining the influences of early-life events on the 
intestinal microbiota and gut function in later life. To this end it is interesting to note that, 
using the pig model described in Chapter 3 of this thesis, differences in intestinal enzyme 
activities were found in pigs born to mothers that were treated with amoxillin before birth 
after being fed a high fed diet between 140 and 169 days of age [197].  
Systems biology approaches including the analysis of microbial function  
Recently developed techniques addressing the functionality of the intestinal microbiota 
beyond compositional analyses, including metatranscriptomic analyses, have recently 
become available using extreme throughput next generation technology sequencing to 
determine the function of certain bacteria within a complex microbial community [386]. To 
this end, efficient bioinformatic pipelines have been developed to deal with large amounts 
of functional genomic data derived from largely uncultured microorganisms such as those 
found in the gut, and application has recently provided a first glimpse of the interacive 
microbial networks responsible for carbohydrate metabolism in the human small intestinal 
tract [125, 387]. This approach will be further applied for intestinal content that we 
collected in the animal trial in Chapter 7. This approach will allow to collect information 
on the microbial activity responsible for RS metabolism, in addition to the microbial 
composition that we have already known. This approach could help answering our current 
questions in Chapter 7, for instance, the cross effects of diet, and the main factor, either RS 
itself or its production SCFA, driving the microbial change. The output of this approach 
will be more reliable and supports the general believe that fermentable fibres have a 
beneficial impact on intestinal health. 
Studies described in this thesis, together with recent breathtaking conceptual and 
technological advances in the field of gut microbiomics and systems biology [388], have  
further reinforced the notion that future studies will have to focus on integrating datasets on 
host factors, intestinal microbiota and environmental influences to understand the 
complexity of host-microbe interactions. 
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Supplemental Table 2 in Chapter 7. All significantly regulated genes (P <0.01) observed in pigs after 2 wk 
consumption of the RS diet compared to 2 wk consumption of the DS diet. 
?  ?  ?  ?  ?  Change per pig 
Abbrevia
tion Name 
Entrez 
ID 
Aver
age 
log2 
Fold 
Cha
nge 
IBM
T 
P-va
lue 1 2 3 4 5 6 7 8 9 10 
LOC1005
21756 
intestinal-type alkaline 
phosphatase-like 
100521
756 1.55 
0.00
037 
3.2
3 
1.6
4 
0.3
4 
0.7
5 
3.0
4 
3.4
7 
-0.
14 
0.6
7 
1.3
2 
1.1
9 
CA2 carbonic anhydrase II 
100154
873 1.35 
0.00
002 
0.9
7 
1.6
8 
1.3
3 
0.3
4 
2.0
3 
3.2
1 
1.0
2 
0.9
8 
0.7
4 
1.1
8 
LOC1006
21113 
uncharacterized 
LOC100621113 
100621
113 1.01 
0.00
004 
1.3
4 
0.4
9 
0.3
3 
0.1
4 
2.0
7 
1.8
3 
1.3
4 
0.5
0 
0.9
1 
1.1
2 
HSD17B2 
hydroxysteroid (17-beta) 
dehydrogenase 2 
100312
973 1.00 
0.00
238 
1.7
2 
0.8
2 
-0.
12 
-0.
35 
2.4
8 
2.7
0 
1.2
0 
0.5
1 
0.8
6 
0.1
8 
LOC1005
13630 
transmembrane 4 L6 
family member 20-like 
100513
630 0.96 
0.00
406 
1.5
9 
0.4
3 
0.4
4 
0.1
7 
2.0
9 
3.0
9 
-0.
33 
0.0
9 
0.6
2 
1.4
0 
LOC1005
25263 
uncharacterized protein 
C5orf4 homolog 
100525
263 0.95 
0.00
056 
1.4
2 
0.4
0 
0.0
5 
0.2
1 
2.1
4 
2.3
4 
0.9
7 
0.3
3 
0.6
3 
0.9
7 
SLC30A1
0 
solute carrier family 30, 
member 10 
100623
097 0.92 
0.00
021 
0.8
0 
0.8
8 
0.8
9 
0.2
3 
1.8
5 
1.4
0 
0.8
6 
-0.
44 
0.8
4 
1.8
5 
LOC1001
57073 angiotensinogen-like 
100157
073 0.86 
0.00
150 
1.6
7 
0.3
5 
0.2
3 
-0.
26 
0.5
9 
2.6
5 
1.1
2 
1.0
3 
0.8
3 
0.3
5 
LOC1001
52749 carbonic anhydrase 12-like 
100152
749 0.83 
0.00
024 
1.1
9 
0.0
8 
0.5
5 
0.1
9 
1.4
3 
2.0
4 
1.0
7 
0.2
4 
0.3
9 
1.1
1 
LOC1005
24810 
carcinoembryonic 
antigen-related cell 
adhesion molecule 7-like 
100524
810 0.81 
0.00
015 
1.2
7 
0.4
7 
0.6
1 
0.3
2 
2.1
9 
0.8
2 
0.7
2 
0.0
5 
0.9
3 
0.7
3 
ABCA6 
ATP-binding cassette, 
sub-family A (ABC1), 
member 6 
100520
861 0.79 
0.00
400 
0.3
8 
-0.
12 
-0.
04 
0.1
9 
0.4
9 
2.3
5 
1.8
3 
1.5
8 
0.9
5 
0.2
3 
LOC1005
19548 
agmatinase, 
mitochondrial-like 
100519
548 0.74 
0.00
022 
1.5
2 
0.1
0 
0.4
5 
0.1
9 
1.5
7 
1.2
3 
0.4
5 
0.1
6 
0.7
7 
1.0
0 
ADAM23 
ADAM metallopeptidase 
domain 23 
100518
044 0.74 
0.00
333 
-0.
05 
0.3
3 
0.4
1 
0.4
7 
0.5
7 
2.1
8 
-0.
37 
1.5
6 
1.4
9 
0.8
2 
CLDN10 claudin 10 
100153
752 0.73 
0.00
001 
0.5
8 
0.7
5 
0.4
6 
0.3
5 
1.0
9 
1.3
6 
0.9
2 
0.1
8 
0.9
4 
0.6
6 
TPMT 
thiopurine 
S-methyltransferase 
100157
630 0.72 
0.00
137 
0.5
0 
0.4
3 
-0.
19 
0.4
0 
1.9
0 
1.8
9 
1.0
6 
0.2
8 
0.5
1 
0.4
5 
LOC1005
20041 
ubiquitin 
carboxyl-terminal 
hydrolase 2-like 
100520
041 0.72 
0.00
051 
0.9
9 
0.2
1 
-0.
18 
0.5
3 
1.1
2 
2.0
2 
0.5
4 
0.7
4 
0.8
8 
0.3
7 
LOC1001
57775 
transient receptor potential 
cation channel subfamily 
M member 6-like 
100157
775 0.71 
0.00
009 
1.0
6 
0.4
4 
0.4
6 
0.0
1 
0.5
6 
1.8
0 
0.9
4 
0.4
0 
0.7
4 
0.7
4 
TMEM11
7 
transmembrane protein 
117 
100524
623 0.71 
0.00
153 
0.9
0 
0.1
8 
0.1
4 
-0.
06 
1.1
5 
2.1
3 
0.3
6 
0.1
4 
1.1
2 
1.0
7 
PARP15 
poly (ADP-ribose) 
polymerase family, 
member 15 
100520
273 0.70 
0.00
014 
0.9
4 
0.5
5 
0.1
4 
0.2
1 
0.7
8 
1.2
1 
0.2
7 
0.8
7 
1.6
9 
0.3
1 
SPTLC3 
serine 
palmitoyltransferase, long 
chain base subunit 3 
100519
280 0.68 
0.00
228 
1.1
6 
0.3
4 
0.1
3 
-0.
29 
1.4
5 
1.9
4 
0.3
1 
0.2
2 
0.8
2 
0.7
3 
LOC1005
16642 
collagen alpha-6(VI) 
chain-like 
100516
642 0.67 
0.00
187 
0.6
3 
0.1
1 
2.1
0 
-0.
14 
0.8
5 
1.2
1 
0.3
3 
0.5
8 
0.7
6 
0.2
3 
GUCA2A 
guanylate cyclase activator 
2A (guanylin) 
100301
560 0.66 
0.00
197 
0.4
6 
0.5
9 
0.4
2 
-0.
42 
1.3
7 
1.7
2 
1.1
3 
0.1
0 
0.1
0 
1.1
7 
EFEMP1 
EGF containing 
fibulin-like extracellular 
matrix protein 1 
100512
046 0.66 
0.00
777 
0.4
2 
1.0
1 
1.3
6 
-0.
38 
0.2
5 
2.4
8 
0.2
7 
-0.
01 
0.8
8 
0.3
6 
PNLIPRP
2 
pancreatic lipase-related 
protein 2 
100462
755 0.66 
0.00
012 
0.7
7 
0.0
8 
0.0
0 
0.2
2 
1.2
9 
1.0
5 
1.1
8 
0.5
8 
0.8
7 
0.5
9 
LOC1007
37562 olfactory receptor 9K2-like 
100737
562 0.66 
0.00
450 
1.6
7 
1.4
9 
0.8
7 
-0.
04 
1.6
6 
0.0
3 
0.4
0 
0.6
9 
-0.
09 
-0.
09 
LOC1005
14834 
uncharacterized 
LOC100514834 
100514
834 0.65 
0.00
040 
0.6
7 
0.7
1 
0.7
8 
0.1
8 
0.8
3 
1.7
7 
0.1
5 
-0.
11 
0.6
9 
0.8
2 
CNNM2 cyclin M2 
100155
831 0.65 
0.00
033 
1.2
4 
0.2
8 
0.1
6 
0.0
1 
0.9
4 
1.5
8 
0.4
5 
0.2
8 
0.8
2 
0.7
1 
TN-X tenascin-X 445520 0.64 
0.00
160 
0.6
9 
0.6
8 
0.9
6 
0.2
4 
0.6
7 
1.5
5 
-0.
60 
0.3
7 
1.4
6 
0.4
2 
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LOC1006
21356 
protein-arginine deiminase 
type-2-like 
100621
356 0.63 
0.00
172 
1.6
0 
0.2
5 
0.0
8 
0.2
2 
1.2
3 
1.5
0 
0.0
5 
0.0
5 
0.8
6 
0.4
9 
IGF1 
insulin-like growth factor 1 
(somatomedin C) 397491 0.62 
0.00
074 
0.3
5 
0.6
8 
0.5
7 
0.0
2 
1.2
3 
1.7
4 
0.1
5 
0.5
3 
0.0
8 
0.8
9 
SLC16A1 
solute carrier family 16, 
member 1 
(monocarboxylic acid 
transporter 1) 
100127
159 0.62 
0.00
015 
1.0
0 
0.2
7 
0.2
3 
0.0
6 
0.9
2 
1.5
6 
0.6
2 
0.3
7 
0.6
3 
0.5
1 
RETNLB resistin like beta 
100037
943 0.61 
0.00
403 
0.9
7 
-0.
19 
0.5
0 
0.0
6 
1.8
2 
1.2
4 
0.7
2 
-0.
26 
1.0
8 
0.2
0 
RBP1 
retinol binding protein 1, 
cellular 
100156
666 0.61 
0.00
031 
0.8
9 
0.3
5 
1.0
5 
0.3
4 
0.5
4 
1.3
9 
0.8
6 
0.2
1 
-0.
11 
0.5
5 
ANGPTL
4 angiopoietin-like 4 397628 0.60 
0.00
427 
0.2
1 
1.7
7 
1.1
5 
0.1
8 
0.7
9 
1.2
3 
0.3
4 
0.7
9 
-0.
42 
0.0
0 
LOC1006
26580 
ankyrin repeat 
domain-containing protein 
40-like 
100626
580 0.60 
0.00
103 
1.1
1 
-0.
17 
0.1
3 
0.5
3 
1.4
2 
0.7
2 
0.3
6 
0.0
1 
1.0
9 
0.7
8 
LOC1007
38347 zinc finger protein 821-like 
100738
347 0.59 
0.00
001 
0.7
8 
0.4
4 
0.1
3 
0.3
2 
0.9
9 
0.7
4 
0.6
8 
0.2
3 
0.7
2 
0.8
4 
LOC1005
15779 
dual specificity 
tyrosine-phosphorylation-r
egulated kinase 2-like 
100515
779 0.59 
0.00
001 
0.6
6 
0.4
6 
0.4
5 
0.2
3 
1.0
9 
0.7
2 
0.2
1 
0.4
5 
1.0
2 
0.5
7 
LOC1005
11032 prolargin-like 
100511
032 0.58 
0.00
863 
0.4
5 
0.1
2 
0.3
7 
-0.
32 
0.6
3 
2.4
6 
0.5
2 
0.8
0 
0.4
4 
0.3
4 
TRPV3 
transient receptor potential 
cation channel, subfamily 
V, member 3 
100515
051 0.58 
0.00
218 
1.1
8 
-0.
08 
0.2
2 
0.1
1 
1.3
1 
0.8
6 
0.1
4 
0.0
4 
1.3
4 
0.6
9 
LOC1005
19087 neurexin-1-alpha-like 
100519
087 0.58 
0.00
544 
0.6
2 
-0.
04 
0.2
6 
-0.
60 
0.7
4 
1.9
2 
0.7
9 
0.8
1 
0.7
8 
0.5
0 
LOC1005
16689 
uncharacterized protein 
C1orf115-like 
100516
689 0.57 
0.00
060 
1.1
5 
0.5
1 
0.1
9 
0.0
3 
1.1
0 
1.3
7 
0.1
7 
0.1
0 
0.6
0 
0.5
2 
HPGD 
hydroxyprostaglandin 
dehydrogenase 15-(NAD) 
100156
186 0.57 
0.00
056 
0.6
8 
-0.
10 
0.3
1 
0.2
3 
1.0
6 
1.0
7 
0.2
4 
0.3
0 
1.4
3 
0.4
9 
LOC1005
15222 
UDP-glucuronosyltransfer
ase 2C1-like 
100515
222 0.57 
0.00
027 
0.9
2 
0.4
1 
0.6
2 
0.0
8 
0.7
8 
1.3
9 
0.7
6 
-0.
15 
0.5
2 
0.3
6 
LOC1005
16366 dermatopontin-like 
100516
366 0.57 
0.00
608 
1.1
6 
0.0
7 
0.1
3 
0.0
4 
0.8
0 
1.9
1 
-0.
09 
0.4
7 
1.1
4 
0.0
3 
LOC1001
52498 
fibroblast growth factor 
12-like 
100152
498 0.57 
0.00
149 
0.4
0 
0.5
6 
0.3
4 
0.6
3 
0.9
7 
1.1
8 
0.0
0 
-0.
39 
0.7
3 
1.2
5 
TM6SF1 
transmembrane 6 
superfamily member 1 
100155
238 0.56 
0.00
513 
1.0
2 
0.1
7 
-0.
32 
-0.
16 
1.7
7 
0.8
5 
0.1
1 
0.5
3 
1.0
6 
0.5
9 
ID4 
inhibitor of DNA binding 
4, dominant negative 
helix-loop-helix protein 
100144
508 0.55 
0.00
026 
1.0
6 
0.4
9 
-0.
24 
0.2
5 
1.0
6 
0.5
1 
0.6
0 
0.2
5 
0.8
6 
0.6
6 
LOC1005
15463 
multiple epidermal growth 
factor-like domains protein 
11-like 
100515
463 0.55 
0.00
373 
-0.
56 
1.0
4 
0.6
1 
0.6
4 
0.8
3 
1.5
2 
0.3
5 
0.7
0 
0.0
6 
0.2
8 
RAI14 retinoic acid induced 14 
100145
886 0.54 
0.00
422 
0.9
7 
0.3
9 
0.4
3 
0.4
5 
1.7
3 
0.6
0 
0.2
1 
-0.
24 
-0.
19 
1.0
2 
PID1 
phosphotyrosine 
interaction domain 
containing 1 
100302
508 0.53 
0.00
057 
0.8
1 
0.3
6 
0.8
2 
0.3
0 
0.5
3 
1.3
3 
0.3
1 
0.7
5 
-0.
28 
0.3
8 
LOC1006
24891 
UDP-glucuronosyltransfer
ase 2B31-like 
100624
891 0.53 
0.00
432 
0.8
2 
0.1
1 
1.1
4 
-0.
21 
0.4
5 
1.6
7 
0.8
3 
-0.
09 
0.2
6 
0.3
2 
PLEKHG
6 
pleckstrin homology 
domain containing, family 
G (with RhoGef domain) 
member 6 
100520
565 0.53 
0.00
012 
0.5
7 
0.0
1 
0.3
6 
0.5
3 
1.2
4 
0.8
8 
0.3
1 
0.1
9 
0.5
9 
0.6
2 
LOC1007
39060 protein PTHB1-like 
100739
060 0.53 
0.00
937 
0.7
9 
0.7
3 
0.5
6 
0.2
0 
0.1
2 
2.0
6 
-0.
13 
-0.
07 
0.9
0 
0.1
1 
LOC1005
20019 
rho-related GTP-binding 
protein RhoC-like 
100520
019 0.52 
0.00
036 
0.9
1 
0.4
5 
0.4
6 
0.9
1 
1.2
7 
0.5
6 
0.1
4 
0.0
7 
0.0
3 
0.4
5 
MAOA monoamine oxidase A 414424 0.52 
0.00
200 
0.7
8 
-0.
25 
0.2
4 
0.0
2 
0.9
9 
1.5
4 
0.5
0 
0.2
4 
0.6
7 
0.4
6 
SCNN1A 
sodium channel, 
non-voltage-gated 1 alpha 
subunit 396608 0.52 
0.00
001 
0.6
4 
0.5
4 
0.1
6 
0.1
6 
0.7
9 
0.8
3 
0.3
2 
0.2
9 
0.7
6 
0.7
0 
LOC1006
26928 
uncharacterized 
LOC100626928 
100626
928 0.52 
0.00
018 
0.3
3 
0.5
9 
0.2
8 
0.0
6 
0.9
7 
1.2
7 
0.3
0 
0.3
0 
0.6
2 
0.4
5 
LOC1001
52247 
tumor protein 
p53-inducible nuclear 
protein 2-like 
100152
247 0.52 
0.00
600 
0.9
3 
0.3
2 
-0.
19 
0.0
2 
1.5
7 
0.9
8 
0.3
5 
-0.
21 
0.3
1 
1.0
7 
LOC1005
21401 
transmembrane and 
immunoglobulin 
domain-containing protein 
1-like 
100521
401 0.51 
0.00
372 
0.9
3 
-0.
22 
-0.
33 
0.0
5 
0.6
3 
1.3
3 
0.7
1 
0.3
2 
1.0
8 
0.5
7 
COX7A1 
cytochrome c oxidase 
polypeptide 399685 0.51 
0.00
690 
0.7
6 
0.1
1 
-0.
21 
-0.
26 
1.4
9 
1.3
5 
0.6
7 
0.1
5 
0.4
6 
0.5
5 
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VIIa-muscle/heart 
LOC1005
21274 protein FAM131C-like 
100521
274 0.51 
0.00
027 
0.7
8 
0.2
8 
0.3
2 
0.1
6 
1.2
6 
0.6
5 
0.5
9 
0.0
6 
0.6
6 
0.3
0 
LOC1005
23347 
uveal autoantigen with 
coiled-coil domains and 
ankyrin repeats 
protein-like 
100523
347 0.51 
0.00
203 
0.7
6 
0.0
3 
0.3
5 
0.2
2 
0.9
7 
1.3
0 
0.4
6 
-0.
18 
0.1
6 
0.9
9 
RNF152 ring finger protein 152 
100155
834 0.50 
0.00
019 
0.9
6 
0.4
2 
0.1
7 
0.5
0 
0.8
5 
0.9
0 
0.5
2 
-0.
18 
0.5
1 
0.3
7 
NOX5 
NADPH oxidase, EF-hand 
calcium binding domain 5 
100156
068 0.50 
0.00
820 
0.1
4 
0.5
1 
1.3
9 
-0.
08 
-0.
22 
1.5
5 
0.1
1 
0.5
1 
0.6
9 
0.3
6 
ACSF2 
acyl-CoA synthetase 
family member 2 
100512
859 0.50 
0.00
010 
0.7
7 
0.2
3 
0.2
6 
0.1
6 
0.3
0 
1.2
3 
0.4
1 
0.4
5 
0.6
5 
0.5
1 
ENTPD5 
ectonucleoside 
triphosphate 
diphosphohydrolase 5 
100154
506 0.50 
0.00
107 
0.8
3 
0.2
4 
0.2
0 
-0.
25 
0.6
6 
1.4
0 
0.3
7 
0.2
8 
0.7
6 
0.4
6 
AHCYL2 
adenosylhomocysteinase-li
ke 2 
100514
931 0.49 
0.00
233 
0.9
1 
-0.
33 
0.2
6 
0.2
8 
1.3
8 
0.7
9 
-0.
06 
0.3
8 
0.8
0 
0.5
3 
NR1H4 
nuclear receptor subfamily 
1, group H, member 4 
100153
960 0.49 
0.00
076 
0.2
9 
0.6
9 
0.4
8 
0.6
1 
-0.
35 
0.5
2 
0.8
9 
0.9
3 
0.7
4 
0.1
4 
HMGCS2 
3-hydroxy-3-methylglutar
yl-CoA synthase 2 
(mitochondrial) 397673 0.49 
0.00
076 
0.7
5 
0.1
0 
0.2
1 
-0.
15 
0.7
6 
1.3
9 
0.5
7 
0.2
6 
0.5
0 
0.5
6 
LOC1001
53698 
acyl-Coenzyme A 
dehydrogenase family, 
member 11 
100153
698 0.49 
0.00
451 
0.6
4 
0.3
1 
0.2
6 
-0.
28 
0.8
1 
1.7
1 
0.3
1 
0.0
1 
0.6
6 
0.4
9 
LOC1007
39411 
transmembrane protease 
serine 2-like 
100739
411 0.49 
0.00
000 
0.7
0 
0.3
3 
0.4
8 
0.4
6 
0.6
5 
0.6
7 
0.1
8 
0.3
8 
0.7
3 
0.3
4 
IYD iodotyrosine deiodinase 403124 0.49 
0.00
053 
1.1
4 
0.3
1 
0.4
8 
0.4
3 
0.7
8 
0.8
1 
0.0
4 
-0.
19 
0.5
6 
0.5
3 
GIF 
gastric intrinsic factor 
(vitamin B synthesis) 
100514
273 0.49 
0.00
879 
0.7
7 
-0.
41 
0.5
2 
-0.
52 
1.3
4 
0.6
0 
0.2
6 
0.5
4 
0.7
9 
0.9
9 
LOC1005
11514 
uncharacterized 
LOC100511514 
100511
514 0.49 
0.00
641 
1.1
0 
0.1
9 
-0.
25 
-0.
40 
0.1
8 
1.4
0 
0.6
8 
0.5
5 
0.8
3 
0.6
1 
CILP 
cartilage intermediate layer 
protein, nucleotide 
pyrophosphohydrolase 397672 0.49 
0.00
293 
0.8
0 
0.3
5 
0.7
8 
-0.
10 
0.5
4 
-0.
37 
0.8
2 
0.5
1 
1.3
1 
0.2
3 
LOC1001
56262 
bifunctional 
3'-phosphoadenosine 
5'-phosphosulfate synthase 
2-like 
100156
262 0.49 
0.00
327 
0.6
3 
-0.
24 
0.3
7 
0.1
2 
1.5
3 
0.7
8 
0.7
1 
-0.
04 
0.2
1 
0.8
0 
RHOV 
ras homolog family 
member V 
100154
565 0.48 
0.00
396 
0.2
7 
0.1
5 
0.1
6 
1.0
5 
1.1
1 
0.5
3 
1.0
4 
-0.
37 
0.1
5 
0.7
5 
PM20D1 
peptidase M20 domain 
containing 1 
100627
595 0.48 
0.00
395 
0.7
7 
0.2
3 
0.2
4 
-0.
19 
0.7
0 
1.5
9 
0.5
7 
0.1
8 
0.0
8 
0.6
4 
LOC1005
20161 
leucine-rich repeat 
neuronal protein 3-like 
100520
161 0.48 
0.00
957 
1.2
4 
-0.
22 
0.4
1 
0.8
3 
1.5
9 
-0.
04 
-0.
05 
0.2
3 
0.3
5 
0.4
6 
TOX3 
TOX high mobility group 
box family member 3 
100519
713 0.48 
0.00
049 
0.9
7 
0.2
8 
0.4
7 
0.5
7 
1.1
5 
0.1
9 
-0.
17 
0.3
6 
0.4
3 
0.5
5 
LOC1005
12372 
organic solute transporter 
alpha 
100512
372 0.48 
0.00
236 
0.9
4 
0.6
9 
0.2
2 
-0.
09 
-0.
11 
1.4
7 
0.3
6 
0.4
7 
0.2
9 
0.5
6 
LOC1001
52200 
uncharacterized protein 
C6orf222-like 
100152
200 0.48 
0.00
818 
0.4
1 
0.2
8 
0.5
1 
-0.
39 
1.5
8 
0.7
1 
-0.
15 
0.2
6 
1.1
3 
0.4
4 
TMPRSS
4 
transmembrane protease, 
serine 4 
100514
419 0.47 
0.00
017 
0.8
6 
0.3
8 
-0.
09 
0.1
9 
0.9
4 
0.4
3 
0.2
1 
0.3
9 
0.7
0 
0.7
4 
LOC1006
22224 
uncharacterized 
LOC100622224 
100622
224 0.47 
0.00
018 
0.6
1 
0.1
3 
0.2
6 
0.5
1 
0.9
2 
0.6
4 
0.8
3 
-0.
01 
0.7
0 
0.1
5 
LOC1001
57954 
disintegrin and 
metalloproteinase 
domain-containing protein 
7-like 
100157
954 0.47 
0.00
005 
0.8
4 
0.4
7 
0.2
0 
0.4
3 
0.2
7 
0.2
7 
0.3
2 
0.4
2 
0.8
4 
0.6
4 
LOC1005
15798 
ADP-ribosylation 
factor-like protein 14-like 
100515
798 0.47 
0.00
242 
0.9
5 
0.3
8 
-0.
04 
0.3
3 
1.0
4 
1.1
1 
-0.
31 
0.2
8 
0.3
2 
0.6
5 
LOC1006
26512 
glycerophosphodiester 
phosphodiesterase 
domain-containing protein 
1-like 
100626
512 0.46 
0.00
609 
0.6
4 
0.5
6 
-0.
04 
0.0
0 
0.3
9 
1.6
1 
-0.
22 
0.4
8 
0.9
6 
0.2
7 
THBS3 thrombospondin 3 
100155
108 0.46 
0.00
285 
0.1
9 
0.5
4 
0.8
2 
0.6
3 
0.7
6 
1.1
8 
-0.
49 
0.3
4 
0.2
5 
0.4
1 
SUS2DD 
dimeric dihydrodiol 
dehydrogenase 397337 0.46 
0.00
038 
0.4
9 
0.1
5 
0.7
3 
0.1
7 
0.3
4 
1.1
6 
0.6
4 
0.0
1 
0.6
3 
0.3
1 
ANK3 
ankyrin 3, node of Ranvier 
(ankyrin G) 
100154
687 0.46 
0.00
588 
0.7
9 
-0.
04 
0.1
8 
-0.
46 
1.2
2 
0.9
7 
0.5
3 
-0.
02 
0.6
8 
0.7
9 
IHH Indian hedgehog 397174 0.46 
0.00
087 
0.9
7 
0.5
1 
0.1
8 
0.1
2 
0.9
9 
0.1
3 
0.2
7 
-0.
05 
0.9
2 
0.5
8 
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GGT1 
gamma-glutamyltransferas
e 1 397095 0.46 
0.00
292 
0.5
5 
0.3
9 
0.0
8 
-0.
53 
0.4
7 
1.0
7 
0.7
3 
0.8
3 
0.2
2 
0.8
0 
SLC9A2 
solute carrier family 9, 
subfamily A (NHE2, 
cation proton antiporter 2), 
member 2 
100101
921 0.46 
0.00
002 
0.5
8 
0.1
9 
0.3
2 
0.1
0 
0.6
5 
0.8
6 
0.6
0 
0.3
4 
0.3
8 
0.5
4 
LOC1006
22888 
transmembrane protein 
150C-like 
100622
888 0.45 
0.00
726 
0.0
9 
0.3
5 
0.4
8 
-0.
22 
0.2
9 
1.7
2 
0.7
2 
0.3
1 
0.0
7 
0.7
3 
CDHR2 
cadherin-related family 
member 2 
100525
685 0.45 
0.00
164 
0.8
1 
0.2
3 
-0.
01 
0.0
3 
1.0
3 
0.9
1 
0.0
7 
0.1
1 
0.9
6 
0.4
0 
LOC1001
51985 
H(+)/Cl(-) exchange 
transporter 4-like 
100151
985 0.45 
0.00
157 
0.8
4 
-0.
02 
-0.
01 
0.4
5 
1.3
1 
0.6
6 
0.2
9 
0.3
0 
0.4
4 
0.2
6 
LOC1005
16309 
glycerophosphoinositol 
inositolphosphodiesterase 
GDPD2-like 
100516
309 0.45 
0.00
401 
0.6
6 
0.2
0 
0.0
6 
-0.
25 
1.3
5 
0.7
2 
0.2
7 
0.1
0 
0.5
3 
0.8
8 
SELENB
P1 selenium binding protein 1 
100152
724 0.45 
0.00
128 
0.6
5 
-0.
07 
0.3
0 
-0.
11 
0.7
5 
1.2
1 
0.7
1 
0.0
8 
0.4
4 
0.5
5 
LOC1006
21791 protein DEPP-like 
100621
791 0.45 
0.00
072 
0.5
1 
0.3
6 
0.0
5 
0.2
5 
1.0
1 
1.1
1 
0.1
8 
0.2
4 
0.1
6 
0.6
1 
LOC1005
22223 
mesoderm induction early 
response protein 3-like 
100522
223 0.45 
0.00
041 
0.4
2 
0.0
5 
0.0
5 
0.3
5 
1.1
3 
0.6
4 
0.1
0 
0.4
0 
0.7
5 
0.5
7 
LOC1005
25560 
cyclin-dependent kinase 4 
inhibitor D-like 
100525
560 0.44 
0.00
006 
0.8
9 
0.5
6 
0.2
8 
0.4
4 
0.6
4 
0.1
4 
0.4
7 
0.2
9 
0.2
5 
0.4
8 
PRDX6 peroxiredoxin 6 399538 0.44 
0.00
119 
0.7
7 
-0.
07 
0.1
8 
0.1
0 
1.0
0 
1.1
6 
0.3
3 
0.2
5 
0.2
8 
0.4
3 
NBEAL1 neurobeachin-like 1 
100514
254 0.44 
0.00
037 
0.7
1 
0.1
1 
-0.
11 
0.3
6 
0.6
1 
0.9
3 
0.5
0 
0.2
1 
0.8
4 
0.2
6 
COL14A
1 
collagen, type XIV, alpha 
1 
100158
059 0.44 
0.00
204 
0.6
4 
0.3
0 
0.6
6 
-0.
04 
0.2
7 
1.3
5 
0.1
2 
-0.
02 
0.8
0 
0.3
5 
RCAN1 regulator of calcineurin 1 
100511
902 0.44 
0.00
374 
0.9
5 
0.4
5 
0.2
4 
-0.
24 
0.8
4 
1.3
1 
-0.
08 
0.3
7 
0.2
2 
0.3
4 
LOC1001
56972 zinc finger protein 664-like 
100156
972 0.44 
0.00
144 
0.4
7 
0.4
2 
0.3
6 
-0.
22 
0.3
9 
1.3
5 
0.6
2 
0.0
6 
0.3
8 
0.6
0 
LOC1007
39604 axin-2-like 
100739
604 0.44 
0.00
230 
0.9
3 
0.2
8 
-0.
02 
0.0
9 
0.5
7 
1.0
3 
0.8
8 
0.5
9 
-0.
02 
0.0
5 
LOC1005
24044 
sodium bicarbonate 
cotransporter 3-like 
100524
044 0.44 
0.00
092 
0.2
0 
0.2
6 
0.3
0 
-0.
13 
0.9
4 
1.1
3 
0.5
2 
0.1
5 
0.5
4 
0.4
6 
LOC1005
24618 
alanine aminotransferase 
1-like 
100524
618 0.43 
0.00
020 
0.5
5 
0.0
0 
0.4
3 
0.4
7 
0.8
9 
0.6
9 
0.2
9 
0.0
8 
0.3
2 
0.6
2 
SEMA6A 
sema domain, 
transmembrane domain 
(TM), and cytoplasmic 
domain, (semaphorin) 6A 
100522
008 0.43 
0.00
000 
0.5
4 
0.4
2 
0.4
0 
0.1
9 
0.5
9 
0.3
4 
0.6
1 
0.2
2 
0.6
6 
0.3
7 
SHROO
M3 shroom family member 3 
100512
481 0.43 
0.00
012 
0.6
2 
0.2
0 
0.2
4 
0.2
4 
0.5
9 
0.7
4 
0.0
9 
0.2
6 
0.8
5 
0.4
8 
ADAMT
S19 
ADAM metallopeptidase 
with thrombospondin type 
1 motif, 19 
100518
181 0.43 
0.00
922 
0.1
8 
-0.
07 
0.4
2 
0.0
1 
0.3
1 
1.5
3 
0.0
5 
0.1
7 
0.9
9 
0.6
9 
LOC1005
14274 harmonin-like 
100514
274 0.43 
0.00
001 
0.7
3 
0.2
0 
0.2
2 
0.3
1 
0.6
6 
0.3
9 
0.4
2 
0.2
4 
0.6
0 
0.5
0 
LOC1005
24831 
dedicator of cytokinesis 
protein 1-like 
100524
831 0.43 
0.00
000 
0.6
2 
0.3
8 
0.3
1 
0.3
8 
0.5
6 
0.6
1 
0.2
6 
0.2
7 
0.3
9 
0.4
8 
LOC1005
18372 
tetratricopeptide repeat 
protein 38-like 
100518
372 0.42 
0.00
103 
0.6
7 
0.0
1 
0.1
4 
0.2
6 
1.1
3 
0.8
2 
0.3
4 
0.0
2 
0.3
2 
0.5
2 
PTPRR 
protein tyrosine 
phosphatase, receptor type, 
R 
100154
962 0.42 
0.00
804 
0.3
0 
0.5
1 
0.0
6 
-0.
11 
0.9
6 
1.4
1 
-0.
21 
0.3
2 
0.5
8 
0.4
0 
LOC1005
18563 protein FAM160A1-like 
100518
563 0.42 
0.00
131 
0.8
5 
0.0
6 
0.1
2 
0.1
6 
0.7
7 
0.8
8 
0.1
5 
-0.
04 
0.7
6 
0.5
0 
LOC1005
15418 
UPF0733 protein C2orf88 
homolog 
100515
418 0.42 
0.00
079 
0.7
5 
-0.
07 
0.4
9 
-0.
11 
0.5
3 
0.8
0 
0.1
7 
0.5
4 
0.5
4 
0.5
7 
LOC1007
37900 
olfactory receptor 
51G2-like 
100737
900 0.42 
0.00
319 
0.0
7 
0.1
8 
-0.
03 
-0.
09 
1.0
0 
0.7
7 
0.3
6 
0.4
2 
0.9
9 
0.5
5 
LOC1005
23465 
transmembrane protein 
100-like 
100523
465 0.42 
0.00
796 
0.3
8 
0.1
8 
1.0
0 
0.0
0 
0.2
9 
1.4
4 
0.1
7 
-0.
11 
0.2
4 
0.5
7 
PLD1 
phospholipase D1, 
phosphatidylcholine-specif
ic 
100519
446 0.41 
0.00
024 
0.7
3 
0.0
9 
0.0
4 
0.4
3 
0.9
3 
0.5
7 
0.3
0 
0.1
7 
0.2
8 
0.5
9 
WNT2B 
wingless-type MMTV 
integration site family, 
member 2B 
100520
560 0.41 
0.00
088 
0.9
4 
0.2
4 
0.3
2 
0.4
0 
0.1
5 
1.1
2 
0.3
8 
0.3
6 
0.1
2 
0.1
0 
RALGPS
1 
Ral GEF with PH domain 
and SH3 binding motif 1 
100157
921 0.41 
0.00
097 
0.6
7 
-0.
14 
0.6
7 
0.1
6 
0.6
3 
0.3
4 
0.5
6 
-0.
11 
0.5
5 
0.8
1 
LOC1007
37624 
E3 ubiquitin-protein ligase 
NEDD4-like 
100737
624 0.41 
0.00
973 
-0.
13 
0.0
4 
1.0
7 
0.0
2 
0.1
4 
1.0
5 
1.0
3 
0.0
9 
0.0
9 
0.6
8 
PLA2G16 
phospholipase A2, group 
XVI 
100512
584 0.41 
0.00
167 
0.2
0 
0.5
5 
0.6
6 
0.0
6 
0.1
2 
0.8
5 
0.0
0 
0.9
2 
0.6
0 
0.1
1 
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LOC1007
39336 
centrosomal protein 
CEP57L1-like 
100739
336 0.41 
0.00
220 
0.4
2 
0.4
1 
0.5
6 
-0.
10 
-0.
03 
1.1
9 
0.3
5 
0.6
0 
0.3
3 
0.3
4 
LOC1001
56793 olfactory receptor 8S1-like 
100156
793 0.40 
0.00
018 
-0.
02 
0.3
1 
0.1
2 
0.7
7 
0.6
6 
0.3
9 
0.4
0 
0.6
8 
0.3
0 
0.4
4 
KIF3A kinesin family member 3A 
100525
739 0.40 
0.00
285 
0.4
6 
0.5
0 
0.2
2 
0.0
3 
0.2
4 
1.4
4 
0.3
7 
0.4
3 
0.2
4 
0.1
3 
LOC1001
56928 
uncharacterized 
LOC100156928 
100156
928 0.40 
0.00
199 
0.8
5 
0.0
6 
0.2
0 
-0.
10 
0.8
2 
0.7
8 
-0.
05 
0.2
4 
0.6
5 
0.5
9 
LOC1005
16628 
UDP-glucuronosyltransfer
ase 2B18-like 
100516
628 0.40 
0.00
872 
0.5
3 
0.7
2 
0.2
6 
0.9
2 
0.9
3 
0.4
8 
0.5
7 
-0.
58 
-0.
26 
0.4
4 
LOC1005
16116 
28S ribosomal protein S36, 
mitochondrial-like 
100516
116 0.40 
0.00
165 
0.4
4 
-0.
19 
0.1
8 
0.2
5 
0.0
6 
0.8
6 
0.7
0 
0.3
4 
0.6
9 
0.6
7 
LOC1005
14093 
pre-B-cell leukemia 
transcription factor 4-like 
100514
093 0.40 
0.00
346 
0.6
1 
-0.
14 
0.2
2 
0.0
2 
0.5
9 
1.0
2 
0.6
1 
-0.
11 
0.3
4 
0.8
0 
LOC1005
24518 
ciliary neurotrophic factor 
receptor subunit alpha-like 
100524
518 0.40 
0.00
135 
0.3
2 
0.4
2 
0.3
3 
0.1
4 
0.8
6 
1.0
4 
-0.
05 
0.0
3 
0.5
0 
0.3
6 
AIFM3 
apoptosis-inducing factor, 
mitochondrion-associated, 
3 
100525
540 0.40 
0.00
903 
0.6
4 
-0.
22 
-0.
07 
0.4
5 
1.1
9 
0.1
1 
0.8
9 
-0.
13 
0.4
0 
0.7
0 
LOC1001
57426 stonin-2-like 
100157
426 0.39 
0.00
015 
0.4
3 
0.1
7 
0.2
4 
0.4
9 
0.8
3 
0.7
1 
0.0
8 
0.2
1 
0.5
4 
0.2
5 
LIPE lipase, hormone-sensitive 397583 0.39 
0.00
263 
-0.
04 
0.6
1 
0.3
3 
-0.
01 
0.2
4 
0.7
7 
1.1
3 
0.1
9 
0.3
0 
0.4
1 
ACADSB 
acyl-CoA dehydrogenase, 
short/branched chain 
100154
810 0.39 
0.00
113 
0.3
3 
-0.
10 
0.4
0 
0.0
6 
0.4
0 
1.1
2 
0.5
9 
0.3
7 
0.5
3 
0.2
2 
LOC1005
19847 
enoyl-CoA hydratase 
domain-containing protein 
2, mitochondrial-like 
100519
847 0.39 
0.00
049 
0.5
1 
0.1
1 
0.0
7 
0.2
2 
0.8
7 
0.7
1 
0.4
2 
-0.
04 
0.4
6 
0.6
0 
LOC1001
57995 5 nucleotidase, ecto 
100157
995 0.39 
0.00
953 
0.2
8 
0.2
1 
0.4
8 
0.0
2 
0.0
1 
1.5
9 
-0.
06 
0.2
2 
0.5
6 
0.5
8 
LOC1001
56815 
small subunit of serine 
palmitoyltransferase 
A-like 
100156
815 0.39 
0.00
156 
0.2
8 
-0.
12 
0.4
1 
0.2
5 
0.7
2 
0.8
0 
0.5
8 
-0.
09 
0.3
1 
0.7
4 
LOC1005
19130 
probable carboxypeptidase 
PM20D1-like 
100519
130 0.39 
0.00
122 
0.0
7 
0.3
8 
0.1
3 
0.2
5 
0.6
1 
0.8
9 
0.8
6 
0.2
1 
0.4
0 
0.0
8 
LOC1005
22399 
uncharacterized 
LOC100522399 
100522
399 0.39 
0.00
148 
0.8
1 
0.2
1 
-0.
19 
0.5
5 
0.4
5 
0.6
0 
0.1
9 
0.1
7 
0.2
0 
0.8
5 
LOC1005
25112 cytochrome P450 2J2-like 
100525
112 0.38 
0.00
178 
0.5
8 
0.2
2 
0.0
4 
0.1
6 
-0.
11 
0.9
2 
0.8
0 
0.2
1 
0.5
4 
0.4
8 
LOC1007
39292 
uncharacterized 
LOC100739292 
100739
292 0.38 
0.00
025 
0.4
5 
0.3
2 
0.4
1 
0.5
8 
0.4
0 
0.3
7 
-0.
01 
0.2
1 
0.9
8 
0.1
4 
ABCC2 
ATP-binding cassette, 
sub-family C 
(CFTR/MRP), member 2 397535 0.38 
0.00
918 
0.8
9 
0.5
5 
0.0
3 
-0.
38 
0.6
8 
0.4
7 
0.7
2 
-0.
26 
0.4
2 
0.7
3 
PLCE1 phospholipase C, epsilon 1 
100157
745 0.38 
0.00
872 
0.9
5 
0.1
8 
0.0
4 
-0.
07 
1.0
4 
0.9
9 
-0.
19 
0.1
2 
0.5
5 
0.2
3 
ART4 
ADP-ribosyltransferase 4 
(Dombrock blood group) 
100152
653 0.38 
0.00
879 
-0.
38 
0.6
7 
0.3
3 
0.3
3 
0.4
7 
1.3
3 
0.2
1 
0.0
7 
0.3
7 
0.4
2 
UCP3 
uncoupling protein 3 
(mitochondrial, proton 
carrier) 397116 0.38 
0.00
009 
0.6
6 
0.4
8 
0.3
6 
0.2
0 
0.5
9 
0.0
6 
0.3
5 
0.1
2 
0.3
5 
0.6
7 
RETSAT 
retinol saturase 
(all-trans-retinol 
13,14-reductase) 
100519
138 0.38 
0.00
184 
0.5
2 
0.0
2 
0.0
8 
0.0
4 
0.5
2 
1.1
3 
0.6
3 
0.0
8 
0.4
2 
0.3
5 
LOC1005
11705 
olfactory receptor 
51F1-like 
100511
705 0.38 
0.00
956 
0.1
6 
-0.
25 
-0.
34 
0.2
4 
0.8
3 
0.8
9 
0.5
5 
0.8
6 
0.4
7 
0.3
6 
LOC1005
23648 
transcription factor 
COE4-like 
100523
648 0.38 
0.00
530 
0.9
6 
0.4
5 
0.3
2 
-0.
20 
0.8
5 
-0.
05 
0.0
6 
0.7
2 
0.4
0 
0.2
5 
C20orf11
8 
Uncharacterized protein 
C20orf118 
100158
114 0.38 
0.00
056 
0.6
4 
0.3
2 
0.1
3 
0.3
9 
0.4
7 
0.8
7 
-0.
12 
0.0
9 
0.4
8 
0.4
8 
GUCY1A
2 
guanylate cyclase 1, 
soluble, alpha 2 
100522
091 0.38 
0.00
609 
-0.
03 
0.0
5 
0.2
8 
-0.
10 
0.6
3 
1.2
7 
0.4
8 
0.5
0 
0.3
2 
0.3
7 
LOC1006
26612 
proline-rich protein 15-like 
protein-like 
100626
612 0.37 
0.00
282 
0.6
0 
0.3
7 
0.1
3 
0.1
2 
0.1
4 
1.2
8 
0.0
3 
0.2
5 
0.5
5 
0.2
6 
LOC1005
21423 
adenylate kinase 
isoenzyme 1-like 
100521
423 0.37 
0.00
446 
0.5
7 
0.0
7 
0.0
7 
0.5
6 
1.1
0 
0.6
7 
0.0
0 
0.0
4 
0.1
0 
0.5
0 
LOC1006
24704 
rap1 GTPase-activating 
protein 2-like 
100624
704 0.37 
0.00
069 
0.7
7 
0.4
1 
0.1
0 
0.0
7 
0.6
9 
0.6
7 
0.1
0 
0.2
3 
0.4
4 
0.2
1 
LOC1005
20886 syntaxin-3-like 
100520
886 0.37 
0.00
432 
0.6
7 
0.3
9 
-0.
03 
0.2
5 
1.0
3 
0.4
7 
-0.
21 
0.0
3 
0.8
1 
0.2
8 
LOC1006
23939 phospholemman-like 
100623
939 0.37 
0.00
735 
0.2
8 
-0.
01 
0.1
9 
-0.
17 
0.5
4 
1.2
6 
0.4
3 
0.1
2 
0.7
7 
0.2
7 
LOC1001
57017 
probable 2-ketogluconate 
reductase-like 
100157
017 0.37 
0.00
146 
0.3
6 
-0.
13 
0.3
2 
0.3
9 
0.5
7 
0.9
6 
0.1
1 
0.2
3 
0.5
4 
0.3
2 
LOC1005
18046 
3-oxo-5-alpha-steroid 
4-dehydrogenase 1-like 
100518
046 0.37 
0.00
085 
0.6
9 
0.2
1 
0.4
0 
0.3
2 
0.6
6 
0.8
1 
0.3
9 
0.0
4 
-0.
14 
0.3
0 
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LOC1006
21032 kelch-like protein 7-like 
100621
032 0.37 
0.00
586 
0.5
1 
-0.
13 
-0.
02 
0.5
3 
0.4
1 
1.0
6 
0.1
8 
0.1
5 
0.9
0 
0.1
0 
LOC1005
24863 
uncharacterized 
LOC100524863 
100524
863 0.36 
0.00
088 
0.3
2 
0.7
8 
0.6
2 
0.3
6 
0.5
6 
0.4
1 
0.2
2 
0.0
3 
-0.
02 
0.3
5 
AGPAT2 
1-acylglycerol-3-phosphat
e O-acyltransferase 2 
(lysophosphatidic acid 
acyltransferase, beta) 
100170
768 0.36 
0.00
002 
0.6
2 
0.2
8 
0.4
1 
0.4
3 
0.2
2 
0.1
6 
0.6
2 
0.3
1 
0.4
0 
0.1
9 
SLIT3 
slit homolog 3 
(Drosophila) 
100513
444 0.36 
0.00
428 
-0.
01 
0.5
7 
0.4
9 
0.0
3 
0.1
0 
0.9
6 
0.0
7 
-0.
06 
0.6
4 
0.8
3 
MFF 
mitochondrial fission 
factor 
100513
442 0.36 
0.00
063 
0.6
6 
-0.
11 
0.3
2 
0.1
4 
0.0
6 
0.7
7 
0.3
9 
0.4
0 
0.3
5 
0.6
4 
LOC1006
27989 
ankyrin repeat 
domain-containing protein 
31-like 
100627
989 0.36 
0.00
047 
0.6
1 
0.0
5 
0.2
5 
0.2
9 
0.7
8 
0.6
8 
0.1
9 
0.1
1 
0.2
9 
0.3
7 
LOC1005
13834 
cytosolic phospholipase 
A2 zeta-like 
100513
834 0.36 
0.00
962 
0.9
4 
0.0
5 
-0.
24 
0.2
4 
0.9
9 
0.5
1 
0.4
7 
-0.
23 
0.4
8 
0.4
1 
LOC1005
21659 
cytochrome P450 
26B1-like 
100521
659 0.36 
0.00
082 
0.5
5 
0.4
6 
0.2
0 
0.6
0 
0.7
8 
0.1
9 
0.1
1 
0.0
8 
0.1
8 
0.4
0 
BTBD3 
BTB (POZ) domain 
containing 3 
100156
598 0.36 
0.00
041 
0.6
2 
0.1
0 
0.0
6 
0.2
4 
0.6
9 
0.7
2 
0.2
2 
0.1
2 
0.5
2 
0.2
8 
ITM2C 
integral membrane protein 
2C 
100144
481 0.35 
0.00
145 
0.5
1 
0.1
4 
0.1
3 
0.0
6 
0.9
3 
0.8
5 
0.2
7 
0.0
2 
0.2
9 
0.3
5 
LOC1005
17092 carboxypeptidase M-like 
100517
092 0.35 
0.00
950 
0.3
7 
0.2
6 
-0.
14 
0.0
3 
0.6
2 
1.3
3 
0.0
6 
0.1
5 
0.2
2 
0.6
1 
CDC42B
PG 
CDC42 binding protein 
kinase gamma 
(DMPK-like) 
100520
358 0.35 
0.00
151 
0.6
7 
0.4
5 
-0.
02 
0.5
1 
0.6
3 
0.0
0 
0.3
3 
-0.
02 
0.6
5 
0.3
0 
LOC1001
58075 
thiosulfate 
sulfurtransferase/rhodanes
e-like domain-containing 
protein 1-like 
100158
075 0.35 
0.00
146 
0.3
7 
-0.
09 
0.0
9 
0.1
0 
0.5
7 
0.9
4 
0.4
6 
0.1
6 
0.4
7 
0.4
5 
LOC1007
38638 
OCIA domain-containing 
protein 2-like 
100738
638 0.35 
0.00
893 
0.3
3 
-0.
03 
0.1
9 
-0.
23 
1.1
5 
0.1
7 
0.2
2 
0.4
3 
0.5
5 
0.7
1 
LOC1006
26467 
heat-stable enterotoxin 
receptor-like 
100626
467 0.35 
0.00
999 
0.7
6 
-0.
09 
0.1
6 
-0.
01 
0.8
7 
0.8
7 
-0.
08 
-0.
12 
0.7
7 
0.3
4 
S100A14 
S100 calcium binding 
protein A14 
100153
930 0.35 
0.00
084 
0.6
6 
0.3
6 
0.6
1 
0.5
5 
0.4
5 
0.5
2 
0.0
2 
-0.
14 
0.2
7 
0.1
6 
FAAH fatty acid amide hydrolase 396949 0.35 
0.00
291 
0.4
7 
-0.
14 
0.2
3 
0.0
6 
0.9
3 
0.2
8 
0.3
1 
0.1
0 
0.5
5 
0.6
8 
LOC1005
14762 F-box only protein 48-like 
100514
762 0.35 
0.00
069 
0.3
1 
-0.
07 
0.3
9 
0.1
0 
0.5
8 
0.5
8 
0.0
4 
0.3
1 
0.6
6 
0.5
6 
LOC1006
20159 
multidrug 
resistance-associated 
protein 4-like 
100620
159 0.34 
0.00
192 
0.5
7 
-0.
11 
0.6
0 
-0.
12 
0.2
0 
0.8
1 
0.4
8 
0.0
7 
0.4
3 
0.5
2 
SCUBE1 
signal peptide, CUB 
domain, EGF-like 1 
100524
621 0.34 
0.00
242 
0.3
3 
0.3
4 
0.0
1 
0.0
7 
0.6
3 
0.1
3 
0.5
4 
0.0
5 
0.9
1 
0.4
3 
PNPLA2 
patatin-like phospholipase 
domain containing 2 
100049
704 0.34 
0.00
501 
0.5
5 
-0.
04 
0.1
3 
0.0
8 
1.1
4 
0.5
1 
0.2
4 
-0.
14 
0.4
2 
0.5
4 
FA2H fatty acid 2-hydroxylase 
100523
966 0.34 
0.00
007 
0.3
6 
0.2
1 
0.2
0 
0.5
0 
0.5
0 
0.1
1 
0.2
2 
0.3
5 
0.6
7 
0.3
0 
LOC1001
56930 
Zinc binding alcohol 
dehydrogenase, domain 
containing 1 
100156
930 0.34 
0.00
472 
0.6
9 
0.2
6 
0.7
5 
-0.
04 
0.2
1 
0.5
6 
0.7
3 
-0.
14 
0.1
0 
0.3
0 
LOC1005
11991 
uncharacterized protein 
C12orf69-like 
100511
991 0.34 
0.00
306 
0.0
3 
0.6
0 
0.6
2 
0.3
9 
0.2
8 
0.9
3 
0.0
8 
0.3
7 
0.1
3 
-0.
01 
C2H11orf
49 
chromosome 11 open 
reading frame 49 ortholog 
100513
582 0.34 
0.00
702 
0.1
5 
-0.
13 
0.2
2 
0.0
1 
0.7
9 
0.6
0 
0.4
1 
-0.
08 
0.7
4 
0.7
0 
LOC1005
13311 olfactory receptor 5K1-like 
100513
311 0.34 
0.00
080 
-0.
17 
0.3
2 
0.8
1 
0.5
0 
0.3
9 
0.4
7 
0.3
7 
0.2
7 
0.0
2 
0.4
2 
TRAK1 
trafficking protein, kinesin 
binding 1 
100522
277 0.34 
0.00
076 
0.3
1 
0.0
7 
0.1
7 
0.3
2 
0.8
8 
0.4
6 
0.0
3 
0.1
3 
0.6
5 
0.3
8 
LOC1006
26257 UPF0632 protein A-like 
100626
257 0.34 
0.00
560 
0.6
9 
0.9
5 
0.2
1 
0.2
6 
0.4
4 
0.0
9 
0.7
2 
-0.
08 
0.0
9 
0.0
4 
LOC1005
13188 
uncharacterized 
LOC100513188 
100513
188 0.34 
0.00
973 
0.8
0 
0.0
1 
0.2
3 
0.2
1 
1.0
9 
0.3
1 
0.5
0 
-0.
34 
0.2
0 
0.3
8 
ROR1 
receptor tyrosine 
kinase-like orphan receptor 
1 
100520
620 0.34 
0.00
103 
0.7
7 
0.0
8 
0.3
1 
0.2
8 
0.6
8 
0.4
5 
0.3
4 
-0.
13 
0.3
0 
0.3
1 
LOC1007
36803 protein S100-A1-like 
100736
803 0.34 
0.00
384 
0.3
9 
0.1
2 
0.5
5 
0.2
0 
0.5
4 
0.8
1 
0.0
9 
-0.
36 
0.5
8 
0.4
6 
PC pyruvate carboxylase 397630 0.34 
0.00
544 
-0.
13 
0.7
8 
0.7
3 
0.2
1 
0.3
7 
0.7
1 
0.3
4 
-0.
14 
-0.
02 
0.5
4 
LOC1005
23460 
transmembrane protein 
236-like 
100523
460 0.34 
0.00
414 
0.3
8 
-0.
12 
0.0
9 
0.5
6 
0.9
6 
0.1
4 
-0.
15 
0.4
4 
0.6
8 
0.3
9 
LOC1006
21218 
hydroxymethylglutaryl-Co
A lyase, 
100621
218 0.34 
0.00
218 
0.5
2 
0.1
6 
0.2
3 
-0.
20 
0.5
1 
0.9
6 
0.5
5 
0.1
4 
0.2
1 
0.3
1 
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mitochondrial-like 
LOC1006
26613 
uncharacterized 
LOC100626613 
100626
613 0.34 
0.00
165 
0.7
3 
0.0
7 
0.2
1 
0.3
8 
-0.
04 
0.3
7 
0.2
3 
0.2
9 
0.8
6 
0.2
8 
CDHR5 
cadherin-related family 
member 5 
100514
561 0.34 
0.00
633 
0.8
1 
0.1
9 
-0.
06 
-0.
14 
0.8
5 
0.6
4 
0.1
0 
-0.
09 
0.5
5 
0.5
2 
TTLL1 
tubulin tyrosine ligase-like 
family, member 1 
100621
517 0.34 
0.00
326 
0.0
3 
0.0
3 
0.4
7 
0.5
0 
0.2
6 
0.8
4 
0.5
8 
0.1
6 
-0.
15 
0.6
6 
LOC1006
21830 
ly6/PLAUR 
domain-containing protein 
6B-like 
100621
830 0.34 
0.00
140 
0.5
3 
0.3
1 
0.3
1 
0.2
5 
0.7
9 
0.4
7 
0.1
5 
-0.
28 
0.3
8 
0.4
4 
LOC1001
55585 
ATP-binding cassette, 
sub-family B, member 6 
100155
585 0.34 
0.00
213 
0.7
2 
0.1
3 
-0.
03 
-0.
04 
0.6
6 
0.6
5 
0.2
8 
-0.
01 
0.5
7 
0.4
3 
LOC1005
10987 
phosphatidylinositol 
4,5-bisphosphate 
5-phosphatase A-like 
100510
987 0.33 
0.00
101 
0.7
7 
0.2
6 
0.2
9 
0.0
3 
0.3
9 
0.2
2 
0.5
1 
-0.
04 
0.4
3 
0.4
8 
VIL1 villin 1 
100156
373 0.33 
0.00
049 
0.5
8 
-0.
13 
0.2
4 
0.1
5 
0.6
3 
0.3
6 
0.3
0 
0.1
1 
0.5
4 
0.5
6 
LOC1007
38323 
neurobeachin-like protein 
1-like 
100738
323 0.33 
0.00
371 
0.5
7 
-0.
05 
0.1
2 
-0.
08 
0.6
3 
0.8
8 
0.4
4 
-0.
06 
0.6
0 
0.2
8 
PSD3 
pleckstrin and Sec7 
domain containing 3 
100623
956 0.33 
0.00
004 
0.4
5 
0.5
4 
0.3
0 
0.3
0 
0.4
2 
0.4
4 
0.2
7 
0.1
9 
0.0
9 
0.3
2 
CLC-2 
chloride channel protein 2 
variant 397147 0.33 
0.00
030 
0.5
0 
0.0
9 
0.4
3 
0.4
2 
0.3
6 
-0.
05 
0.5
9 
0.0
6 
0.4
1 
0.5
3 
ACY1 aminoacylase 1 396930 0.33 
0.00
255 
0.0
5 
-0.
01 
0.3
9 
0.4
4 
0.8
2 
0.3
2 
0.3
5 
-0.
12 
0.4
4 
0.6
5 
LOC1005
25667 
uncharacterized protein 
C8orf48-like 
100525
667 0.33 
0.00
051 
0.5
4 
0.5
4 
0.0
0 
0.3
5 
0.3
6 
0.5
2 
0.3
1 
0.2
5 
0.4
2 
0.0
3 
LDHD lactate dehydrogenase D 
100523
064 0.33 
0.00
160 
0.7
0 
-0.
13 
0.1
9 
0.1
4 
0.8
1 
0.4
0 
0.2
8 
0.1
6 
0.5
7 
0.2
2 
LOC1005
19703 
proteinase-activated 
receptor 2-like 
100519
703 0.33 
0.00
093 
0.4
3 
0.1
8 
0.1
8 
0.0
9 
0.8
3 
0.3
5 
-0.
06 
0.1
8 
0.6
1 
0.5
3 
HOXD10 homeobox D10 
100515
344 0.33 
0.00
332 
0.8
5 
-0.
06 
0.1
5 
0.1
0 
0.6
9 
0.0
7 
0.4
6 
0.0
1 
0.5
8 
0.4
7 
LOC1005
19058 frizzled-5-like 
100519
058 0.33 
0.00
032 
0.5
8 
0.3
5 
0.0
1 
0.1
0 
0.4
9 
0.4
2 
0.2
4 
0.0
4 
0.5
8 
0.4
9 
BMP2 
bone morphogenetic 
protein 2 
100157
103 0.33 
0.00
252 
0.4
3 
0.9
3 
0.3
0 
0.2
7 
0.3
7 
0.1
4 
-0.
12 
0.4
1 
0.6
2 
-0.
05 
TDP2 
tyrosyl-DNA 
phosphodiesterase 2 
100157
860 0.33 
0.00
182 
0.5
2 
0.0
5 
0.1
6 
0.1
8 
0.2
4 
0.8
2 
0.0
4 
0.0
4 
0.7
5 
0.5
1 
LOC1005
18407 
E3 ubiquitin-protein ligase 
Praja-1-like 
100518
407 0.33 
0.00
544 
0.6
0 
0.0
5 
0.1
2 
-0.
30 
0.8
1 
0.5
0 
0.4
3 
0.0
7 
0.4
4 
0.5
7 
LOC1006
23447 
ribonucleoprotein 
PTB-binding 2-like 
100623
447 0.33 
0.00
341 
0.6
3 
0.0
0 
-0.
03 
0.0
5 
0.6
0 
0.9
8 
0.1
3 
0.1
9 
0.4
6 
0.2
8 
LOC1006
22354 
pro-neuregulin-3, 
membrane-bound 
isoform-like 
100622
354 0.33 
0.00
170 
0.0
0 
0.0
0 
0.7
2 
0.7
1 
0.4
5 
0.3
3 
0.4
7 
0.2
1 
-0.
05 
0.4
4 
LRIG2 
leucine-rich repeats and 
immunoglobulin-like 
domains 2 
100154
795 0.33 
0.00
103 
0.6
5 
0.5
1 
0.0
0 
0.0
0 
0.3
4 
0.6
9 
0.1
8 
0.2
4 
0.5
6 
0.0
9 
PPARG 
peroxisome 
proliferator-activated 
receptor gamma 397671 0.33 
0.00
030 
0.7
2 
0.2
9 
0.0
0 
0.0
6 
0.4
0 
0.5
8 
0.4
0 
0.1
4 
0.3
3 
0.3
2 
VSIG10 
V-set and immunoglobulin 
domain containing 10 
100153
531 0.32 
0.00
016 
0.4
9 
0.1
9 
0.3
1 
0.1
6 
0.5
0 
0.2
4 
0.3
6 
0.1
1 
0.6
3 
0.2
5 
LOC1005
16232 
uncharacterized 
LOC100516232 
100516
232 0.32 
0.00
449 
0.9
9 
0.3
6 
0.2
2 
0.2
1 
0.2
4 
0.5
1 
0.1
4 
0.2
3 
-0.
14 
0.4
7 
LOC1005
19192 
diphosphoinositol 
polyphosphate 
phosphohydrolase 2-like 
100519
192 0.32 
0.00
395 
0.4
4 
0.1
6 
-0.
01 
-0.
11 
0.5
1 
1.0
4 
0.4
5 
0.2
3 
0.1
2 
0.4
0 
HYAL1 
hyaluronoglucosaminidase 
1 404698 0.32 
0.00
295 
0.5
9 
0.4
2 
0.1
3 
0.1
0 
0.5
2 
-0.
25 
0.3
1 
0.1
1 
0.8
3 
0.4
4 
ADAMT
S5 
ADAM metallopeptidase 
with thrombospondin type 
1 motif, 5 
100522
952 0.32 
0.00
861 
0.1
7 
0.2
4 
0.7
2 
0.0
1 
0.4
9 
0.8
6 
0.3
9 
0.2
8 
-0.
38 
0.4
3 
LOC1005
18838 
uncharacterized 
LOC100518838 
100518
838 0.32 
0.00
524 
0.4
2 
0.3
3 
0.6
5 
0.7
1 
0.4
2 
0.1
0 
-0.
42 
0.3
2 
0.5
0 
0.1
7 
PAMR1 
peptidase domain 
containing associated with 
muscle regeneration 1 
100626
770 0.32 
0.00
321 
0.3
6 
-0.
01 
0.6
4 
0.4
2 
0.1
2 
0.6
9 
-0.
05 
0.7
1 
0.0
5 
0.2
6 
RFC4 
replication factor C 
(activator 1) 4, 37kDa 
100157
731 0.32 
0.00
105 
0.6
3 
0.0
1 
0.1
6 
0.3
6 
0.8
6 
0.2
6 
0.2
7 
0.2
6 
0.2
2 
0.1
4 
ADH5 
alcohol dehydrogenase 5 
(class III), chi polypeptide 
100513
555 0.32 
0.00
162 
0.4
1 
0.1
7 
0.3
3 
0.2
1 
0.4
0 
1.0
2 
0.2
5 
0.1
9 
0.1
5 
0.0
3 
LOC1005
18535 olfactory receptor 9G1-like 
100518
535 0.32 
0.00
934 
0.2
8 
0.6
7 
0.0
7 
-0.
06 
0.1
7 
-0.
29 
0.2
8 
0.4
2 
0.7
0 
0.9
3 
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LOC1001
55431 
beta-1,3-galactosyltransfer
ase 4-like 
100155
431 0.32 
0.00
088 
0.4
4 
0.0
1 
0.4
2 
0.2
7 
0.7
1 
0.2
4 
0.3
1 
0.1
0 
0.2
7 
0.3
9 
LOC1005
22516 glycerate kinase-like 
100522
516 0.32 
0.00
567 
0.7
1 
0.1
7 
0.0
7 
0.2
5 
0.8
3 
0.2
4 
0.0
4 
-0.
14 
0.4
5 
0.5
4 
LOC1005
24216 protein FAM101B-like 
100524
216 0.31 
0.00
082 
0.7
0 
0.4
0 
0.1
8 
0.2
7 
0.7
1 
0.1
4 
0.3
0 
-0.
08 
0.2
4 
0.3
0 
LOC1005
24459 
mitochondrial 
carnitine/acylcarnitine 
carrier protein-like 
100524
459 0.31 
0.00
852 
0.7
7 
-0.
02 
0.1
7 
-0.
04 
0.6
2 
0.8
9 
0.0
4 
0.0
2 
0.1
6 
0.5
3 
LOC1006
22182 
uncharacterized 
LOC100622182 
100622
182 0.31 
0.00
343 
0.3
2 
0.0
9 
0.0
8 
0.4
2 
0.8
9 
0.6
3 
-0.
05 
0.1
0 
0.5
7 
0.0
8 
ANO9 anoctamin 9 
100627
366 0.31 
0.00
056 
0.3
5 
0.2
5 
-0.
13 
0.1
0 
0.4
8 
0.3
4 
0.4
2 
0.2
0 
0.6
8 
0.4
1 
LOC1005
16303 
riboflavin transporter 
2-like 
100516
303 0.31 
0.00
760 
0.7
1 
0.4
8 
-0.
41 
0.4
0 
0.6
0 
0.3
8 
0.1
8 
-0.
12 
0.5
8 
0.3
1 
FRRS1 ferric-chelate reductase 1 
100151
766 0.31 
0.00
598 
0.5
8 
0.1
6 
-0.
17 
0.0
1 
0.3
1 
0.9
7 
0.2
2 
0.1
2 
0.3
1 
0.5
9 
LOC1006
23545 olfactory receptor 6C3-like 
100623
545 0.31 
0.00
212 
0.0
9 
0.2
1 
0.0
6 
0.2
8 
0.8
1 
0.2
8 
0.7
1 
0.2
2 
0.2
9 
0.1
5 
TXNIP 
thioredoxin interacting 
protein 733688 0.31 
0.00
009 
0.5
4 
0.2
0 
0.0
8 
0.0
7 
0.5
9 
0.4
2 
0.2
2 
0.2
8 
0.4
3 
0.2
7 
STYK1 
serine/threonine/tyrosine 
kinase 1 
100523
437 0.31 
0.00
950 
0.4
0 
0.2
2 
0.0
5 
0.1
4 
0.6
8 
0.9
2 
-0.
42 
0.2
5 
0.6
2 
0.2
4 
LOC1001
52988 
3-ketodihydrosphingosine 
reductase-like 
100152
988 0.31 
0.00
370 
0.5
0 
0.0
0 
-0.
11 
0.2
9 
0.4
7 
0.8
1 
0.2
6 
-0.
02 
0.6
5 
0.2
3 
LOC1005
25333 mu-crystallin homolog 
100525
333 0.31 
0.00
899 
0.1
8 
0.3
2 
0.1
2 
-0.
33 
0.3
7 
1.0
2 
0.4
5 
0.5
6 
0.2
3 
0.1
8 
LOC1005
24003 
taste receptor type 2 
member 41-like 
100524
003 0.31 
0.00
550 
0.2
8 
0.1
8 
0.1
6 
-0.
07 
0.7
8 
0.1
8 
0.6
6 
0.0
9 
0.1
5 
0.6
7 
USP32 
ubiquitin specific 
peptidase 32 
100512
129 0.31 
0.00
202 
0.7
1 
0.5
9 
0.1
0 
-0.
01 
0.1
1 
0.2
2 
0.3
6 
0.5
0 
0.4
2 
0.0
8 
CDKN2B 
cyclin-dependent kinase 
inhibitor 2B (p15, inhibits 
CDK4) 397227 0.31 
0.00
655 
0.8
6 
0.0
7 
0.2
1 
0.3
3 
0.7
4 
0.5
6 
0.0
2 
-0.
25 
0.3
2 
0.2
0 
LOC1001
55473 
dedicator of cytokinesis 
protein 1-like 
100155
473 0.31 
0.00
627 
0.8
6 
-0.
28 
0.1
9 
0.1
9 
0.5
5 
0.5
9 
0.1
1 
0.1
4 
0.1
3 
0.6
0 
VEGFA 
vascular endothelial 
growth factor A 397157 0.31 
0.00
432 
0.5
3 
0.6
8 
0.3
2 
0.2
5 
0.8
2 
0.3
3 
0.0
4 
-0.
15 
-0.
01 
0.2
7 
LOC1007
38721 neurexin-1-alpha-like 
100738
721 0.31 
0.00
937 
0.2
8 
0.3
9 
0.1
8 
-0.
18 
0.6
6 
0.7
9 
0.5
3 
0.0
4 
0.5
4 
-0.
15 
LOC1005
16823 consortin-like 
100516
823 0.31 
0.00
409 
0.3
8 
0.2
1 
0.4
3 
-0.
04 
0.1
0 
0.9
1 
0.0
7 
0.1
2 
0.6
4 
0.2
3 
SLC9A3
R1 
solute carrier family 9, 
subfamily A (NHE3, 
cation proton antiporter 3), 
member 3 regulator 1 
100233
201 0.31 
0.00
007 
0.5
4 
0.1
5 
0.1
6 
0.0
8 
0.3
8 
0.4
3 
0.3
1 
0.2
1 
0.4
9 
0.2
9 
LOC1005
21068 
olfactory receptor 
7E24-like 
100521
068 0.31 
0.00
255 
-0.
06 
0.6
5 
0.0
6 
0.4
7 
0.5
1 
-0.
16 
0.2
6 
0.4
8 
0.4
4 
0.4
1 
LOC1005
15293 
TOMM20-like protein 
1-like 
100515
293 0.30 
0.00
542 
0.6
3 
0.5
6 
0.3
2 
-0.
03 
0.2
0 
-0.
09 
0.6
8 
0.0
5 
0.5
5 
0.1
7 
SLC45A4 
solute carrier family 45, 
member 4 
100154
055 0.30 
0.00
440 
0.4
6 
0.2
7 
-0.
21 
0.2
2 
0.9
8 
0.3
6 
0.2
5 
0.1
4 
0.2
9 
0.3
0 
LOC1005
18272 
growth hormone-regulated 
TBC protein 1-like 
100518
272 0.30 
0.00
906 
0.4
2 
-0.
16 
-0.
22 
0.3
5 
0.8
1 
0.2
4 
0.5
1 
-0.
04 
0.7
7 
0.3
7 
LOC1006
21023 
uncharacterized protein 
KIAA0146-like 
100621
023 0.30 
0.00
382 
0.5
1 
-0.
10 
0.2
8 
0.2
2 
0.2
7 
0.9
0 
0.0
1 
0.2
3 
0.2
2 
0.5
0 
TMEM63
B 
transmembrane protein 
63B 
100151
872 0.30 
0.00
459 
0.7
8 
0.1
8 
0.5
6 
0.0
5 
0.4
5 
0.0
4 
0.4
1 
-0.
16 
0.1
1 
0.6
1 
LOC1005
20536 olfactory receptor 8H3-like 
100520
536 0.30 
0.00
245 
-0.
01 
0.0
3 
0.6
0 
0.4
7 
0.5
5 
0.3
9 
0.3
7 
-0.
20 
0.2
3 
0.6
0 
LOC1005
17243 
adipose most abundant 
gene transcript 2 
protein-like 
100517
243 0.30 
0.00
667 
0.0
9 
0.3
0 
0.5
6 
0.0
7 
0.6
1 
0.8
8 
0.0
1 
0.2
0 
0.0
3 
0.2
8 
LOC1005
20493 
uncharacterized 
LOC100520493 
100520
493 0.30 
0.00
217 
0.7
5 
0.4
6 
0.4
3 
0.0
5 
-0.
12 
0.0
7 
0.1
5 
0.3
4 
0.3
6 
0.5
3 
LOC1005
22085 RELT-like protein 1-like 
100522
085 0.30 
0.00
023 
0.3
5 
0.4
3 
0.1
2 
0.2
0 
0.5
6 
0.5
3 
0.1
0 
0.0
9 
0.2
6 
0.3
6 
COL4A5 collagen, type IV, alpha 5 
100519
180 0.30 
0.00
088 
0.6
0 
0.2
5 
0.0
1 
0.2
6 
0.4
8 
0.5
2 
0.2
0 
0.1
3 
0.1
5 
0.4
2 
GPR39 
G protein-coupled receptor 
39 
100158
236 0.30 
0.00
143 
0.4
8 
0.5
7 
-0.
04 
0.3
4 
0.2
6 
0.6
0 
0.0
6 
0.4
1 
0.0
7 
0.2
6 
KIAA167
1 
Uncharacterized protein 
KIAA1671 
100154
475 0.30 
0.00
029 
0.2
5 
0.2
9 
0.2
6 
0.2
2 
0.6
7 
0.2
9 
0.2
2 
0.1
3 
0.5
7 
0.0
9 
BCORL1 BCL6 corepressor-like 1 
100525
271 0.30 
0.00
487 
0.6
4 
-0.
25 
0.4
5 
0.5
4 
0.3
1 
0.2
3 
0.3
2 
-0.
05 
0.5
0 
0.3
2 
ABCD3 
ATP-binding cassette, 
sub-family D (ALD), 
100626
343 0.30 
0.00
260 
0.6
3 
0.0
4 
0.4
7 
-0.
03 
0.4
3 
0.6
8 
0.0
0 
0.0
5 
0.2
1 
0.4
9 
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member 3 
LHFPL2 
lipoma HMGIC fusion 
partner-like 2 
100523
234 0.30 
0.00
081 
0.3
3 
0.2
9 
0.4
3 
0.4
6 
0.7
3 
0.2
6 
0.2
3 
0.0
2 
-0.
04 
0.2
7 
IGSF3 
immunoglobulin 
superfamily, member 3 
100512
602 0.30 
0.00
095 
0.5
9 
0.4
2 
0.2
8 
0.2
7 
0.2
1 
0.4
7 
0.0
5 
0.1
0 
0.1
1 
0.4
6 
LOC1006
21650 protein furry homolog 
100621
650 0.29 
0.00
307 
0.5
2 
0.2
0 
0.1
8 
0.2
2 
0.8
3 
0.3
7 
-0.
18 
0.0
4 
0.3
6 
0.4
0 
LOC1006
24014 
SPRY domain-containing 
SOCS box protein 4-like 
100624
014 0.29 
0.00
661 
0.3
4 
0.2
6 
0.0
3 
0.7
2 
0.9
0 
0.1
2 
0.1
8 
-0.
05 
0.1
5 
0.3
0 
LOC1001
57757 
serine/threonine-protein 
kinase Sgk2-like 
100157
757 0.29 
0.00
826 
0.3
1 
-0.
08 
0.2
5 
-0.
10 
0.3
8 
0.8
0 
0.1
3 
0.0
1 
0.3
9 
0.8
5 
EPHX2 
epoxide hydrolase 2, 
cytoplasmic 414425 0.29 
0.00
200 
0.1
9 
-0.
22 
0.2
8 
0.3
5 
0.4
9 
0.7
5 
0.2
3 
0.3
2 
0.2
9 
0.2
5 
ITPK1 
inositol-tetrakisphosphate 
1-kinase 
100152
339 0.29 
0.00
193 
0.4
8 
0.1
5 
0.2
2 
0.3
5 
0.6
7 
0.3
3 
0.4
9 
-0.
09 
-0.
13 
0.4
5 
LOC1005
13365 
microsomal glutathione 
S-transferase 2-like 
100513
365 0.29 
0.00
659 
0.4
8 
0.4
7 
-0.
20 
0.1
1 
-0.
03 
0.9
5 
0.2
7 
0.2
1 
0.4
0 
0.2
2 
LOC1001
53684 
uncharacterized protein 
C14orf43-like 
100153
684 0.29 
0.00
139 
0.8
6 
0.3
8 
0.1
7 
0.0
5 
0.2
1 
0.2
2 
0.2
8 
0.3
4 
0.3
0 
0.0
9 
BDH1 
3-hydroxybutyrate 
dehydrogenase, type 1 
100155
725 0.29 
0.00
896 
0.4
4 
-0.
13 
-0.
12 
0.1
9 
0.6
2 
0.8
1 
0.4
2 
-0.
12 
0.5
9 
0.1
9 
CPT1A 
carnitine 
palmitoyltransferase 1A 
(liver) 399527 0.29 
0.00
497 
0.2
7 
0.4
5 
0.4
7 
0.4
6 
0.4
8 
-0.
51 
0.3
7 
0.3
3 
0.2
5 
0.2
8 
CLDN3 claudin 3 431781 0.28 
0.00
383 
0.7
9 
-0.
03 
0.1
2 
0.1
5 
0.5
4 
0.2
0 
0.2
0 
-0.
08 
0.5
9 
0.3
6 
LOC1005
13308 
transmembrane 4 L6 
family member 5-like 
100513
308 0.28 
0.00
849 
0.5
5 
0.2
1 
-0.
19 
0.3
2 
0.7
6 
0.3
7 
0.2
9 
-0.
13 
0.2
7 
0.3
8 
LOC1005
12228 
uncharacterized 
LOC100512228 
100512
228 0.28 
0.00
468 
0.6
6 
0.3
2 
0.0
4 
0.4
0 
0.2
8 
-0.
26 
0.3
0 
0.2
7 
0.5
6 
0.2
6 
LOC1005
15771 
transmembrane protein 
205-like 
100515
771 0.28 
0.00
819 
-0.
03 
-0.
04 
0.4
0 
-0.
15 
0.7
9 
0.6
1 
0.2
8 
0.2
4 
0.4
9 
0.2
0 
LOC1007
36625 
protein ETHE1, 
mitochondrial-like 
100736
625 0.28 
0.00
283 
0.1
7 
-0.
07 
0.3
3 
0.0
8 
0.5
4 
0.8
0 
0.0
5 
0.1
9 
0.2
3 
0.4
7 
LOC1005
16533 
uncharacterized 
LOC100516533 
100516
533 0.28 
0.00
067 
0.2
7 
0.2
2 
0.6
6 
0.4
2 
-0.
07 
0.3
4 
0.2
3 
0.1
4 
0.2
9 
0.2
8 
CAMK1
D 
calcium/calmodulin-depen
dent protein kinase ID 
100511
150 0.28 
0.00
232 
0.5
5 
0.3
0 
0.3
3 
-0.
25 
0.1
1 
0.3
9 
0.2
5 
0.2
4 
0.6
1 
0.2
4 
LOC1005
11570 protein FAM46B-like 
100511
570 0.28 
0.00
751 
0.2
7 
0.1
7 
-0.
13 
0.2
0 
0.7
1 
-0.
02 
0.6
7 
0.2
3 
0.1
7 
0.5
0 
MYH1 
myosin, heavy chain 1, 
skeletal muscle, adult 
100125
538 0.28 
0.00
949 
0.0
2 
0.4
4 
0.5
1 
0.4
2 
0.2
9 
-0.
03 
0.7
8 
0.1
9 
0.3
6 
-0.
21 
LOC1001
57003 protein amnionless-like 
100157
003 0.28 
0.00
498 
0.7
7 
0.1
4 
0.1
0 
0.1
6 
0.7
0 
0.2
7 
0.0
1 
0.0
3 
0.3
0 
0.3
0 
LOC1005
24283 
calcium-binding 
mitochondrial carrier 
protein Aralar1-like 
100524
283 0.28 
0.00
868 
0.3
2 
-0.
27 
0.3
5 
0.1
8 
0.6
0 
0.3
0 
0.7
1 
-0.
10 
0.0
8 
0.5
8 
SYBU 
syntabulin 
(syntaxin-interacting) 
100157
483 0.28 
0.00
987 
0.4
5 
0.1
6 
0.0
7 
0.0
2 
0.2
2 
0.5
4 
-0.
06 
0.2
5 
0.9
5 
0.1
6 
SLC39A1
4 
solute carrier family 39 
(zinc transporter), member 
14 
100152
468 0.28 
0.00
029 
0.6
2 
0.2
3 
0.2
2 
0.2
3 
0.3
6 
0.3
0 
0.0
8 
0.0
2 
0.3
9 
0.2
9 
INPP5F 
inositol 
polyphosphate-5-phosphat
ase F 
100144
587 0.27 
0.00
321 
0.3
7 
0.2
4 
-0.
15 
-0.
01 
0.0
2 
0.5
3 
0.3
1 
0.5
9 
0.5
2 
0.3
3 
NGFRAP
1 
nerve growth factor 
receptor (TNFRSF16) 
associated protein 1 
100513
514 0.27 
0.00
860 
0.3
7 
0.2
7 
0.4
6 
-0.
18 
0.9
0 
0.1
5 
0.1
4 
0.2
5 
0.0
8 
0.3
0 
LOC1005
11910 coronin-2A-like 
100511
910 0.27 
0.00
268 
0.6
0 
-0.
10 
0.3
4 
0.3
3 
-0.
09 
0.3
9 
0.2
6 
0.2
0 
0.6
1 
0.2
1 
MAGI1 
membrane associated 
guanylate kinase, WW and 
PDZ domain containing 1 
100520
932 0.27 
0.00
034 
0.3
8 
0.0
7 
0.3
7 
0.3
4 
0.3
2 
0.0
5 
0.2
4 
0.2
4 
0.3
1 
0.4
2 
RHOF 
ras homolog family 
member F (in filopodia) 
100144
500 0.27 
0.00
368 
-0.
14 
-0.
11 
0.2
8 
0.4
0 
0.2
8 
0.2
1 
0.3
4 
0.3
0 
0.7
6 
0.4
2 
PALM paralemmin 654410 0.27 
0.00
522 
0.5
2 
0.4
1 
0.1
5 
-0.
01 
0.6
7 
0.3
3 
0.4
6 
0.0
1 
-0.
09 
0.2
8 
CDX2 caudal type homeobox 2 
100127
132 0.27 
0.00
072 
0.7
1 
0.1
1 
0.3
0 
0.1
3 
0.1
5 
0.1
8 
0.4
0 
0.0
7 
0.3
1 
0.3
7 
HS3ST2 
heparan sulfate 
(glucosamine) 
3-O-sulfotransferase 2 
100522
426 0.27 
0.00
273 
0.3
5 
-0.
03 
0.0
9 
0.3
7 
0.5
6 
0.3
2 
0.3
6 
0.4
1 
0.2
7 
0.0
4 
LOC1005
18697 nostrin-like 
100518
697 0.27 
0.00
716 
0.2
3 
0.0
4 
0.5
0 
0.2
1 
-0.
28 
0.4
3 
0.2
4 
0.0
9 
0.6
6 
0.5
8 
RNF157 ring finger protein 157 
100522
340 0.27 
0.00
427 
0.3
5 
0.1
3 
0.2
8 
-0.
10 
0.4
9 
0.4
8 
0.1
2 
-0.
07 
0.6
3 
0.4
0 
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LOC1005
20809 
uncharacterized 
LOC100520809 
100520
809 0.27 
0.00
042 
0.4
3 
0.2
5 
0.1
3 
0.1
5 
0.5
1 
0.2
3 
0.2
1 
-0.
01 
0.5
1 
0.3
1 
ARHGAP
42 
Rho GTPase activating 
protein 42 
100519
555 0.27 
0.00
617 
0.4
6 
-0.
03 
0.0
5 
0.1
0 
0.4
3 
0.7
7 
-0.
15 
0.1
8 
0.5
0 
0.3
9 
LOC1006
26073 
major facilitator 
superfamily 
domain-containing protein 
9-like 
100626
073 0.27 
0.00
179 
0.5
1 
0.1
7 
0.1
6 
0.1
2 
0.6
3 
0.1
7 
0.4
9 
0.2
1 
0.0
7 
0.1
7 
LOC1005
21277 
receptor-type 
tyrosine-protein 
phosphatase F-like 
100521
277 0.27 
0.00
654 
0.8
2 
0.3
5 
0.2
4 
0.0
0 
0.5
0 
-0.
08 
0.3
0 
-0.
16 
0.4
1 
0.3
0 
LOC1005
24521 
keratin-like protein 
KRT222-like 
100524
521 0.27 
0.00
904 
0.2
3 
0.2
4 
0.0
4 
0.2
8 
0.5
9 
0.2
0 
0.1
1 
-0.
07 
0.8
2 
0.2
4 
LOC1005
15686 
transmembrane protein 
92-like 
100515
686 0.27 
0.00
057 
0.2
9 
0.1
3 
0.2
1 
0.3
6 
0.5
6 
0.4
1 
0.1
1 
-0.
03 
0.3
2 
0.3
1 
ADAM15 
ADAM metallopeptidase 
domain 15 
100153
483 0.27 
0.00
519 
0.6
8 
0.4
7 
0.1
6 
0.1
5 
0.5
8 
-0.
03 
0.4
1 
-0.
12 
0.2
3 
0.1
5 
LOC1006
24870 
myeloma-overexpressed 
gene 2 protein homolog 
100624
870 0.27 
0.00
055 
0.3
4 
0.2
8 
0.1
9 
0.3
0 
0.4
2 
0.1
5 
0.0
3 
0.3
3 
0.5
6 
0.0
7 
LOC1005
22569 
complement C1q tumor 
necrosis factor-related 
protein 9A-like 
100522
569 0.27 
0.00
621 
0.2
9 
0.1
8 
0.0
4 
0.4
6 
0.4
9 
-0.
04 
0.6
8 
0.2
5 
-0.
01 
0.3
2 
LOC1006
22619 liprin-beta-2-like 
100622
619 0.27 
0.00
605 
0.5
4 
0.1
4 
-0.
03 
0.2
3 
0.4
8 
0.1
5 
0.6
4 
-0.
15 
0.3
4 
0.3
3 
MLXIPL 
MLX interacting 
protein-like 
100170
769 0.27 
0.00
765 
-0.
01 
0.5
6 
0.5
7 
0.1
6 
0.4
6 
0.3
7 
0.1
3 
-0.
08 
0.4
8 
0.0
3 
MYOG 
myogenin (myogenic 
factor 4) 497618 0.27 
0.00
849 
0.3
5 
0.0
3 
-0.
21 
0.4
9 
0.5
1 
0.2
4 
0.4
5 
0.1
6 
0.5
8 
0.0
6 
KLF4 Kruppel-like factor 4 (gut) 595111 0.27 
0.00
123 
0.5
4 
0.3
4 
0.4
2 
0.0
7 
0.1
8 
0.0
9 
0.3
1 
-0.
11 
0.5
3 
0.2
8 
FRY 
furry homolog 
(Drosophila) 
100155
799 0.26 
0.00
803 
0.2
7 
0.2
0 
0.0
1 
0.1
8 
0.8
8 
0.3
6 
-0.
28 
0.2
5 
0.4
0 
0.3
9 
LOC1005
24254 
NADH-cytochrome b5 
reductase 3-like 
100524
254 0.26 
0.00
396 
0.4
9 
-0.
02 
0.2
3 
0.2
0 
0.5
8 
0.6
5 
0.0
5 
-0.
09 
0.3
5 
0.2
0 
LOC1005
22555 
abhydrolase 
domain-containing protein 
FAM108C1-like 
100522
555 0.26 
0.00
248 
0.6
4 
0.2
8 
0.1
3 
0.2
1 
0.6
4 
0.3
2 
0.1
1 
-0.
05 
0.1
4 
0.1
9 
LOC1005
22154 
uncharacterized 
LOC100522154 
100522
154 0.26 
0.00
246 
0.5
6 
0.2
3 
0.0
4 
0.2
2 
0.2
7 
0.2
5 
0.0
4 
0.1
8 
0.6
0 
0.2
3 
LOC1005
12084 
TBC1 domain family 
member 2A-like 
100512
084 0.26 
0.00
471 
0.6
8 
0.4
3 
-0.
08 
0.1
4 
0.0
7 
0.3
5 
0.0
1 
0.4
5 
0.5
1 
0.0
6 
DNAH1 
dynein, axonemal, heavy 
chain 1 
100156
016 0.26 
0.00
828 
-0.
01 
0.1
7 
-0.
08 
0.6
1 
0.5
5 
0.0
0 
0.3
9 
0.1
8 
0.3
2 
0.4
7 
LOC1007
36656 
calcium/calmodulin-depen
dent protein kinase type 
1D-like 
100736
656 0.26 
0.00
722 
0.3
1 
0.1
7 
0.0
1 
-0.
10 
0.4
7 
0.4
9 
0.5
8 
-0.
15 
0.6
1 
0.2
0 
LOC1005
22322 
transmembrane protein 
82-like 
100522
322 0.26 
0.00
762 
0.1
2 
0.1
3 
0.3
4 
0.3
9 
0.4
9 
0.0
1 
0.0
7 
-0.
06 
0.5
0 
0.5
9 
RBFOX2 
RNA binding protein, 
fox-1 homolog (C. 
elegans) 2 
100513
594 0.26 
0.00
839 
0.4
2 
0.1
5 
0.2
9 
0.0
9 
0.6
0 
0.7
6 
-0.
02 
-0.
15 
0.2
2 
0.2
2 
LOC1007
38902 interleukin-17D-like 
100738
902 0.26 
0.00
768 
0.0
7 
0.1
9 
0.5
8 
0.3
1 
0.3
3 
0.4
1 
-0.
10 
0.0
4 
0.5
8 
0.1
6 
LOC1006
27497 
FH2 domain-containing 
protein 1-like 
100627
497 0.26 
0.00
394 
0.2
9 
0.3
8 
0.2
9 
0.1
7 
0.6
1 
-0.
14 
0.1
6 
0.1
3 
0.3
2 
0.3
6 
PPP2R5D 
protein phosphatase 2, 
regulatory subunit B', delta 
100134
967 0.25 
0.00
054 
0.3
4 
0.2
2 
0.1
6 
0.1
7 
0.1
5 
0.5
5 
0.3
3 
0.1
1 
0.2
3 
0.2
8 
THRA 
thyroid hormone receptor, 
alpha 397387 0.25 
0.00
371 
0.5
6 
0.1
4 
0.0
5 
0.0
3 
0.3
8 
0.4
5 
0.2
5 
-0.
17 
0.5
5 
0.3
0 
LOC1006
21118 
abhydrolase 
domain-containing protein 
14B-like 
100621
118 0.25 
0.00
410 
0.4
3 
0.0
5 
-0.
03 
0.0
1 
0.7
1 
0.3
8 
0.1
5 
0.0
7 
0.4
4 
0.3
4 
LOC1005
12279 
BTB/POZ 
domain-containing protein 
KCTD17-like 
100512
279 0.25 
0.00
396 
0.3
5 
0.1
7 
0.4
2 
0.0
8 
0.4
8 
0.3
1 
0.5
1 
-0.
12 
0.0
9 
0.2
5 
ARHGEF
19 
Rho guanine nucleotide 
exchange factor (GEF) 19 
100521
628 0.25 
0.00
808 
0.1
3 
0.4
3 
-0.
11 
0.1
8 
0.6
3 
-0.
03 
0.1
7 
0.2
3 
0.2
9 
0.6
1 
LOC1006
23005 
uncharacterized protein 
C14orf43-like 
100623
005 0.25 
0.00
812 
0.8
1 
0.4
8 
0.0
0 
0.2
3 
0.4
6 
0.2
5 
0.1
8 
0.0
0 
0.2
3 
-0.
09 
LOC1001
51957 
par-6 partitioning defective 
6 homolog beta 
100151
957 0.25 
0.00
833 
0.5
7 
0.5
2 
-0.
01 
0.3
1 
-0.
03 
0.4
1 
0.0
6 
0.6
1 
0.2
4 
-0.
15 
TDRD7 tudor domain containing 7 
100152
652 0.25 
0.00
982 
0.4
8 
0.1
3 
0.0
6 
-0.
19 
0.4
9 
0.6
4 
0.0
4 
0.0
6 
0.6
5 
0.1
8 
LOC1005
18983 
rap guanine nucleotide 
exchange factor 5-like 
100518
983 0.25 
0.00
464 
0.4
3 
0.2
7 
-0.
15 
0.1
0 
0.1
1 
0.7
2 
0.1
5 
0.2
2 
0.4
6 
0.2
1 
MAST2 
microtubule associated 
serine/threonine kinase 2 
100512
112 0.25 
0.00
403 
0.3
1 
0.7
1 
-0.
10 
0.0
2 
0.3
8 
0.3
5 
0.2
5 
0.3
6 
0.2
4 
0.0
0 
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LOC1005
18575 
coiled-coil 
domain-containing protein 
56-like 
100518
575 0.25 
0.00
063 
0.2
1 
0.1
7 
-0.
06 
0.3
0 
0.2
7 
0.5
7 
0.1
4 
0.2
7 
0.3
3 
0.3
1 
LOC1005
17809 
uncharacterized 
LOC100517809 
100517
809 0.25 
0.00
945 
0.3
1 
0.0
8 
0.1
3 
0.4
8 
0.6
8 
0.1
9 
0.4
8 
-0.
22 
0.2
5 
0.1
3 
LUZP1 leucine zipper protein 1 
100620
499 0.25 
0.00
273 
0.5
0 
0.2
2 
0.0
9 
0.1
2 
0.6
0 
0.3
9 
0.2
0 
-0.
15 
0.2
0 
0.3
3 
LOC1005
24975 
olfactory receptor 
10H1-like 
100524
975 0.25 
0.00
524 
0.2
2 
0.2
9 
-0.
15 
0.5
6 
0.2
8 
0.0
1 
0.4
1 
0.2
9 
0.4
3 
0.1
4 
CPAMD8 
C3 and PZP-like, 
alpha-2-macroglobulin 
domain containing 8 
100515
128 0.25 
0.00
747 
0.3
9 
0.2
7 
-0.
20 
0.3
9 
0.4
9 
0.1
0 
0.0
2 
0.3
4 
0.3
6 
0.3
3 
LNX2 ligand of numb-protein X 2 
100510
925 0.25 
0.00
018 
0.4
6 
0.2
3 
0.1
6 
0.2
2 
0.1
9 
0.3
3 
0.2
6 
0.0
8 
0.3
5 
0.1
8 
DGAT 
diacylglycerol 
acyltransferase 397118 0.25 
0.00
743 
0.3
3 
-0.
06 
0.1
2 
0.1
3 
0.6
2 
0.5
5 
0.2
5 
-0.
23 
0.3
3 
0.4
3 
LOC1006
25977 
dynein intermediate chain 
1, axonemal-like 
100625
977 0.25 
0.00
462 
0.2
3 
0.3
1 
0.2
9 
0.5
3 
0.4
2 
-0.
22 
0.2
2 
0.0
9 
0.3
2 
0.2
5 
LRRFIP2 
leucine rich repeat (in 
FLII) interacting protein 2 
100626
059 0.24 
0.00
200 
0.1
7 
-0.
04 
0.0
1 
0.2
3 
0.4
7 
0.5
4 
0.2
1 
0.0
9 
0.4
4 
0.3
3 
MGLL monoglyceride lipase 
100233
193 0.24 
0.00
252 
0.2
9 
-0.
10 
0.3
7 
0.2
7 
0.2
1 
0.4
9 
0.1
6 
0.0
5 
0.1
6 
0.5
3 
GJD3 
gap junction protein, delta 
3, 31.9kDa 
100048
959 0.24 
0.00
507 
0.3
9 
0.2
3 
0.3
3 
0.1
7 
0.6
8 
0.1
8 
0.1
2 
-0.
04 
-0.
05 
0.4
2 
MYO1E myosin IE 
100154
204 0.24 
0.00
053 
0.5
1 
0.0
7 
0.0
7 
0.3
1 
0.3
0 
0.1
6 
0.2
7 
0.0
9 
0.3
1 
0.3
3 
MICAL2 
microtubule associated 
monoxygenase, calponin 
and LIM domain 
containing 2 
100519
075 0.24 
0.00
316 
0.5
0 
0.2
4 
0.0
1 
0.1
1 
0.6
8 
0.3
0 
0.2
3 
-0.
08 
0.1
9 
0.2
5 
ANKRD4
6 ankyrin repeat domain 46 
100152
758 0.24 
0.00
359 
0.2
8 
0.3
9 
-0.
04 
0.2
3 
0.3
2 
0.6
6 
0.0
0 
0.1
0 
0.3
8 
0.0
9 
LOC1005
18928 
putative cleavage and 
polyadenylation specificity 
factor subunit 4-like 
protein-like 
100518
928 0.24 
0.00
954 
0.1
2 
0.5
4 
0.1
5 
0.6
7 
0.1
4 
0.0
5 
0.2
7 
0.0
4 
0.3
7 
0.0
7 
FOXO3 forkhead box O3 733621 0.24 
0.00
075 
0.2
6 
0.0
9 
0.0
3 
0.2
3 
0.4
7 
0.4
9 
0.1
8 
0.3
2 
0.2
5 
0.0
9 
CYP17A1 cytochrome P450 17A1 403330 0.24 
0.00
954 
0.2
5 
0.0
8 
0.0
4 
0.5
2 
0.2
5 
0.3
9 
-0.
12 
0.0
0 
0.5
4 
0.4
6 
LOC1006
25066 zinc finger protein 500-like 
100625
066 0.24 
0.00
905 
0.1
1 
0.1
1 
0.5
3 
0.2
7 
0.5
1 
-0.
23 
0.2
3 
0.3
7 
0.2
1 
0.3
0 
LOC1001
54044 bcl-2-like protein 2-like 
100154
044 0.24 
0.00
899 
0.1
7 
0.4
1 
0.3
9 
0.1
1 
0.5
7 
0.3
9 
0.1
5 
-0.
18 
0.2
1 
0.2
0 
SMAD6 SMAD family member 6 
100152
069 0.24 
0.00
372 
0.6
6 
0.2
4 
0.1
9 
0.0
6 
0.3
4 
0.2
6 
0.2
6 
0.1
1 
0.1
1 
0.1
7 
ZNF605 zinc finger protein 605 
100155
634 0.24 
0.00
576 
0.2
3 
0.2
8 
0.3
0 
-0.
05 
0.3
4 
0.0
6 
0.4
1 
0.0
3 
0.5
7 
0.2
2 
LOC1001
56267 CLRN3 protein 
100156
267 0.24 
0.00
522 
0.0
2 
0.1
5 
-0.
20 
0.3
0 
0.3
6 
0.4
5 
0.2
0 
0.2
1 
0.6
7 
0.2
3 
LOC1001
56669 protein FAM89A-like 
100156
669 0.24 
0.00
192 
0.3
5 
0.5
0 
0.1
6 
-0.
02 
0.2
4 
0.1
4 
0.2
5 
0.2
8 
0.3
3 
0.1
7 
LOC1001
52820 
UPF0235 protein 
C15orf40 homolog 
100152
820 0.24 
0.00
516 
0.3
9 
0.4
1 
0.2
4 
-0.
15 
0.3
4 
0.4
1 
0.1
2 
0.1
5 
0.1
9 
0.2
6 
LOC1005
16293 
phosphoinositide 3-kinase 
regulatory subunit 4-like 
100516
293 0.24 
0.00
162 
0.4
0 
-0.
02 
0.1
7 
0.0
4 
0.4
7 
0.0
6 
0.2
5 
0.1
8 
0.4
0 
0.4
2 
AKAP12 
A kinase (PRKA) anchor 
protein 12 
100152
595 0.24 
0.00
531 
0.3
0 
0.1
2 
-0.
09 
-0.
03 
0.2
9 
0.7
0 
0.3
6 
0.1
2 
0.3
3 
0.2
7 
RMND5
A 
required for meiotic 
nuclear division 5 homolog 
A (S. cerevisiae) 
100516
072 0.24 
0.00
529 
0.4
4 
0.1
4 
0.1
7 
-0.
10 
0.2
1 
0.6
7 
0.1
2 
0.2
1 
0.4
8 
0.0
1 
LOC1005
25411 nesprin-3-like 
100525
411 0.23 
0.00
252 
0.3
3 
0.0
2 
0.2
6 
0.4
2 
0.4
1 
0.1
0 
0.2
5 
-0.
01 
0.3
2 
0.2
5 
ACAP2 
ArfGAP with coiled-coil, 
ankyrin repeat and PH 
domains 2 
100627
914 0.23 
0.00
206 
0.3
4 
0.1
2 
0.2
1 
0.2
4 
0.0
2 
0.6
2 
0.0
7 
0.3
8 
0.2
5 
0.1
0 
LOC1006
21028 
RING finger protein 
223-like 
100621
028 0.23 
0.00
487 
0.5
3 
0.2
0 
0.0
6 
0.5
8 
0.4
4 
-0.
03 
0.0
7 
0.1
0 
0.2
2 
0.1
6 
LOC1001
53977 
Glutamate-cysteine ligase, 
modifier subunit 
100153
977 0.23 
0.00
543 
0.2
6 
0.1
1 
0.6
4 
0.3
2 
-0.
18 
0.0
5 
0.2
8 
0.2
1 
0.4
0 
0.2
5 
LOC1005
16614 plasmolipin-like 
100516
614 0.23 
0.00
454 
0.5
7 
0.2
6 
0.1
4 
0.1
3 
0.2
7 
-0.
15 
0.3
1 
0.0
0 
0.3
5 
0.4
6 
LOC1005
12419 
lipid phosphate 
phosphohydrolase 3-like 
100512
419 0.23 
0.00
696 
0.6
4 
0.1
7 
0.5
0 
-0.
22 
0.2
2 
0.3
2 
0.3
8 
0.0
5 
0.0
5 
0.2
1 
ZSWIM6 
zinc finger, SWIM-type 
containing 6 
100620
165 0.23 
0.00
142 
0.4
0 
0.1
4 
0.0
4 
0.1
6 
0.5
9 
0.0
6 
0.2
4 
0.0
9 
0.2
8 
0.3
0 
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LOC1005
26142 
uncharacterized 
LOC100526142 
100526
142 0.23 
0.00
590 
0.2
9 
0.0
9 
-0.
07 
0.1
8 
0.2
9 
0.1
8 
0.4
3 
0.0
7 
0.3
9 
0.4
5 
KREME
N1 
kringle containing 
transmembrane protein 1 
100154
052 0.23 
0.00
987 
0.6
4 
0.0
7 
0.2
4 
0.3
3 
0.5
3 
-0.
07 
0.1
0 
-0.
14 
0.4
5 
0.1
5 
GLTP glycolipid transfer protein 396765 0.23 
0.00
180 
0.2
0 
0.3
7 
0.1
6 
0.1
3 
0.5
0 
0.5
0 
-0.
09 
0.1
6 
0.1
9 
0.1
7 
KCNH6 
potassium voltage-gated 
channel, subfamily H 
(eag-related), member 6 
100514
537 0.23 
0.00
778 
0.1
0 
-0.
05 
0.4
3 
0.3
2 
0.2
8 
-0.
07 
0.2
5 
0.3
5 
0.3
1 
0.4
0 
LOC1005
22542 
uncharacterized 
LOC100522542 
100522
542 0.23 
0.00
600 
-0.
03 
0.4
1 
-0.
04 
0.3
9 
0.6
0 
0.0
5 
0.1
9 
0.2
0 
0.2
3 
0.2
9 
ASXL3 
additional sex combs like 3 
(Drosophila) 
100518
495 0.23 
0.00
869 
0.2
4 
0.3
9 
0.2
9 
0.5
7 
0.4
7 
0.0
4 
-0.
02 
0.1
4 
0.2
5 
-0.
10 
LOC1005
17478 
putative hydroxypyruvate 
isomerase-like 
100517
478 0.23 
0.00
788 
0.2
9 
-0.
12 
0.3
2 
0.3
0 
0.6
8 
0.3
1 
0.0
4 
0.0
7 
0.1
8 
0.2
0 
LMNA lamin A/C 
100126
859 0.23 
0.00
600 
0.5
2 
-0.
01 
0.2
2 
0.3
9 
0.5
6 
0.1
6 
-0.
09 
-0.
05 
0.2
2 
0.3
5 
TMEM17
1 
transmembrane protein 
171 
100514
277 0.23 
0.00
660 
0.1
1 
0.4
3 
0.0
0 
0.3
5 
0.2
8 
0.7
0 
-0.
17 
0.2
0 
0.2
3 
0.1
4 
SERINC2 serine incorporator 2 
100626
004 0.23 
0.00
148 
0.3
3 
0.0
8 
0.2
7 
0.1
8 
0.2
4 
0.2
5 
0.3
1 
-0.
16 
0.3
9 
0.3
7 
LOC1005
23918 
LIM domain only protein 
7-like 
100523
918 0.22 
0.00
979 
0.1
2 
0.0
5 
0.2
2 
0.5
4 
-0.
01 
-0.
17 
0.2
3 
0.5
6 
0.5
2 
0.1
8 
MBOAT1 
membrane bound 
O-acyltransferase domain 
containing 1 
100152
017 0.22 
0.00
020 
0.1
1 
0.0
8 
0.1
5 
0.2
5 
0.3
2 
0.2
1 
0.1
9 
0.2
6 
0.3
1 
0.3
6 
LOC1005
25150 CD44 antigen-like 
100525
150 0.22 
0.00
143 
0.2
4 
0.2
2 
0.2
1 
-0.
08 
0.3
3 
0.5
4 
0.3
4 
0.2
0 
0.0
6 
0.1
7 
HSD17B8 
hydroxysteroid (17-beta) 
dehydrogenase 8 
100154
372 0.22 
0.00
671 
0.0
5 
-0.
14 
0.2
5 
0.0
6 
0.5
6 
0.4
5 
0.3
4 
0.1
0 
0.2
8 
0.2
7 
LOC1006
21404 
protein unc-13 homolog 
B-like 
100621
404 0.22 
0.00
508 
-0.
07 
0.0
3 
0.2
4 
0.0
9 
0.4
4 
0.3
3 
0.0
1 
0.2
6 
0.5
6 
0.3
3 
LOC1005
15636 
2-oxoglutarate 
dehydrogenase, 
mitochondrial-like 
100515
636 0.22 
0.00
636 
0.4
9 
-0.
06 
-0.
07 
0.0
4 
0.4
5 
0.1
8 
0.3
3 
0.0
3 
0.3
4 
0.4
8 
COX10 
COX10 homolog, 
cytochrome c oxidase 
assembly protein, heme A: 
farnesyltransferase (yeast) 
100521
863 0.22 
0.00
063 
0.2
0 
0.0
8 
0.1
5 
0.2
4 
0.2
9 
0.2
1 
0.2
0 
0.4
3 
0.1
5 
0.2
7 
LOC1007
37883 
UPF0366 protein 
C11orf67 homolog 
100737
883 0.22 
0.00
561 
0.3
8 
0.1
5 
0.1
9 
0.2
1 
0.2
0 
0.4
6 
-0.
01 
0.0
7 
0.1
3 
0.4
4 
FAM107
A 
family with sequence 
similarity 107, member A 
100516
512 0.22 
0.00
237 
0.4
1 
0.2
1 
0.3
3 
0.2
7 
0.1
0 
0.3
3 
0.1
7 
0.1
5 
0.0
3 
0.2
3 
ZNF410 zinc finger protein 410 
100512
059 0.22 
0.00
205 
0.2
6 
0.3
2 
0.0
7 
0.3
8 
0.0
7 
0.3
9 
0.1
6 
0.1
5 
0.3
5 
0.0
6 
LOC1007
39329 
uncharacterized 
LOC100739329 
100739
329 0.22 
0.00
959 
0.5
9 
0.2
1 
0.1
8 
0.3
1 
0.3
2 
0.4
7 
0.1
7 
-0.
28 
0.0
4 
0.1
8 
LOC1006
25487 
lon protease homolog 2, 
peroxisomal-like 
100625
487 0.22 
0.00
136 
0.4
3 
0.2
8 
0.2
0 
0.1
0 
0.0
0 
0.3
0 
0.1
5 
0.2
7 
0.4
0 
0.0
8 
BCL2L13 
BCL2-like 13 (apoptosis 
facilitator) 
100517
587 0.22 
0.00
847 
0.3
2 
0.3
4 
0.1
9 
-0.
13 
0.1
5 
0.7
3 
0.0
1 
0.1
9 
0.2
5 
0.1
3 
OSBPL10 
oxysterol binding 
protein-like 10 
100526
184 0.22 
0.00
396 
0.1
1 
0.0
3 
0.1
8 
0.1
1 
0.5
4 
0.1
0 
0.4
7 
0.0
8 
0.1
6 
0.3
9 
TXNRD1 thioredoxin reductase 1 396681 0.22 
0.00
020 
0.2
7 
0.1
8 
0.2
9 
0.3
7 
0.0
7 
0.1
8 
0.1
9 
0.3
0 
0.2
0 
0.1
3 
LOC1001
56717 
heparan-sulfate 
6-O-sulfotransferase 1-like 
100156
717 0.22 
0.00
889 
0.2
0 
0.5
8 
0.2
5 
0.2
4 
0.5
7 
0.0
0 
0.1
6 
0.1
1 
-0.
06 
0.1
3 
B4GALT
5 
UDP-Gal:betaGlcNAc 
beta 1,4- 
galactosyltransferase, 
polypeptide 5 
100522
653 0.22 
0.00
070 
0.3
5 
0.1
7 
0.1
5 
0.0
7 
0.5
0 
0.0
2 
0.2
1 
0.1
6 
0.2
8 
0.2
7 
DOK4 docking protein 4 
100620
637 0.22 
0.00
970 
0.5
8 
0.4
4 
-0.
15 
0.2
6 
0.0
5 
0.2
9 
0.1
4 
0.0
4 
0.1
6 
0.3
4 
LOC1005
17911 
ankyrin repeat and SOCS 
box protein 13-like 
100517
911 0.22 
0.00
277 
0.3
8 
0.1
4 
0.3
4 
0.1
0 
0.3
9 
0.3
5 
0.1
2 
-0.
12 
0.2
8 
0.1
6 
LOC1001
58185 
adenine nucleotide 
translocator 2 
100158
185 0.21 
0.00
183 
0.2
8 
0.1
1 
-0.
19 
0.2
7 
0.1
6 
0.4
0 
0.1
9 
0.3
0 
0.4
0 
0.2
2 
LOC1007
36777 
E3 SUMO-protein ligase 
NSE2-like 
100736
777 0.21 
0.00
725 
0.0
8 
0.3
6 
0.2
3 
0.2
5 
0.2
2 
0.4
3 
-0.
15 
0.0
7 
0.3
6 
0.2
8 
PTPRS 
protein tyrosine 
phosphatase, receptor type, 
S 
100515
359 0.21 
0.00
697 
0.4
5 
0.1
2 
0.1
8 
0.1
9 
0.5
9 
0.3
9 
0.0
8 
-0.
02 
-0.
03 
0.1
8 
SBF2 SET binding factor 2 
100521
123 0.21 
0.00
728 
0.4
0 
-0.
09 
0.2
6 
-0.
11 
0.2
3 
0.5
9 
0.2
6 
0.1
6 
0.2
4 
0.1
9 
NECD necdin 
100144
475 0.21 
0.00
652 
0.1
5 
0.2
0 
0.0
4 
0.3
1 
0.1
9 
0.1
8 
0.2
5 
0.4
1 
0.0
2 
0.3
7 
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LOC1006
22361 
uncharacterized protein 
C7orf36-like 
100622
361 0.21 
0.00
997 
0.5
6 
0.0
1 
0.2
9 
0.2
2 
0.4
8 
0.1
1 
0.0
3 
-0.
10 
0.3
0 
0.2
2 
LOC1005
23432 protein deltex-2-like 
100523
432 0.21 
0.00
837 
-0.
13 
0.2
7 
0.2
9 
0.0
6 
0.3
5 
0.0
8 
0.1
2 
0.4
5 
0.1
9 
0.4
4 
CAPN5 calpain 5 
100524
513 0.21 
0.00
407 
0.5
5 
0.1
2 
0.1
9 
0.2
2 
0.4
1 
0.0
2 
0.1
1 
-0.
09 
0.3
4 
0.2
5 
LOC1005
20165 
transmembrane protein 
164-like 
100520
165 0.21 
0.00
324 
0.4
3 
0.2
8 
0.2
4 
0.0
4 
0.1
7 
0.1
2 
0.0
9 
0.0
3 
0.3
9 
0.3
1 
SGK1 
serum/glucocorticoid 
regulated kinase 1 
100625
739 0.21 
0.00
716 
-0.
07 
0.0
4 
0.4
8 
0.3
7 
0.5
3 
0.1
6 
0.2
6 
-0.
01 
0.0
1 
0.3
2 
TET3 
tet methylcytosine 
dioxygenase 3 
100520
484 0.21 
0.00
640 
0.6
1 
0.3
8 
0.1
6 
0.0
9 
0.1
9 
0.2
2 
0.0
0 
0.2
2 
0.2
1 
0.0
0 
LOC1005
16943 SET-binding protein-like 
100516
943 0.21 
0.00
933 
0.1
5 
0.0
5 
0.5
7 
0.5
1 
0.1
9 
0.2
1 
0.1
9 
0.1
2 
0.0
1 
0.0
9 
NHSL1 NHS-like 1 
100156
257 0.21 
0.00
437 
0.4
1 
0.3
5 
0.0
0 
0.1
6 
0.3
1 
0.0
4 
0.2
7 
-0.
04 
0.2
6 
0.3
3 
LOC1006
27727 
UDP-glucose 
6-dehydrogenase-like 
100627
727 0.21 
0.00
414 
0.3
6 
-0.
08 
0.2
2 
0.1
1 
0.0
3 
0.5
1 
0.0
6 
0.4
5 
0.2
0 
0.1
9 
LOC1005
25860 clathrin light chain B-like 
100525
860 0.21 
0.00
516 
0.3
4 
0.3
4 
0.1
0 
0.3
0 
0.0
0 
0.1
4 
-0.
10 
0.2
4 
0.5
7 
0.1
4 
LOC1006
27418 
cyclin-dependent kinase 
18-like 
100627
418 0.21 
0.00
403 
0.3
5 
0.0
7 
0.3
3 
-0.
10 
0.4
7 
0.1
7 
0.2
3 
0.1
4 
0.0
8 
0.3
2 
LOC1005
24137 
ankyrin repeat 
domain-containing protein 
43-like 
100524
137 0.20 
0.00
131 
0.2
4 
0.0
3 
0.2
8 
0.1
9 
0.2
9 
0.2
9 
0.2
1 
0.0
4 
0.2
4 
0.2
3 
NET1 
neuroepithelial cell 
transforming 1 
100516
825 0.20 
0.00
459 
0.3
5 
0.0
8 
-0.
04 
-0.
02 
0.4
1 
0.4
3 
0.1
0 
0.0
6 
0.3
5 
0.2
9 
LOC1005
10946 
band 4.1-like protein 
4B-like 
100510
946 0.20 
0.00
492 
0.3
7 
0.1
9 
-0.
01 
-0.
01 
0.2
0 
0.5
5 
0.0
8 
0.1
2 
0.4
2 
0.1
3 
LOC1005
22629 
oligoribonuclease, 
mitochondrial-like 
100522
629 0.20 
0.00
666 
0.4
6 
0.0
2 
0.1
3 
0.2
2 
0.3
8 
0.4
3 
0.2
6 
-0.
07 
0.1
5 
0.0
4 
LOC1007
39472 
transmembrane BAX 
inhibitor motif-containing 
protein 1-like 
100739
472 0.20 
0.00
145 
0.3
5 
0.1
5 
0.1
1 
0.4
2 
0.3
7 
0.0
6 
0.0
8 
0.1
4 
0.1
4 
0.1
8 
LRP6 
low density lipoprotein 
receptor-related protein 6 
100515
777 0.20 
0.00
582 
0.4
9 
0.1
1 
0.1
5 
-0.
07 
0.1
9 
0.5
1 
0.1
4 
0.0
7 
0.2
2 
0.1
8 
SOCS6 
suppressor of cytokine 
signaling 6 
100155
619 0.20 
0.00
841 
0.2
7 
0.4
6 
-0.
14 
0.2
4 
-0.
02 
0.4
3 
0.1
7 
0.3
6 
0.1
8 
0.0
5 
ACOT7 acyl-CoA thioesterase 7 
100514
773 0.20 
0.00
904 
0.1
3 
0.5
4 
0.1
0 
0.1
8 
-0.
08 
0.4
1 
0.1
4 
0.4
5 
0.0
2 
0.0
9 
LOC1007
37982 protein FAM59A-like 
100737
982 0.20 
0.00
921 
0.4
0 
-0.
10 
0.0
0 
0.3
8 
0.2
4 
0.2
3 
0.1
2 
0.0
8 
0.5
5 
0.0
6 
MYH14 
myosin, heavy chain 14, 
non-muscle 
100525
110 0.20 
0.00
818 
0.6
0 
0.0
8 
0.0
2 
-0.
06 
0.1
7 
0.1
2 
0.2
9 
0.1
9 
0.4
3 
0.1
2 
LOC1005
23232 olfactory receptor 2L2-like 
100523
232 0.19 
0.00
650 
0.0
2 
0.3
4 
0.1
1 
-0.
16 
0.1
9 
0.2
4 
0.1
5 
0.3
6 
0.2
5 
0.4
5 
AGAP1 
ArfGAP with GTPase 
domain, ankyrin repeat and 
PH domain 1 
100620
812 0.19 
0.00
888 
0.4
3 
0.2
3 
0.1
7 
0.2
0 
0.5
3 
0.2
1 
-0.
02 
0.0
6 
0.1
0 
0.0
4 
TIPARP 
TCDD-inducible 
poly(ADP-ribose) 
polymerase 
100626
111 0.19 
0.00
972 
0.0
6 
0.4
8 
0.0
1 
0.1
8 
0.1
8 
0.6
3 
0.0
8 
0.1
6 
0.1
3 
0.0
4 
BMP4 
bone morphogenetic 
protein 4 
100113
425 0.19 
0.00
198 
0.3
8 
0.2
3 
0.2
4 
0.1
1 
0.1
2 
0.3
0 
0.1
9 
-0.
10 
0.2
4 
0.2
3 
DST dystonin 
100152
205 0.19 
0.00
464 
0.3
4 
0.2
3 
0.1
7 
-0.
01 
0.0
1 
0.3
6 
0.0
6 
0.2
7 
0.4
0 
0.1
0 
LRRC1 
leucine rich repeat 
containing 1 
100154
780 0.19 
0.00
203 
0.1
1 
0.1
2 
0.1
8 
0.0
5 
0.1
0 
0.2
3 
0.1
2 
0.2
7 
0.4
9 
0.2
6 
MPP5 
membrane protein, 
palmitoylated 5 (MAGUK 
p55 subfamily member 5) 
100152
635 0.19 
0.00
656 
0.2
2 
0.3
3 
0.1
2 
0.1
5 
-0.
02 
0.5
1 
-0.
06 
0.3
0 
0.2
2 
0.1
3 
LOC1001
55640 
trace amine-associated 
receptor 3-like 
100155
640 0.19 
0.00
848 
0.2
6 
-0.
04 
0.2
5 
0.3
1 
0.2
4 
0.1
1 
0.1
5 
0.1
3 
0.5
1 
-0.
02 
LOC1005
23552 
F-actin-capping protein 
subunit alpha-3-like 
100523
552 0.19 
0.00
454 
0.2
8 
0.0
2 
0.0
4 
0.3
3 
0.4
0 
0.2
1 
0.1
8 
0.0
6 
0.3
5 
0.0
5 
LOC1006
20929 anamorsin-like 
100620
929 0.19 
0.00
534 
0.3
6 
0.1
7 
0.2
5 
0.1
4 
0.2
8 
0.3
2 
0.2
6 
-0.
10 
0.0
5 
0.1
9 
ALDH18
A1 
aldehyde dehydrogenase 
18 family, member A1 
100151
977 0.19 
0.00
449 
0.3
1 
0.0
9 
0.0
0 
0.0
9 
0.4
9 
0.2
6 
0.1
8 
-0.
06 
0.2
7 
0.2
8 
COX7A2 COX7A2 protein 
100038
000 0.19 
0.00
669 
0.1
9 
0.3
2 
0.4
8 
-0.
01 
0.0
3 
0.4
3 
0.1
0 
0.1
7 
0.0
5 
0.1
2 
CTR1 
high-affinity copper uptake 
protein 397186 0.19 
0.00
317 
0.3
2 
0.1
0 
0.2
2 
-0.
03 
0.2
6 
0.5
1 
0.2
8 
0.1
1 
0.0
5 
0.0
7 
LOC1005
24666 
abhydrolase 
domain-containing protein 
FAM108A-like 
100524
666 0.19 
0.00
291 
0.2
3 
0.1
4 
0.0
9 
0.3
4 
0.3
6 
0.0
1 
0.1
5 
0.0
5 
0.1
5 
0.3
6 
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WDR20 WD repeat domain 20 
100516
626 0.19 
0.00
821 
-0.
11 
0.2
9 
0.2
3 
0.3
2 
0.2
9 
0.3
2 
0.1
0 
0.0
8 
0.2
0 
0.1
6 
LOC1006
22421 
inactive phospholipase 
D5-like 
100622
421 0.19 
0.00
625 
0.2
7 
0.0
4 
0.2
8 
0.2
9 
0.3
0 
0.1
3 
0.0
5 
0.1
9 
0.0
3 
0.2
9 
LOC1005
24456 
gamma-glutamylaminecyc
lotransferase-like 
100524
456 0.19 
0.00
606 
0.4
7 
0.1
3 
0.0
8 
0.3
1 
0.3
6 
0.1
6 
0.1
3 
0.0
0 
0.1
8 
0.0
7 
MKRN1 
makorin ring finger protein 
1 
100514
261 0.18 
0.00
216 
0.2
3 
0.0
1 
-0.
03 
0.1
2 
0.1
5 
0.2
8 
0.2
6 
0.2
0 
0.3
5 
0.2
6 
NCK2 NCK adaptor protein 2 
100192
439 0.18 
0.00
346 
0.2
5 
0.1
1 
0.3
6 
0.1
8 
0.1
6 
0.0
5 
0.1
7 
-0.
01 
0.2
7 
0.2
8 
FAT1 
FAT tumor suppressor 
homolog 1 (Drosophila) 
100154
043 0.18 
0.00
207 
0.3
4 
0.2
3 
0.0
4 
0.2
2 
0.3
5 
0.0
5 
0.1
1 
0.1
8 
0.0
5 
0.2
4 
LOC1006
25597 
lon protease homolog 2, 
peroxisomal-like 
100625
597 0.18 
0.00
317 
0.2
7 
0.0
5 
0.2
0 
0.1
2 
0.0
4 
0.4
1 
0.2
3 
0.0
8 
0.0
8 
0.3
2 
LOC1007
36865 
uncharacterized 
LOC100736865 
100736
865 0.18 
0.00
769 
0.3
2 
0.1
4 
0.1
5 
0.1
1 
0.2
5 
0.3
0 
0.0
6 
-0.
18 
0.3
7 
0.2
8 
LOC1005
17160 proline-rich protein 13 
100517
160 0.18 
0.00
713 
0.4
7 
0.0
1 
0.2
0 
0.2
1 
0.2
8 
0.3
5 
0.0
1 
0.0
5 
0.1
9 
0.0
3 
LOC1005
17855 
protein SCO1 homolog, 
mitochondrial-like 
100517
855 0.18 
0.00
568 
0.2
5 
0.2
2 
0.0
4 
0.0
6 
0.1
8 
0.2
9 
0.1
8 
0.1
2 
0.4
6 
-0.
01 
CAB39 calcium binding protein 39 
100157
453 0.18 
0.00
404 
0.2
8 
0.1
4 
0.1
2 
0.0
4 
0.0
6 
0.3
4 
0.1
1 
0.1
7 
0.4
4 
0.0
6 
LOC1005
24832 
sphingosine-1-phosphate 
phosphatase 2-like 
100524
832 0.18 
0.00
385 
0.3
5 
0.1
9 
0.2
0 
0.0
1 
0.0
6 
0.2
0 
0.1
6 
0.1
5 
0.3
8 
0.0
5 
LOC1001
53898 ezrin-like 
100153
898 0.17 
0.00
549 
0.2
0 
0.0
5 
-0.
05 
0.2
4 
0.4
6 
0.1
4 
0.0
1 
0.1
7 
0.3
9 
0.1
4 
LOC1005
18956 
coiled-coil 
domain-containing protein 
124-like 
100518
956 0.17 
0.00
614 
0.2
4 
0.0
2 
0.3
6 
0.2
0 
0.0
7 
0.3
4 
0.3
1 
0.0
1 
0.0
9 
0.1
0 
LOC1005
17953 
uncharacterized 
LOC100517953 
100517
953 0.17 
0.00
678 
0.2
9 
0.0
6 
0.0
7 
0.1
6 
0.1
6 
0.3
8 
0.0
6 
0.2
4 
0.1
7 
0.1
1 
LOC1001
37084 EPLIN-b 
100137
084 0.17 
0.00
849 
0.4
0 
-0.
04 
0.1
9 
0.1
3 
0.1
8 
0.1
3 
0.0
9 
-0.
07 
0.3
5 
0.3
2 
LOC1006
23017 olfactory receptor 5B2-like 
100623
017 0.17 
0.00
317 
0.1
2 
0.0
2 
0.0
8 
0.1
6 
0.1
7 
0.1
5 
0.2
9 
0.2
2 
0.3
0 
0.1
6 
LOC1005
22603 olfactory receptor 8K3-like 
100522
603 0.17 
0.00
675 
0.2
1 
0.0
6 
0.1
0 
0.2
8 
0.1
5 
-0.
02 
0.1
5 
0.1
6 
0.4
0 
0.1
7 
LOC1005
21654 
uncharacterized 
LOC100521654 
100521
654 0.17 
0.00
907 
-0.
11 
0.2
3 
0.1
8 
0.1
9 
0.0
1 
0.2
7 
0.1
8 
0.1
0 
0.2
9 
0.3
4 
ZFAND6 
zinc finger, AN1-type 
domain 6 
100155
656 0.16 
0.00
712 
0.0
4 
0.1
0 
-0.
01 
0.2
2 
0.1
5 
0.4
3 
0.1
8 
0.1
3 
0.2
6 
0.1
1 
LOC1006
25283 
lon protease homolog 2, 
peroxisomal-like 
100625
283 0.16 
0.00
595 
0.2
6 
0.1
0 
0.0
6 
0.1
6 
0.1
1 
0.4
4 
0.1
7 
0.0
1 
0.1
3 
0.1
5 
SLK STE20-like kinase 
100156
642 0.15 
0.00
780 
0.2
6 
-0.
13 
0.2
4 
0.0
8 
0.1
9 
0.2
6 
0.0
7 
0.1
1 
0.2
4 
0.2
2 
JARID2 
jumonji, AT rich 
interactive domain 2 
100524
569 0.15 
0.00
931 
0.2
1 
0.2
2 
0.2
6 
0.0
5 
-0.
03 
-0.
03 
0.2
8 
0.1
6 
0.2
2 
0.2
0 
LOC1000
37981 HC12887 
100037
981 0.15 
0.00
429 
0.0
7 
0.2
5 
0.0
5 
0.0
5 
0.2
2 
0.2
0 
0.2
6 
0.0
6 
0.1
6 
0.1
4 
LGALS3 
lectin, galactoside-binding, 
soluble, 3 
100038
033 0.10 
0.00
934 
0.1
7 
0.0
3 
0.0
9 
0.1
1 
0.0
2 
0.1
8 
0.0
5 
0.1
5 
0.1
0 
0.1
5 
LOC1005
16361 
UPF0458 protein 
C7orf42-like 
100516
361 -0.14 
0.00
708 
-0.
31 
-0.
23 
-0.
20 
-0.
03 
-0.
12 
-0.
16 
-0.
07 
-0.
13 
-0.
06 
-0.
07 
MED12 
mediator complex subunit 
12 
100157
450 -0.14 
0.00
662 
-0.
19 
-0.
15 
-0.
04 
-0.
19 
-0.
14 
-0.
29 
-0.
01 
-0.
13 
-0.
13 
-0.
17 
LOC1001
52422 
5-formyltetrahydrofolate 
cyclo-ligase-like 
100152
422 -0.16 
0.00
791 
-0.
21 
-0.
33 
-0.
19 
0.0
0 
-0.
18 
0.0
8 
-0.
20 
-0.
15 
-0.
24 
-0.
17 
TLN1 talin 1 
100157
220 -0.16 
0.00
965 
-0.
19 
-0.
12 
-0.
06 
-0.
15 
-0.
02 
-0.
44 
-0.
17 
0.0
3 
-0.
27 
-0.
19 
ODF2 
outer dense fiber of sperm 
tails 2 
100156
735 -0.16 
0.00
739 
-0.
25 
0.0
1 
0.0
7 
-0.
17 
-0.
25 
-0.
28 
-0.
14 
-0.
18 
-0.
22 
-0.
18 
TCF4 transcription factor 4 
100511
671 -0.16 
0.00
991 
-0.
29 
-0.
20 
-0.
06 
-0.
18 
-0.
20 
-0.
19 
-0.
04 
0.0
2 
-0.
48 
-0.
01 
SLC30A7 
solute carrier family 30 
(zinc transporter), member 
7 
100156
498 -0.17 
0.00
721 
-0.
39 
-0.
24 
-0.
19 
-0.
11 
-0.
07 
0.0
1 
-0.
01 
-0.
23 
-0.
35 
-0.
07 
LOC1005
21760 
uncharacterized 
LOC100521760 
100521
760 -0.17 
0.00
298 
-0.
15 
-0.
29 
0.0
1 
-0.
15 
-0.
19 
-0.
19 
-0.
13 
-0.
16 
-0.
37 
-0.
08 
KDM3A 
lysine (K)-specific 
demethylase 3A 
100517
522 -0.17 
0.00
542 
-0.
08 
-0.
24 
-0.
14 
-0.
01 
-0.
16 
-0.
16 
-0.
40 
-0.
05 
-0.
17 
-0.
29 
RUFY1 
RUN and FYVE domain 
containing 1 
100519
354 -0.17 
0.00
947 
-0.
32 
-0.
47 
-0.
11 
-0.
16 
-0.
07 
-0.
21 
-0.
24 
-0.
09 
-0.
03 
0.0
0 
HDLBP 
high density lipoprotein 
binding protein 
100233
187 -0.17 
0.00
503 
-0.
11 
-0.
02 
-0.
04 
-0.
02 
-0.
21 
-0.
41 
-0.
17 
-0.
22 
-0.
37 
-0.
15 
CLDND1 
claudin domain containing 
1 
100154
619 -0.17 
0.00
403 
-0.
43 
-0.
29 
-0.
19 
-0.
06 
-0.
08 
-0.
24 
-0.
04 
0.0
4 
-0.
23 
-0.
21 
Appendices 
208 
CDKAL1 
CDK5 regulatory subunit 
associated protein 1-like 1 
100512
355 -0.18 
0.00
472 
-0.
32 
-0.
30 
-0.
28 
-0.
18 
-0.
30 
0.0
0 
-0.
09 
-0.
14 
0.0
5 
-0.
24 
NXF1 
nuclear RNA export factor 
1 
100628
213 -0.19 
0.00
541 
-0.
13 
-0.
06 
-0.
25 
-0.
46 
-0.
42 
-0.
05 
-0.
09 
-0.
08 
-0.
28 
-0.
06 
LOC1006
24587 
non-histone chromosomal 
protein HMG-14-like 
100624
587 -0.19 
0.00
615 
-0.
39 
-0.
30 
0.0
1 
-0.
13 
-0.
41 
0.0
4 
-0.
16 
-0.
14 
-0.
20 
-0.
20 
LOC1007
38762 
WW domain-binding 
protein 11-like 
100738
762 -0.19 
0.00
869 
-0.
39 
-0.
23 
-0.
11 
-0.
12 
-0.
53 
0.0
4 
-0.
12 
-0.
20 
-0.
25 
0.0
1 
RPN1 ribophorin I 397606 -0.19 
0.00
930 
-0.
31 
0.0
1 
0.0
4 
-0.
15 
-0.
47 
-0.
09 
-0.
08 
-0.
10 
-0.
56 
-0.
20 
GRN granulin 733645 -0.19 
0.00
827 
-0.
60 
-0.
20 
0.0
2 
-0.
16 
-0.
06 
-0.
32 
-0.
31 
-0.
15 
-0.
23 
0.0
9 
ABCE1 
ATP-binding cassette, 
sub-family E (OABP), 
member 1 
100524
881 -0.19 
0.00
970 
-0.
39 
-0.
47 
-0.
05 
0.0
5 
-0.
33 
-0.
24 
0.1
9 
-0.
18 
-0.
32 
-0.
19 
LOC1007
38870 alpha-enolase-like 
100738
870 -0.20 
0.00
255 
-0.
17 
-0.
21 
0.0
9 
-0.
07 
-0.
29 
-0.
22 
-0.
28 
-0.
12 
-0.
50 
-0.
21 
LOC1005
24280 
guanine 
nucleotide-binding protein 
subunit beta-4-like 
100524
280 -0.20 
0.00
498 
-0.
50 
-0.
15 
-0.
14 
0.0
8 
-0.
28 
-0.
25 
-0.
08 
-0.
26 
-0.
31 
-0.
14 
LOC1005
13892 
dolichyl-diphosphooligosa
ccharide--protein 
glycosyltransferase 
subunit 2-like 
100513
892 -0.20 
0.00
412 
-0.
38 
0.0
4 
-0.
03 
-0.
11 
-0.
38 
-0.
16 
-0.
12 
-0.
25 
-0.
55 
-0.
10 
LOC1001
54836 
deoxycytidylate 
deaminase-like 
100154
836 -0.21 
0.00
635 
0.0
9 
0.0
2 
-0.
28 
-0.
03 
-0.
51 
-0.
26 
-0.
31 
-0.
27 
-0.
15 
-0.
38 
LOC1007
37879 
thyroid 
adenoma-associated 
protein homolog 
100737
879 -0.21 
0.00
862 
-0.
31 
-0.
52 
-0.
25 
-0.
33 
-0.
32 
-0.
28 
-0.
07 
-0.
06 
-0.
19 
0.2
4 
LOC1005
12373 
transmembrane protein 
163-like 
100512
373 -0.21 
0.00
819 
-0.
21 
-0.
28 
-0.
20 
-0.
21 
-0.
03 
-0.
28 
-0.
08 
-0.
46 
-0.
40 
0.0
6 
ANAPC1
6 
anaphase promoting 
complex subunit 16 
100155
019 -0.21 
0.00
502 
-0.
34 
-0.
49 
-0.
31 
-0.
23 
-0.
21 
0.1
9 
-0.
32 
-0.
25 
-0.
13 
-0.
02 
LOC1007
37320 olfactomedin-4-like 
100737
320 -0.21 
0.00
723 
-0.
20 
0.1
0 
-0.
09 
-0.
13 
-0.
79 
-0.
21 
-0.
08 
-0.
21 
-0.
32 
-0.
19 
ARPC1B 
actin related protein 2/3 
complex, subunit 1B, 
41kDa 
100174
964 -0.21 
0.00
657 
-0.
39 
-0.
11 
-0.
08 
0.1
0 
-0.
32 
-0.
37 
-0.
07 
-0.
02 
-0.
58 
-0.
30 
LOC1007
38598 
disintegrin and 
metalloproteinase 
domain-containing protein 
17-like 
100738
598 -0.22 
0.00
968 
-0.
31 
0.0
0 
0.1
0 
-0.
26 
-0.
28 
-0.
69 
-0.
17 
0.0
7 
-0.
29 
-0.
33 
HIVEP2 
human immunodeficiency 
virus type I enhancer 
binding protein 2 
100525
369 -0.22 
0.00
897 
-0.
51 
0.0
1 
-0.
04 
-0.
33 
-0.
56 
-0.
14 
-0.
19 
0.0
9 
-0.
22 
-0.
29 
LOC1007
37847 
pleckstrin homology 
domain-containing family 
A member 2-like 
100737
847 -0.22 
0.00
793 
-0.
58 
-0.
03 
-0.
13 
-0.
62 
-0.
20 
-0.
13 
-0.
01 
-0.
03 
-0.
20 
-0.
25 
DNAJC1
0 
DnaJ (Hsp40) homolog, 
subfamily C, member 10 
100523
288 -0.22 
0.00
256 
-0.
08 
-0.
32 
-0.
01 
-0.
12 
-0.
50 
-0.
22 
-0.
40 
-0.
32 
0.0
6 
-0.
26 
RARS arginyl-tRNA synthetase 414410 -0.22 
0.00
959 
-0.
16 
-0.
19 
0.2
0 
-0.
12 
-0.
21 
-0.
65 
-0.
01 
-0.
27 
-0.
42 
-0.
38 
SRSF6 
serine/arginine-rich 
splicing factor 6 768102 -0.22 
0.00
436 
-0.
52 
0.1
6 
-0.
07 
-0.
04 
-0.
30 
-0.
34 
-0.
14 
-0.
25 
-0.
47 
-0.
25 
SH3KBP
1 
SH3-domain kinase 
binding protein 1 
100522
530 -0.22 
0.00
834 
-0.
29 
-0.
23 
-0.
08 
-0.
04 
-0.
35 
-0.
43 
0.0
3 
-0.
01 
-0.
72 
-0.
11 
HCFC1 
host cell factor C1 
(VP16-accessory protein) 
100523
834 -0.22 
0.00
178 
-0.
14 
-0.
25 
0.0
0 
-0.
12 
-0.
26 
-0.
47 
-0.
20 
-0.
12 
-0.
44 
-0.
24 
RAMP2 
receptor (G 
protein-coupled) activity 
modifying protein 2 397155 -0.23 
0.00
684 
-0.
64 
-0.
36 
0.0
8 
-0.
15 
-0.
41 
-0.
09 
-0.
06 
-0.
17 
-0.
41 
-0.
05 
ADAM19 
ADAM metallopeptidase 
domain 19 
100521
528 -0.23 
0.00
861 
-0.
36 
-0.
17 
0.0
1 
0.0
2 
0.0
5 
-0.
74 
-0.
37 
-0.
17 
-0.
36 
-0.
17 
LOC1006
20483 
mis18-binding protein 
1-like 
100620
483 -0.23 
0.00
728 
-0.
49 
-0.
11 
0.0
2 
-0.
20 
-0.
62 
-0.
20 
-0.
21 
0.0
1 
-0.
21 
-0.
27 
TGIF1 
TGFB-induced factor 
homeobox 1 
100625
732 -0.23 
0.00
161 
-0.
04 
-0.
12 
-0.
09 
-0.
16 
-0.
27 
-0.
49 
-0.
33 
-0.
22 
-0.
14 
-0.
43 
LYST 
lysosomal trafficking 
regulator 
100049
676 -0.23 
0.00
323 
-0.
38 
-0.
05 
-0.
24 
-0.
43 
-0.
15 
-0.
45 
0.0
4 
-0.
10 
-0.
45 
-0.
08 
LOC1005
22211 
E3 ubiquitin-protein ligase 
RNF135-like 
100522
211 -0.23 
0.00
810 
-0.
63 
-0.
42 
0.1
5 
-0.
17 
-0.
33 
-0.
19 
0.0
1 
-0.
34 
-0.
20 
-0.
18 
MIC-2 
MHC class I related 
antigen 2 
100135
034 -0.23 
0.00
711 
-0.
07 
-0.
29 
-0.
61 
-0.
04 
-0.
42 
-0.
14 
-0.
14 
-0.
23 
-0.
29 
-0.
07 
ERCC4 
excision repair 
cross-complementing 
rodent repair deficiency, 
complementation group 4 
100516
427 -0.23 
0.00
094 
-0.
34 
-0.
15 
-0.
26 
-0.
24 
-0.
27 
-0.
17 
-0.
36 
-0.
21 
-0.
22 
-0.
10 
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LOC1005
25611 
protein 
O-glucosyltransferase 
1-like 
100525
611 -0.23 
0.00
332 
-0.
25 
-0.
10 
-0.
17 
-0.
35 
-0.
43 
-0.
62 
-0.
04 
-0.
23 
-0.
18 
0.0
1 
TGFBR1 
transforming growth 
factor, beta receptor 1 396665 -0.24 
0.00
505 
-0.
51 
-0.
52 
-0.
06 
-0.
07 
-0.
22 
-0.
27 
-0.
28 
0.1
9 
-0.
39 
-0.
22 
LOC1006
21521 
ABI gene family member 
3-like 
100621
521 -0.24 
0.00
773 
-0.
05 
-0.
49 
-0.
10 
0.0
2 
-0.
36 
-0.
46 
-0.
15 
0.0
6 
-0.
42 
-0.
40 
GPX1 glutathione peroxidase 1 397403 -0.24 
0.00
145 
-0.
56 
-0.
14 
0.1
1 
-0.
12 
-0.
36 
-0.
32 
-0.
23 
-0.
20 
-0.
40 
-0.
13 
LOC1005
17301 
dTDP-D-glucose 
4,6-dehydratase-like 
100517
301 -0.24 
0.00
139 
-0.
17 
-0.
08 
-0.
25 
-0.
14 
-0.
51 
-0.
35 
-0.
28 
-0.
14 
-0.
09 
-0.
36 
FLVCR2 
feline leukemia virus 
subgroup C cellular 
receptor family, member 2 
100217
391 -0.24 
0.00
694 
-0.
17 
0.0
8 
-0.
16 
0.1
0 
-0.
56 
-0.
39 
-0.
41 
-0.
18 
-0.
40 
-0.
28 
TLR2 toll-like receptor 2 396623 -0.24 
0.00
971 
-0.
31 
0.1
3 
-0.
13 
0.1
2 
-0.
65 
-0.
40 
-0.
38 
-0.
01 
-0.
32 
-0.
42 
LOC1001
53642 
ankyrin repeat 
domain-containing protein 
37-like 
100153
642 -0.24 
0.00
334 
-0.
35 
-0.
13 
-0.
35 
-0.
43 
-0.
09 
-0.
38 
-0.
37 
-0.
07 
-0.
13 
-0.
14 
ELOVL6 
ELOVL fatty acid 
elongase 6 
100312
970 -0.24 
0.00
848 
-0.
37 
-0.
25 
0.1
3 
0.2
5 
-0.
66 
-0.
26 
-0.
28 
-0.
44 
-0.
31 
-0.
25 
LRP11 
low density lipoprotein 
receptor-related protein 11 
100153
355 -0.25 
0.00
690 
-0.
22 
-0.
13 
-0.
06 
0.0
4 
-0.
52 
-0.
38 
-0.
42 
-0.
16 
-0.
06 
-0.
55 
FUT8 
fucosyltransferase 8 (alpha 
(1,6) fucosyltransferase) 396933 -0.25 
0.00
610 
-0.
39 
-0.
22 
0.1
0 
-0.
30 
-0.
66 
-0.
26 
0.0
1 
0.0
1 
-0.
59 
-0.
16 
ARRDC3 
arrestin domain containing 
3 
100520
233 -0.25 
0.00
365 
-0.
45 
-0.
18 
0.0
9 
-0.
20 
-0.
34 
-0.
05 
-0.
72 
-0.
13 
-0.
13 
-0.
36 
SCLT1 
sodium channel and 
clathrin linker 1 
100518
025 -0.25 
0.00
362 
-0.
32 
-0.
37 
-0.
22 
-0.
25 
-0.
22 
-0.
36 
-0.
69 
0.0
0 
0.0
7 
-0.
15 
B3GALN
T1 
beta-1,3-N-acetylgalactosa
minyltransferase 1 
(globoside blood group) 397634 -0.25 
0.00
277 
-0.
22 
-0.
36 
-0.
08 
0.0
6 
-0.
51 
-0.
17 
-0.
33 
-0.
36 
-0.
32 
-0.
25 
MAP3K1 
mitogen-activated protein 
kinase kinase kinase 1, E3 
ubiquitin protein ligase 396617 -0.26 
0.00
053 
-0.
45 
-0.
05 
-0.
17 
-0.
41 
-0.
49 
-0.
30 
-0.
08 
-0.
05 
-0.
31 
-0.
29 
LOC1001
55363 
UPF0536 protein 
C12orf66-like 
100155
363 -0.27 
0.00
175 
-0.
30 
0.0
4 
-0.
30 
-0.
23 
-0.
29 
-0.
44 
-0.
45 
-0.
33 
-0.
05 
-0.
30 
LOC1001
57723 purinergic receptor P2X4 
100157
723 -0.27 
0.00
544 
-0.
29 
-0.
73 
-0.
41 
-0.
19 
-0.
09 
-0.
40 
-0.
45 
-0.
31 
-0.
05 
0.2
5 
LOC1005
15590 
coiled-coil 
domain-containing protein 
69-like 
100515
590 -0.27 
0.00
715 
-0.
55 
-0.
07 
-0.
29 
-0.
29 
-0.
30 
-0.
76 
0.1
0 
0.0
4 
-0.
23 
-0.
31 
LOC1001
52536 
multidrug 
resistance-associated 
protein 4-like 
100152
536 -0.27 
0.00
461 
-0.
07 
-0.
20 
-0.
30 
0.0
2 
0.0
9 
-0.
68 
-0.
41 
-0.
10 
-0.
58 
-0.
47 
CXCL14 
chemokine (C-X-C motif) 
ligand 14 494467 -0.27 
0.00
160 
-0.
08 
-0.
45 
-0.
06 
0.0
8 
0.0
1 
-0.
47 
-0.
54 
-0.
43 
-0.
50 
-0.
27 
WIPI1 
WD repeat domain, 
phosphoinositide 
interacting 1 
100462
758 -0.27 
0.00
631 
-0.
29 
-0.
87 
0.2
0 
-0.
18 
-0.
30 
-0.
25 
-0.
15 
-0.
50 
-0.
33 
-0.
03 
LOC1006
23014 
transient receptor potential 
cation channel subfamily 
M member 2-like 
100623
014 -0.28 
0.00
120 
-0.
26 
-0.
04 
-0.
29 
-0.
46 
-0.
52 
-0.
31 
-0.
11 
-0.
21 
-0.
34 
-0.
21 
GALE 
UDP-galactose-4-epimeras
e 
100621
392 -0.28 
0.00
669 
-0.
31 
-0.
17 
-0.
05 
0.2
1 
-0.
21 
-0.
80 
-0.
44 
-0.
59 
-0.
38 
-0.
01 
LOC1001
54996 
glycoprotein 
endo-alpha-1,2-mannosida
se-like 
100154
996 -0.28 
0.00
664 
-0.
64 
-0.
35 
-0.
21 
-0.
18 
-0.
76 
0.2
3 
-0.
13 
0.0
3 
-0.
49 
-0.
25 
NCALD neurocalcin delta 
100156
785 -0.28 
0.00
658 
-0.
92 
-0.
39 
-0.
18 
-0.
14 
-0.
11 
-0.
19 
-0.
16 
-0.
40 
0.1
4 
-0.
40 
GBA glucosidase, beta, acid 449572 -0.28 
0.00
237 
-0.
57 
-0.
09 
0.1
6 
-0.
12 
-0.
67 
-0.
40 
-0.
19 
-0.
19 
-0.
44 
-0.
25 
LOC1005
17795 
AP-1 complex subunit 
sigma-2-like 
100517
795 -0.28 
0.00
115 
-0.
57 
-0.
27 
-0.
35 
-0.
10 
-0.
58 
0.0
6 
-0.
06 
-0.
29 
-0.
22 
-0.
39 
NIN 
ninein (GSK3B interacting 
protein) 
100157
402 -0.28 
0.00
736 
-0.
38 
-0.
02 
0.1
3 
-0.
32 
-0.
37 
-0.
55 
-0.
17 
-0.
04 
-0.
89 
-0.
18 
TANK 
TRAF family 
member-associated NFKB 
activator 
100156
366 -0.28 
0.00
953 
-0.
62 
-0.
03 
0.1
3 
-0.
22 
-0.
60 
-0.
68 
-0.
05 
0.1
4 
-0.
57 
-0.
27 
DEGS1 
delta(4)-desaturase, 
sphingolipid 1 
100135
677 -0.28 
0.00
307 
-0.
63 
0.1
0 
0.0
4 
-0.
09 
-0.
19 
-0.
44 
-0.
35 
-0.
34 
-0.
67 
-0.
23 
VRK2 vaccinia related kinase 2 
100511
127 -0.28 
0.00
345 
-0.
34 
-0.
30 
-0.
14 
-0.
43 
-0.
78 
0.0
2 
-0.
15 
-0.
08 
-0.
19 
-0.
41 
LOC1005
16193 
uncharacterized 
LOC100516193 
100516
193 -0.28 
0.00
339 
-0.
33 
-0.
16 
0.0
9 
-0.
37 
-0.
92 
-0.
25 
-0.
13 
-0.
39 
-0.
12 
-0.
22 
LOC1006
24193 
lysosomal-associated 
transmembrane protein 
5-like 
100624
193 -0.28 
0.00
607 
-0.
72 
-0.
34 
0.0
5 
-0.
37 
-0.
56 
-0.
58 
-0.
06 
0.2
8 
-0.
25 
-0.
24 
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STK38 serine/threonine kinase 38 
100153
410 -0.28 
0.00
810 
-0.
19 
-0.
11 
0.0
8 
-0.
65 
-0.
83 
-0.
44 
0.1
2 
-0.
01 
-0.
42 
-0.
41 
SMC4 
structural maintenance of 
chromosomes 4 
100152
361 -0.28 
0.00
835 
-0.
70 
-0.
28 
0.1
4 
-0.
46 
-0.
77 
0.1
8 
-0.
19 
-0.
08 
-0.
51 
-0.
17 
BIRC2 
baculoviral IAP repeat 
containing 2 
100622
859 -0.29 
0.00
762 
-0.
35 
-0.
07 
-0.
21 
-0.
06 
-0.
70 
-0.
89 
-0.
19 
0.0
4 
-0.
22 
-0.
21 
HIF1A 
hypoxia inducible factor 1, 
alpha subunit (basic 
helix-loop-helix 
transcription factor) 396696 -0.29 
0.00
897 
-0.
21 
-0.
03 
-0.
02 
0.0
1 
-0.
48 
-0.
56 
-0.
22 
-0.
24 
-1.
08 
-0.
05 
LOC1005
13036 
39S ribosomal protein 
L51, mitochondrial-like 
100513
036 -0.29 
0.00
432 
-0.
20 
0.0
6 
-0.
39 
-0.
41 
-0.
76 
-0.
17 
-0.
23 
0.0
5 
-0.
44 
-0.
40 
LOC1005
11129 
uncharacterized 
LOC100511129 
100511
129 -0.29 
0.00
909 
-0.
64 
0.4
3 
-0.
42 
-0.
24 
0.1
1 
-0.
36 
-0.
66 
-0.
56 
-0.
26 
-0.
31 
ARHGAP
4 
Rho GTPase activating 
protein 4 
100523
659 -0.30 
0.00
346 
-0.
69 
-0.
32 
-0.
05 
-0.
24 
-0.
23 
-0.
79 
0.1
1 
-0.
21 
-0.
29 
-0.
24 
TPST2 
tyrosylprotein 
sulfotransferase 2 
100154
448 -0.30 
0.00
655 
-0.
88 
-0.
09 
0.0
2 
0.0
9 
-0.
50 
-0.
52 
-0.
07 
-0.
19 
-0.
69 
-0.
16 
SOAT1 sterol O-acyltransferase 1 
100628
166 -0.30 
0.00
120 
-0.
35 
-0.
26 
0.0
5 
-0.
35 
-0.
61 
-0.
61 
0.0
5 
-0.
31 
-0.
30 
-0.
32 
ARHGAP
25 
Rho GTPase activating 
protein 25 
100514
401 -0.30 
0.00
937 
-0.
59 
-0.
19 
0.0
1 
-0.
29 
-0.
86 
-0.
67 
0.2
8 
-0.
02 
-0.
31 
-0.
36 
PIP4K2A 
phosphatidylinositol-5-pho
sphate 4-kinase, type II, 
alpha 
100520
446 -0.30 
0.00
720 
-0.
69 
-0.
36 
0.0
8 
-0.
44 
-0.
73 
-0.
33 
-0.
05 
0.2
9 
-0.
29 
-0.
49 
LOC1006
20551 latexin-like 
100620
551 -0.30 
0.00
179 
-0.
60 
-0.
34 
-0.
18 
0.2
5 
-0.
54 
-0.
50 
-0.
39 
-0.
24 
-0.
13 
-0.
33 
FADS1 fatty acid desaturase 1 444995 -0.30 
0.00
385 
-0.
80 
-0.
28 
0.2
1 
-0.
46 
-0.
29 
-0.
15 
-0.
26 
-0.
35 
-0.
66 
0.0
2 
LOC1005
22138 protein FAM65A-like 
100522
138 -0.30 
0.00
336 
-0.
21 
-0.
53 
-0.
05 
-0.
62 
-0.
37 
-0.
60 
0.0
3 
-0.
11 
-0.
55 
0.0
0 
PHF19 PHD finger protein 19 
100156
643 -0.30 
0.00
101 
-0.
36 
-0.
38 
0.0
2 
-0.
19 
-0.
12 
-0.
60 
-0.
54 
-0.
33 
-0.
29 
-0.
22 
LOC1005
21836 
phosphofurin acidic cluster 
sorting protein 1-like 
100521
836 -0.31 
0.00
445 
-0.
61 
-0.
53 
-0.
13 
-0.
61 
-0.
32 
-0.
54 
0.3
6 
-0.
07 
-0.
35 
-0.
30 
LOC1007
38945 
integral membrane protein 
GPR137B-like 
100738
945 -0.31 
0.00
843 
-0.
72 
-0.
33 
-0.
06 
0.2
6 
-0.
69 
-0.
28 
-0.
80 
-0.
05 
-0.
27 
-0.
15 
LOC1007
36908 
folylpolyglutamate 
synthase, 
mitochondrial-like 
100736
908 -0.31 
0.00
306 
-0.
48 
-0.
15 
-0.
46 
-0.
08 
-0.
33 
-0.
76 
-0.
28 
-0.
62 
0.0
9 
-0.
06 
FADS2 fatty acid desaturase 2 444997 -0.31 
0.00
385 
-0.
58 
-0.
05 
0.2
5 
-0.
06 
-0.
49 
-0.
29 
-0.
37 
-0.
43 
-0.
79 
-0.
32 
LOC1005
25431 
uncharacterized 
LOC100525431 
100525
431 -0.31 
0.00
627 
-0.
74 
0.0
1 
-0.
28 
-0.
64 
-0.
55 
-0.
19 
0.1
6 
-0.
30 
-0.
04 
-0.
57 
ZNF318 zinc finger protein 318 
100153
069 -0.31 
0.00
192 
-0.
07 
-0.
65 
-0.
46 
-0.
65 
-0.
22 
-0.
28 
-0.
16 
-0.
36 
0.1
4 
-0.
43 
LOC1006
21251 
alpha-N-acetylneuraminid
e 
alpha-2,8-sialyltransferase
-like 
100621
251 -0.31 
0.00
296 
-0.
48 
-0.
19 
-0.
54 
-0.
60 
-0.
37 
-0.
22 
-0.
26 
0.1
0 
-0.
63 
0.0
3 
LOC1005
26199 
cysteine-rich hydrophobic 
domain 1 protein-like 
100526
199 -0.32 
0.00
402 
-0.
68 
-0.
38 
-0.
46 
-0.
48 
-0.
71 
-0.
02 
-0.
34 
0.0
6 
0.0
6 
-0.
19 
SCFD2 
sec1 family domain 
containing 2 
100738
927 -0.32 
0.00
117 
-0.
53 
-0.
11 
-0.
10 
-0.
27 
-0.
66 
-0.
06 
-0.
35 
0.0
3 
-0.
69 
-0.
39 
LOC1005
15572 
scm-like with four MBT 
domains protein 2-like 
100515
572 -0.32 
0.00
604 
-0.
79 
0.0
2 
-0.
41 
-0.
67 
-0.
74 
-0.
22 
-0.
07 
0.1
7 
-0.
23 
-0.
22 
LOC1005
25694 
PQ-loop repeat-containing 
protein 3-like 
100525
694 -0.32 
0.00
236 
-0.
77 
-0.
51 
0.0
0 
0.0
8 
-0.
44 
-0.
38 
-0.
09 
-0.
23 
-0.
68 
-0.
16 
LOC1006
22758 
FCH and double SH3 
domains protein 2-like 
100622
758 -0.32 
0.00
079 
-0.
37 
-0.
23 
-0.
28 
-0.
47 
-0.
47 
-0.
77 
-0.
06 
0.1
1 
-0.
27 
-0.
36 
ADAM17 
ADAM metallopeptidase 
domain 17 397343 -0.32 
0.00
401 
-0.
47 
0.2
7 
-0.
20 
-0.
18 
-0.
59 
-0.
74 
-0.
37 
0.1
0 
-0.
58 
-0.
42 
LOC1005
11896 
KDEL motif-containing 
protein 1-like 
100511
896 -0.32 
0.00
313 
-0.
16 
0.0
9 
-0.
15 
-0.
67 
-0.
18 
-0.
28 
-0.
35 
-0.
18 
-0.
76 
-0.
55 
LOC1001
57186 
carbohydrate 
sulfotransferase 11-like 
100157
186 -0.32 
0.00
424 
-0.
60 
-0.
28 
-0.
23 
0.0
8 
-0.
29 
-0.
85 
0.0
2 
-0.
08 
-0.
71 
-0.
26 
DGKA 
diacylglycerol kinase, 
alpha 80kDa 397097 -0.32 
0.00
464 
-0.
50 
-0.
66 
0.0
5 
-0.
80 
-0.
28 
-0.
41 
0.2
0 
-0.
23 
-0.
52 
-0.
06 
CD40 
CD40 molecule, TNF 
receptor superfamily 
member 5 397395 -0.32 
0.00
946 
-0.
91 
-0.
14 
-0.
16 
-0.
29 
-1.
00 
-0.
36 
0.0
5 
0.1
2 
-0.
19 
-0.
33 
LOC1006
25637 
ena/VASP-like 
protein-like 
100625
637 -0.32 
0.00
650 
-0.
82 
-0.
26 
0.0
8 
-0.
74 
-0.
76 
-0.
27 
-0.
11 
0.0
7 
-0.
08 
-0.
34 
PITPNC1 
phosphatidylinositol 
transfer protein, 
cytoplasmic 1 
100233
199 -0.32 
0.00
977 
-0.
21 
-0.
32 
0.0
9 
-0.
21 
-0.
73 
-0.
90 
0.3
2 
-0.
11 
-0.
49 
-0.
66 
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LOC1001
54822 
WAS/WASL-interacting 
protein family member 
1-like 
100154
822 -0.32 
0.00
314 
-1.
00 
-0.
37 
-0.
08 
-0.
54 
-0.
41 
-0.
42 
-0.
12 
0.1
1 
-0.
30 
-0.
10 
BPI 
bactericidal/permeability-i
ncreasing protein 
100286
800 -0.33 
0.00
077 
-0.
50 
-0.
26 
0.0
4 
0.0
9 
-0.
59 
-0.
66 
-0.
37 
-0.
59 
-0.
14 
-0.
29 
LOC1005
25217 tribbles homolog 2-like 
100525
217 -0.33 
0.00
559 
-0.
39 
-0.
17 
0.2
3 
-0.
64 
-0.
59 
-0.
12 
-0.
14 
-0.
31 
-0.
90 
-0.
21 
LOC1005
15873 septin-6-like 
100515
873 -0.33 
0.00
221 
-0.
95 
-0.
42 
-0.
02 
-0.
36 
-0.
60 
-0.
33 
0.0
7 
-0.
04 
-0.
25 
-0.
37 
LOC1007
39736 
uncharacterized 
LOC100739736 
100739
736 -0.33 
0.00
584 
-0.
51 
-0.
08 
-0.
54 
-0.
14 
-0.
81 
-0.
69 
-0.
14 
0.3
5 
-0.
58 
-0.
11 
MUC20 
mucin 20, cell surface 
associated 
100134
954 -0.33 
0.00
634 
-0.
61 
-0.
41 
-0.
73 
-0.
40 
-0.
26 
-0.
69 
-0.
01 
-0.
17 
0.3
7 
-0.
37 
RASGRP
2 
RAS guanyl releasing 
protein 2 (calcium and 
DAG-regulated) 
100626
093 -0.33 
0.00
763 
-0.
49 
-0.
20 
-0.
27 
-0.
96 
0.0
8 
-0.
39 
0.2
3 
-0.
19 
-0.
63 
-0.
46 
PION 
pigeon homolog 
(Drosophila) 
100512
622 -0.33 
0.00
275 
-0.
82 
-0.
63 
0.0
5 
-0.
42 
-0.
38 
-0.
48 
-0.
21 
0.2
1 
-0.
33 
-0.
29 
LOC1001
52824 
Fc receptor-like protein 
1-like 
100152
824 -0.33 
0.00
161 
-0.
50 
-0.
59 
-0.
31 
-0.
77 
-0.
28 
-0.
25 
-0.
12 
-0.
19 
0.0
9 
-0.
39 
LOC1007
39768 beta-parvin-like 
100739
768 -0.33 
0.00
746 
-0.
13 
-0.
42 
-0.
13 
-0.
17 
0.2
8 
-0.
80 
-0.
31 
-0.
36 
-1.
00 
-0.
27 
REL 
v-rel reticuloendotheliosis 
viral oncogene homolog 
(avian) 
100525
104 -0.33 
0.00
591 
-0.
85 
-0.
33 
0.1
2 
-0.
48 
-0.
92 
-0.
51 
0.0
4 
0.0
9 
-0.
20 
-0.
30 
C3 complement component 3 397072 -0.33 
0.00
509 
-0.
64 
-0.
19 
-0.
39 
-0.
65 
-0.
97 
0.0
1 
0.2
9 
-0.
25 
-0.
48 
-0.
08 
LOC1005
12775 
beta-galactoside 
alpha-2,6-sialyltransferase 
2-like 
100512
775 -0.34 
0.00
739 
0.1
3 
-0.
28 
-0.
43 
-0.
32 
-0.
61 
-0.
81 
-0.
62 
-0.
32 
0.4
8 
-0.
59 
LOC1006
23009 
large neutral amino acids 
transporter small subunit 
4-like 
100623
009 -0.34 
0.00
206 
-0.
69 
-0.
24 
-0.
16 
-0.
12 
-0.
16 
-0.
97 
-0.
38 
-0.
09 
-0.
54 
-0.
03 
LIMD2 LIM domain containing 2 
100512
735 -0.34 
0.00
602 
-0.
75 
-0.
46 
-0.
37 
-0.
41 
-0.
01 
-0.
83 
0.1
3 
0.2
4 
-0.
61 
-0.
36 
LOC1005
25406 
non-histone chromosomal 
protein HMG-14-like 
100525
406 -0.34 
0.00
407 
-0.
54 
-0.
46 
-0.
63 
-0.
12 
-0.
85 
-0.
23 
0.2
1 
0.0
0 
-0.
34 
-0.
44 
OBFC2A 
nucleic acid binding 
protein 1 
100155
066 -0.34 
0.00
967 
-0.
25 
0.0
9 
-0.
14 
-0.
31 
-0.
83 
-0.
91 
0.0
8 
0.1
8 
-0.
89 
-0.
45 
SPINK4 
serine peptidase inhibitor, 
Kazal type 4 396872 -0.34 
0.00
095 
-0.
18 
-0.
42 
0.0
4 
0.0
4 
-0.
47 
-0.
88 
-0.
50 
-0.
58 
-0.
09 
-0.
39 
IL2RA 
interleukin 2 receptor, 
alpha 396814 -0.35 
0.00
041 
-0.
48 
-0.
29 
-0.
40 
0.0
6 
-0.
46 
-0.
09 
-0.
46 
-0.
30 
-0.
51 
-0.
50 
LOC1007
38285 
ER degradation-enhancing 
alpha-mannosidase-like 
1-like 
100738
285 -0.35 
0.00
026 
-0.
48 
-0.
40 
-0.
36 
0.0
3 
-0.
58 
-0.
67 
-0.
26 
0.0
1 
-0.
51 
-0.
27 
IL10RA 
interleukin 10 receptor, 
alpha 
100525
654 -0.35 
0.00
698 
-0.
96 
-0.
34 
0.1
7 
-0.
11 
-0.
55 
-1.
02 
-0.
32 
0.0
7 
-0.
38 
-0.
07 
LOC1005
24615 
AT-rich interactive 
domain-containing protein 
5A-like 
100524
615 -0.35 
0.00
420 
-0.
86 
-0.
15 
-0.
01 
-0.
25 
-0.
83 
-0.
49 
-0.
08 
-0.
01 
-0.
74 
-0.
10 
PHF11 PHD finger protein 11 
100518
446 -0.35 
0.00
011 
-0.
56 
-0.
20 
-0.
15 
-0.
30 
-0.
49 
-0.
66 
-0.
22 
-0.
03 
-0.
58 
-0.
34 
FAP 
fibroblast activation 
protein, alpha 
100736
572 -0.35 
0.00
249 
-0.
07 
-0.
42 
-0.
35 
0.3
5 
-0.
30 
-0.
84 
-0.
78 
-0.
40 
-0.
34 
-0.
35 
ARG2 arginase, type II 
100155
893 -0.35 
0.00
982 
-0.
01 
0.0
2 
-0.
46 
0.1
0 
-0.
60 
-1.
16 
-0.
21 
-0.
02 
-0.
78 
-0.
42 
SRM spermidine synthase 414385 -0.35 
0.00
990 
-0.
09 
-0.
26 
0.0
1 
0.3
9 
-0.
18 
-1.
18 
-0.
48 
-0.
58 
-0.
74 
-0.
44 
LOC1006
22759 
uncharacterized 
LOC100622759 
100622
759 -0.36 
0.00
258 
-0.
62 
-0.
19 
-0.
19 
-0.
89 
-0.
88 
0.0
7 
0.0
0 
-0.
10 
-0.
38 
-0.
38 
SGK3 
serum/glucocorticoid 
regulated kinase family, 
member 3 
100521
447 -0.36 
0.00
567 
-0.
50 
-0.
08 
0.1
6 
-0.
22 
-1.
03 
-0.
59 
-0.
02 
0.0
1 
-0.
82 
-0.
52 
AHI1 
Abelson helper integration 
site 1 
100514
806 -0.36 
0.00
138 
-0.
84 
-0.
31 
-0.
30 
-0.
81 
-0.
39 
-0.
21 
0.1
2 
-0.
14 
-0.
25 
-0.
50 
FAM49B 
family with sequence 
similarity 49, member B 
100157
574 -0.36 
0.00
399 
-0.
72 
-0.
32 
-0.
11 
0.0
0 
-0.
92 
-0.
84 
0.1
8 
-0.
01 
-0.
47 
-0.
42 
ARHGDI
B 
Rho GDP dissociation 
inhibitor (GDI) beta 
100155
466 -0.36 
0.00
921 
-1.
13 
-0.
66 
0.0
3 
-0.
39 
-0.
80 
-0.
44 
0.2
6 
0.1
2 
-0.
56 
-0.
06 
ITGA8 integrin, alpha 8 
100512
676 -0.37 
0.00
897 
-0.
26 
-0.
24 
0.0
7 
-0.
55 
-0.
29 
0.1
0 
-0.
64 
-0.
39 
-1.
39 
-0.
08 
SLAMF1 
signaling lymphocytic 
activation molecule family 
member 1 
100511
325 -0.37 
0.00
376 
-1.
00 
-0.
65 
-0.
17 
-0.
20 
-0.
19 
-0.
79 
-0.
01 
-0.
04 
-0.
52 
-0.
11 
SMPDL3
A 
sphingomyelin 
phosphodiesterase, 
acid-like 3A 
100153
442 -0.37 
0.00
067 
-0.
88 
-0.
47 
-0.
37 
0.0
6 
-0.
17 
-0.
55 
-0.
61 
-0.
09 
-0.
52 
-0.
09 
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LOC1007
38208 
solute carrier organic anion 
transporter family member 
5A1-like 
100738
208 -0.37 
0.00
935 
-0.
54 
-0.
16 
-0.
45 
-0.
79 
-0.
47 
-0.
07 
0.0
6 
0.3
9 
-0.
64 
-1.
02 
LOC1005
24363 proline-rich protein 16-like 
100524
363 -0.37 
0.00
243 
0.0
0 
-0.
37 
0.0
0 
-0.
68 
-0.
30 
-0.
26 
-0.
23 
-0.
30 
-1.
06 
-0.
53 
Sep-01 septin 1 
100514
708 -0.37 
0.00
285 
-0.
87 
-0.
78 
-0.
15 
-0.
67 
-0.
24 
-0.
67 
0.1
7 
-0.
01 
-0.
31 
-0.
19 
LOC1005
18524 
GTPase IMAP family 
member 6-like 
100518
524 -0.37 
0.00
454 
-1.
08 
-0.
40 
-0.
04 
-0.
15 
-0.
94 
-0.
40 
-0.
16 
0.2
2 
-0.
49 
-0.
33 
LOC1005
11860 
protein tyrosine 
phosphatase receptor type 
C-associated protein-like 
100511
860 -0.38 
0.00
231 
-1.
06 
-0.
39 
-0.
31 
-0.
48 
-0.
41 
-0.
79 
0.2
3 
0.0
1 
-0.
30 
-0.
28 
SPI1 
spleen focus forming virus 
(SFFV) proviral 
integration oncogene spi1 414912 -0.38 
0.00
795 
-0.
84 
-0.
12 
0.1
0 
0.0
2 
-0.
81 
-1.
02 
-0.
02 
-0.
04 
-0.
88 
-0.
17 
LOC1005
18506 protein FAM177B-like 
100518
506 -0.38 
0.00
094 
-0.
28 
-0.
51 
-0.
33 
0.3
7 
-0.
50 
-0.
68 
-0.
65 
-0.
67 
-0.
28 
-0.
23 
LOC1006
20522 
transcription regulator 
protein BACH2-like 
100620
522 -0.38 
0.00
386 
-0.
33 
-0.
11 
-0.
41 
-1.
16 
-0.
29 
-0.
45 
0.2
7 
-0.
30 
-0.
46 
-0.
53 
DOCK8 dedicator of cytokinesis 8 
100153
522 -0.38 
0.00
186 
-0.
94 
-0.
34 
-0.
07 
-0.
44 
-0.
57 
-0.
92 
-0.
08 
0.1
0 
-0.
19 
-0.
34 
ABAT 
4-aminobutyrate 
aminotransferase 397500 -0.38 
0.00
946 
-0.
57 
-0.
32 
0.0
5 
0.1
5 
-0.
21 
-1.
03 
-0.
63 
-1.
07 
-0.
33 
0.1
6 
LOC1005
20583 
C4b-binding protein beta 
chain-like 
100520
583 -0.38 
0.00
103 
-0.
42 
-0.
42 
-0.
21 
0.0
6 
-0.
86 
-0.
55 
-0.
65 
-0.
45 
0.0
7 
-0.
37 
MAP4K2 
mitogen-activated protein 
kinase kinase kinase kinase 
2 
100523
716 -0.38 
0.00
685 
-0.
65 
-0.
32 
-0.
18 
-0.
75 
-0.
32 
-1.
21 
0.3
6 
-0.
32 
-0.
25 
-0.
16 
LOC1005
14466 protein THEMIS2-like 
100514
466 -0.38 
0.00
414 
-0.
19 
-0.
15 
-0.
47 
-0.
07 
-0.
27 
-1.
39 
-0.
09 
-0.
34 
-0.
57 
-0.
30 
LOC1007
37965 
runt-related transcription 
factor 2-like 
100737
965 -0.38 
0.00
326 
-0.
83 
-0.
39 
-0.
21 
-0.
72 
-0.
50 
-0.
42 
-0.
02 
0.2
9 
-0.
94 
-0.
09 
LOC1005
18347 
GTPase IMAP family 
member 4-like 
100518
347 -0.38 
0.00
770 
-1.
11 
-0.
45 
0.0
4 
-0.
27 
-1.
05 
-0.
60 
0.0
9 
0.1
3 
-0.
56 
-0.
04 
MST4 
serine/threonine protein 
kinase MST4 
100233
205 -0.38 
0.00
376 
-0.
93 
-0.
29 
0.2
0 
-0.
59 
-0.
86 
-0.
54 
0.0
0 
0.1
1 
-0.
41 
-0.
51 
ST8SIA4 
ST8 
alpha-N-acetyl-neuraminid
e 
alpha-2,8-sialyltransferase 
4 641356 -0.38 
0.00
243 
-0.
74 
-0.
39 
-0.
06 
-0.
16 
-0.
66 
-0.
65 
-0.
24 
0.2
0 
-0.
99 
-0.
16 
LOC1005
12951 
uncharacterized 
LOC100512951 
100512
951 -0.38 
0.00
214 
-0.
97 
-0.
11 
-0.
04 
-0.
70 
-0.
56 
-0.
64 
0.2
1 
-0.
28 
-0.
34 
-0.
42 
CIITA 
class II, major 
histocompatibility 
complex, transactivator 
100736
732 -0.39 
0.00
948 
-1.
33 
-0.
07 
-0.
11 
-0.
43 
-1.
03 
-0.
42 
-0.
12 
0.2
1 
-0.
29 
-0.
26 
GCET2 
germinal 
center-associated, 
signaling and motility 
100626
350 -0.39 
0.00
881 
-0.
80 
-0.
84 
-0.
25 
-0.
70 
-0.
63 
-0.
14 
-0.
16 
0.1
3 
0.3
8 
-0.
86 
LOC1005
20025 
cysteine-rich with 
EGF-like domain protein 
2-like 
100520
025 -0.39 
0.00
346 
-0.
49 
0.1
3 
0.0
3 
-0.
14 
-1.
04 
-0.
60 
-0.
51 
0.0
4 
-0.
84 
-0.
47 
APOBEC
3F 
apolipoprotein B mRNA 
editing enzyme, catalytic 
polypeptide-like 3F 
100037
939 -0.39 
0.00
238 
-1.
00 
-0.
67 
0.1
6 
-0.
38 
-0.
48 
-0.
69 
-0.
31 
0.0
1 
-0.
14 
-0.
39 
LOC1005
21239 
coatomer subunit 
epsilon-like 
100521
239 -0.39 
0.00
873 
0.1
2 
-0.
34 
0.1
2 
0.0
2 
-0.
60 
-0.
41 
-0.
36 
-1.
12 
-0.
24 
-1.
10 
LOC1005
12932 acid ceramidase-like 
100512
932 -0.39 
0.00
369 
-0.
87 
-0.
33 
-0.
11 
0.1
0 
-1.
23 
-0.
64 
-0.
34 
-0.
13 
-0.
21 
-0.
16 
LOC1006
25333 
high mobility group 
protein B2-like 
100625
333 -0.39 
0.00
246 
-0.
78 
-0.
16 
0.3
1 
-0.
46 
-1.
05 
-0.
40 
-0.
22 
-0.
10 
-0.
59 
-0.
48 
PARP8 
poly (ADP-ribose) 
polymerase family, 
member 8 
100511
108 -0.39 
0.00
281 
-0.
83 
-0.
63 
0.0
3 
-0.
41 
-0.
88 
-0.
53 
0.0
9 
0.1
8 
-0.
70 
-0.
27 
LOC1001
52849 
EMI domain-containing 
protein 1-like 
100152
849 -0.40 
0.00
295 
-0.
23 
-0.
73 
-0.
04 
0.1
9 
-0.
49 
-1.
21 
-0.
01 
-0.
48 
-0.
50 
-0.
46 
BCL6 B-cell CLL/lymphoma 6 
100156
549 -0.40 
0.00
070 
-0.
59 
-0.
01 
-0.
33 
-0.
46 
-0.
63 
-0.
62 
0.0
0 
0.0
5 
-0.
85 
-0.
56 
LOC1005
25029 protein FAM111A-like 
100525
029 -0.40 
0.00
086 
-0.
50 
-0.
13 
-0.
53 
-0.
08 
-1.
06 
-0.
49 
-0.
29 
0.0
3 
-0.
68 
-0.
27 
LOC1006
25253 
DNA-binding protein 
Ikaros-like 
100625
253 -0.40 
0.00
064 
-0.
69 
-0.
66 
-0.
18 
-0.
36 
-0.
69 
-0.
68 
-0.
09 
0.2
4 
-0.
53 
-0.
40 
LOC1005
24418 
prostaglandin D2 
receptor-like 
100524
418 -0.40 
0.00
193 
-0.
74 
0.0
2 
-0.
05 
-1.
00 
-0.
21 
-0.
63 
-0.
11 
-0.
36 
-0.
70 
-0.
27 
LOC1005
18723 
interleukin-21 
receptor-like 
100518
723 -0.41 
0.00
890 
-1.
12 
-0.
21 
-0.
31 
-0.
91 
-0.
57 
-0.
22 
0.2
0 
0.3
8 
-0.
73 
-0.
58 
LOC1006
25140 protein CASC4-like 
100625
140 -0.41 
0.00
159 
-0.
24 
-0.
10 
-1.
17 
0.0
8 
-0.
32 
-0.
20 
-0.
80 
-0.
42 
-0.
28 
-0.
63 
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BIN2 bridging integrator 2 
100519
772 -0.41 
0.00
821 
-1.
30 
-0.
70 
0.2
5 
-0.
40 
-0.
45 
-0.
83 
-0.
12 
0.0
2 
-0.
66 
0.0
7 
APOD apolipoprotein D 
100157
318 -0.41 
0.00
105 
-0.
27 
-0.
62 
-0.
07 
-0.
59 
-0.
28 
-0.
49 
-0.
10 
-1.
13 
-0.
32 
-0.
23 
FCRL3 Fc receptor-like 3 
100158
069 -0.41 
0.00
520 
-0.
56 
-0.
22 
-0.
21 
-0.
58 
-1.
20 
-0.
73 
0.5
1 
-0.
31 
-0.
39 
-0.
41 
DOCK2 dedicator of cytokinesis 2 
100512
021 -0.41 
0.00
470 
-1.
05 
-0.
60 
-0.
31 
-0.
57 
-0.
89 
-0.
59 
-0.
05 
0.4
6 
-0.
46 
-0.
05 
LOC1001
52206 
C2 calcium-dependent 
domain-containing protein 
4A-like 
100152
206 -0.41 
0.00
922 
-0.
26 
0.0
5 
-0.
64 
0.5
7 
-0.
41 
-1.
22 
-0.
43 
-0.
46 
-0.
41 
-0.
91 
LOC1007
39094 
phospholipase B-like 
1-like 
100739
094 -0.41 
0.00
333 
0.3
2 
-0.
64 
0.1
3 
-0.
40 
-0.
56 
-0.
32 
-0.
49 
-0.
33 
-0.
99 
-0.
86 
DUOX2 dual oxidase 2 397060 -0.42 
0.00
305 
-0.
16 
0.0
5 
-0.
47 
-0.
14 
-0.
38 
-0.
36 
-1.
38 
-0.
01 
-0.
85 
-0.
47 
LOC1005
18944 
dedicator of cytokinesis 
protein 11-like 
100518
944 -0.42 
0.00
355 
-1.
15 
-0.
62 
-0.
12 
-0.
74 
-0.
81 
-0.
65 
0.0
1 
0.1
9 
-0.
15 
-0.
16 
RHOH 
ras homolog family 
member H 
100513
215 -0.42 
0.00
685 
-1.
23 
-0.
35 
0.1
8 
-0.
33 
-0.
85 
-0.
87 
0.2
0 
0.0
2 
-0.
72 
-0.
27 
LOC1001
54617 
histidine 
ammonia-lyase-like 
100154
617 -0.42 
0.00
499 
-0.
43 
-0.
69 
-0.
27 
0.2
3 
-0.
82 
-1.
15 
-0.
83 
-0.
06 
0.0
8 
-0.
31 
LOC1005
25094 
SAM and SH3 
domain-containing protein 
3-like 
100525
094 -0.43 
0.00
064 
-1.
03 
-0.
44 
-0.
27 
-0.
29 
-0.
49 
-0.
88 
0.1
0 
-0.
05 
-0.
41 
-0.
50 
LOC1007
38167 
mitogen-activated protein 
kinase kinase kinase kinase 
1-like 
100738
167 -0.43 
0.00
284 
-0.
94 
-0.
51 
-0.
02 
-0.
51 
-0.
82 
-0.
92 
0.1
7 
0.2
5 
-0.
52 
-0.
46 
AKNA 
AT-hook transcription 
factor 
100152
364 -0.43 
0.00
011 
-0.
69 
-0.
43 
-0.
24 
0.0
1 
-0.
41 
-0.
84 
-0.
25 
-0.
78 
-0.
45 
-0.
21 
CHIA chitinase, acidic 
100155
231 -0.43 
0.00
063 
-0.
61 
-0.
93 
-0.
61 
-0.
14 
-0.
74 
-0.
19 
-0.
21 
-0.
67 
-0.
15 
-0.
04 
LOC1006
20588 
synaptosomal-associated 
protein 25-like 
100620
588 -0.43 
0.00
056 
-0.
41 
-0.
20 
-0.
07 
-0.
30 
-0.
55 
-0.
60 
-0.
39 
-0.
25 
-1.
16 
-0.
39 
LOC1005
16246 
EGF-like 
module-containing 
mucin-like hormone 
receptor-like 3-like 
100516
246 -0.43 
0.00
426 
-0.
26 
-0.
27 
-1.
00 
-0.
75 
-0.
44 
-1.
12 
-0.
08 
-0.
16 
-0.
61 
0.3
7 
RASSF2 
Ras association 
(RalGDS/AF-6) domain 
family member 2 
100157
105 -0.43 
0.00
083 
-0.
64 
-0.
02 
-0.
24 
-0.
07 
-0.
68 
-1.
13 
-0.
28 
-0.
06 
-0.
71 
-0.
50 
BHLHE4
0 
basic helix-loop-helix 
family, member e40 
100514
873 -0.43 
0.00
625 
-0.
63 
0.2
9 
-0.
57 
0.1
8 
-0.
26 
-1.
39 
-0.
56 
-0.
11 
-0.
92 
-0.
38 
ELK3 
ELK3, ETS-domain 
protein (SRF accessory 
protein 2) 
100622
445 -0.44 
0.00
722 
-0.
61 
-0.
36 
0.0
5 
-0.
29 
-0.
31 
-0.
77 
-0.
20 
-0.
21 
-1.
68 
0.0
3 
LOC1005
23976 
uncharacterized 
LOC100523976 
100523
976 -0.44 
0.00
524 
-1.
34 
-0.
43 
-0.
30 
-0.
80 
-0.
59 
-0.
79 
0.1
0 
0.2
4 
-0.
05 
-0.
41 
ACAP1 
ArfGAP with coiled-coil, 
ankyrin repeat and PH 
domains 1 
100623
422 -0.44 
0.00
103 
-1.
04 
-0.
66 
0.0
5 
-0.
35 
-0.
57 
-0.
86 
0.0
5 
-0.
20 
-0.
55 
-0.
27 
LOC1001
57293 Transmembrane protein 71 
100157
293 -0.44 
0.00
943 
-0.
78 
0.3
6 
0.0
2 
-0.
52 
-0.
29 
-1.
61 
-0.
43 
-0.
22 
-0.
63 
-0.
32 
PDE3B 
phosphodiesterase 3B, 
cGMP-inhibited 
100516
060 -0.44 
0.00
740 
-1.
35 
-0.
64 
0.1
7 
-0.
45 
-0.
89 
-0.
89 
-0.
03 
0.3
3 
-0.
40 
-0.
27 
LOC1005
21317 
myeloid cell nuclear 
differentiation antigen-like 
100521
317 -0.44 
0.00
080 
-0.
35 
-0.
14 
-0.
15 
-1.
29 
-0.
31 
-0.
73 
-0.
33 
-0.
29 
-0.
58 
-0.
27 
SUSD1 sushi domain containing 1 
100516
174 -0.44 
0.00
191 
-0.
54 
-0.
47 
-0.
21 
0.0
2 
-0.
83 
-1.
37 
-0.
15 
-0.
24 
-0.
48 
-0.
17 
KLHL6 kelch-like 6 (Drosophila) 
100625
137 -0.44 
0.00
025 
-0.
86 
0.0
1 
-0.
59 
-0.
68 
-0.
45 
-0.
28 
0.0
0 
-0.
62 
-0.
33 
-0.
65 
CCR7 
chemokine (C-C motif) 
receptor 7 396663 -0.45 
0.00
305 
-1.
09 
-0.
18 
-0.
33 
-0.
53 
-0.
42 
-1.
13 
0.3
0 
-0.
01 
-0.
53 
-0.
57 
TTC39C 
tetratricopeptide repeat 
domain 39C 
100511
088 -0.45 
0.00
151 
-1.
25 
-0.
29 
-0.
03 
-0.
90 
-0.
76 
-0.
37 
-0.
29 
-0.
15 
-0.
08 
-0.
38 
LOC1005
20045 
fas apoptotic inhibitory 
molecule 3-like 
100520
045 -0.45 
0.00
408 
-1.
03 
-0.
45 
-0.
38 
-1.
37 
-0.
41 
-0.
65 
0.2
7 
-0.
06 
-0.
18 
-0.
25 
C2 complement component 2 448981 -0.45 
0.00
476 
-1.
10 
-0.
03 
-0.
14 
-0.
57 
-1.
52 
-0.
56 
-0.
16 
-0.
24 
0.0
3 
-0.
26 
SLC5A8 
solute carrier family 5 
(iodide transporter), 
member 8 
100524
807 -0.46 
0.00
065 
-0.
40 
-0.
55 
-0.
40 
-0.
29 
-0.
88 
-1.
01 
-0.
48 
-0.
44 
0.2
7 
-0.
37 
LOC1006
24581 
lysosome-associated 
membrane glycoprotein 
3-like 
100624
581 -0.46 
0.00
982 
-1.
06 
0.1
8 
-0.
06 
-1.
28 
-0.
41 
-1.
21 
0.2
4 
-0.
14 
-0.
44 
-0.
41 
LOC1005
26183 
SLAIN motif-containing 
protein 1-like 
100526
183 -0.46 
0.00
787 
-1.
12 
-0.
33 
-0.
78 
-1.
04 
-0.
89 
-0.
41 
0.3
8 
0.3
5 
-0.
60 
-0.
15 
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LOC1005
23216 
alkaline phosphatase, 
placental type-like 
100523
216 -0.46 
0.00
387 
-0.
15 
-1.
28 
-1.
02 
-0.
32 
-0.
60 
-0.
56 
-0.
57 
0.4
6 
-0.
36 
-0.
20 
CFH complement factor H 397525 -0.46 
0.00
564 
-0.
91 
-0.
17 
-0.
10 
-0.
39 
-1.
80 
-0.
03 
-0.
51 
-0.
19 
-0.
33 
-0.
21 
IKZF2 
IKAROS family zinc 
finger 2 (Helios) 
100510
935 -0.47 
0.00
578 
-1.
37 
-0.
78 
-0.
33 
-0.
40 
-1.
04 
-0.
41 
-0.
19 
0.4
5 
0.0
7 
-0.
68 
LOC1005
24935 
peptidyl-prolyl cis-trans 
isomerase FKBP11-like 
100524
935 -0.47 
0.00
018 
-0.
58 
-0.
60 
0.1
3 
-0.
17 
-0.
53 
-0.
63 
-0.
44 
-0.
61 
-1.
01 
-0.
25 
WDFY3 
WD repeat and FYVE 
domain containing 3 
100157
904 -0.47 
0.00
130 
-0.
70 
0.0
1 
-0.
17 
-0.
84 
-0.
58 
-1.
23 
0.0
5 
-0.
15 
-0.
60 
-0.
46 
HVCN1 
hydrogen voltage-gated 
channel 1 
100152
115 -0.47 
0.00
041 
-0.
73 
-0.
51 
-0.
46 
-1.
13 
-0.
35 
-0.
51 
-0.
03 
-0.
10 
-0.
81 
-0.
07 
LOC3967
57 trappin 8 396757 -0.47 
0.00
000 
-0.
36 
-0.
21 
-0.
43 
-0.
28 
-0.
98 
-0.
67 
-0.
53 
-0.
48 
-0.
41 
-0.
37 
LOC1006
24751 
rho GTPase-activating 
protein 30-like 
100624
751 -0.47 
0.00
100 
-1.
21 
-0.
20 
-0.
23 
-0.
64 
-0.
91 
-0.
87 
-0.
16 
0.0
6 
-0.
37 
-0.
20 
LOC1005
22792 
protein kinase C beta 
type-like 
100522
792 -0.48 
0.00
156 
-1.
11 
-0.
40 
-0.
03 
-0.
98 
-0.
98 
-0.
45 
0.1
8 
-0.
03 
-0.
57 
-0.
37 
P2RY10 
purinergic receptor P2Y, 
G-protein coupled, 10 
100157
702 -0.48 
0.00
688 
-1.
64 
-0.
56 
-0.
07 
-0.
99 
-0.
49 
-0.
24 
-0.
42 
0.1
5 
0.1
6 
-0.
69 
LOC1005
22493 
SHC SH2 domain-binding 
protein 1-like 
100522
493 -0.48 
0.00
926 
-1.
46 
-0.
09 
0.0
7 
-0.
60 
-0.
59 
-0.
03 
-0.
19 
0.0
4 
-1.
48 
-0.
49 
LOC1005
18072 
calpain small subunit 
2-like 
100518
072 -0.48 
0.00
902 
-0.
16 
-0.
39 
-0.
72 
0.4
5 
-0.
30 
-1.
39 
-0.
68 
-1.
27 
0.2
2 
-0.
59 
LOC1007
36918 protein EURL homolog 
100736
918 -0.48 
0.00
900 
-0.
83 
0.1
6 
0.0
7 
-0.
67 
-1.
51 
-0.
61 
0.1
8 
0.0
4 
-1.
25 
-0.
42 
CD79A 
CD79a molecule, 
immunoglobulin-associate
d alpha 
100190
992 -0.49 
0.00
456 
-1.
36 
-0.
32 
-0.
51 
-1.
05 
-0.
38 
-0.
14 
0.5
3 
-0.
19 
-0.
93 
-0.
52 
LCP1 
lymphocyte cytosolic 
protein 1 (L-plastin) 
100156
254 -0.49 
0.00
346 
-1.
14 
-0.
51 
0.0
2 
-0.
29 
-0.
91 
-1.
38 
-0.
01 
0.2
2 
-0.
55 
-0.
35 
CD79B 
CD79b molecule, 
immunoglobulin-associate
d beta 
100511
898 -0.49 
0.00
088 
-0.
54 
-0.
38 
-0.
49 
-1.
36 
-0.
52 
-0.
03 
0.0
8 
-0.
54 
-0.
84 
-0.
30 
CCL28 
chemokine (C-C motif) 
ligand 28 554303 -0.49 
0.00
119 
-0.
39 
-0.
69 
-1.
08 
-0.
20 
-1.
21 
-0.
16 
-0.
73 
0.0
8 
0.0
3 
-0.
60 
PIK3AP1 
phosphoinositide-3-kinase 
adaptor protein 1 
100155
165 -0.50 
0.00
657 
-0.
49 
-0.
08 
-0.
26 
-0.
36 
-0.
77 
-1.
86 
0.3
3 
-0.
23 
-0.
82 
-0.
44 
LOC1005
13515 
uncharacterized protein 
C14orf105-like 
100513
515 -0.50 
0.00
000 
-0.
37 
-0.
49 
-0.
33 
-0.
43 
-0.
36 
-0.
50 
-0.
86 
-0.
66 
-0.
49 
-0.
48 
LOC1005
25302 protein EVI2A-like 
100525
302 -0.50 
0.00
512 
-1.
16 
-0.
34 
0.2
6 
-0.
63 
-0.
99 
-1.
36 
0.1
6 
-0.
38 
-0.
37 
-0.
17 
LOC1001
52851 
leukocyte differentiation 
antigen CD84 
100152
851 -0.50 
0.00
253 
-1.
02 
-0.
55 
0.1
4 
-0.
58 
-0.
88 
-1.
29 
-0.
04 
0.1
7 
-0.
57 
-0.
37 
RGS16 
regulator of G-protein 
signaling 16 397544 -0.50 
0.00
102 
-0.
78 
-0.
02 
-0.
72 
-0.
53 
-0.
21 
-0.
92 
-0.
24 
0.1
6 
-1.
14 
-0.
61 
CD69 CD69 molecule 397165 -0.50 
0.00
961 
-0.
99 
0.0
2 
-0.
10 
-0.
40 
-1.
22 
-1.
26 
0.0
9 
0.3
6 
-1.
27 
-0.
26 
KMO 
kynurenine 
3-monooxygenase 
(kynurenine 
3-hydroxylase) 397148 -0.50 
0.00
141 
-1.
25 
-0.
48 
-0.
14 
-0.
33 
-1.
21 
-0.
77 
-0.
28 
-0.
41 
0.2
8 
-0.
45 
LOC1007
37508 cytochrome P450 2G1-like 
100737
508 -0.50 
0.00
992 
-0.
39 
-0.
36 
-0.
01 
-0.
61 
0.0
2 
-0.
32 
-2.
02 
-0.
90 
0.1
2 
-0.
56 
LOC1007
37086 
putative sodium-coupled 
neutral amino acid 
transporter 11-like 
100737
086 -0.51 
0.00
681 
0.1
9 
-0.
40 
-0.
33 
0.4
8 
-0.
73 
-1.
18 
-1.
20 
-0.
81 
-0.
08 
-0.
98 
LOC1007
38552 
receptor-type 
tyrosine-protein 
phosphatase C-like 
100738
552 -0.51 
0.00
271 
-1.
09 
-0.
52 
0.0
8 
-0.
66 
-1.
21 
-0.
99 
0.1
6 
0.2
2 
-0.
59 
-0.
46 
LOC1006
22217 
mitogen-activated protein 
kinase kinase kinase 8-like 
100622
217 -0.51 
0.00
515 
-0.
73 
-0.
78 
-0.
13 
0.0
3 
-0.
93 
-1.
80 
-0.
29 
0.0
0 
-0.
23 
-0.
22 
PARVG parvin, gamma 
100520
379 -0.51 
0.00
052 
-1.
20 
-0.
56 
-0.
14 
-0.
34 
-0.
62 
-1.
15 
-0.
39 
-0.
20 
-0.
43 
-0.
05 
AFF2 
AF4/FMR2 family, 
member 2 
100512
515 -0.52 
0.00
041 
-0.
74 
-0.
32 
0.0
0 
-0.
66 
-0.
75 
-0.
51 
0.0
1 
-0.
22 
-0.
91 
-1.
09 
LOC1006
21326 
protein kinase C theta 
type-like 
100621
326 -0.52 
0.00
846 
-1.
56 
-0.
59 
0.0
5 
-1.
08 
-1.
02 
-0.
84 
0.3
2 
0.3
2 
-0.
22 
-0.
59 
LOC1005
13324 
interleukin-22 receptor 
subunit alpha-2-like 
100513
324 -0.52 
0.00
191 
-0.
83 
-0.
27 
-0.
33 
-0.
14 
-0.
20 
-1.
64 
0.0
5 
-0.
53 
-0.
52 
-0.
82 
LOC1006
27882 
cytohesin-interacting 
protein-like 
100627
882 -0.52 
0.00
991 
-1.
57 
-0.
37 
0.0
0 
-0.
20 
-0.
78 
-1.
44 
0.2
6 
0.2
4 
-1.
08 
-0.
29 
STAT4 
signal transducer and 
activator of transcription 4 397261 -0.53 
0.00
248 
-1.
46 
-0.
52 
-0.
12 
-0.
59 
-1.
22 
-0.
67 
-0.
18 
0.2
6 
-0.
46 
-0.
29 
PTPRC 
protein tyrosine 
phosphatase, receptor type, 
C 
100522
631 -0.53 
0.00
194 
-1.
01 
-0.
69 
-0.
01 
-0.
59 
-1.
21 
-1.
08 
0.1
6 
0.2
5 
-0.
58 
-0.
49 
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LOC1005
22635 
G-protein coupled receptor 
183-like 
100522
635 -0.53 
0.00
896 
-1.
74 
-0.
15 
0.4
2 
-0.
30 
-1.
30 
-0.
85 
-0.
13 
0.0
4 
-0.
83 
-0.
43 
WAP-3 elafin family member 
100607
966 -0.53 
0.00
665 
-0.
28 
-0.
16 
-0.
61 
-0.
71 
-1.
59 
-1.
58 
-0.
31 
-0.
24 
-0.
02 
0.2
1 
LOC1001
56280 gremlin-1-like 
100156
280 -0.54 
0.00
283 
-0.
04 
-0.
47 
-0.
13 
-1.
69 
-0.
21 
-1.
03 
0.1
7 
-0.
91 
-0.
36 
-0.
69 
LOC1001
57947 GTPase SLIP-GC-like 
100157
947 -0.54 
0.00
083 
-0.
38 
-0.
08 
-0.
69 
-0.
96 
-0.
98 
-0.
48 
-0.
04 
-0.
32 
-0.
14 
-1.
34 
LCN2 lipocalin 2 
100153
501 -0.54 
0.00
390 
-0.
35 
-0.
05 
-0.
25 
-0.
03 
-0.
72 
-0.
52 
-0.
79 
-0.
36 
-2.
00 
-0.
33 
LY96 lymphocyte antigen 96 
100125
555 -0.54 
0.00
351 
-0.
55 
-0.
78 
0.3
1 
-0.
65 
-1.
45 
-1.
32 
-0.
18 
-0.
27 
-0.
59 
0.0
5 
CHGB 
chromogranin B 
(secretogranin 1) 397154 -0.55 
0.00
687 
-0.
05 
-0.
84 
-0.
46 
0.4
9 
-0.
64 
-1.
41 
-1.
36 
-0.
85 
0.3
7 
-0.
73 
LOC1007
39847 
SLAIN motif-containing 
protein 1-like 
100739
847 -0.55 
0.00
338 
-1.
52 
-0.
71 
-0.
05 
-0.
48 
-0.
73 
-0.
40 
0.4
0 
-0.
05 
-1.
17 
-0.
81 
CD19 CD19 molecule 397669 -0.55 
0.00
928 
-0.
34 
-0.
30 
-0.
45 
-2.
08 
-0.
81 
-0.
21 
0.6
3 
-0.
86 
-0.
45 
-0.
66 
LOC1000
37944 
chitinase 3-like 2 isoform 
A 
100037
944 -0.56 
0.00
018 
-0.
74 
-0.
17 
-0.
40 
-0.
29 
-1.
47 
-0.
52 
-0.
29 
-0.
37 
-0.
64 
-0.
68 
CD48 CD48 molecule 
100511
130 -0.57 
0.00
808 
-1.
42 
-0.
38 
-0.
17 
0.0
5 
-0.
99 
-1.
53 
0.2
8 
0.2
0 
-1.
34 
-0.
35 
IL6R interleukin 6 receptor 399522 -0.57 
0.00
334 
-1.
47 
-0.
06 
0.0
1 
-0.
66 
-0.
68 
-1.
36 
0.0
6 
0.0
9 
-1.
16 
-0.
46 
LOC1005
24827 protein EVI2B-like 
100524
827 -0.57 
0.00
385 
-1.
34 
-0.
44 
0.1
7 
-0.
32 
-1.
05 
-1.
65 
-0.
07 
0.0
2 
-0.
91 
-0.
14 
C4 complement C4 445467 -0.58 
0.00
039 
-0.
93 
-0.
21 
-0.
24 
-0.
83 
-1.
54 
-0.
94 
-0.
28 
-0.
39 
-0.
05 
-0.
40 
CMAH 
cytidine 
monophosphate-N-acetyln
euraminic acid 
hydroxylase 396918 -0.58 
0.00
245 
-0.
80 
-0.
52 
-0.
44 
-0.
24 
-1.
10 
-1.
78 
0.2
5 
-0.
81 
0.1
5 
-0.
52 
LOC1005
18428 
lymphoid-restricted 
membrane protein-like 
100518
428 -0.59 
0.00
061 
-0.
96 
-0.
49 
-0.
07 
-1.
19 
-1.
30 
-0.
85 
0.1
2 
-0.
11 
-0.
47 
-0.
61 
BCL2A1 BCL2-related protein A1 
100156
860 -0.60 
0.00
820 
-0.
70 
-0.
09 
-0.
31 
0.0
2 
-0.
89 
-2.
43 
0.1
4 
-0.
41 
-0.
74 
-0.
60 
SERPINA
1 
serpin peptidase inhibitor, 
clade A (alpha-1 
antiproteinase, 
antitrypsin), member 1 397688 -0.60 
0.00
933 
0.0
0 
0.4
2 
0.0
4 
-1.
36 
-0.
16 
-1.
93 
-1.
25 
-0.
82 
-0.
16 
-0.
79 
LOC1001
53460 
A-kinase anchor protein 
5-like 
100153
460 -0.60 
0.00
441 
-1.
99 
-0.
85 
-0.
11 
-0.
95 
-1.
21 
-0.
60 
-0.
15 
-0.
14 
-0.
03 
0.0
2 
IL2RG 
interleukin 2 receptor, 
gamma 397156 -0.60 
0.00
076 
-1.
46 
-0.
50 
-0.
10 
-0.
50 
-1.
00 
-1.
40 
0.0
8 
-0.
20 
-0.
58 
-0.
38 
PCD1B CD1B antigen 
100038
007 -0.62 
0.00
066 
-1.
08 
-0.
31 
-0.
41 
0.0
2 
-1.
49 
-0.
55 
-0.
57 
-1.
16 
0.0
3 
-0.
63 
CLU clusterin 397025 -0.63 
0.00
158 
-0.
76 
0.0
4 
-0.
26 
-1.
94 
-0.
50 
-0.
64 
0.1
1 
-0.
53 
-1.
27 
-0.
52 
AOAH 
acyloxyacyl hydrolase 
(neutrophil) 
100522
290 -0.64 
0.00
528 
-1.
88 
-0.
43 
-0.
31 
-0.
15 
-1.
24 
-0.
97 
0.3
4 
-0.
02 
-1.
49 
-0.
22 
LOC1005
20876 sorting nexin-10-like 
100520
876 -0.66 
0.00
926 
-1.
41 
0.4
6 
0.0
1 
-0.
23 
-2.
03 
-1.
53 
0.1
2 
-0.
19 
-1.
16 
-0.
64 
SLAMF6 SLAM family member 6 
100156
912 -0.67 
0.00
020 
-1.
57 
-0.
70 
-0.
34 
-0.
76 
-1.
17 
-1.
10 
-0.
13 
0.0
2 
-0.
44 
-0.
56 
MS4A1 
membrane-spanning 
4-domains, subfamily A, 
member 1 
100627
952 -0.68 
0.00
603 
-1.
08 
0.3
6 
-0.
90 
-2.
35 
-0.
77 
-0.
37 
0.4
8 
-0.
78 
-0.
43 
-0.
93 
LOC1005
25349 
transmembrane protein 
156-like 
100525
349 -0.69 
0.00
007 
-1.
17 
-0.
27 
-0.
60 
-0.
74 
-1.
46 
-0.
79 
-0.
63 
0.0
8 
-0.
67 
-0.
69 
LEF1 
lymphoid 
enhancer-binding factor 1 
100170
126 -0.70 
0.00
123 
-1.
10 
0.1
4 
-0.
38 
-1.
81 
-0.
91 
-0.
71 
0.0
8 
-0.
30 
-1.
55 
-0.
51 
LOC1007
39042 
monocarboxylate 
transporter 7-like 
100739
042 -0.71 
0.00
146 
-0.
85 
-0.
34 
-0.
83 
0.0
0 
-0.
25 
-2.
18 
-0.
33 
-0.
70 
-1.
38 
-0.
21 
ARHGAP
15 
Rho GTPase activating 
protein 15 
100520
808 -0.74 
0.00
209 
-1.
40 
-0.
47 
-0.
11 
-0.
81 
-1.
34 
-1.
81 
0.4
8 
-0.
06 
-1.
48 
-0.
41 
LOC1005
12873 antileukoproteinase-like 
100512
873 -0.74 
0.00
065 
-0.
73 
-0.
25 
-0.
94 
-0.
09 
-2.
23 
-0.
58 
-0.
88 
-0.
35 
-1.
22 
-0.
15 
LOC1005
25175 
placenta-specific gene 8 
protein-like 
100525
175 -0.78 
0.00
046 
-1.
23 
-0.
08 
0.1
2 
-1.
11 
-2.
17 
-0.
89 
-0.
48 
-0.
65 
-0.
66 
-0.
67 
LOC1001
54053 
SLAM family member 
7-like 
100154
053 -0.78 
0.00
584 
-1.
04 
-0.
32 
-0.
10 
-0.
43 
-1.
34 
-2.
92 
0.0
0 
0.0
4 
-1.
40 
-0.
30 
C4H1orf1
62 
chromosome 1 open 
reading frame 162 ortholog 
100627
962 -0.78 
0.00
624 
0.2
2 
-0.
24 
-0.
75 
-1.
15 
-0.
68 
-2.
16 
0.8
2 
-0.
84 
-2.
07 
-1.
00 
TPH1 tryptophan hydroxylase 1 
100511
002 -0.80 
0.00
065 
-0.
29 
-0.
73 
-0.
48 
0.4
5 
-1.
10 
-1.
88 
-1.
59 
-1.
04 
-0.
36 
-0.
95 
BPIFB2 
BPI fold containing family 
B, member 2 
100113
424 -0.84 
0.00
003 
-0.
62 
-0.
69 
-0.
90 
-0.
59 
-1.
24 
-2.
01 
-0.
57 
-0.
85 
-0.
13 
-0.
80 
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LOC1005
24766 P2Y purinoceptor 13-like 
100524
766 -0.86 
0.00
809 
-1.
72 
0.0
3 
-0.
26 
0.2
5 
-1.
94 
-2.
62 
0.0
0 
-0.
18 
-2.
01 
-0.
19 
CXCR4 
chemokine (C-X-C motif) 
receptor 4 396659 -0.89 
0.00
005 
-1.
42 
-0.
21 
-0.
50 
-0.
37 
-0.
76 
-1.
62 
-0.
54 
-0.
49 
-1.
85 
-1.
16 
IRG1 
immunoresponsive 1 
homolog (mouse) 
100524
951 -0.93 
0.00
558 
-1.
17 
0.3
4 
-0.
21 
0.2
4 
-2.
07 
-2.
59 
-0.
24 
-0.
15 
-2.
28 
-1.
17 
CLEC7A 
C-type lectin domain 
family 7, member A 
100038
025 -0.94 
0.00
372 
-1.
29 
-0.
66 
0.0
8 
-0.
16 
-2.
36 
-2.
98 
0.0
7 
-0.
49 
-1.
14 
-0.
47 
SLPI 
secretory leukocyte 
peptidase inhibitor 396886 -1.13 
0.00
003 
-1.
07 
-0.
08 
-0.
20 
-0.
39 
-1.
92 
-1.
47 
-1.
83 
-1.
91 
-1.
48 
-0.
93 
LOC1005
20761 
C4b-binding protein alpha 
chain-like 
100520
761 -1.42 
0.00
190 
-1.
41 
-0.
65 
-0.
27 
-0.
08 
-2.
39 
-3.
61 
-0.
45 
-1.
12 
-4.
00 
-0.
25 
CHI3L1 
chitinase 3-like 1 (cartilage 
glycoprotein-39) 396865 -1.88 
0.00
008 
-2.
96 
0.3
2 
-0.
66 
-1.
84 
-2.
84 
-3.
82 
-0.
53 
-2.
38 
-2.
89 
-1.
24 
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